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ABSTRACT 
Nicotinamide adenine dinucleotide (β-NAD+) is a primary metabolite involved in 
fundamental biological processes. Its molecular structure with characteristic functional 
groups, such as the quaternary nitrogen of the nicotinamide ring, and the two high-
energy pyrophosphate and nicotinamide N-glycosidic bonds, allows it to undergo 
different reactions depending on the reactive moiety. Well known as a redox substrate 
owing to the redox properties of the nicotinamide ring, β-NAD+ is also fundamental as a 
substrate of NAD
+
-consuming enzymes that cleave either high-energy bonds to catalyse 
their reactions. In this study, a panel of novel adenine-modified NAD
+
 derivatives was 
synthesized and biologically evaluated against different NAD
+
-consuming enzymes. 
The synthesis of NAD
+
 derivatives, modified in position 2, 6 or 8 of the adenine ring 
with aryl/heteroaryl groups, was accomplished by Suzuki-Miyaura cross-couplings. 
Their biological activity as inhibitors and/or non-natural substrates was assessed against 
a selected range of NAD
+
-consuming enzymes. The fluorescence of 8-aryl/heteroaryl 
NAD
+
 derivatives allowed their use as biochemical probes for the development of 
continuous biochemical assays to monitor NAD
+
-consuming enzyme activities. The 
introduction of different substituents in position 8 on the adenine ring allowed the 
modulation of their fluorescence, resulting in the development of more sensitive and 
alternative probes compared to the known fluorophore ε-NAD+. The different 
substitutions introduced on the adenine ring also allowed us to probe the active site of 
an NAD
+
-dependent bacterial DNA ligase. The selective activity of 8-aryl/heteroaryl 
NAD
+
 derivatives against different NAD
+
-consuming enzymes offers excellent 
opportunities for their application as tool compounds in in-vitro/in-vivo studies, and as 
inhibitor templates for drug discovery.  
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1 β-NAD+: AN ESSENTIAL BIOLOGICAL MOLECULE 
1.1 β-NAD+ structure 
Nicotinamide adenine dinucleotide, β-NAD+, is a ubiquitous biological molecule found 
in all living cells that is involved in many major biological processes. Its structure 
consists of two nucleotides, adenosine 5′-monophosphate (AMP) and β-nicotinamide 
mononucleotide (β-NMN), joined by a pyrophosphate bond through their phosphate 
groups (Figure 1.1).
1
 
 
 
Figure 1.1 β-NAD+ structure. AMP (yellow box) and β-NMN (blue box) joined by a pyrophosphate bond. 
Its discovery and structure assignment in the 1930s attributed to β-NAD+ the main 
function of reversible hydride donor/acceptor because of the ability of the nicotinamide 
(NaM) ring to shuttle between the oxidized and reduced form by the transfer of a proton 
and two electrons (Figure 1.2). Because of this property, β-NAD+ was classified as a 
redox co-substrate for enzymes catalyzing redox reactions. The reduction potential for 
the β-NAD+/β-NADH couple, E0NAD+/NADH, is equal to -0.320 V; therefore, the 
oxidation of β-NADH to β-NAD+ is strongly favoured compared to its reduction and 
this makes β-NADH a strong reducing agent (Figure 1.2).2  
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Figure 1.2 β-NAD+/β-NADH redox reaction. The redox reaction can go through a two-electron 
mechanism (1, in black) or a one-electron mechanism (1a, 1b, in red), depending on the redox potential of 
the coupled substrate, and, in case of enzymatic reactions, on the pH, the polarity of the solvent and steric 
requirement.
2, 3
 Generally, enzymatic reactions proceed via 1, where the enantiotopic protons, pro-R and 
pro-S, can be preferentially transferred depending on the enzymes. The one-electron reduction potential 
for the couple β-NAD·/β-NADH is E0NAD·/NADH = 0.282 V (1a); for the couple β-NAD
+
/ β-NAD·, it is 
E0NAD+/NAD· = -0.922 V (1b). The overall reaction (1) generates β-NAD
+
 from β-NADH by the loss of a 
proton and two electrons (E0NAD+/NADH = (E
0
NAD·/NADH + E
0
NAD+/NAD·)/2 = -0.320 V). 
Besides its redox property, the structure of β-NAD+ is characterized by two high-energy 
bonds, the nicotinamide N-glycosidic bond and the pyrophosphate bond, and cleavage 
of either releases a substantial amount of energy (Figure 1.3). The cleavage of the 
nicotinamide N-glycosidic bond (a) results in the formation of NaM and adenosine 
diphosphate ribose (ADPR); on the other hand, cleavage of the pyrophosphate bond (b) 
generates β-NMN and AMP. These bonds, extremely labile and unstable, make β-NAD+ 
easily susceptible to enzymatic and chemical hydrolytic degradation.  
The enzymatic cleavage of either high-energy bond in the structure of β-NAD+ is 
catalyzed by NAD
+
-consuming enzymes.
4-7
 These enzymes use β-NAD+ as a substrate 
to generate important signalling molecules (e.g. cyclic ADPR, or cADPR, and ADPR), 
or covalently modify the acceptors involved in their enzymatic reactions.  
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Figure 1.3 β-NAD+ and its high-energy bonds. The cleavage of nicotinamide N-glycosidic bond (a) 
generates NaM and ADPR; the cleavage of pyrophosphate bond (b) generates β-NMN and AMP. 
Regarding its chemical hydrolytic degradation, β-NAD+ is very unstable under basic 
conditions, while relatively stable under acidic conditions.
8
 It has been shown that, at 
concentrations below 1 M KOH, the main hydrolytic reaction is the cleavage of the 
nicotinamide N-glycosidic bond (Figure 1.3 a, Figure 1.4 a). Indeed, under these 
conditions the ionization of the ribose diol (pKa = 11.9) would accelerate the release of 
NaM because of the electron-donating ability of the anion that stabilizes the 
oxocarbenium ion intermediate; evidence of this effect is given by the stability of O-
isopropylidene protected nicotinamide ribonucleoside (NR) to the cleavage of the 
nicotinamide N-glycosidic bond. At concentrations above 1 M KOH, the primary 
reaction would become the nucleophilic attack of the hydroxide on the nicotinamide 
ring to generate 2-hydroxy-3-pyridinecarboxaldehyde (2HPC) by ring opening, 
elimination and reclosing (Figure 1.4 b).
9-11
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Figure 1.4 β-NAD+ decomposition pathways in basic conditions. a) The cleavage of nicotinamide N-
glycosidic bond with formation of NaM and ADPR occurs at concentration ≤ 1 M KOH. b) The 
hydroxylation of NaM, ring opening, release of 1′′-amino adenosine diphosphate ribose (ADPRNH2), ring 
closing with formation of 2HPC occurs at concentration > 1 M KOH. 
1.1.1 Redox properties of β-NAD+ 
Owing to its reversible redox activity, β-NAD+(H) is involved in fundamental metabolic 
processes occurring in prokaryotes and eukaryotes, such as glycolysis, the Krebs cycle 
and cellular respiration (Figure 1.5).
1
 During the oxidative catabolism of different 
substances (e.g. carbohydrates, lipids, proteins) to a common intermediate (acetyl 
coenzyme A, or acetyl-CoA), the energy released can be used to reduce β-NAD+ to β-
NADH (endergonic reduction) in the cytosol. β-NADH molecules are then re-oxidized 
into β-NAD+ at the surface of the mitochondrial membrane in eukaryotes, generating 
electrons that are transferred to the electron transport chain, comprising an enzymatic 
series of redox reactions across the mitochondrial inner membrane, to finally reduce O2 
to H2O. During the reactions occurring in the electron transport chain, a proton gradient 
across the mitochondrial membrane is generated, providing the energy to catalyze the 
endergonic synthesis of adenosine triphosphate, ATP, from adenosine diphosphate, 
ADP, and phosphate, Pi (oxidative phosphorylation).
1
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Figure 1.5 Glucose metabolism and enzymatic reactions involving β-NAD+(H) as a redox substrate. a) 
refers to processes occurring in the cytosol, b) to the oxidative phosphorylation occurring in eukaryotes at 
the interface with the mitochondrial membrane. 
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Enzymes using β-NAD+(H) as a redox substrate keep constant the cytosolic 
concentration of the dinucleotide that shuttles between its oxidized and reduced form. 
The β-NAD+:β-NADH ratio is connected to the intracellular redox state and influences 
several metabolic processes; changes in this ratio reflect metabolic changes in the 
cells,
12
 hence the importance to cellular functions to monitor the β-NAD+:β-NADH 
ratio.  
Intracellular β-NAD+(H) can be present in the free and enzyme-bound form; the total 
(free + bound) intracellular β-NAD+:β-NADH ratio fluctuates between 0.1 and 10 in 
different organisms, while the cytosolic free β-NAD+:β-NADH ratio is around 500, 
since most β-NADH is in its enzyme-bound form.12, 13 The β-NAD+:β-NADH ratio has 
been estimated in different cellular compartments, for example in the cytosol and the 
mitochondria, showing quite similar values, with the oxidized form favoured to the 
reduced form.
12
 The preference for a substantial free pool of β-NAD+ compared to β-
NADH reflects the requirement of β-NAD+ in the catabolic processes occurring in the 
cytosol. 
1.1.2 β-NAD+ catabolism and NAD+-consuming enzymes 
As mentioned in 1.1.1, the use of β-NAD+(H) as a substrate by redox enzymes does not 
alter its concentration in living cells. By contrast, β-NAD+ is used up by NAD+-
consuming enzymes,
7
 strictly involved in the catabolism of β-NAD+.  
ADP-ribosyl cyclases (ADPRCs), NAD
+
-glycohydrolases (NADases), ADP-ribosyl 
transferases (ARTs), polyADP-ribosyl polymerases (PARPs) and sirtuins all share the 
same substrate/co-substrate, β-NAD+, and catalyze the cleavage of the nicotinamide N-
glycosidic bond with consequent release of NaM as a reaction product. In ADPRCs and 
NADases, β-NAD+ is the only enzyme substrate and it is used to generate cADPR and 
ADPR (Figure 1.6). In addition, ADPRCs can also catalyze the exchange of the 
nicotinamide ring with the nicotinic acid (NA) from β-NAD(P)+, or (2′-phosphate) 
nicotinamide adenosine dinucleotide, to generate β-NAAD(P)+, or (2′-phosphate) 
nicotinic acid adenosine dinucleotide, not consuming the β-NAD+ scaffold. All these 
molecules have been shown to be involved in Ca
2+
 signalling, although through 
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completely different pathways (Figure 1.6).
4, 6, 7, 13
 ARTs and PARPs use β-NAD+ as a 
co-substrate in their reactions, where they catalyze respectively the transfer of one unit 
of ADPR, or many branched polymers of ADPR, to amino acid protein residues (Figure 
1.6). Protein modification by ARTs would have a regulatory and signalling role, acting 
by inhibition of the normal activities of the protein acceptors. Regarding PARPs, a 
variety of these enzymes have been found in mammals; the best studied is PARP-1, for 
which the modification of the protein is triggered by breaks in the DNA and, therefore, 
it is involved in the DNA repair response and transcriptional activation. Another 
important PARP is tankyrase-1, which regulates the maintenance of telomere length 
(Figure 1.6).
4, 6, 7
 Finally, sirtuins use β-NAD+ as a co-substrate to mainly catalyze the 
deacetylation of proteins and generate NaM and 2′′(3′′)-acetate-ADPR, or 2′′(3′′)-OAc-
ADPR (Figure 1.6). The deacetylation of proteins is a fundamental regulatory biological 
process; hence, the interest toward sirtuins has increased since they appear to be 
involved in epigenetic, ageing and several human diseases.
5, 6
 In addition, the reaction 
product, 2′′(3′′)-OAc-ADPR, seems to be a signalling molecule involved again in Ca2+ 
release.
6, 7, 13
 Sirtuins could also have a secondary activity as ARTs, but it is still not 
clear in which conditions this activity would be stimulated (Figure 1.6).
14
 
Nucleotide pyrophosphatases (NPPs) and NAD
+
-dependent DNA ligases use β-NAD+ 
respectively as a substrate and a co-substrate.
15, 16
 Indeed, both enzymes catalyze the 
cleavage of the pyrophosphate bond to generate AMP and β-NMN (Figure 1.6); in the 
case of the DNA ligases, this reaction is in conjunction with the ligation of a single 
strand DNA break. With respect to AMP generated from NPPs, which are generally 
ecto-enzymes with the catalytic site in the extracellular space, this can be recycled by 
ecto-5′-nucleotidases to obtain adenosine, involved in purinergic signalling (Figure 
1.6).
17
 The other reaction product, β-NMN, is not a direct precursor of β-NAD+ in its 
biosynthesis, as will be shown in 1.1.3; nevertheless, there is evidence for the existence 
of enzymes that would generate precursors of β-NAD+ from β-NMN, such as NR or 
NaM.
18, 19
 These enzymes have not been well characterized yet in humans but highlight 
the existence of many pathways for the biosynthesis of β-NAD+. 
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Figure 1.6 NAD
+
 derivatives from NAD
+
-consuming enzymes activities and their functions. Ca
2+
-
signalling messengers in the blue boxes; purinergic signalling messenger from AMP, and β-NAD+ 
precursors from β-NMN in the green box; regulatory protein modifications (e.g. DNA repair, 
transcription activation, ageing) in the red box. The overlap between the boxes indicates the strong 
relations occurring between the activities of all these enzymes. Abbreviations used: NAD
+
, nicotinamide 
adenine dinucleotide; ADPR, adenosine diphosphate ribose; cADPR, cyclic ADPR; cADPRP, 2′-
phosphate cADPR; NADP
+, 2′-phosphate NAD+; NAADP+, 2′-phosphate nicotinic acid adenine 
dinucleotide; 2′′(3′′)-OAc-ADPR, 2′′(3′′)-acetate-ADPR; ADPRC, ADPR cyclase; NADase, NAD+-
glycohydrolase; NADK, NAD
+
 kinase; NPP, nucleotide pyrophosphate; PARP, polyADPR polymerase; 
ART, ADPR transferase; SIRT, sirtuins; DNA Lig, DNA ligase. 
Extremely important among the enzymes that transform but do not consume the β-
NAD
+
 scaffold is the NAD
+
 kinase (NADK); this enzyme catalyzes the phosphorylation 
of β-NAD+ on 2′-OH to give β-NADP+ (Figure 1.6).13 In turn, two other fundamental 
Ca
2+
-signalling messengers, β-NAADP+ and cADPRP (2′-phosphate cyclic ADPR), can 
be generated from β-NADP+ by the action of ADPRCs (Figure 1.6). 
β-NADP+, having the same reduction potential as β-NAD+, can undergo reduction on 
the nicotinamide ring to obtain β-NADPH. The concentration of the two dinucleotide 
couples is regulated by set of different enzymes; in particular, the concentration of β-
NADP
+
 is generally much lower than β-NAD+ for similar concentrations of β-NADPH 
and β-NADH (Table 1.1). Therefore, the β-NADP+:β-NADPH ratio is in favour of the 
b-NAD+
cADPR
ADPR
2’’(3’’)-OAc-ADPR
b-NAADP+ cADPRP
b-NADP+
Acceptor-ADPR
Acceptor-polyADPR
b-NMN + 
AMP
b-NAAD+
ADPRC
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reduced form, in contrast to what is observed for the β-NAD+:β-NADH ratio.13, 20 This 
fact reflects the importance of β-NADP+(H) on the balance of the intracellular redox 
state in response to cellular oxidative stress; indeed, the substantial free pool of β-
NADPH compared to β-NADH is needed to react and inactivate the reactive oxygen 
species (ROS), that are responsible for oxidative stress and, therefore, a significant 
cause of cellular damages. 
 
Metabolite Concentration [M] 
β-NAD+ 2.6 x 10-3 
β-NADH 8.3 x 10-5 
β-NADP+ 2.1 x 10-6 
β-NADPH 1.2 x 10-4 
Table 1.1 Intracellular metabolite concentrations in E. coli.
20
 
When extensive DNA damage occurs in cells, it triggers a cascade of enzyme activities 
responsible for DNA repair; PARP-1, one of the most important DNA-repair enzymes 
in mammals, begins to produce very long ADPR branches as part of its function, almost 
completely depleting the intracellular free pool of β-NAD+, and substantially altering 
the intracellular β-NAD+:β-NADH ratio. This change would dramatically reflect on the 
intracellular lack of β-NADH, hence in ROS protection; therefore, this underscores the 
importance of the free pool of β-NADPH to respond to cellular oxidative stress.13  
Moreover, the different ratios of β-NAD+(H) and β-NADP+(H) reflect another important 
difference between the two dinucleotide couples. While β-NAD+(H) is mostly in its 
oxidized form, hence it is used in oxidative catabolic reactions, β-NADP+(H), mostly 
present in its reduced form, is almost exclusively used in reductive anabolic reactions, 
where complex substances (e.g. carbohydrates, lipids, proteins) are formed by reductive 
steps from acetyl-CoA (Figure 1.7). This is a fascinating example of how nature has 
developed independent catabolic and anabolic pathways depending respectively on 
similar dinucleotides exploiting differently their reversible redox activity.
1
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Figure 1.7 Catabolic processes (blue arrow) mainly involving the reduction of β-NAD+ to β-NADH; 
anabolic processes (red arrow) involving the oxidation of β-NADPH to β-NADP+. 
1.1.3 β-NAD+ biosynthesis 
Since redox enzymes keep the β-NAD+(H) concentration constant while NAD+-
consuming enzymes use it in their reactions and decrease its concentration, β-NAD+(H) 
homeostasis in living cells is maintained by two different biosynthetic pathways that 
regenerate β-NAD+. These pathways are classified as the de novo pathway, in which β-
NAD
+
 is generated from tryptophan (Trp) by different enzyme-catalyzed steps, and the 
salvage pathway, where β-NAD+ is formed from recycling products, such as NaM, NA, 
also known as niacin or vitamin B3, and NR, which come from the depletion of β-
NAD
+
 or are introduced by diet into the cells (Figure 1.8).
18, 21
 The two different 
pathways converge at a certain point and share the same enzymes to give the final β-
NAD
+
. 
Different organisms show different preferences towards the de novo and salvage 
pathway; generally, the salvage pathway is preferred to the de novo one. In addition, 
different organisms exhibit clear preferences toward salvage pathway precursors: for 
instance, yeast prefers NA to NaM, since it expresses the enzyme nicotinamide 
deamidase, which deamidates NaM to NA, which is not present in mammals. In yeast 
and bacteria, another salvage precursor can be NR, which can be converted into β-NMN 
by NRK (NR kinase). 
anabolism
AcetylCoA
Carbohydrates, 
lipids, proteins
catabolism
b-
b- b-
b-
Chapter 1 
 
11 
 
In the salvage pathway of mammals, the precursor NaM is directly transformed to β-
NMN by the action of NaMPRT (NaM phospho-ribosyl transferase), which undergoes 
the coupling with AMP by NMNAT (NMN adenylyl transferase) to give β-NAD+. In 
yeast, NA, obtained from NaM by nicotinamide deamidase, is transformed in nicotinic 
acid mononucleotide (NAMN) by NAPRT (NA phospho-ribosyl transferase); then, 
NAMN is coupled to AMP by NAMNAT (NAMN adenylyl transferase) to give β-
NAAD
+
, which is amidated by NAD
+
-synthetase to finally give β-NAD+ (Figure 1.8). 
 
 
Figure 1.8 β-NAD+ biosynthesis and metabolism. De novo pathway (red box); salvage pathway (blue 
boxes); products from NAD
+
 metabolism (green boxes). Abbreviations used: Trp, tryptophan; QA, 
quinolic acid; QAPRT, QA phospho-ribosyl transferase; NA, nicotinic acid; NaM, nicotinamide; NAMN, 
nicotinic acid mononucleotide; NMN, NaM mononucleotide; NR, NaM ribonucleoside; NRK, NR kinase; 
N(A)MNAT, NaM (NA) mononucleotide adenylyltransferase; NAAD
+
, NA adenine dinucleotide; NAD
+
, 
NaM adenine dinucleotide; NAPRT, NA phospho-ribosyl transferase; NaMPRT, NaM phospho-ribosyl 
transferase; NADK, NaM adenine dinucleotide kinase; NADP
+
, 2′-phosphate NaM adenine dinucleotide; 
ADPR, adenine diphosphate ribose; ADPRC, ADPR cyclase; cADPR, cyclic ADPR; NPP, nucleotide 
pyrophosphatase; AMP, adenosine monophosphate; SIRT, sirtuins; 2′′(3′′)-OAc-ADPR, 2′′(3′′)-acetate-
ADPR; NADase, NAD
+
-glycohydrolase; ART, ADPR transferase; PARP, polyADPR polymerase. 
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Therefore, each organism has a similar set of enzymes (e.g. phospho-ribosyl 
transferases and adenylyl transferases) to perform the salvage pathway but with 
specificity depending on the favoured precursor. Structural studies of the active site of 
mammalian, yeast and bacterial enzymes involved in salvage pathways have shown 
substantial differences responsible for the different substrate specificity in spite of their 
same function; hence, although the sequence of reactions is conserved among different 
organisms, an evolutionary divergence has allowed them to differentiate the pathway 
specificity.
22
 
In the human salvage pathway the rate-limiting enzyme is NaMPRT, which catalyzes 
the phosphoribosylation of NaM from 5-phosphoribosyl-1-pyrophosphate with release 
of β-NMN and pyrophosphate, PPi. This enzyme is crucially involved in the β-NAD
+
 
biosynthesis and, therefore, in the activity of NAD
+
-consuming enzymes, responsible 
for many biological processes involved in human diseases; hence, there is an increasing 
interest toward NaMPRT as a therapeutic target.
21, 23
 Less crucial, but still important, is 
NMNAT, which catalyzes the adenylation of β-NMN from ATP with release of β-
NAD
+
 and PPi; also the control of its activity could potentially influence the metabolism 
of β-NAD+ and, therefore, have an impact on the cure of some human diseases.21 
In mammals, NA is essential due to its role as a precursor of β-NAD+. It can be obtained 
by diet or synthesized from Trp; consequently, lack of NA or Trp in the diet can cause 
pellagra in humans, a deficiency disease. Hence, the de novo pathway is fundamental to 
provide NA from Trp and β-NAD+ in mammals in the case of restricted NA availability. 
The de novo pathway synthesizes β-NAD+ starting from Trp through the kynurenine 
pathway (Scheme 1.1).
18
 The opening of the pyrrole ring of Trp in conjuction with its 
oxidation, catalyzed by indoleamine-2,3-dioxygenase (IDO) in most tissues and 
tryptophan-2,3-dioxygenase (TDO) in the liver, generates formylkynurenine; the latter 
is hydrolysed to L-kynurenine by kynurenine formamidase (KFase). L-Kynurenine 
undergoes hydroxylation in position 3 by kynurenine-3-hydroxylase (K3H) to give 3-
hydroxykynurenine, which is converted to 3-hydroxyanthranilic acid and L-alanine by 
kynureninase (kyase). Then, 3-hydroxyanthranilate-3,4-dioxygenase (3HAO) catalyzes 
the opening of the phenyl ring and its oxidation by insertion of molecular oxigen to give 
2-amino-3-carboxy muconate semialdehyde, which spontaneously cyclizes into 
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quinolinic acid (QA). The latter is transformed to NAMN by the action of quinolinate 
phospho-ribosyl transferase (QAPRT) (Figure 1.8); hence, the de novo pathway 
converges on the salvage pathway to finally give β-NAD+.  
The rate-limiting steps in the de novo pathway are the reactions catalyzed by IDO/TDO 
and QAPRT; the rates of these reactions influence the rate of the de novo pathway and 
strictly forces it toward the conjunction with the salvage pathway.
18
 IDO and K3H have 
shown to be potential therapeutic targets toward a wide class of human diseases.
21
 
 
 
Scheme 1.1 De novo pathway. Abbreviations used: L-Trp, L-tryptophan; IDO, indoleamine-2,3-
dioxygenase; TDO, tryptophan-2,3-dioxygenase; KFase, kynurenine formamidase; K3H, kynurenine-3-
hydroxylase; kyase, kynureninase; 3HAO, 3-hydroxyanthranilate-3,4-dioxygenase; N.E., not enzymatic. 
1.2 NAD+-consuming enzymes 
The main NAD
+
-consuming enzymes, their activities and reaction products have been 
highlighted in 1.1.2. Since the main product released from the activity of NAD
+
-
consuming enzymes is NaM, the principal salvage precursor for the biosynthesis of β-
NAD
+
 in mammals (Figure 1.8), it is clear that a strong relationship exists between the 
activity of these enzymes and the biosynthesis of β-NAD+; hence, every enzymatic 
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reaction and its substrates and products are connected in a delicate equilibrium which 
controls the homeostasis of such an essential molecule as β-NAD+.4-7, 18  
Herein, the attention will be focused on the relationship existing between the activities 
of NAD
+
-consuming enzymes, discussing how they influence each other and the 
extracellular and intracellular homeostasis of β-NAD+. Later, this chapter will present a 
short review of the existing synthetic NAD
+
 derivatives and their use as inhibitors for 
drug therapies, or biochemical tools for the development of assays to monitor the 
activity of NAD
+
-consuming enzymes. In this context, the project and its objectives will 
be introduced as an alternative and innovative solution to solve biochemical questions 
involving the NAD
+
-consuming enzymes. 
1.2.1 NAD+-consuming enzymes: similarities and relationships 
The majority of NAD
+
-consuming enzymes catalyze the cleavage of the nicotinamide 
N-glycosidic bond with consequent release of NaM. The cleavage of this bond is an 
exergonic reaction;
24
 in particular, the energy released is equal to -8.2 kcal·mol
-1 
(for 
comparison, the cleavage of ATP to generate ADP and Pi,
25
 a very well known 
exergonic reaction occurring in biochemical processes, is equal to -7.3 kcal·mol
-1
). 
Within cells, exergonic reactions are generally coupled with endergonic processes but, 
in the case of NAD
+
-consuming enzyme activities, it is not always clear what the energy 
released is used for. Indeed, the reaction products from their activities do not keep the 
energy released under the form of high-energy bonds, as often occurs in reactions using 
ATP; moreover, the catalytic mechanisms of NAD
+
-consuming enzymes do not justify 
the release of such a large amount of free energy. 
NAD
+
-consuming enzymes catalyzing the cleavage of the nicotinamide N-glycosidic 
bond have in common an NAD
+
-glycohydrolase activity; then, other enzymatic 
reactions can be coupled to this common one, for instance the cyclization of ADPR to 
cADPR (ADPRCs), the transfer of ADPR to protein acceptors (ARTs, PARPs), and 
protein deacetylation (sirtuins). The cleavage of the nicotinamide N-glycosidic bond by 
these enzymes occurs via a two-step mechanism resembling its chemical hydrolysis, 
where the ionization of the ribose diol stabilizes the formation of an oxocarbenium 
Chapter 1 
 
15 
 
intermediate accelerating the release of NaM (Figure 1.4). In the enzymatic catalysis, 
the interaction of 2′′-OH and 3′′-OH of the nicotinamide ribose with a carboxylic 
residue in the active site, would form a partial negative charge on the diol (Figure 1.9). 
The latter would exert an electron-donating effect on the ribose ring destabilizing the 
nicotinamide N-glycosidic bond and, therefore, favouring the release of NaM and the 
formation of an oxocarbenium intermediate.
8
 This intermediate, stabilized on the 
nicotinamide ribose by H-bonds, would then undergo different fates. 
 
 
Figure 1.9 Formation of an oxocarbenium intermediate during the NAD
+
-glycohydrolase activity of 
NAD
+
-consuming enzymes. A carboxylic acid residue stabilizes the oxocarbenium intermediate by H-
bonds, which can evolve afterwards into different compounds by nucleophilic attack on C-1′′. 
ADPRCs, NADases, PARPs, and ARTs mechanisms all proceed via the hypothetical 
oxocarbenium intermediate, as demonstrated by the presence in each of these enzymes 
of highly conserved glutamate residues.
8, 26-30
 Still controversial is the mechanism 
adopted by sirtuins; indeed, it could involve an SN1 reaction via the oxocarbenium 
intermediate,
31
 or an SN2 reaction with concurrent nucleophilic attack and elimination of 
NaM.
32
 The energy released by the cleavage of the nicotinamide N-glycosidic bond is 
temporarily conserved in the highly reactive oxocarbenium intermediate; however, the 
following transformations in which it is involved are not very endergonic reactions. For 
instance, in ADPRCs the cyclization of the intermediate into cADPR requires the 
adenine ring to turn from anti into syn conformation (Chapter 4, see 4.2.3);
26
 in 
NADases, the intermediate can undergo nucleophilic attack by water (hydrolysis) to 
form ADPR, or by other nucleophiles to undergo an exchange reaction;
24
 in ARTs and 
Chapter 1 
 
16 
 
PARPs the intermediate reacts with the nucleophilic residues of a protein acceptor to 
give an ADP-ribosylated acceptor;
28
 and, finally, in sirtuins the eventual oxocarbenium 
intermediate undergoes acetylation on 2′′(3′′)-OH to give 2′′(3′′)-OAc-ADPR and the 
corresponding deacetylated protein.
31
 Therefore, the energy conserved in the 
oxocarbenium intermediate is thought in part to be used for the former transformations, 
even if not highly endergonic, but also to be coupled to other biological processes, not 
immediately connected to the enzyme catalytic mechanisms. Hence, in the human 
ADPRC, CD38, it has been shown the necessity for this ecto-enzyme, that binds β-
NAD
+
 from the extracellular space, to dimerize to actively produce cADPR and 
transport it inside the cells (Figure 1.12); this process would require energy, which 
could come from the cleavage of the nicotinamide N-glycosidic bond.
33
 Furthermore, in 
PARPs the formation of ADPR branches as post-transcriptional modification is required 
as a signal to actively recruit other proteins involved in DNA repair, and energy would 
be needed in this process;
7
 in addition, but not yet fully demonstrated, the ADPR 
branches could be used as a source to synthesize ATP.
34
 Finally, in sirtuins the 
deacetylation of histones, proteins required for the compacting of chromatin, would be 
coupled to chromatin condensation, an active process for which the energy released 
could be used.
25
 
In contrast to ADPRCs, NADases, PARPs, ARTs and sirtuins, NPPs and NAD
+
-
dependent DNA ligases catalyze the exergonic cleavage of the β-NAD+ pyrophosphate 
bond; in both enzymes, the energy released is conserved by the formation of active 
enzyme-AMP complexes in the first step of their catalytic mechanisms. Afterwards, 
NPPs release AMP with an apparent loss of free energy (see 4.1, Scheme 4.1); by 
contrast, DNA ligases transfer the energy from the active enzyme-AMP complex to the 
active DNA-AMP complex, to eventually form the phosphodiester bond on the nicked 
DNA strand (see 5.1, Scheme 5.1). In the case of NPPs, the apparent loss of energy 
could be coupled to more complex biological processes, such as the formation of 
adenosine from AMP and, therefore, be linked to its role in purinergic signalling.
17
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It is interesting to study the complex relationship existing between the different NAD
+
-
consuming enzymes and how they influence major biological processes connected to 
many human diseases; a summary of the main effects exerted by these connections will 
be provided. An aspect shared by all those enzymes with NAD
+
-glycohydrolase activity 
(ADPRCs, NADases, PARPs, ARTs and sirtuins) is the inhibitory effect exerted by 
NaM, their reaction product, on their activities. High concentrations of NaM from the 
activity of any NAD
+
-consuming enzyme inhibit the activities of all the others; hence, 
the depletion of NaM via the salvage β-NAD+ biosynthetic pathway5, 18 is fundamental 
(Figure 1.10). In mammals, the activity of PARPs and CD38,
35
 having both ADPRC 
and NADase activities, is responsible for the depletion of large amounts of β-NAD+ at a 
very fast rate.
7
 Therefore, NaM produced by these enzymes can strongly inhibit sirtuins, 
which activity can be re-established by removal of NaM through the action of NaMPRT 
in mammals,
23
 or NaM deamidase (PNC1) in yeast
7
 to form precursors of β-NAD+. 
Since sirtuins are proposed to be involved in many critical biological processes 
(glucose, fat and insulin metabolism, ageing and life span increase, DNA transcription 
and repair, apoptosis), the regulation of their activity seems crucial; hence, it is 
important to develop sirtuins inhibitors/activators, or CD38/PARPs inhibitors to block 
the depletion of β-NAD+ that inhibits sirtuins.35 Since the activities of all these enzymes 
are important in cells, the choice of the process to block with a drug is crucial to avoid 
possible side effects. 
 
 
Figure 1.10 β-NAD+ metabolism and its influence on the activity of sirtuins. Abbreviations used: NAD+, 
nicotinamide adenine dinucleotide; NaM, nicotinamide; PARP, polyADPR polymerase; NaMPRT, NaM 
phospho-ribosyl transferase. 
b-NAD+ NaM sirtuins inhibitionsirtuins activation
CD38,PARPs
NaMPRT (mammals)
NaM deamidase (yeast)
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Sirtuins, PARPs and DNA ligases are intracellular enzymes involved in DNA repair 
processes (Figure 1.11).
36
 When DNA damages occur in the cells, PARP-1 starts 
immediately its ADP-ribosylation or that of other proteins as a signal to trigger the 
recruitment to the DNA break of all proteins involved in DNA repair process (1). The 
formation of branches of ADPR, up to 200 units in length, occurs in a very short time 
and almost completely depletes the free intracellular β-NAD+ pool with a huge increase 
of NaM concentration in the proximity of the DNA break.
7
 The latter affects the activity 
of sirtuins, strongly inhibited by NaM (2), which therefore are not able to deacetylate 
histones (3).
5
 Therefore, the DNA is unwound because of the fully acetylated histones 
in chromatin and the proteins for the DNA repair, including DNA ligases, can move 
close to the DNA and interact with it to fix its damage. When ADPR branches have 
reached the critical length, PARP-1 decreases its activity and, consequently, the NaM 
concentration near to the DNA break decreases as well; then, sirtuins can deacetylate 
histones re-compacting again the chromatin (4).
36
 However, the inhibition of sirtuins 
can affect the activity of other biological processes. For instance, sirtuins can 
deacetylate p53, a protein responsible for DNA repair or apoptosis when the DNA 
damage is irreparable; p53 acetylation (7), in the case of the inhibition of sirtuins, 
corresponds to its activation and, therefore, to cell apoptosis (8). On the other hand, 
sirtuins can deacetylate FOXO transcription factors, involved as well as p53 in 
apoptotic processes; oppositely to the effect exerted on p53, FOXO acetylation (5), in 
the case of the inhibition of sirtuins, corresponds to their deactivation and, therefore, to 
cell survival (6).  
Moreover, a PARP-overstimulation leads directly to cell apoptosis (9) because of the 
complete depletion of the intracellular β-NAD+ pool, which cannot be formed in a short 
time by the β-NAD+ biosynthetic pathways. Conversely, the inhibition of PARPs can be 
connected to cell survival (18), despite the loss in DNA repair response, because it leads 
to the activation of sirtuins (11). The latter effect can in turn lead to apoptosis or cell 
survival depending on the activity exerted respectively on FOXO transcription factors 
(14) or p53 (16)/histones (12). Hence, the inhibition/activation of sirtuins by PARP 
activity can result in completely different cellular fates depending on the main cellular 
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responses and their activation times compared to the DNA repair processes (Figure 
1.11).
36
 
 
 
Figure 1.11 Inhibition/activation of sirtuins by the activity of PARPs in response to DNA damage. Cells 
can undergo different fates (1-18) depending on the related activities of sirtuins and PARPs and their 
modes of action. FOXO (Forkhead box proteins, class O) are involved in cellular proliferation, lifespan 
and stress tolerance. p53 (protein 53) is a tumor suppressor. 
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1.2.2 Intracellular and extracellular β-NAD+ balance 
A delicate balance exists between extracellular and intracellular β-NAD+ concentration 
in multicellular organisms to regulate the functions of such a fundamental biological 
molecule.
37
 It has been estimated that in multicellular organisms extracellular β-NAD+ 
concentration is normally in the order of submicromolar range (10 – 50 nM), much 
lower than the intracellular one (0.1 – 3 mM).7 These concentrations are the result of the 
activities of an intricate network of nucleoside/nucleotide receptors and NAD
+
-
consuming enzymes that keep a constant extracellular balance between β-NAD+ and its 
degradation products, regulating the release of intracellular β-NAD+ and its degradation 
outside the cells (Figure 1.12).
38, 39
  
The main cause of intracellular β-NAD+ release and, consequently, extracellular β-
NAD
+
 increase is cellular apoptosis and lysis. In addition, β-NAD+ transporters 
(Connexin 43 transmembrane hemi channels) have recently been identified as 
responsible for the influx/efflux of β-NAD+ into/outside the cells, allowing the 
regulation of its concentration in response to different biological processes, and to 
modulate intercellular communications.
40
 Indeed, it has been shown that extracellular β-
NAD
+
 concentration substantially increases during inflammatory responses, since β-
NAD
+
 can act as a cytokine that triggers signalling cascade responses through its 
binding to specific purinergic receptors. For instance, its binding to P2Y11 causes an 
elevated intracellular Ca
2+
 release and cAMP (cyclic AMP) changes leading to anti-
inflammatory responses (Figure 1.12).
37, 39, 41
  
Extracellular β-NAD+ homeostasis is further controlled by its degradation through the 
activities of some NAD
+
-consuming enzymes, for instance mammalian ADPRC 
(CD38), NADases, ARTs and NPPs. All these enzymes belong to the ecto-enzyme 
class, characterized by the presence of their catalytic active site in the extracellular 
space. As discussed in 1.1.2, they catalyze the cleavage of extracellular β-NAD+ to 
generate signalling molecules (e.g. cADPR, ADPR, β-NAADP+) or protein ADP-
ribosyl modifications that potentially act in the intracellular space. Hence, it emerges the 
paradox of these enzymes, that are active in the extracellular space but involved in 
intracellular processes (e.g. Ca
2+
 release, post-transcriptional modifications, regulation 
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of intracellular sirtuins and PARPs activities).
7
 The first issue in solving this paradox is 
due to the low extracellular β-NAD+ concentration, below the Km of NAD
+
-consuming 
enzymes, which makes their activity rate very low. However, this allows to modulate 
finely their activity, since even small increases in extracellular β-NAD+ concentration 
by the action of β-NAD+ transporters,40 favouring the release of intracellular β-NAD+ in 
the extracellular space, could dramatically increase the activity of ecto NAD
+
-
consuming enzymes. 
Another issue is the connection between the extracellular activity of these enzymes and 
the triggered intracellular processes. In the case of the cyclase activity of CD38, mostly 
present as an ecto-enzyme, the extracellular β-NAD+ is bound into the catalytic site to 
generate cADPR, which stimulates intracellular Ca
2+
 release from the endoplasmic 
reticulum. The discovery of the dimerization and internalization of CD38 to catalyze the 
enzymatic reaction and actively transport the product inside the cell explained the link 
between the extracellular β-NAD+ binding site and the intracellular product release.33 
Moreover, specific cADPR-transporters have been found in the cellular membrane, 
responsible for the intracellular uptake of cADPR.
42
 Regarding the NADase activity of 
CD38, it generates extracellular ADPR, which promotes intracellular Ca
2+
 release
41
 via 
pathways mediated by IP3 (inositol 1,4,5-triphosphate), possibly binding to the 
extracellular P2Y purinergic receptor.
43
 This process is completely independent from 
the Ca
2+
-permeable TRPM2 channel transport, which mediates intracellular Ca
2+
 release 
from internal compartments and/or Ca
2+
 influx from the extracellular space by the 
action of second messengers, such as intracellular ADPR (produced by degradation of 
ADPR branches), cADPR, 2′′(3′′)-OAc-ADPR (produced by sirtuins) and β-NAADP+.43 
The extended activation of this non-selective cation channel causes cell death. β-
NAADP
+
, generated by the exchange activity of CD38 from extracellular β-NADP+, can 
be, in turn, transported inside the cells via specific β-NAADP+ transporters (Figure 
1.12).
44
 
Mammalian ARTs have been discovered quite recently and most of them are classified 
as ecto-enzymes, therefore acting in the extracellular space and generating ADP-ribosyl 
modifications of extracellular proteins; in particular, they are involved in receptor 
modifications and triggering signalling cascades during immune and inflammatory 
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responses.
7
 For instance, in mouse T-cells the ADP-ribosylation of the purinergic 
receptor P2X7 by ART2 induces its activation and a cascade of signalling processes, 
finally leading to cell death.
37
 A large number of intracellular proteins undergo ADP-
ribosylation, which cannot be ascribed to ecto-ARTs; therefore, the existence of 
intracellular ARTs or the secondary ART activity of sirtuins
14
 would be responsible for 
intracellular modifications (Figure 1.12).
7
 
Finally, NPPs, as well as the previous enzymes, belong to the ecto-enzymes class. The 
presence of NPPs on the cellular surface is fundamental for the recycling of 
extracellular nucleotides and for keeping the balance between nucleotides/nucleosides. 
For instance, the CD38-generated ADPR can be transformed by NPPs into AMP, which 
in turn can be hydrolysed into adenosine (Ado), which is able to bind to purinergic 
receptors and stimulate signalling responses (Figure 1.12). 
 
 
Figure 1.12 Pathways for the extracellular/intracellular β-NAD+ balance. Abbreviations used: NAD+, 
nicotinamide adenine dinucleotide; ADPR, adenosine diphosphate ribose; cADPR, cyclic ADPR; 
NAADP
+, 2′-phosphate nicotinic acid adenine dinucleotide; 2′′(3′′)-OAc-ADPR, 2′′(3′′)-acetate-ADPR; 
AMP, adenosine monophosphate; Ado, adenosine; Cx43, Connexin 43; ART2, ADPR transferase 2; NPP, 
nucleotide pyrophosphatase. 
All these ecto-enzymes are therefore involved, not only in the homeostasis of 
extracellular β-NAD+, but in fundamental signalling pathways, where activation triggers 
anti-inflammatory and immunosuppressive responses. The increased extracellular β-
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NAD
+
 concentration in connection with increased expression of NAD
+
-consuming ecto-
enzymes and purinergic receptors is the effect observed following cellular stress at the 
beginning of inflammatory responses; tumor cells seem to modulate these interactions 
to escape the immune response.
39
 
Intracellular β-NAD+, as already shown in 1.1.3, is synthesized in the cytosol by the 
salvage or de novo pathways and used by intracellular enzymes, such as redox (NAD
+
-
dependent dehydrogenases) and NAD
+
-consuming enzymes (PARPs, sirtuins, NAD
+
-
dependent DNA ligases). Some of these enzymes perform their crucial activities inside 
the mitochondria, where an appropriate β-NAD+:β-NADH ratio is fundamental for a 
variety of biological processes; however, for a long time it was thought that β-NAD+(H) 
was unable to permeate the mitochondrial membrane. Recently, a mitochondrial β-
NAD
+
 transporter, Ndt1p, has been identified in Saccharomyces cerevisiae as a specific 
β-NAD+ carrier. It imports β-NAD+ into the mitochondria preferentially by exchange 
with mitochondrial deoxy-AMP (dAMP) and deoxy-GMP (dGMP), and to a small 
extent by uniport reaction (Figure 1.12).
45
 
1.3 NAD+ derivatives as mechanistic probes for NAD+-dependent enzymes 
As shown in the previous sections, NAD
+
-dependent enzymes play a fundamental role 
in many biological processes and alterations and modifications to their normal status are 
linked to several human diseases. Therefore, the necessity to investigate and, eventually, 
modulate or block NAD
+
-dependent enzymes has led to the development of NAD
+
 
derivatives that mimic the natural substrate (NS) and act either as non-natural substrates 
(NNSs) for biochemical applications or potential enzyme inhibitors for drug discovery.  
In general, designing derivatives of the natural substrates requires minor modifications 
of the natural molecule scaffold in order to keep intact the essential groups interacting 
with the enzymes and allowing its binding to the catalytic sites. Then, depending on the 
modifications, it is possible to generate NNSs, that are metabolized with the same 
fashion as the NS, and are consequently its competitive inhibitors; or, simply, enzyme 
inhibitors, if the modifications allow their binding but not their metabolism by the 
enzymes. In the development of NAD
+
 derivatives it is therefore necessary to look at 
the natural β-NAD+ structure and identify the chemical groups that can be subjected to 
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modifications; then, depending on the need of inhibitors or NNSs, the right 
modifications have to be considered.  
In the design of inhibitors, if the enzyme structure and mechanism are well known, the 
modifications are aimed to block essential groups for the catalytic reactions. In contrast, 
in the design of NNSs, the modifications are needed to investigate and monitor the 
enzyme structure and/or the related mechanism, without consequently affecting the 
essential interactions responsible for the enzymatic catalytic mechanisms. For instance, 
an ideal NNS should have an enzyme affinity similar or higher compared to the NS (Km 
NNS ≤ Km NS) to bind properly in the active site. In addition, a kcat (turnover number) 
lower than the NS (kcat NNS < kcat NS) would allow a slower metabolism of NNS by the 
enzyme, permitting in some cases easier kinetic studies and mechanism visualizations 
without altering the reaction mechanism itself. By definition, NNSs are competitive 
inhibitors of the NS; however, if their Km and kcat are similar to the NS, the enzyme 
activity will not be inhibited overall, since both substrates can be used with the same 
efficacy. If their Km and kcat are lower (higher affinity and slow turnover) compared to 
the NS, then the final effect will be a slowdown of the enzymatic reaction and, 
therefore, inhibition; hence, under such conditions, NNSs can be potentially used as 
enzyme inhibitors or modulators, or at least give the basis for the design of new 
inhibitors. In addition, in the design of NNS, the labelling of the natural molecule 
scaffold by groups monitored by sensitive techniques, such as fluorescence, UV 
absorbance and immunoanalytical methods, can be extremely useful for the 
development of assays that are more sensitive compared to those using the NS. The 
labelling of nucleosides/nucleotides with the purpose to generate fluorescent probes will 
be discussed in detail in Chapter 3, where the attention will be focused on the 
nucleobase substitutions; however, the ribose or phosphate conjugation with 
fluorophores by linkers,
46-48
 where the length is crucial to avoid steric hindrances with 
the substrate, is a common labelling method. Also, the introduction of biotin on the 
natural molecule scaffold represents a useful labelling method, allowing very sensitive 
detections and selective purification due to the strong affinity of biotin and 
streptavidin.
49
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The structure of β-NAD+ is characterized by a variety of functional groups, that are 
involved differently in enzyme recognitions and activities; therefore, their modifications 
lead to different responses to different enzymes (Figure 1.13).  
 
 
Figure 1.13 Relationship between group modifications on β-NAD+ structure and specific enzyme 
responses. NaM (green box) and nicotinamide ribose (purple box) modifications lead to the inhibition of 
dehydrogenases (DHs) and enzymes with NAD
+
-glycohydrolase activity (ADPRCs, NADases, ARTs, 
PARPs, sirtuins). Pyrophosphate bond (yellow box) modifications lead to the inhibition of nucleotide 
pyrophosphatases (NPPs). Adenine (blue box) modifications lead to the inhibition of sirtuins (SIRT) and 
NAD
+
-dependent DNA ligases. 
Dehydrogenases (DHs), which use the nicotinamide ring for its redox activity, are 
mainly inhibited by its modification. NAD
+
-consuming enzymes that share the NADase 
activity (ADPRCs, NADases, ARTs, PARPs, sirtuins, see 1.2.1) are especially inhibited 
by NaM/NR modifications, since the formation of an oxocarbenium intermediate is 
crucial for their catalytic mechanisms (Figure 1.9). NPPs are mainly inhibited by 
pyrophosphate bond modifications, since they catalyze its cleavage. Finally, NAD
+
-
dependent DNA ligases and sirtuins, which closely interact with the adenine moiety of 
β-NAD+ in their catalytic sites (see Chapter 5, respectively 5.1 and 5.2), can be inhibited 
by adenine modification in particular positions. By aiming for selective inhibitions 
following specific modifications, hypothetically it should be possible to design NNSs of 
NAD
+
-dependent enzymes by modifying the chemical groups not involved in their 
inhibition.  
  
NPPs inhibitors
DHs/NADases
inhibitors
SIRT/DNA Lig
inhibitors
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1.3.1 NAD+ derivatives as inhibitors of NAD+-dependent enzymes 
1.3.1.1 Nicotinamide modification 
NaM is an essential component of β-NAD+, required for its recognition/binding to 
several enzymes as well as for their activities. Indeed, the nicotinamide portion is 
responsible for the β-NAD+ redox activity, hence for its use as a co-substrate by DHs; in 
addition, its positive charge makes the nicotinamide N-glycosidic bond extremely labile, 
allowing the use of β-NAD+ as a substrate/co-substrate of NAD+-consuming enzymes. 
The modification of NaM is effective in generating inhibitors, NAD
+
-like or not, for 
NAD
+
-dependent DHs and NAD
+
-consuming enzymes. A variety of studies aimed at 
the discovery of inhibitors for important DHs have been focused on the nicotinamide 
substitution within the β-NAD+ structure with a variety of aryl/heteroaryl rings (Figure 
1.14, benzamide 1, C-nicotinamide 2, picolinamide 3, isonicotinamide 4, thiazole-4-
carboxamide 5, and many others). These main substitutions, in combination with ribose 
and pyrophosphate bond modifications, have successfully brought the development of 
effective inhibitors of DHs.
50, 51
 Some of the DH inhibitors have been found to inhibit 
also NADK, responsible for the phosphorylation of the 2′-OH of β-NAD+ to generate β-
NADP
+
.
52
  
As mentioned in 1.2.1, NaM, the reaction product of ARTs, PARPs, sirtuins, ADPRCs 
and NADases activities, is a common inhibitor for these enzymes, in particular as a 
competitive inhibitor for ARTs and PARPs,
53, 54
 a non-competitive inhibitor for 
sirtuins,
55
 and a mixed inhibitor for ADPRCs
56
 and NADases.
24
 Many nicotinamide 
derivatives have been developed as potential inhibitors for these enzymes (e.g. 8-13) 
(Figure 1.14). All the developed nicotinamide derivatives contain in their structure 
essential features to act as inhibitors of ARTs, PARPs and sirtuins. For instance, a 
primary or secondary amide, responsible for the interactions between NaM and the 
enzyme active sites, is engaged in H-bonding by its carbonyl and amine groups,
31
 and 
its anti conformation is specifically required for the compounds activity toward ARTs 
and PARPs. In addition, an aromatic ring more electron-rich than the pyridine, and a 
non cleavable bond contribute to the inhibitory activity of nicotinamide derivatives.
53, 54
 
β-NADH (14) and β-NAAD+ (15), where NaM is substituted with the reduced pyridine 
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ring and NA respectively, act as inhibitors of sirtuins.
57
 Moreover, BAD (1), AAD (16) 
and HHD (17) inhibit ADPRCs activity (Figure 1.14).
58
 All these inhibitors give an 
example of the essential nature of the nicotinamide portion for the activity of NAD
+
-
dependent enzymes. 
 
 
Figure 1.14 Inhibitors of DHs, NADKs, ARTs, PARPs, sirtuins, ADPRCs and NADases based on 
nicotinamide modifications. Abbreviations used: NAD
+
, nicotinamide adenine dinucleotide; BAD, 
benzamide adenine dinucleotide; C-NAD, C-nicotinamide adenine dinucleotide; C-PAD, C-picolinamide 
adenine dinucleotide; NADH, nicotinamide adenine dinucleotide (reduced form); NAAD
+
, nicotinic acid 
adenine dinucleotide; AAD, bis-adenine dinucleotide; HHD, bis-hypoxanthine dinucleotide. 
Acceptor H-bonding
Donor H-bonding
Not cleavable bond
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1.3.1.2 Nicotinamide ribose modification 
The nicotinamide ribose plays a fundamental role in the activities of NAD
+
-dependent 
enzymes. In particular, as shown in 1.2.1, it is actively involved in the reaction 
mechanisms of NAD
+
-consuming enzymes with a common NADase activity due to the 
formation of a stabilized oxocarbenium intermediate. Its modification has been 
undertaken to generate inhibitors for NAD
+
-consuming enzymes, such as ARTs, 
PARPs, sirtuins, ADPRCs and NADases. However, it has also been targeted to improve 
the efficacy of inhibitors for DHs
50
 and NADKs.
52
 The most common modifications of 
the nicotinamide ribose have been suggested by the knowledge of the reaction 
mechanism for enzymes with NADase activity (Figure 1.9). The substitution of O-1 of 
the ribose with a methylene group (CH2) causes the loss of stabilization of the 
oxocarbenium intermediate by the oxygen lone pairs; therefore, the replacement of the 
ribose ring with a 2,3-dihydroxycyclopentane ring generates a dinucleotide 
diastereomers mixture, containing carba-NAD
+
 (1, with D-2,3-dihydroxycyclopentane 
ring) and pseudo carba-NAD
+
 (2, ψ carba-NAD+, with L-2,3-dihydroxycyclopentane 
ring) (Figure 1.15).
59
 In particular, ψ carba-NAD+ is more active than carba-NAD+ as an 
inhibitor of ARTs, PARPs, sirtuins, NADases and CD38,
54, 60
 while both derivatives are 
inactive toward ADPRC from Aplysia californica,
60
 shown to be insensitive to ribose 
modifications.
58
 By contrast to its inhibitory properties toward enzymes with NADase 
activities, carba-NAD
+
 acts as a NNS for DHs, while ψ carba-NAD+ is completely 
inactive.
59
  
The substitution of the 2′′-OH of the nicotinamide ribose with a fluorine (F) deletes its 
H-bonding interactions with glutamate residues or electron-withdrawing groups in the 
active site, which help in stabilizing the oxocarbenium intermediate. Further 
modifications, such as the change of the ribose with arabinose, where the 2′′-OH (F) 
points toward the other face of the ribose; or the removal of the 2′′-OH in 2′′-deoxy 
nicotinamide ribonucleoside derivatives,
61
 achieve the same destabilizing effect on the 
oxocarbenium intermediate. Therefore, 2′′-deoxy nicotinamide ribonucleoside 
derivatives (3-5), 2′′-FNAD+ (6), ara-NAD+ (7), ara-2′′-FNAD+ (8) and ara-2′′-FNMN 
(9) are all good inhibitors of NAD
+
-dependent enzymes (Figure 1.15), in particular of 
DHs, in combination with nicotinamide modifications,
50
 NADKs,
52
 NADases,
62
 and 
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CD38.
30, 61, 63
 Finally, the change of nicotinamide ribose conformation from β-D-ribose 
to α-D-ribose generates α-NAD+ that inhibits sirtuins.57 
 
 
Figure 1.15 Inhibitors of DHs, NADKs, sirtuins and NADases based on nicotinamide ribose 
modifications. Abbreviations used: NAD
+
, nicotinamide adenine dinucleotide; 2′′-FNAD+, 2′′-
fluoroNAD
+
; ara-NAD
+
, arabinose-NAD
+
; ara-2′′-FNAD+, arabinose-2′′-fluoroNAD+; ara-2′′-FNMN, 
arabinose-2′′-fluoro nicotinamide mononucleotide. 
1.3.1.3 Pyrophosphate bond modification 
The β-NAD+ structure is largely dynamic because of the variety of flexible bonds and 
rotational angles that it can assume in generating different conformations.
64
 The 
pyrophosphate bond that joins the two nucleosides is the most flexible part of the 
molecule because of the three dihedral angles, ζ, α and γ, able to rotate and confer 
different orientations and conformations to the nucleosides (Figure 1.16). Due to its 
high flexibility, the pyrophosphate bond is generally not strictly involved in recognition 
by enzymes. However, its modification in the synthesis of dinucleotide derivatives is 
very important because it confers stability to potential inhibitors or NNSs against in vivo 
enzymatic degradation by nucleases, which are often responsible for the cleavage of 
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nucleic acid phosphodiester or dinucleotide pyrophosphate bonds. Therefore, 
modifications of the pyrophosphate bond have been used to inhibit nucleases, or, in the 
particular case of β-NAD+, NPPs.65 However, its coupling to other modifications has 
allowed generation of effective DHs, NADKs and NAD
+
-consuming enzyme inhibitors. 
The most common modifications on the pyrophosphate bond (Figure 1.16) involve the 
substitution of the oxygen bridge between the two phosphates with a CH2 or 
difluoromethylene (CF2) group to generate phosphonate derivatives (1, 2).
50, 66
 These 
modifications do not alter the three-dimensional shape of the molecule since the size of 
these groups is similar to the oxygen, but they do provide resistance to attack by 
nucleases and make the dinucleotides more lipophilic and able to penetrate inside cells. 
Moreover, CF2 is a better bioisostere than CH2, since the electron-withdrawing effect of 
the fluorine atoms increases the pKa of the phosphate groups, making them more similar 
to the natural pyrophosphate bond. Other substitutions
67
 can be the introduction of 
phosphatephosphonate groups (3, 4), sulphonamide groups (5), amidephosphonate 
groups (6), thioethylenephosphonate (7) or disulphide
68
 (8) groups.  
 
 
Figure 1.16 Inhibitors of DHs, NADKs and NPPs based on pyrophosphate bond modifications. 
Abbreviations used: NAD
+
, nicotinamide adenine dinucleotide. 
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1.3.1.4 Adenine modification 
The adenine moiety in β-NAD+ is fundamental for recognition and binding by enzymes. 
With the exception of NAD
+
-dependent DNA ligases, sirtuins and ADPRCs, DHs, 
NADKs and all other NAD
+
-consuming enzymes do not actively involve the adenine 
moiety in their catalytic mechanisms. Therefore, its modification within the β-NAD+ 
structure is generally aimed at the synthesis of NNSs for these enzymes. As discussed in 
1.3, the NNS activity implies a competitive inhibition with β-NAD+. Hence, from the 
design of NNSs with high affinity for the enzyme (low Km) and slow turnover (low kcat), 
it is possible to generate effective inhibitors. The latter is a common case and a good 
example is given by NNSs for ADPRC from Aplysia californica. This enzyme has 
shown broad substrate tolerance related to the adenine moiety, which has been 
substituted with guanine (1), hypoxanthine (2), xanthine and ε-adenine to generate 
NNSs which are also good inhibitors for ADPRC (Figure 1.17).
58, 69
  
Whilst the NNS activity often coincides with the competitive inhibition of the NS, the 
reverse is not always true. For instance, 8-aryl/heteroaryl NAD
+
 derivatives are 
inhibitors but not NNSs for sirtuins (3, Figure 1.17),
70
 indicating that the substitutions in 
position 8 on the adenine ring allow the binding of the compounds to the enzyme active 
site but inhibit their metabolism (see 5.2.2). Another example is given by 2-fluoroNAD
+
 
(2-FNAD
+
) (4, Figure 1.17);
71
 indeed, this compound is cleaved by ADPRC from 
Aplysia californica on the nicotinamide N-glycosidic bond, but its cyclization is 
inhibited by the fluorine in position 2 on the adenine ring, with consequent release of 2-
FADPR. Therefore, the compound acts as a substrate for the NADase activity of 
ADPRC, but as an inhibitor toward its main cyclase activity. 
Beyond the adenine-modified NAD
+
 derivatives, adenine-based compounds (5) and 
adenine-modified adenosine derivatives (6, 7) (Figure 1.17) have been developed, 
respectively, as inhibitors of sirtuins
72
 and NAD
+
-dependent DNA ligases,
73, 74
 
indicating the strong influence of the adenine moiety in both enzymes.  
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Figure 1.17 Inhibitors of ADPRCs, NPPs, sirtuins and DNA ligases based on adenine modifications. 
Abbreviations used: NAD
+
, nicotinamide adenine dinucleotide; NGD
+
, nicotinamide guanine 
dinucleotide; NHD
+
, nicotinamide hypoxanthine dinucleotide; 2-FNAD
+
, 2-fluoroNAD
+
. 
1.3.2 NAD+ derivatives as non-natural substrates of NAD+-dependent enzymes 
The development of NNSs can help to investigate the active sites and catalytic 
mechanisms of enzymes. Therefore, targeted modifications and labelling are required to 
generate useful biochemical tools. As mentioned in 1.3.1.4, the adenine modifications 
are generally aimed at the synthesis of NNSs for NAD
+
-dependent enzymes. The 
adenine base has been modified preferentially in a few favourite positions, such as N-1, 
NH2 in 6 position and C-8 position. The correlation between different NNS activities 
and the modifications in different positions highlight the structure and the fundamental 
interactions occurring between the β-NAD+ scaffold and the active sites of enzymes. 
However, modifications on the nicotinamide ring can also generate NNSs for NAD
+
-
dependent enzymes, as long as they keep unchanged the labile N-glycosidic bond or the 
redox activity of the nicotinamide ring that is still used as a substrate. 
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NNSs for DHs have mostly been modified in N-1 (4-6), NH2 in 6 position (1, 2, 7-9) or 
both (3) on the adenine ring (Figure 1.18).
75, 76
 Other NAD
+
 derivatives have been 
synthesized substituting the amide group on the pyridine ring (14-18), still maintaining 
its redox activity (Figure 1.18).
77, 78
 Different DHs have shown selective specificities 
toward the differently substituted NAD
+
 derivatives, demonstrating the existence of 
structural differences within the same class of enzymes.  
 
 
Figure 1.18 NAD
+
 derivatives with NNS activities toward NAD
+
-dependent enzymes. Abbreviations 
used: NAD
+
, nicotinamide adenine dinucleotide; NHD
+
, nicotinamide hypoxanthine dinucleotide; NFD
+
, 
nicotinamide formycin dinucleotide; ε-NAD+, 1,N6-etheno-NAD+; NGD+, nicotinamide guanine 
dinucleotide; NXD
+
, nicotinamide xanthine dinucleotide; 3AcPAD
+
, 3-acetyl pyridine adenine 
dinucleotide; 3AlPAD
+
, 3-aldehyde pyridine adenine dinucleotide; thio-NAD
+
, thio-nicotinamide adenine 
dinucleotide; ADPR-pNP, adenosine diphosphate ribose para-nitrophenol. 
NNSs for NAD
+
-consuming enzymes have mostly been modified on the adenine ring 
(1, 3, 10-13, Figure 1.18). Also in this case, each enzyme has shown preferences toward 
particular substrates depending on their active site. For example, PARPs has shown 
preferences toward 12 compared to 1 or 3,
79
 indicating the importance of a free amino 
group on the adenine ring; and, furthermore, PARPs, sirtuins and NADases have higher 
affinity for 10 compared to 11.
14, 80, 81
 In addition, some of the pyridine-modified 
derivatives have been used as NNSs for sirtuins (14, 18, 19),
57
 and PARPs (21).
82
 Many 
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substitutions introduced in the NNSs shown in Figure 1.18 have allowed the 
development of binding and kinetic assays for NAD
+
-dependent enzymes, as discussed 
in the next section. 
At this point it is worth to introduce the most common NNS of β-NAD+, 1,N6-etheno-
NAD
+
 (ε-NAD+, Figure 1.19), which has been used since the 1970s to investigate many 
NAD
+
-dependent enzymes.
83
 Its structure is characterized by the introduction of an 
etheno bridge between the N-1 and the exocyclic amino group in 6 position on the 
adenine ring; this modification, extending the electron delocalization along the adenine 
ring, makes the latter strongly fluorescent. Owing to this property, ε-NAD+ has been 
extensively used as a fluorescent probe for NAD
+
-dependent enzymes; indeed, the small 
modification on the adenine ring does not generally interfere with binding to enzyme 
active sites, allowing structural studies of the relevant enzymes. Moreover, changes in 
fluorescence following the enzymatic metabolism of the compound by the action of 
NAD
+
-consuming enzymes have allowed the development of fluorescence-based assays 
for accurate kinetic and mechanistic studies, which will be examined later in this 
chapter; the characteristic fluorescence properties of this compound and its derivatives 
will also be considered further in Chapter 3 (see 3.7.1).  
 
 
Figure 1.19 Chemical structure of ε-NAD+. 
Despite its extensive use for the study of many NAD
+
-dependent enzymes, ε-NAD+ has 
shown some limitations due to its modification on the adenine ring. Indeed, as will be 
shown later, ε-NAD+ is not a good substrate for PARPs (see 1.4.2), ADPRC from 
Aplysia kurodai
56
 and some NPPs (see 4.1.2). Moreover, its use for the investigation of 
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sirtuins and NAD
+
-dependent DNA ligases has never been reported, indicating its 
unsuitability to act as an inhibitor and/or NNS toward these enzymes. Hence, the 
development of novel classes of NAD
+
 derivatives with different features compared to 
ε-NAD+ would provide a better insight into the knowledge of many NAD+-dependent 
enzymes. 
1.4 Assays for NAD+-consuming enzymes 
The investigation of enzyme structures, reaction mechanisms and kinetic measurements 
is fundamental to the understanding of the enzyme activities and how they correlate to 
major biological processes. Therefore, the development of NNSs as biochemical probes 
allows us to answer several biochemical questions. As previously discussed, the 
chemical modification of different positions on adenine or pyridine rings, and how they 
influence the corresponding NNS activities, provides an improved understanding of the 
active site structure and the requirement of fundamental moieties in the natural molecule 
scaffold. Moreover, the labelling of NNSs with groups that are detectable by sensitive 
techniques allows the development of more sensitive binding, kinetic and screening 
assays, compared to those using the NS. These assays generally exploit the labelled 
NNSs or the corresponding reaction products to monitor their consumption/formation in 
a continuous or non-continuous format by sensitive techniques. Alternatively, the 
labelling of the remaining β-NAD+ or reaction products can be performed in a second 
step of the assay to provide steady-state/endpoint measurements of the enzymatic 
activities.  
Herein, attention will be focused on the existing assays and their principles to monitor 
the activities of NAD
+
-consuming enzymes. As will be shown, assays in a continuous 
format have been generally developed for those enzymes having β-NAD+ as the only 
substrate. In contrast, steady-state/endpoint assays have been the only way to monitor 
the activity of NAD
+
-consuming enzymes that have more than one substrate involved in 
their reaction. Indeed, the different complexities of the reaction mechanisms involving 
one or more substrates reflects on the substrate/co-substrate binding specificity, which 
becomes higher if the enzyme has to coordinate the entrance, binding in the active site 
and metabolism of more than one substrate. Therefore, the development of labelled 
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NNSs which are tolerated by enzymes with complex reaction mechanisms is an open 
challenge. In this perspective, novel classes of NAD
+
 derivatives with NNS activities 
toward NAD
+
-consuming enzymes could be exploited for the development of new 
advantageous assays.  
1.4.1 Cyanide and dehydrogenase assays 
One of the oldest methods to detect NAD
+
-consuming enzyme activities is the reaction 
of the quaternary nitrogen of NaM in β-NAD+ with cyanide to form a complex that 
absorbs at 325 nm (Figure 1.20).
84
 Adenine nitrogens, free NaM, or 
dihydronicotinamide in β-NADH do not interfere with this reaction, which is specific 
for quaternary amines. Moreover, β-NMN can react with cyanide and give a complex 
with the same spectral properties of β-NAD+, thus interfering with the assay. While the 
activity of NADases can be monitored by an absorbance decrease at 325 nm, 
proportional to the consumption of β-NAD+, the activity of NPPs cannot be detected, 
since β-NAD+ and NPP‟s reaction product, β-NMN, give exactly the same absorbance 
reading.  
A parallel method to detect changes in β-NAD+ concentration consists of the reaction of 
the remaining β-NAD+ with DHs to generate β-NADH, formation of which can be 
monitored by absorbance at 340 nm or emission at 475 nm (Figure 1.20),
84
 where β-
NAD
+
 does not interfere. Indeed, β-NAD+ and β-NADH are both characterized by a 
maximum absorbance at 260 nm with an extinction coefficient of 16900 M
-1
·cm
-1
 due to 
the adenine ring; in addition, β-NADH has another absorbance peak at 340 nm with an 
extinction coefficient of 6220 M
-1
·cm
-1
, due exclusively to the reduced nicotinamide 
ring. Exciting β-NAD+ and β-NADH at 360 nm, the compounds emit respectively at 
445 and 475 nm; however, β-NAD+ emission is very weak compared to that of β-
NADH and, therefore, working with in vivo concentrations is possible to 
fluorimetrically detect only β-NADH.85, 86 
Identical values for the activity of NADases are obtained by the measurements via both 
cyanide and DH methods, unless β-NAD+ contains β-NMN impurities that give negative 
interference. A combination of cyanide and DH methods allows determination of 
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whether NPPs, NADases or both activities are responsible for the β-NAD+ 
consumption. Indeed, a positive absorbance difference between the readings obtained 
with cyanide and DH methods indicates the presence of NPPs activity beyond that of 
the NADases. 
 
Figure 1.20 Cyanide and dehydrogenase (DH) assays to detect NAD
+
-consuming activities. Abbreviations 
used: NAD
+
, nicotinamide adenine dinucleotide; NMN, nicotinamide mononucleotide; ADP, adenosine 
diphosphate; Pi, phosphate; NAD-CN, NAD-cyanide complex; NADH, reduced NAD
+
. 
1.4.2 -NAD+ and its application for NAD+-consuming enzyme assays 
ε-NAD+ (Figure 1.21), as mentioned in 1.3.2 and discussed in detail in Chapter 3, has 
been largely employed as a fluorescent NNS to monitor the activity of NAD
+
-
consuming enzymes. Its fluorescence properties, more than its absorbance properties, 
have been used for the development of continuous or steady-state fluorescence-based 
assays depending on the examined enzymes, or to gain more sensitivity in HPLC 
analysis. As will be discussed in more detail in Chapter 3, ε-NAD+ is characterized by a 
strong internal fluorescence quenching due to stacking interactions between the ε-
adenine and the nicotinamide rings in the intact β-NAD+ structure.83, 87, 88 When the ε-
NAD
+
 structure is disrupted by the activities of NAD
+
-consuming enzymes, the 
fluorescence of the ε-adenine moiety is re-established with a consequent fluorescence 
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increase, which can be spectroscopically monitored. NPPs,
89
 ADPRCs,
69, 90
 NADases
87, 
91
 and ARTs
92, 93
 activities can be evaluated by ε-NAD+ continuous fluorescence-based 
assays. Indeed, all enzymatic products from the activity of these enzymes are more 
fluorescent than ε-NAD+ because of the disruption of the internal quenching between 
the aromatic rings (Figure 1.21). Therefore, a fluorescence increase during the 
enzymatic reactions can be detected at 410 nm (λex = 300 nm), allowing monitoring of 
enzyme activities and kinetic measurements. 
 
Figure 1.21 ε-NAD+ as a NNS of NADases, NPPs, ADPRCs and ARTs for the development of 
continuous fluorescence-based assays. A fluorescence increase is monitored at 410 nm (λex = 300 nm) 
during the enzymatic reactions of the above NAD
+
-consuming enzymes. Abbreviations used: ε-NAD+, 
1,N
6
-etheno-nicotinamide adenine dinucleotide; ε-ADPR, 1,N6-etheno-adenosine diphosphate ribose; ε-
AMP, 1,N
6
-etheno-adenosine monophosphate; cεADPR, cyclic 1,N6-etheno-adenosine diphosphate 
ribose. 
  
Chapter 1 
 
39 
 
Unfortunately, because all these enzymes use ε-NAD+ as a NNS, it is not possible 
simply by fluorescence measurements to distinguish the single enzymatic activities 
when they are all present. In addition, since these enzymes belong to the same class of 
ecto-enzymes, this causes a lack of enzyme compartment differentiation, not allowing 
any enzymatic activity distinction in vitro/in vivo. Consequently, only the discovery of 
fluorescent NNSs selective for particular enzymes or HPLC analysis can allow the 
distinction of the different enzymatic activities in vitro/in vivo. Hence, modifications to 
the ε-NAD+ structure have been performed in the attempt to generate specific substrates 
for different enzymes. For example, ε-PdAD+ and ε-hy4PdAD+ (Figure 1.22) have 
similar fluorescent properties to ε-NAD+, with ε-PdAD+ acting as a specific substrate 
toward NPPs, but not toward NADases.
89
 Moreover, the fluorescent properties of ε-
NAD
+
 and its different enzymatic products have allowed the development of HPLC 
assays with fluorescence detection, which are much more sensitive than those using the 
natural β-NAD+.92, 94 
 
 
Figure 1.22 ε-NAD+ and its derivatives. Abbreviations used: ε-NAD+, 1,N6-etheno-nicotinamide adenine 
dinucleotide; ε-PdAD+, 1,N6-etheno-pyridine adenine dinucleotide; ε-hy4PdAD+, 1,N6-etheno-4-
hydrazinocarbonyl-pyridine adenine dinucleotide. 
PARPs use ε-NAD+ as a NNS, but they do not have a very good affinity for it since the 
formation of poly(ε-ADPR) is very slow and the length of the polymers much shorter 
compared to those from β-NAD+.79 In principle, a fluorescence increase should be 
observed in relation to the activity of PARPs that catalyzes the removal of NaM and, 
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therefore, the disruption of the internal quenching in ε-NAD+. However, a strong 
fluorescence quenching occurs in the polymers of ε-ADPR, not allowing a continuous 
monitoring of the activity of PARPs by increase in fluorescence emission.
95
 By contrast, 
the degradation of poly(ε-ADPR) generates a fluorescence increase due to the release of 
ε-ADPR units, which gives information about the extent of PARPs activity.79 The 
poly(ε-ADPR) degradation can be performed by phosphodiesterases, but not by 
NADases or PARP-glycohydrolases (PARGs);
79, 96
 the latter enzymes are indeed 
inhibited by poly(ε-ADPR).96 To avoid the slow formation of poly(ε-ADPR) using ε-
NAD
+
 as a NNS for PARPs, poly(ε-ADPR) can be generated in situ from poly(ADPR), 
obtained by the reaction of PARPs with the natural β-NAD+, by staining with 
chloroacetaldehyde.
79, 96
 Alternatively, poly(ADPR) can be degraded by NPPs to ADPR 
units, which can be stained in situ with chloroacetaldehyde to obtain ε-ADPR.97 Since 
the activity of PARPs cannot be directly monitored by fluorescence changes using ε-
NAD
+
 as a NNS, an immunohistochemical reaction between the ε-adenosine moiety and 
a specific antibody has been developed to detect in situ the formation of poly(ε-
ADPR);
95
 this method is more sensitive and specific than another immunohistochemical 
reaction involving the natural adenosine moiety and allowing the in situ detection of 
poly(ADPR).
98
 
1.4.3 NGD+, NHD+ and NXD+ for ADPRC fluorescence-based assays 
NGD
+
, NHD
+
 and NXD
+
 have been used for the development of continuous 
fluorescence-based assays to monitor the activity of ADPRCs.
69
 Indeed, these 
compounds, not fluorescent in the form of dinucleotides, become strongly fluorescent 
after their cyclization by ADPRCs (Figure 1.23). 
The acquired fluorescence properties seem to be due to the cyclization of the 
compounds in N-7, generating a different electron delocalization along the ring because 
of the generated positive charge. Therefore, a fluorescence increase during the 
enzymatic reaction can be detected at 410 nm (λex = 300 nm), allowing monitoring of 
the activity of ADPRCs and estimation of kinetic inhibition parameters for this enzyme. 
Detailed discussions about these NNSs for ADPRC from Aplysia californica and their 
assays will be provided in Chapter 4 (see 4.2.3). 
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Figure 1.23 NGD
+
, NHD
+
 and NXD
+
 as NNSs of ADPRCs for the development of continuous 
fluorescence-based assays. A fluorescence increase is monitored at 410 nm (λex = 300 nm) during the 
enzymatic reaction of ADPRCs with NGD
+
, NHD
+
 and NXD
+
. Abbreviations used: β-NMN, 
nicotinamide mononucleotide; NGD
+
, nicotinamide guanine dinucleotide; NHD
+
, nicotinamide 
hypoxanthine dinucleotide; NXD
+
, nicotinamide xanthine dinucleotide; cGDPR, cyclic guanosine 
diphosphate ribose; cIDPR, cyclic inosine diphosphate ribose; cXDPR, cyclic xanthosine diphosphate 
ribose. 
1.4.4 6 and 8-alkyne NAD+ for NADase activity assays 
As discussed in 1.2.1, NADases, ARTs, PARPs and sirtuins are characterized by 
NADase activity since they all cleave the nicotinamide N-glycosidic bond with release 
of NaM. Then, the generated oxocarbenium intermediate can react in different ways 
depending on the considered enzyme.  
A new assay has been developed by Lin and co-workers involving the use of 6 or 8-
alkyne NAD
+
 as NNSs to label and monitor the activities and the targets of NADase 
(CD38), ARTs, PARPs and sirtuins.
14, 80, 81
 The principle of the assay is based on the 
labelling of the different ADPR enzymatic products by reaction of the alkyne moiety, 
introduced in the 6 or 8 position on the adenine ring, with rhodamine or biotin tagged 
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azides via click chemistry (Figure 1.24). Generally, 6-alkyne NAD
+
 has been shown to 
be a better substrate than 8-alkyne NAD
+
 for the enzymes examined.  
In the case of the activities of ARTs and PARPs, the labelling of mono-ADPR or poly-
ADPR acceptors via rhodamine has allowed their detection in gel electrophoresis by 
fluorescence; by contrast, the labelling via biotin has allowed their isolation and 
purification by affinity chromatography, with identification by LC-MS/MS.
80
 In the 
case of sirtuins, the assay has been used to monitor their suspected ART activity. 
However, even if 6 or 8-alkyne NAD
+
 have been shown to be NNSs for the 
deacetylation activity, they were not able to detect any ART activity exerted by sirtuins, 
probably because of its weakness compared to the deacetylation process.
14
 Finally, the 
alternative substrates have been used to covalently label CD38.
81
 Indeed, it is known 
that ara-2′′-FNAD+ inhibits CD38 by covalently binding the ADPR moiety by C-1′′ to a 
glutamate residue.
63
 The introduction of a 6 or 8-alkyne moiety on ara-2′′-FNAD+ has 
therefore allowed fluorescent labelling of CD38 in living cells. 
 
 
Figure 1.24 6 and 8-alkyne NAD
+
 as NNSs of NADases, ARTs, PARPs and sirtuins for the development 
of fluorescence or immunohistochemical assays. After the enzymatic reaction using 6 or 8-alkyne NAD
+
 
as NNSs, the different enzymatic products can undergo click chemistry to introduce the biotin or the 
rhodamine tag. 
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1.4.5 β-NAD+ quantification by reaction with acetophenone 
Another non-continuous assay to monitor the activity of PARPs and sirtuins is based on 
the quantification of the unreacted β-NAD+ by its reaction with acetophenone to 
generate a fluorescent NAD
+
 derivative (1, Figure 1.25).
99-101
 The treatment of the 
enzymatic reactions with solutions of KOH and acetophenone, followed by addition of 
formic acid and heating, leads to the formation of a cyclized fluorescent product, 1, 
which can be detected by fluorescence emission at 444 nm (λex = 372 nm); at this 
wavelength, β-NAD+ and NaM do not have any intrinsic fluorescence, therefore they 
cannot interfere with the assay. Even though it is an endpoint assay requiring different 
reaction steps, the possibility to perform it on 96 well-plates is a great advantage in 
terms of large screening of inhibitors.  
 
Figure 1.25 Quantification of the unreacted β-NAD+ by its reaction with acetophenone to generate the 
fluorescent NAD
+
 derivative, 1. A KOH solution is added to the enzymatic reaction to generate the a-
carbinol intermediate. Then, the addition of acetophenone generates a highly reactive a-adduct, which 
spontaneously cyclizes to a cyclized non-fluorescent a-adduct; the latter, after heating at 110 °C, 
dehydrogenates to give the fluorescent NAD
+
 derivative, 1. 
1.4.6 A continuous colourimetric assay for the detection of PARP activity 
A continuous colourimetric assay has been developed for the study of the activity of 
PARPs; its principle is based on the colour changes occurring during the enzymatic 
reaction of an NAD
+
 derivative, used as a NNS of PARPs, in which the nicotinamide 
ring is substituted with a para-nitrophenol ring.
82
 The latter is a well known pH 
indicator, indeed, it is colourless at acidic/neutral pH and bright yellow at basic pH (pKa 
= 7.16), when it is in the form of para-nitrophenolate. PARPs are able to cleave the O-
glycosidic bond between the C-1′′ of the ribose and the para-nitrophenol ring, which is 
released under its phenolate form to be monitored by absorbance increase at 405 nm 
(Figure 1.26). 
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Figure 1.26 ADPR-para-nitrophenol (ADPR-pNP) as a NNS of PARPs for the development of a 
continuous colourimetric assay. During the enzymatic reaction, the release of the yellow para-
nitrophenolate can be monitored at 405 nm. 
1.4.7 Alternative assays for the detection of sirtuins activity 
Many assays have been developed in the past years to test the activity of sirtuins. Most 
of the initial assays involved the use of radioactive β-NAD+, labelled with 14C/32P on the 
nicotinamide ring or the pyrophosphate bond, or, alternatively, radioactive acetylated 
peptides, labelled with 
3
H on the acetate group.
102
 However, radioactive measurements, 
despite their sensitivity, involve a considerable health hazard, cost and waste issues. 
More recently, several non-continuous fluorescence-based assays to monitor the activity 
of sirtuins have been developed: one of them, described in 1.4.5, is based on the 
detection of the unreacted β-NAD+ by transformation of the latter in a fluorescent 
derivative. Other assays rely on fluorescence changes during the enzymatic reaction of 
internally quenched fluorescent peptide substrates. A common assay based on this 
principle is the Fluor de Lys, commercially available in kits, which uses as a substrate a 
peptide comprising amino acids 379-382 of human p53 (Arg-His-Lys-Lys[Ac]), 
containing at the C terminus the fluorophore AMC (7-amino-4-methylcoumarin). Other 
assays are based on the same principle, using as substrates MAL (Boc-Lys[Ac]-
AMC)
103
 or Z-MAL (Cbz-Lys[Ac]-AMC).
104
 In the first step of the assay, sirtuins are 
incubated with β-NAD+ and the fluorescent quenched acetylated peptide substrate (for 
instance, Z-MAL, Figure 1.27) in the reaction buffer. The peptide, deacetylated by the 
activity of sirtuins, ZML, is a trypsin substrate; therefore, after the addition into the 
reaction mixture of a stop solution containing trypsin, the fluorescent product, AMC is 
released in solution with consequent fluorescence increase. The developed fluorescence 
is proportional to the deacetylation performed by sirtuins.
103, 104
 This assay has been 
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used for the biological evaluation of 8-aryl/heteroaryl substituted NAD
+
 derivatives 
described in Chapter 5. 
 
 
Figure 1.27 Fluorescence-based assay for sirtuins activity. Z-MAL (Cbz-Lys[Ac]-AMC) is incubated with 
sirtuins and β-NAD+ to give the deacetylated product, ZML (Cbz-Lys-AMC). The latter is hydrolysed by 
trypsin to release the fluorophore, AMC (7-amino-4-methylcoumarin), and Z-lysine. The fluorescence is 
proportional to the deacetylation exerted by sirtuins. 
1.4.8 Assays for the detection of DNA ligase activity 
The gel electrophoresis technique is commonly used to monitor the DNA ligation 
experiments. Its principle is based on the detection of fluorescently or radioactively 
labelled single strand nicked DNA and its corresponding eventually joined DNA, 
migrating differently on the gel because of their different molecular sizes. This 
technique, exploiting a fluorescently labelled single strand nicked DNA, has been used 
to evaluate the NAD
+
 derivatives synthesized in Chapter 2 (more details in Chapter 5, 
see 5.1.1) toward the ligation activity of EcLigA. However, the gel electrophoresis 
technique is generally time-consuming and laborious, especially in the screening of 
many compounds, and its results strongly depend on the batches of enzyme activity and 
DNA substrates. For this reason, other assays for high-throughput screening of potential 
inhibitors of DNA ligases have been developed to simplify and overcome the 
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limitations of the gel electrophoresis assay. Some of them are based on FRET 
(fluorescence resonance energy transfer) signals generated upon ligation of DNA 
strands carrying a fluorescence donor and acceptor (Figure 1.28 a);
73
 others on the 
fluorescence changes upon ligation of molecular beacons carrying a fluorophore (Figure 
1.28 b),
105
 or a fluorophore and a quencher at the extremities.
106
 These assays, although 
non-continuous and involving different steps (e.g. ligation reaction, denaturation, 
washing), allow high-throughput screening of potential inhibitors of DNA ligases in 96 
well-plates with great accuracy and reproducibility. 
 
 
Figure 1.28 Ligation assays based on the generation of FRET signals (a), or on the fluorescence detection 
of ligated molecular beacons
105
 (b) upon ligation and denaturation conditions. 
1.5 Project Objectives  
Interest towards NAD
+
-consuming enzymes has increased in the past years since a 
deeper knowledge of fundamental biological processes has shown the involvement of 
this class of enzymes in their regulation and, consequently, in a number of human 
diseases. Therefore, the necessity to further investigate their structure and catalytic 
mechanism and, eventually, to modulate or block their activities has brought an 
admirable scientific effort in the development of efficient and accurate assays to 
monitor their enzymatic reactions and screen large numbers of inhibitors.  
As reviewed within this chapter, many improvements have been made in targeting and 
regulating these enzymes. Since β-NAD+ is the common substrate of NAD+-consuming 
enzymes, a major effort has been made in generating NAD
+
 derivatives that could act as 
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inhibitors and/or NNSs for these enzymes. A continuous increase and updating of 
information about the reaction mechanism and active site structure of NAD
+
-consuming 
enzymes has allowed more specific design of compounds that could show some 
biological activity toward them.  
At the outset of this project, a review of the existing NAD
+
 derivatives and their 
activities toward NAD
+
-consuming enzymes has shown that, among the different 
modifications on the β-NAD+ scaffold, those on the adenine ring can generate different 
biological activities depending on the enzymes examined. For example, the adenine 
modifications are tolerated by a large number of NAD
+
-consuming enzymes, such as 
NADases, ADPRCs, ARTs and PARPs, generating NNSs that have been exploited for 
the development of binding and kinetic assays. On the other hand, two interesting 
classes of enzymes, such as NAD
+
-dependent DNA ligases and sirtuins, belonging to 
the NAD
+
-consuming enzymes but characterized by complex reaction mechanisms, had 
shown a strong involvement of the adenine moiety in the enzyme binding and reaction 
mechanism, suggesting that its modifications can generate potential inhibitors 
interfering with their activities.  
This project has been developed on the basis of these arguments, in an attempt to 
generate novel adenine-modified NAD
+
 derivatives, that could provide new biochemical 
information about NAD
+
-consuming enzymes. The main objectives proposed in this 
project are summarised below and in Figure 1.29. 
 Synthesis of novel NAD+ derivatives, modified in the position 2, 6 or 8 of the 
adenine ring with aryl/heteroaryl groups by palladium-mediated cross-couplings 
(Figure 1.29 a) (see Chapter 2). The successful application of these couplings would 
offer the opportunity to insert many different chemical groups on the adenine ring, 
keeping intact its skeleton. These modifications, although already applied to the 
synthesis of nucleosides, nucleotides and DNA derivatives, have never been used 
for the synthesis of NAD
+
 derivatives.  
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 Spectroscopic analysis of the novel NAD+ derivatives in view of their potential 
activity as NNSs for NAD
+
-consuming enzymes and, therefore, their application to 
the development of sensitive assays based on spectroscopic techniques (see Chapter 
3). 
 Evaluation of the novel NAD+ derivatives toward NAD+-consuming enzymes as 
inhibitors for drug discovery and/or NNSs for the development of advantageous, 
continuous or non-continuous, assays as an alternative to those already existing 
(Figure 1.29 b). NPPs, NADases and ADPRCs were chosen as model enzymes to 
test the activities of the NAD
+
 derivatives because of the simplicity of their reaction 
mechanism, involving β-NAD+ as the only substrate (see Chapter 4). In contrast, 
NAD
+
-dependent DNA ligases and sirtuins were chosen as examples of complex 
NAD
+
-consuming enzymes, using β-NAD+ as a co-substrate (see Chapter 5). 
 
 
Figure 1.29 Synthetic (a) and biological (b) targets of the project. The synthetic targets (a) are 
represented by the novel NAD
+
 derivatives, modified in the position 2, 6 or 8 of the adenine ring with 
aryl/heteroaryl substituents (R). The biological targets (b) are represented by the listed NAD
+
-consuming 
enzymes, divided in two classes depending on the activity of β-NAD+ as a substrate/co-substrate in their 
reactions. 
β-NAD+ NAD+-consuming enzyme
substrate
NPP
NADase
ADPRC
co-substrate
NAD+-dependent DNA ligase
sirtuins
a
b
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 Analysis of the different activities exerted on different enzymes by NAD+ 
derivatives substituted in the same position on the adenine ring and, therefore, their 
ability to target specific biological processes. The enzyme specificity is a 
fundamental requirement in the drug development for in vitro/in vivo studies (see 
Chapter 6).  
Therefore, the development of novel adenine-modified NAD
+
 derivatives as 
biochemical probes for NAD
+
-consuming enzymes provides new tools for the 
investigation of this important class of enzymes. 
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2 SYNTHESIS OF ARYL/HETEROARYL ADENINE-MODIFIED NAD+ 
DERIVATIVES 
2.1 Synthetic strategies to aryl/heteroaryl adenine-modified NAD+ derivatives 
β-NAD+ is a fundamental biological molecule found in all living cells and used by a 
variety of enzymes involved in many different biological processes. Its structure with 
two labile high-energy bonds, i.e. the pyrophosphate and the nicotinamide N-glycosidic 
bond (see 1.1), underpins the biological activity of β-NAD+ as a substrate/co-substrate 
of NAD
+
-consuming enzymes, but also makes it an extremely fragile molecule.
5, 7, 13
 
Indeed, β-NAD+ can be subject to degradation even under mild conditions, which 
complicates its chemical synthesis and derivatisation. Nevertheless, given the 
importance of β-NAD+ in biology, the development of NAD+ derivatives is of 
considerable interest and importance, as such derivatives can be used as biochemical 
tools to investigate NAD
+
-dependent enzymes, their reaction mechanisms and their 
biological roles. 
Owing to its limited chemical stability, the chemical modification of β-NAD+ is not 
always straightforward. Only a few reactions have been reported in the literature where 
a modification is applied directly on the β-NAD+ scaffold,70, 83, 107-109 generally 
involving the introduction of substituents on the nucleobases or the riboses. However, 
because of the extreme fragility of β-NAD+, the most common method to obtain NAD+ 
derivatives substituted on the nucleobases, the riboses or the pyrophosphate bond, 
consists of the introduction of a modification on a stable precursor of the β-NAD+ 
scaffold, such as the nucleoside/nucleotide moieties, and the following synthesis of the 
NAD
+
 target.  
As discussed in Chapter 1 (see 1.5), the project aim was the synthesis of NAD
+
 
derivatives modified on C-2, C-6 or C-8 of the adenine ring with aryl/heteroaryl groups, 
and their following biological evaluation toward NAD
+
-consuming enzymes. Therefore, 
the synthesis of adenine-modified NAD
+
 derivatives was explored. The most common 
pathway toward adenine-modified NAD
+
 derivatives is the multistep synthesis (pathway 
a, Scheme 2.1), which starts with the substitution of the adenosine in the desired 
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position, subsequently undergoing the phosphorylation of 5′-OH, the phosphate 
activation and the final coupling with β-NMN to generate the pyrophosphate bond.110-112 
Alternative routes were explored to shorten the synthesis of adenine-modified NAD
+
 
derivatives: the pathway b (Scheme 2.1) via nucleoside phosphoramidite intermediates 
gives in one step the phosphorylation/phosphate activation of substituted adenosines for 
their following coupling with β-NMN;113 the pathway c (Scheme 2.1) allows 
bromination and substitution by Suzuki-Miyaura cross-coupling in one-pot, on position 
8 of the natural β-NAD+.70  
 
 
Scheme 2.1 General synthetic pathways to aryl/heteroaryl adenine-modified NAD
+
 derivatives. Pathway 
a) via AMP-morpholidates; pathway b) via nucleoside phosphoramidites; pathway c) via one-pot, two-
step synthesis of 8-substituted NAD
+
 derivatives. Abbreviations used: β-NAD+, nicotinamide adenine 
dinucleotide; AMP, adenosine monophosphate; β-NMN, nicotinamide mononucleotide. 
The pathway a, though more laborious and time-consuming, is the most flexible to 
successfully obtain different substitutions on the β-NAD+ scaffold, since even the 
modifications requiring harsh reaction conditions are introduced on the stable adenosine 
precursors. Indeed, this pathway was used to synthesize all the final NAD
+
 derivatives 
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studied in this thesis. Through substitution of the adenosine on C-2, C-6 or C-8 of the 
adenine ring and phosphorylation of the 5′-OH, the NAD+ multistep synthesis converges 
to two final steps, in common for all the substituted adenosines, leading to the final 
NAD
+
 derivatives. This route will be discussed first, starting with the synthesis of the 
differently adenine-modified AMP derivatives (see 2.3, 2.4 and 2.5), converging then to 
the common steps to obtain the final NAD
+
 derivatives (see 2.6). The pathway b and c 
will be explored as well, though subject to many future further studies (see 2.7). 
2.2 Substitution of the adenine ring by palladium-mediated cross-couplings 
Since the 1940s and 1950s, the study of nucleosides, nucleotides and their derivatives 
has become more and more important, in parallel with the improved and deeper 
knowledge of DNA and metabolic processes involving these compounds. Their several 
biological roles have made them a constant source of interest as therapeutics and 
molecular probes to understand biological systems. From the first attempts to modify 
the natural substrates on the nucleobase or the ribose, to the most successful attempts to 
substantially change the structure, improving the derivatives stability and selectivity, an 
extensive study to new approaches for these modifications has been undertaken 
resulting in the development of many useful synthetic pathways.
114
 
Since this project aimed to synthesize of NAD
+
 derivatives modified on the adenine 
ring, attention was mainly focused on the modified purines, also found in nature, well 
known for their extremely various and important biological properties.
115
 Several have 
therapeutic activity as modulators of adenosine receptors or stimulators of plant cell 
growth and division (cytokinines); others inhibit DNA polymerases exhibiting antiviral, 
antibacterial, anticancer properties. Moreover, purines modified by metabolically 
activated mutagens and carcinogens introduced in the cells by dietary and 
environmental exposure, can cause DNA alteration, and even oncogenesis. Indeed, the 
modification of the purine ring in different positions can substantially alter the normal 
nucleoside/nucleotide conformation, the H-bonding ability and, consequently, the 
intercalation in DNA and the interaction with proteins.  
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Figure 2.1 Purine structure and numbering. 
The purine ring, which skeleton is given by the fusion of imidazole and pyrimidine 
rings (Figure 2.1), can be substituted on C-2, C-6 and C-8 and on N-1, N-3, N-7 and N-
9.
116
 Substituted purines can be obtained by different methods:  
 Heterocyclization from pyrimidine or imidazole; however, in particular cases the 
methods are not efficient and require many reaction steps with quite low yield;
115, 117
  
 SNAr, where halogenated electrophilic purines can undergo displacement of the 
halogen with a good nucleophile;
118
 
 SEAr, where nucleophilic purines can be substituted with electrophilic reagents (e.g. 
alkylation).
119
 
The last two methods require particular electronic properties and drastic reaction 
conditions; consequently, other easier synthetic pathways have been explored. The 
recent development of metal-mediated couplings has considerably facilitated the 
synthesis of purine derivatives.
114, 120, 121
 In general, metal-catalyzed couplings are 
economically advantageous; in addition, they are suitable for introducing a broad range 
of substituents. A wide variety of palladium-mediated reactions, such as Sonogashira, 
Heck, Stille and Suzuki-Miyaura cross-couplings, has been developed since the 1960s, 
and adapted and optimized to prepare respectively alkynyl, alkenyl and aryl/heteroaryl 
purine derivatives.
114, 116, 120-127
    
The synthetic part of this project was focused on the substitution of C-2, C-6 or C-8 of 
the adenine ring in adenosine and/or adenosine monophosphate with aryl/heteroaryl 
groups, as intermediates to synthesize the final targets, the corresponding adenine-
modified NAD
+
 derivatives. In particular, the introduction of phenyl and pyrrolyl 
groups in different positions on the adenine ring was considered in order to screen and 
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compare eventual structural and biological differences caused by the hydrophobic 
interactions exerted by the phenyl group, with those due to H-bonding formation of the 
pyrrolyl group. In addition, the substitution of the adenine with a pyrrolyl group could 
be particularly interesting because of the presence of pyrrole units in many biological 
molecules.   
Suzuki-Miyaura and Stille cross-couplings were the most suitable palladium-mediated 
reactions for our purposes. They catalyze respectively the C-C bond formation between 
aryl/heteroaryl boronic acids, XB(OH)2, or stannanes, XSnBu3, and activated aromatic 
halides (Scheme 2.2). Owing to the commercial availability and relatively easy 
halogenation of purine nucleosides/nucleotides (1-3), the general cross-coupling 
strategy uses the halogenated nucleosides/nucleotides in the favoured position as 
starting materials (4-6), followed by the coupling with boronic acids (a) or stannanes (b) 
via palladium-mediated reactions. Palladium-mediated cross-couplings can be 
performed directly on adenosine, avoiding the halogenation step, although this generally 
requires harsh reaction conditions; only recently, mild reaction conditions have been 
found, also suitable for the direct substitution of the unstable and unprotected 2′-
deoxyadenosine.
128-130
  
 
 
Scheme 2.2 General synthetic strategy to aryl/heteroaryl adenine-modified nucleotides. Guanosine (1) as 
starting material for 2-substituted adenosine monophosphate (7); inosine (2) as starting material for 6-
substituted purine nucleotide (8); adenosine (3) as starting material for 8-substituted adenosine 
monophosphate (9). After the halogenation of the nucleosides, 1-3, in the favoured positions, 4-6 undergo 
Suzuki-Miyaura (a) or Stille cross-coupling (b) by Pd/lig catalyst (lig = phosphine) to introduce the 
aryl/heteroaryl group, X. The following phosphorylation generates the corresponding nucleotides, 7-9. 
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The Suzuki-Miyaura
131
 and Stille
132
 cross-couplings proceed via a catalytic cycle, 
involving an oxidative addition, transmetallation and reductive elimination (Scheme 
2.3). In the first step, the reactive species, Pd(0), is oxidized to Pd(II) after the addition 
of an organic halide, R-X, forming a cis complex, that rapidly isomerizes to trans: this 
is generally the rate-limiting step in the catalytic cycle, depending on the reactivity of 
the halide and the ζ-donating ability of the ligands coordinating Pd(0). During the 
transmetallation step, the second organic group, R′, is transferred to Pd(II) from another 
metallic species. In the Suzuki-Miyaura cross-coupling this is a boronic acid, while in 
the Stille cross-coupling it is an organic stannane. The use of a base in the Suzuki-
Miyaura cross-coupling is fundamental to activate the organic boronic acid during the 
transmetallation step; indeed, the organic group on the boron, because of the 
predominantly covalent B-C bond, would not otherwise be nucleophilic enough to take 
part in the transmetallation step. In contrast, the organic stannanes do not need any 
activation because of the weaker Sn-C bond. The last step in the catalytic cycle, the 
reductive elimination, requires a slow isomerization of the trans Pd(II) complex to cis 
with elimination of the cross-coupled product, R-R′, and the re-establishment of the 
reactive species, Pd(0).  
 
 
Scheme 2.3 Catalytic cycle of palladium-mediated cross-couplings. 
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The toxicity of stannanes and their difficult disposal, compared to the high stability, 
easy handling, low toxicity and huge variety of available boronic acids has favoured the 
development of the Suzuki-Miyaura cross-coupling compared to the Stille cross-
coupling. Nevertheless, in some cases only the Stille cross-couplings are really effective 
for the formation of certain types of C-C bonds.
131-133
 
2.3 Synthetic route to 2-aryl/heteroaryl AMP derivatives 
The synthetic route to 2-aryl/heteroaryl AMP derivatives starts with the halogenation of 
C-2 on the adenine ring in order to form the organic halide, which will undergo the 
Suzuki-Miyaura or Stille cross-coupling for the introduction of the aryl/heteroaryl 
substituent.  
The most common substitutions on C-2 are normally achieved by halogenation of this 
position, followed by nucleophilic aromatic substitutions, formation of palladium-
catalyzed C-N bonds, or Sonogashira cross-couplings; the latter is an alternate copper-
catalyzed palladium-mediated cross-coupling to obtain 2-alkynyl adenine derivatives.
134, 
135
 Very few examples of Suzuki-Miyaura and Stille cross-couplings on C-2 of 
adenosine are present in the literature.
127, 136-138
 Most of these substitutions start from 
guanosine (1) and proceed via the installation of an iodine on C-2, as this generates the 
most reactive halide (4) (Scheme 2.2). Indeed, the substitutions on C-2 of the adenine 
ring are complicated by the low reactivity of this position, which is on the electron-poor 
pyrimidine ring of the purine skeleton; hence, the introduction of a very good leaving 
group is necessary. To date, the cross-coupling reactions described in the literature for 
the 2-substitution have only been applied on the adenosine, but not on the adenosine 
monophosphate. Indeed, these reactions are carried out in organic phase with apolar 
reagents and solvents, requiring for this reason the protection of the hydroxyl groups of 
adenosine with different protecting groups.
127, 136-138
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Our synthetic strategy aimed at the synthesis of 2-iodo AMP (7a), 2-phenyl AMP (7b) 
and 2-(N-Me-pyrrol-2-yl) AMP (7c). It proceeded through the iodination of adenosine 
on C-2 (4) and the protection of the 2′, 3′-OH on the ribose with acetone to form the 
isopropylidene protecting group (4a). After the Pd-mediated cross-couplings for the 
introduction of phenyl and N-Me-2-pyrrolyl groups (4a-c), the phosphorylation of 5′-
OH via phosphoramidite intermediates (4d-f) or by POCl3 afforded 4g-i, finally 
deprotected to give the final compounds (7a-c) (Scheme 2.4).  
 
 
Scheme 2.4 Synthetic route to 2-substituted AMP derivatives. (i)-(v) Iodination of adenosine on C-2 from 
guanosine (1); (vi) 2′,3′-O-isopropylidene protection; (vii) palladium-mediated cross-coupling; (viii) 
phosphorylation of 5′-OH; (ix) deprotection of 2′,3′-OH. 
2.3.1 Iodination of C-2 and 2′,3′-O-isopropylidene protection of adenosine 
The first step in the synthesis of 2-substituted AMP derivatives is the iodination of C-2 
in adenosine, particularly required to have the most reactive halide in the following 
Suzuki-Miyaura and Stille cross-couplings. The halogenation of aromatic rings is 
generally achieved by SEAr; in the case of the adenine ring, the halogenation in position 
2 is less straightforward than that in position 8 because of a lower reactivity of C-2 
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compared to C-8 in SEAr. For this reason, the iodination of C-2 is generally achieved by 
a long synthetic strategy, well described in the literature, which avoids the use of SEAr. 
It starts from guanosine (1), converting it to the fully acetylated 2-amino-6-chloro 
purine nucleoside (1a); the latter is converted by diazotization-iodine substitution in the 
fully acetylated 2-iodo-6-chloro purine nucleoside (1b), which undergoes amination and 
deprotection to finally give the 2-iodo adenosine (4) (Scheme 2.5).
134, 139, 140
 
 
 
Scheme 2.5 Iodination of adenosine on C-2 from 1. (i) Acetic anhydride, DMF, pyridine, 75 °C, 4 h, 
87%; (ii) POCl3, N,N-dimethylaniline, 100 °C, 10 min, 85%; (iii) acetic anhydride, DMAP, TEA, 
acetonitrile, rt, 1 h, 89%; (iv) CuI, I2, CH2I2, isoamyl nitrite in THF, 70 °C, 4 ‒ 12 h, 85% from 1a, 51% 
from 1c; (v) NH3/MeOH, 60 °C, 12 h, 40% from 1b, 30% from 1d; 33% overall from 1a, 21% overall 
from 1c. 
Our synthesis, described in Scheme 2.5, started from the commercially available 2-
amino-6-chloro purine nucleoside (1c), which was fully protected by acetylation to 
obtain 1a (89%). Afterwards, the next reactions were carried out on the protected 
nucleosides as described in the literature, until the final amination/deprotection step, 
which gave compound 4 with 33% yield overall (compared to 70% yield in the 
literature).
139
 The same pathway was performed on the unprotected nucleosides, starting 
with the diazotization-iodine substitution of 1c to give 1d (51%), finally converted in 
the compound 4 with 21% yield overall. Therefore, this pathway, although giving 
product 4 in lower yields, allowed to avoid the protection/deprotection steps. 
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Afterwards, the obtained 2-iodo adenosine (4) had to be protected on the ribose to 
undergo the subsequent palladium-mediated cross-coupling in organic phase. Because 
of our synthetic strategy, the isopropylidene protecting group was the most convenient 
to install. Indeed, because of its acetal nature, it was resistant to the basic conditions of 
the Suzuki-Miyaura cross-coupling, and allowed the protection of the vicinal hydroxyl 
groups in C-2′ and C-3′, leaving the primary alcohol in C-5′ free for the subsequent 
phosphorylation.  
The 2′,3′-O-isopropylidene protecting group can be introduced by reaction of the 
nucleoside with acetone in acidic conditions (Scheme 2.6);
135, 141
 the acetal formation is 
a reversible equilibrium, hence the deprotection occurs again in acidic conditions. The 
2′,3′-O-isopropylidene protection of 4 was carried out as described in the literature, 
affording the desired product 4a with 98% yield. 
 
 
Scheme 2.6 2′,3′-O-isopropylidene protection of 2-iodo adenosine, 4. (vi) Acetone, 70% HClO4, rt, 1 h; 
then, NH4OH, rt, 3 h, 98%. 
2.3.2 Suzuki-Miyaura and Stille cross-couplings on C-2 of 2′,3′-O-isopropylidene-2-
iodo adenosine 
As mentioned in 2.3, the reactivity of C-2 on the adenine ring toward palladium-
mediated cross-couplings is lower compared to other positions, due to the electron-poor 
nature of the pyrimidine ring; indeed, the electrophilicity of the organic iodide is 
decreased because of a strong mesomeric effect competing with the inductive effect.  
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In the literature, the optimized conditions for the Suzuki-Miyaura cross-coupling on the 
protected 2-iodo adenosine (4a) allow the successful coupling with simple aryl boronic 
acids,
127, 136-138
 such as phenyl or biphenyl boronic acids; Pd(OAc)2, (2-
biphenyl)dicyclohexylphosphine, K3PO4, in anhydrous 1,4-dioxane at 100 °C is the 
optimal catalytic system, affording the desired products in 60% yield.
136
 In this project, 
these conditions using phenyl boronic acid were successfully applied to obtain the 2′,3′-
O-isopropylidene-2-phenyl adenosine (4b) in 43% yield (Scheme 2.7).  
No references in the literature have been found on Suzuki-Miyaura cross-couplings at 
C-2 with heteroaryl boronic acids. The installation of a pyrrolyl group on the adenine 
ring by Suzuki-Miyaura cross-coupling would require the use of 2-pyrrole boronic acid. 
However, the latter is a difficult substrate because it can dimerize or protodeboronate, 
and the free amino group can coordinate Pd(0) inhibiting the catalytic cycle
142, 143
. The 
protection of the amino group of the pyrrole with different protecting groups (Boc, 
TIPS) has solved these problems in many cases affording the pyrrolyl cross-coupled 
products with quite good yields. Nevertheless, the Suzuki-Miyaura cross-coupling on C-
2 of the 2′,3′-O-isopropylidene-2-iodo adenosine (4a) with the N-Boc-2-pyrrole boronic 
acid failed using the optimized conditions for the phenyl substitution.
136
  
The only example found in the literature for the synthesis of 2-heteroaryl substituted 
protected adenosine has used the Stille cross-coupling to introduce thienyl and furanyl 
groups
137
 on the fully tert-butyldimethylsilyl protected 2-iodo adenosine. In the context 
of this project, the commercially available tributyl-(N-Me-pyrrol-2-yl) stannane was 
used to test the Stille cross-coupling conditions on 2′,3′-O-isopropylidene-2-iodo 
adenosine (4a), requiring PdCl2(PPh3)2 as catalyst. Effectively, under these conditions, 
using anhydrous 1,4-dioxane instead of anhydrous THF, about 43% of 4a was 
converted in 4c, slightly improved to 50% when anhydrous LiCl was added to the 
reaction; indeed, the addition of chloride in Stille cross-couplings can often accelerate 
the catalytic reaction during the transmetallation step (Scheme 2.7). However, the 
purification by silica gel chromatography of the product 4c from the excess of stannane 
was unsuccessful, causing a substantial stannane contamination of the reaction product 
even after several purifications; therefore, the next synthetic steps were performed on 
the crude mixture.  
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Scheme 2.7 Palladium-mediated cross-couplings on C-2 of 2′,3′-O-isopropylidene-2-iodo adenosine, 4a. 
Suzuki-Miyaura cross-coupling (1): phenyl boronic acid, Pd(OAc)2, (2-biphenyl)dicyclohexylphosphine, 
K3PO4 in anhydrous 1,4-dioxane, 100 °C, 24 h, 43% for 4b. Stille cross-coupling (2): tributyl-(N-Me-
pyrrol-2-yl) stannane, optional anhydrous LiCl, PdCl2(PPh3)2 in anhydrous 1,4-dioxane, 100 °C, 48 h, 43-
50% conversion for 4c.   
2.3.3 Phosphorylation of 5′-OH of 2′,3′-O-isopropylidene-2-substituted adenosine 
and subsequent deprotection to 2-aryl/heteroaryl AMP derivatives 
A common method to phosphorylate the 5′-OH of protected and/or unprotected 
nucleosides uses POCl3 as phosphorylating agent (method 1). In the past, many studies 
have been performed to optimize this reaction affording quite good yields, even in the 
difficult case of the phosphorylation of unprotected nucleosides, where the selective 
phosphorylation of 5′-OH is required. The optimized reaction conditions require the 
addition of a base to the reaction mixture to buffer the acidic pH generated along the 
reaction course; indeed, adenosine is subjected to depurination under acidic conditions. 
Moreover, the solvents commonly used are acetonitrile or triethylphosphate, the latter 
accelerating the phosphorylation in a selective way towards the 5′-OH.144-146  
In this study, when the phosphorylation was performed on 2′,3′-O-isopropylidene-2-
phenyl adenosine (4b) using POCl3, proton sponge as a base and triethylphosphate as 
solvent, the conversion was so low that, in some cases, no product could be recovered. 
In addition, when the reaction failed, the recovery of the starting material was 
complicated because of the difficult purification from triethylphosphate and proton 
sponge. The phosphorylation by POCl3 was also attempted on 2′,3′-O-isopropylidene-2-
iodo adenosine (4a), substituting the triethylphosphate with acetonitrile and removing 
the proton sponge to facilitate the purification step. However, a poor conversion was 
observed also in this case, probably due to a substantial substitution of the iodide with 
the chloride generated in the course of the reaction (Scheme 2.8).  
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Because of the unsatisfactory results obtained in the phosphorylation of 4a and 4b by 
POCl3, this phosphorylation method was not applied on the crude 2′,3′-O-
isopropylidene-2-(N-Me-pyrrol-2-yl) adenosine (4c). 
 
 
Scheme 2.8 Phosphorylation of 5′-OH of 2′,3′-O-isopropylidene-2-substituted adenosine by POCl3 
(method 1). (viii) Optional proton sponge, triethylphosphate or anhydrous acetonitrile, 0 °C, 12 h, 9% 
from 4a; (ix) Dowex 88 (H
+
), rt, 12 h, 36% for 7a; 3% overall for 7a. 
Therefore, an alternative phosphorylation method was chosen using the 
phosphoramidite as a highly reactive phosphorylating agent (method 2).
113
 The new 
phosphorylation strategy required the reaction of 2′,3′-O-isopropylidene-2-substituted 
adenosines (4a-c) with 2-cyanoethyl N,N-diisopropylchlorophosphoramidite to obtain 
the phosphoramidite nucleoside intermediates (4d-f). These could then be oxidized to 
the phosphate intermediates by 
t
BuOOH, and deprotected from 2-cyanoethyl and N,N-
diisopropyl groups by treatment with NH4OH, to afford the 2′,3′-O-isopropylidene-2-
substituted adenosines 5′-monophosphate (4g-i). After removal of the O-isopropylidene 
protecting group by treatment with Dowex 88 (H
+
), the final 2-substituted AMP 
derivatives (7a-c) were obtained (Scheme 2.9). 
This synthetic route, though involving more steps compared to the POCl3 method and 
the use of an expensive reagent in the form of 2-cyanoethyl N,N-
diisopropylchlorophosphoramidite, turned out to be successful in the phosphorylation of 
2′,3′-O-isopropylidene-2-substituted adenosines (4a-c), affording 7a and 7b in 19% and 
17% yield overall respectively.  
Chapter 2 
 
63 
 
Unfortunately, 7c was never recovered pure, even after several purifications, due to the 
stannane contamination from the previous Stille cross-coupling.  
 
 
Scheme 2.9 Phosphorylation of 5′-OH of 2′,3′-O-isopropylidene-2-substituted adenosine via 
phosphoramidite (method 2). (viii) DIPEA, anhydrous CH2Cl2, rt, 1 h; then, 5.0 – 6.0 M 
t
BuOOH in 
nonane, rt, 1 h; NH4OH, rt, 3 h; (ix) Dowex 88 (H
+
), rt, 12 h; 19% overall for 7a, 17% overall for 7b; 
yield not estimated for 7c. 
As will be discussed in 2.7.1, the phosphoramidite strategy could be used to form the 
pyrophosphate bond between the activated phosphite intermediates and β-NMN, to 
generate the final NAD
+
 targets. However, this route still needs further investigations 
and optimizations. 
2.4 Synthetic route to 6-aryl/heteroaryl AMP derivatives 
The synthetic strategy to 6-phenyl and 6-(pyrrol-2-yl) AMP derivatives, respectively 8a 
and 8b, started with the Suzuki-Miyaura cross-coupling on the commercially available 
6-chloro purine nucleoside (5), that could be otherwise readily synthesized from inosine 
(2) by treatment with POCl3 and N,N-diethylaniline.
140
 To avoid the difficult 
phosphorylation step on unprotected nucleosides, the 6-substituted purine nucleosides 
(5a-b) were protected on the 2′, 3′-OH by O-isopropylidene protecting group (5c-d). 
Then, these intermediates were phosphorylated on the 5′-OH via phosphoramidite 
intermediates (5e-f) or by POCl3 to afford 5g-h, then finally deprotected to obtain the 6-
substituted AMP derivatives (8a-b) (Scheme 2.10). 
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Scheme 2.10 Synthetic route to 6-aryl/heteroaryl AMP derivatives. (i) Suzuki-Miyaura cross-coupling; 
(ii) 2′,3′-O-isopropylidene protection; (iii) phosphorylation of 5′-OH; (iv) deprotection of 2′,3′-OH. 
2.4.1 Suzuki-Miyaura cross-coupling on C-6 of 6-chloro purine nucleoside 
The Suzuki-Miyaura cross-coupling on C-6 of purine nucleosides is well described in 
the literature and remarkable improvements have been achieved in the optimization of 
its conditions. The first examples of substitutions on C-6 concerned the cross-coupling 
of simple substituted aryl groups on the protected purine nucleosides.
147
 Since the 
unprotected compounds showed cytostatic activities, the scientific interest toward these 
substitutions enhanced. Later, the attention was focused on the introduction of 
heteroaryl groups that exhibited, in addition to the cytostatic activities, strong anti-HCV 
(Hepatitis C Virus) activities.
148
 Hence, a large number of heteroaryl substituents have 
been introduced on the fully protected purine nucleosides using different methods, such 
as the Suzuki-Miyaura cross-coupling, the heterocyclization by 1,3-dipolar 
cycloadditions, or the palladium-mediated Negishi cross-coupling, involving organozinc 
reagents.
148, 149
 More recently, Suzuki-Miyaura cross-couplings on the unprotected 6-
chloro purine nucleoside (5) have been successfully carried out in the aqueous phase for 
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the introduction of some heteroaryl or unprotected phenylalanine substituents.
149, 150
 
However, no references have been found for the Suzuki-Miyaura cross-coupling on the 
unprotected 6-chloro purine nucleoside (5) in an aqueous phase with N-Boc-2-pyrrole 
boronic acid. 
In this project, the aqueous cross-coupling conditions described in the literature for the 
synthesis of unprotected 8-substituted adenosine and guanosine, requiring Na2PdCl4, 
TPPTS and K2CO3 as catalytic system,
144, 151, 152
 were applied to the synthesis of the 6-
phenyl (5a) and 6-(pyrrol-2-yl) (5b) purine nucleosides, affording the desired products 
in 50% and 37% yield respectively (Scheme 2.11). Interestingly, during the synthesis of 
5b, the Boc-deprotection of the pyrrolyl substituent occurred directly under the basic 
cross-coupling conditions.
153, 154
  
 
 
Scheme 2.11 Suzuki-Miyaura cross-coupling on C-6 of 6-chloro purine nucleoside, 5. Phenyl or N-Boc-2-
pyrrole boronic acid, Na2PdCl4, TPPTS, K2CO3 in water, 100 °C, 1 h (5a), 24 h (5b); 50% for 5a, 37% 
for 5b. 
Substantial differences in polarity between the phenyl (5a) and the pyrrolyl (5b) 
substituted purine nucleosides were noticed during their purifications. Indeed, 5a was 
isolated and purified from the reaction mixture by extraction in organic phase and 
following recrystallization from water. By contrast, 5b was soluble in water and needed 
to be purified by ion-pair chromatography. Moreover, the reaction mixture from the 
cross-coupling with the N-Boc-2-pyrrole boronic acid was quite complex, and only a 
very slow gradient during the ion-pair purification allowed the separation between a 
multitude of different peaks. These were not isolated and analysed, but some of them 
could potentially be attributed to the dimer of the pyrrole,
142
 or to the N-arylated 
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product, formed by coupling of the nitrogen of the pyrrole with the chlorine of the 6-
chloro purine nucleoside.
149
 
2.4.2 2′,3′-O-isopropylidene protection and phosphorylation of 5′-OH of 6-
substituted purine nucleosides, with subsequent deprotection to 6-aryl/heteroaryl 
AMP derivatives 
The 2′,3′-O-isopropylidene protection of 6-substituted purine nucleosides (5a-b) was 
carried out with the same conditions described in 2.3.1, affording 5c-d with 85% and 
39% yield respectively. Afterwards, the phosphorylation of 5′-OH of 2′,3′-O-
isopropylidene-6-substituted purine nucleosides (5c-d) was performed by POCl3 
(method 1) and via the phosphoramidite (method 2), as previously described in 2.3.3 
(Scheme 2.12).  
 
Scheme 2.12 Phosphorylation of 5′-OH and following deprotection of 2′,3′-O-isopropylidene-6-
substituted purine nucleosides. (iii) Method 1 by POCl3: POCl3, anhydrous acetonitrile, 0 °C, 12 h. (iii) 
Method 2 via phosphoramidite: 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, DIPEA, anhydrous 
CH2Cl2, rt, 1 h; then, 5.0 – 6.0 M 
t
BuOOH in nonane, rt, 1 h; NH4OH, rt, 3 h. (iv) (Method 1): Dowex 88 
(H
+
), rt, 12 h, 30% for 8a. (iv) (Method 2): AcOH/H2O (1:9), 90 °C, 3 h, complete conversion for 8b; 
28% for 8a and 50% for 8b overall via phosphorylation method 1; 7% for 8a overall via phosphorylation 
method 2.  
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The phosphoramidite method, selected for the phosphorylation of 2′,3′-O-
isopropylidene-2-substituted adenosines, allowed the phosphorylation of the 2′,3′-O-
isopropylidene-6-phenyl purine nucleoside (5c), affording the desired product 8a with 
7% yield overall. By contrast, when the same phosphorylation method was applied to 
the 2′,3′-O-isopropylidene-6-(pyrrol-2-yl) purine nucleoside (5d), no product was 
recovered after the different deprotection steps. In particular, the final treatment with 
Dowex 88 (H
+
) to remove the O-isopropylidene protecting group on the ribose seemed 
to be responsible for the loss of the material. Indeed, 5h, especially if present in small 
amounts, could have remained attached to resin; hence, the use of a weak acid cation 
exchange resin could have allowed an easier and more efficient recovery of the material.  
Owing to the poor yields obtained for the phosphorylation via phosphoramidite (method 
2), the method with POCl3 (method 1) was reconsidered and slightly modified to allow, 
in case of failure, the recovery of the starting materials. Therefore, the reactions were 
performed in anhydrous acetonitrile without the additional proton sponge to simplify the 
purification step. Under these conditions, a partial deprotection of the O-isopropylidene 
protecting group occurred because of the acidic pH developed during the reaction 
course. Then, the complete O-isopropylidene deprotection of 5g was carried out by the 
usual treatment with Dowex 88 (H
+
). However, a new deprotection method was used for 
5h, requiring its treatment with an acetic acid solution at 90 °C for 3 h, yielding a 
complete deprotection. Compounds 8a-b were obtained in 28% and 50% yield overall 
respectively (Scheme 2.12). 
2.5 Synthetic route to 8-aryl/heteroaryl AMP derivatives 
The synthetic strategy to 8-aryl/heteroaryl AMP derivatives started with the 
bromination of adenosine (3) or adenosine monophosphate (3a) in position 8 of the 
adenine ring; this reaction is selective for C-8, as this position is very reactive to SEAr, 
as mentioned in 2.3.1.
155, 156
  
The subsequent Suzuki-Miyaura cross-coupling in position 8 is very well documented 
in the literature and a large variety of aryl/heteroaryl groups have been introduced in 
this position. The development of hydrophilic ligands and palladium sources has 
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allowed its performance in aqueous phase with unprotected nucleosides/nucleotides, 
avoiding time-consuming protection and deprotection steps.
144, 150-152, 157-159
  
Two routes can be followed to obtain the final 8-aryl/heteroaryl AMP derivatives (9) 
(Scheme 2.13). The longest route starts from adenosine (3), via its bromination in 
position 8 to give 6. The latter can alternatively undergo the phosphorylation of 5′-OH 
by POCl3 to obtain 9a, or the Suzuki-Miyaura cross-couplings to obtain the 8-
aryl/heteroaryl adenosine derivatives. These intermediates can be further 
phosphorylated on 5′-OH to give the final 8-aryl/heteroaryl AMP derivatives (9). The 
shortest route starts from adenosine monophosphate (3a), via its bromination in position 
8 to give 9a. The latter can directly undergo the Suzuki-Miyaura cross-coupling to give 
the final 8-aryl/heteroaryl AMP derivatives (9). In this project, the choice to follow the 
shortest synthetic route led in a short period of time to the synthesis of a small library of 
8-aryl/heteroaryl AMP derivatives (9b-n). 
 
 
Scheme 2.13 Synthetic route to 8-aryl/heteroaryl AMP derivatives. (i) Bromination on C-8; (ii) Suzuki-
Miyaura cross-coupling; (iii) phosphorylation of 5′-OH (R is an aryl/heteroaryl group).  
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2.5.1 Bromination of C-8 of adenosine and adenosine monophosphate 
The bromination on C-8 of adenosine (3) has been performed by adding saturated 
bromine water to the adenosine solution in sodium acetate buffer (pH 4). The buffered 
conditions are fundamental to avoid the pH dropping down dramatically because of the 
release of HBr from the reaction, with consequent depurination. Under these conditions, 
the product 6 crashed out from the reaction mixture as a solid in 80% yield.
155, 156
 
The bromination on C-8 of adenosine monophosphate (3a) described in the literature 
requires the same conditions as for the bromination of adenosine,
155, 156
 starting from its 
sodium salt. Slight modifications were performed in this study to simplify this 
procedure, using neat bromine instead of saturated bromine water. Since the formation 
of side-products was observed during the reaction in sodium acetate buffer, the solvent 
was substituted with a 0.25 M KH2PO4 solution (pH 4). An almost complete conversion 
of 3a to 9a was obtained with 50-60% yield after ion-pair chromatography purification 
(Scheme 2.14). 
 
 
Scheme 2.14 Bromination on C-8 of adenosine, 3, and AMP, 3a. Method 1: 3, saturated bromine water, 1 
M NaOAc buffer (pH 4), rt, 24 h, 80%. Method 2: 3a, neat bromine, 0.25 M KH2PO4 (pH 4), rt, 24 h, 50-
60%. 
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2.5.2 Suzuki-Miyaura cross-coupling on C-8 of 8-bromo adenosine monophosphate 
to 8-aryl/heteroaryl AMP derivatives 
The Suzuki-Miyaura cross-coupling on C-8 of purine nucleosides/nucleotides has been 
investigated in detail and successful conditions are well established in the literature, 
using Na2PdCl4, TPPTS and K2CO3 in water as the optimal catalytic system.
144, 150-152, 
157-160
 
This project was aimed in particular at the challenging synthesis of N-heteroaryl or 
amino-aryl substituted AMP derivatives. Indeed, the cross-coupling reactions with free 
amino moieties are generally complicated by the inhibition of the catalytic center by N-
coordination, or polymerization, in addition to the low reactivity of electron-deficient N-
heteroaryl boronic acids.
142, 143, 161, 162
 Therefore, an accurate optimization of the 
reaction conditions was required to successfully afford the desired products.   
A small library of 8-aryl/heteroaryl AMP derivatives (9b-n) (Table 2.1, Scheme 2.15) 
was generated and their conformational and spectroscopic properties investigated in 
Chapter 3. A range of aryl, electron-poor and electron-rich substituents was introduced 
in position 8 of the adenine ring. The Suzuki-Miyaura cross-coupling conditions were 
optimized to obtain decent yields even for the most difficult substitutions with electron-
deficient N-heteroaryl groups.  
 
cmpd R (substituent on C-8) Yield (%)
a 
9b Phenyl 80-90 
9c 3-(N-Boc-aminomethyl)phenyl 78 
9d 3-(Aminomethyl)phenyl 85 
9e Pyridin-3-yl 70 
9f Pyridin-4-yl 80 
9g 2,4-DMT-pyrimidin-5-yl 75 
9h Pyrrol-2-yl 57 
9i Furan-2-yl 67 
9j 1H-Pyrazol-4-yl 57 
9k 5-Formyl-thien-2-yl 52 
9l 5-Bromo-thien-2-yl 17 
9m Indol-2-yl 83 
9n Benzofuran-2-yl 10 
a
Yield of isolated products 
Table 2.1 Synthesis of the 8-aryl/heteroaryl AMP derivatives (9b-n). 
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Scheme 2.15 Suzuki-Miyaura cross-coupling on C-8 of 8-bromo AMP, 9a. (ii) Aryl/heteroaryl boronic 
acid, Na2PdCl4, TPPTS, K2CO3 in water, Δ, 1 – 24 h, 10-90%. 
Generally, the Suzuki-Miyaura cross-couplings with simple aryl boronic acids can be 
performed at low temperature using small amounts of base and palladium/ligand 
catalyst. For example, 9b and 9c could be synthesized at only 40 °C using the right 
catalytic system. In contrast, the Suzuki-Miyaura cross-couplings with electron-poor 
boronic acids generally require stronger reaction conditions, using very high 
temperature and more equivalents of base and palladium/ligand catalyst to react in the 
transmetallation step.  
In this study, the pyridinyl group was the most electron-poor in the range of selected 
substituents to introduce on the position 8 of the adenine ring. Due to the electron-poor 
nature of the pyridine ring, the boron in the 3-pyridinyl boronic acid has a pronounced 
Lewis acid behavior, which makes it poorly reactive. However, in water the 3-pyridinyl 
boronic acid is normally present as a zwitterion, with a positive charge on the pyridine 
basic nitrogen and a negative charge on the boron (Figure 2.2). Therefore, the aqueous 
conditions increase the reactivity of the boron and block the pyridine basic nitrogen 
from inhibiting the catalytic palladium centre.
162, 163
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Figure 2.2 Ionization equilibrium of the 3-pyridinyl boronic acid in water. 
Due to its poor reactivity, the Suzuki-Miyaura cross-coupling of 9a with the 3-pyridinyl 
boronic acid to obtain 9e, required high temperature (100 °C) and a Pd/ligand ratio 1:3. 
A screening of base equivalents, ranging from 1.5 to 10, showed a slow conversion with 
1.5 equiv., fast with 3 and 5, but no conversion with 10 equiv. of base. The application 
of micellar-catalyzed Suzuki-Miyaura cross-coupling was considered to perform the 
reaction at lower temperature in water and in absence of co-solvent. Indeed, the 
formation of micelles should improve the solubility of the boronic acid in water 
accelerating the reaction.
164-166
 In particular, the use of surfactants, such as PTS 
(polyoxyethanyl α-tocopheryl sebacate, a nonionic amphiphile) and TBAF, was 
investigated, performing parallel reactions between 9a and the 3-pyridinyl boronic acid 
at 40 °C for 2 days to obtain 9e. While the reactions did not work with the standard 
amounts of Pd catalyst (2 – 2.5 mol%), adding more (10 mol%), a conversion was 
observed, higher in the reactions performed with PTS (> 60%) than those with TBAF (≤ 
40%).  
Several interesting observations were made during the synthesis of 9c and 9d. When the 
Suzuki-Miyaura cross-coupling was performed with the 3-(N-Boc-aminomethyl)phenyl 
boronic acid at 80 °C in 1 h, no Boc-deprotection occurred in the basic reaction 
conditions. By contrast, when the same reaction was performed at 40 °C over two days, 
an almost complete deprotection occurred, affording 9d. To obtain the unprotected 9d, 
two different synthetic routes were used (Scheme 2.16). In the first istance, the 
deprotection of the cross-coupled 9c was carried out by refluxing with TFA in methanol 
until the disappearance of the starting material was observed. In the second route, the 
deprotection of the 3-(N-Boc-aminomethyl)phenyl boronic acid with TFA in CH2Cl2 at 
room temperature was performed to use the unprotected boronic acid in the subsequent 
Suzuki-Miyaura cross-coupling with 9a to afford 9d.  
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Scheme 2.16 Synthesis of 9d. (i) TFA, MeOH, reflux; (ii) TFA, CH2Cl2, rt, 1 h, quantitative yield; (iii) 
Suzuki-Miyaura cross-coupling: 9a, Na2PdCl4, TPPTS, K2CO3 in water, 80 °C, 2 h. 
With the first strategy, after the disappearance of the starting material 9c, two new spots 
could be observed by TLC (thin layer chromatography), one very polar and one less 
polar than the starting 9c. Probably, a mixture of the differently protonated forms of 9d, 
in equilibrium with each other during the TLC run in iPA/H2O/NH4OH (6:3:1), was 
observed. After purification by ion-pair chromatography, 9d was recovered as a single 
product corresponding to the most polar spot in TLC. 
A titration of the obtained 9d was performed with NaOH and HCl to investigate its 
different protonation states. At pH < 1, 9d should be completely protonated on the 
phosphate group, the amino group on the substituent and N-1.
167
 Increasing the pH, the 
phosphate would lose the first proton (pK1 Pi ≈ 0.9),
167
 followed by N-1 (pKa N-1 ≈ 
3.4), the second proton on the phosphate (pK2 Pi ≈ 6.6) and, finally, the primary amine 
on the substituent (pKa NH2 ≈ 9.2) (Figure 2.3). These pKa values are comparable with 
those in the literature for the related groups.
167
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Figure 2.3 Acid-base titration of 3-(aminomethyl)phenyl AMP (9d) using a pH meter. To a solution of 9d 
in water (pH 6.7), 370 μL of 0.1 N HCl (left) and 390 μL of 0.1 N NaOH (right) were added respectively 
in portions of 10 μL each. The pH was read and recorded after each addition. The equivalence point 
(E.P.) volumes were found plotting the first derivative [ΔpH/ΔmL] as a function of the titration volume 
[μL]: each maximum in the first derivative corresponded to the equivalence point volume. The pKa values 
were calculated in correspondence of each half-equivalence point (red circles), where pH = pKa. 
When 9d was synthesized by Suzuki-Miyaura cross-coupling of 9a with 3-
(aminomethyl)phenyl boronic acid (Scheme 2.16), two different new spots could be 
observed by TLC during the cross-coupling reaction. In this case, it was possible to 
isolate by ion-pair purification the two corresponding different products, and investigate 
their nature by
 1
H NMR and HR-MS. Both techniques confirmed the same identity for 
both products as 9d; however, differences in the 
1
H NMR spectra, in particular in the 
phenyl and CH2NH2 regions, suggested their forms as two possible distinct conformers 
(Figure 2.4). Examining the CH2NH2 peaks, the enantiotopic protons appeared as a 
singlet in the possible conformer a, where the aminomethyl substituent heads far from 
the phosphate; indeed, in this case these protons would be too similar to be 
distinguished. By contrast, in the other possible conformer b, stabilized by salt 
formation between the 5′-phosphate on the adenosine and the amino group on the 
substituent, the enantiotopic protons would have a very different electronic environment 
and, therefore, appear as a doublet. 
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Figure 2.4 
1
H NMR spectra of the two isolated conformers, a and b, for 9d. 
To support this hypothesis, it was observed that 9d(a) had 1.3 mol TEA as a counter 
ion, while 9d(b) had only 0.5 mol TEA because of the involvement of the phosphate 
group in a salt formation with the amino group of the substituent. Hence, it was 
suggested that, when 9d was synthesized by deprotection of 9c, only the kinetically 
favoured conformer 9d(a) was obtained. Indeed, in 9c the hindered substituent 
containing the Boc group would assume the conformation where it heads far from the 
phosphate; since the deprotection occurred rapidly, the product 9d would preferentially 
remain in the conformation assumed by its precursor. In contrast, when 9d was 
synthesized by Suzuki-Miyaura cross-coupling with the unprotected boronic acid, the 
substituted phenyl ring was able to rotate and to assume both the different positions 
compared to the phosphate group, leading to the formation of both kinetically and 
thermodynamically favoured conformers. An useful experiment to prove the existence 
of the two different conformers would be to increase the temperature during the 
1
H 
NMR experiment; indeed, the energy provided would allow the phenyl substituent to 
rotate freely around its bond with C-8 of the adenine ring, avoiding the stabilization of 
the two different conformers and giving an average NMR signal for phenyl and 
CH2NH2 peaks. 
Phenyla)
b)
CH2NH2
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2.6 Synthesis of aryl/heteroaryl adenine-modified NAD+ derivatives (pathway a) 
2.6.1 AMP activation via phosphoromorpholidate intermediate 
The formation of the pyrophosphate bond between the aryl/heteroaryl adenine-modified 
AMP derivatives and β-NMN to generate the final aryl/heteroaryl adenine-modified 
NAD
+
 derivatives, requires the activation of either phosphate group of the reactants. 
The Khorana-Moffatt procedure, involving the coupling between a nucleotide and a 
nucleotide phosphoromorpholidate, was chosen in our project to perform the 
pyrophosphate bond formation. Indeed, the nucleotide phosphoromorpholidate 
intermediates are reactive enough phosphate derivatives, but also sufficiently stable to 
be handled and stored.
168, 169
  
Because of the fragility of β-NMN due to its labile nicotinamide N-glycosidic bond, it 
was chosen to synthesize the phosphoromorpholidate intermediates of the 
aryl/heteroaryl adenine-modified AMP derivatives, to subsequently couple them with β-
NMN. The synthesis of the phosphoromorpholidate intermediates was performed by an 
oxidation-reduction condensation under the Mukaiyama‟s conditions,170, 171 which had 
already been successfully used for the preparation of different pyrophosphate bonds.
112, 
151
 A complete conversion occurred from all the starting materials and the obtained 
products were usually precipitated as sodium salts and used in the next step without any 
further purification (Scheme 2.17). 
 
 
Scheme 2.17 Synthesis of aryl/heteroaryl adenine-modified AMP-morpholidate derivatives. (i) 
Morpholine, 2,2′-dithiopyridine, PPh3, anhydrous DMSO, rt, 1 h, 70-97% (X is an aryl/heteroaryl group, 
see Scheme 2.18, Table 2.2). 
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2.6.2 Coupling with β-NMN 
Once the aryl/heteroaryl adenine-modified AMP-morpholidate derivatives were 
synthesized, it was possible to proceed to their coupling with β-NMN to obtain the final 
aryl/heteroaryl adenine-modified NAD
+
 derivatives. As described in the literature,
110
 the 
Khorana-Moffatt coupling for the synthesis of β-NAD+ needs the presence of Lewis 
acid additives to make the morpholidates more reactive. Indeed, β-NMN in the reaction 
conditions (pH 7) is probably an inner salt, with a poorly nucleophilic phosphate and, 
therefore, unable to efficiently attack the activated phosphoromorpholidates. A MnCl2 
solution in formamide has been used for this purpose.
110-112, 172
 A fundamental 
requirement for the success of the reaction is the dryness of the system; indeed, because 
of its nucleophilicity, the water could hydrolyse the phosphoromorpholidates or the 
newly formed pyrophosphate bond, decreasing the final yields. Therefore, the MnCl2 
solution in formamide needs to be dried over molecular sieves for several days prior its 
use. Furthermore, anhydrous MgSO4 is added to the reaction mixture to capture any 
excess water.  
The literature conditions report the use of 1.1 equiv. of β-NMN to the morpholidate. 
However, because of the high value of β-NMN, the use of its excess was reconsidered 
in our procedure. In contrast, where possible, an excess of morpholidate was used to 
improve the reaction yields (Scheme 2.18, Table 2.2). The aryl/heteroaryl adenine-
modified NAD
+
 derivatives, 13a-b, 14a-b, 15b, c, e, g, h, were obtained with yields 
ranging from 24 to 87%. The same variability along the reaction yields was noticed in 
the literature, where the Khorana-Moffatt coupling gave the NAD
+
 derivatives with 
yields between 30 and 70%.
110-112
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Scheme 2.18 Synthesis of aryl/heteroaryl adenine-modified NAD
+
 derivatives. (ii) β-NMN, anhydrous 
MgSO4, 0.2 M MnCl2 in formamide, rt, 12 h, 24-87% (R is an aryl/heteroaryl group, see Table 2.2). 
 
compd Position of substitution R (substituent) Yield (%)
a 
13a 2 Iodo 53 
13b 2 Phenyl 28 
14a 6 Phenyl 56 
14b 6 Pyrrol-2-yl 87 
15b 8 Phenyl 41 
15c 8 3-(N-Boc-aminomethyl)phenyl 61 
15e 8 Pyridin-3-yl 24 
15g 8 2,4-DMT-pyrimidin-5-yl 43 
15h 8 Pyrrol-2-yl 30 
a
Yield of isolated products 
Table 2.2 Synthesis of the aryl/heteroaryl adenine-modified NAD
+
 derivatives 13a-b, 14a-b, 15b,c,e,g,h. 
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β-NAD+ and its derivatives are relatively fragile compounds and need to be handled 
extremely carefully to prevent their decomposition. As discussed in 1.1, the 
nicotinamide N-glycosidic bond is sensitive to basic conditions, since the hydroxyde 
can act as a nucleophile and substitute the nicotinamide ring to give the corresponding 
ADPR derivative. During the acquisition of 
31
P NMR spectra, the addition of 
triethylamine to the samples in D2O is required to sharpen the peaks and show the 
coupling constants, JP,P, between the two phosphorus of the pyrophosphate bond. 
Therefore, the acquisition of these spectra is particularly tricky for the NAD
+
 
derivatives, since the smallest quantity of TEA has to be added to the cold samples to 
avoid their immediate degradation, detected by a sudden change in the colour of the 
solution from colourless to orange. 
2.7 Alternative synthetic strategies to aryl/heteroaryl adenine-modified NAD+ 
derivatives 
2.7.1 Aryl/heteroaryl adenine-modified NAD+ derivatives via phosphoramidite 
method (pathway b) 
One of the approaches to shorten the synthesis of the NAD
+
 derivatives is the 
phosphoramidite method. The phosphoramidite chemistry is commonly used for the 
solid-phase synthesis of oligonucleotides, where a 3′-phosphoramidite nucleoside 
intermediate reacts with the 5′-OH of a nucleoside to form the 3′,5′-phosphodiester 
bond. The phosphoramidite intermediate is very reactive, allowing successful couplings 
with almost quantitative yields, a fundamental requirement for the synthesis of long 
oligonucleotide sequences.
173-175
 In the case of the formation of the pyrophosphate bond 
in dinucleotides, this method allows the coupling between a phosphoramidite nucleoside 
intermediate and the phosphate group of a nucleotide.
113
 
For the synthesis of aryl/heteroaryl adenine-modified NAD
+
 derivatives, the substitution 
of the adenosine with aryl/heteroaryl groups in the favourite position is followed by the 
preparation of the corresponding reactive phosphoramidite intermediate, ready to 
undergo the coupling with β-NMN (Scheme 2.19). Therefore, the phosphorylation and 
activation of the phosphate occur in a single step and with the purification of a single 
intermediate compared to the multistep synthesis (pathway a).  
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In this project, the pathway b was tested starting from the 2′,3′-O-isopropylidene-2-
phenyl adenosine (4b), forming its corresponding phosphoramidite intermediate and 
attempting its coupling with β-NMN under the conditions described in the literature.113 
However, the coupling turned out to be unsuccessful despite the high reactivity of the 
phosphoramidite intermediate. The reason could be due, as in the Khorana-Moffatt 
procedure, to the poor nucleophilicity of the phosphate of β-NMN in the reaction 
conditions. In addition, the insolubility of β-NMN in the reaction solvent (acetonitrile) 
could negatively influence the effectiveness of the reaction. The addition of small 
DMF/DMSO percentages in the reaction media was tried to improve the solubility of β-
NMN; however, the reaction did not proceed. Further investigations and optimizations 
studies should be performed to exploit the potential of this synthetic pathway. 
 
 
Scheme 2.19 Synthesis of 13b via phosphoramidite method (pathway b). (i) Phosphoramidite synthesis: 
2-cyanoethyl N,N-diisopropylchlorophosphoramidite, DIPEA, anhydrous CH2Cl2, rt, 1 h; (ii) coupling 
with β-NMN: β-NMN, DCI, anhydrous acetonitrile, rt, 1 – 2 h; then, 5.0 – 6.0 M tBuOOH in nonane, rt, 1 
h; NH4OH, rt, 3 h; (iii) 2′,3′-O-isopropylidene deprotection: Dowex 88 (H
+
), rt, 12 h.  
2.7.2 Aryl/heteroaryl adenine-modified NAD+ derivatives via one-pot, two-step 
procedure (pathway c) 
β-NAD+ is a very sensitive molecule, difficult to handle and to work with because of the 
labile bonds present in its structure. Its derivatives are rarely synthesized directly from 
the natural β-NAD+ because of its easy degradation even under mild reaction 
conditions. For this reason, the most common pathway to synthesize NAD
+
 derivatives 
is the multistep synthesis (pathway a, Scheme 2.1).  
The direct introduction of aryl/heteroaryl substituents on the β-NAD+ scaffold by 
Suzuki-Miyaura cross-coupling has been an open challenge, since β-NAD+ is 
susceptible to the required basic reaction conditions. The first step for the substitution of 
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the adenine ring of β-NAD+ by Suzuki-Miyaura cross-coupling is its halogenation in the 
favoured position. References for the halogenation of β-NAD+ have been found in the 
literature,
107, 108
 using neat bromine to brominate the reactive C-8 of the adenine ring at 
room temperature in 30 min. Unfortunately, the halogenation of the adenine ring in 
other positions is not as straightforward as that on C-8 and, therefore, this pathway can 
exclusively be applied to the synthesis of 8-aryl/heteroaryl NAD
+
 derivatives.  
The subsequent Suzuki-Miyaura cross-coupling on C-8 requires an accurate 
optimization of every reaction parameters, such as the catalyst, the amount of base, the 
temperature and the reaction time, to guarantee the occurrence of the cross-coupling 
before the beginning of the degradation of the starting material at basic pH.
70
 As already 
shown in the Wagner group, the combination of Na2PdCl4 with the electron-rich 
phosphine, TXPTS, allowed fast Suzuki-Miyaura cross-couplings at 40 °C on 8-bromo 
NAD
+
, using aryl/heteroaryl, electron-rich and electron-poor substituents (Scheme 
2.20).
70
 
To further shorten this synthesis, a one-pot, two-step procedure was set up, where, 
immediately after the bromination, the aqueous solution was extracted with CHCl3 to 
remove the bromine excess, and the residue evaporated to dryness. The crude material 
was directly used in the Suzuki-Miyaura cross-coupling, adding more equivalents of 
base to bring the pH 4 to the optimum pH 9. The yields obtained with this method were 
comparable to those obtained with the multistep synthesis.
70
  
 
 
Scheme 2.20 Synthesis of 8-aryl/heteroaryl adenine-modified NAD
+
 derivatives via one-pot, two-step 
procedure (pathway c). (i) Bromination: neat bromine, 1 M NaOAc buffer (pH 4), rt, 30 min; then, 
Suzuki-Miyaura cross-coupling: aryl/heteroaryl boronic acid, Na2PdCl4, TXPTS, K2CO3 in water, 40 °C, 
20 – 30 min, 36-64% (experimental procedures in reference 70). 
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Although this method works for a large range of boronic acids, including aryl/heteroaryl 
and electron-rich/electron-poor ones, the Suzuki-Miyaura cross-couplings with 
pyridinyl and pyrrolyl boronic acids required a too basic pH and high temperature to be 
applied to the β-NAD+ without any decomposition. The use of surfactants, discussed in 
2.5.2, to perform the couplings with electron-poor boronic acids at low temperature was 
attempted during the one-pot, two-step procedure with β-NAD+ without any positive 
result. Therefore, for certain classes of boronic acids, this pathway still remains 
unsuccessful and needs further investigations. 
2.8 Conclusions 
Owing to the importance of β-NAD+ as a substrate for many different enzymes involved 
in major biological processes, the interest toward the synthesis of NAD
+
 derivatives as 
biochemical tools has become more and more relevant, making necessary the 
development of efficient, rapid and robust synthetic routes. 
After the optimization of the already known multistep synthesis (pathway a), which 
allows us to synthesize any NAD
+
 derivatives starting from the nucleoside precursors, 
new routes were explored to improve and shorten the synthesis of NAD
+
 derivatives. 
The phosphoramidite strategy (pathway b) failed but, because of its attractive potential 
in remarkably shortening the synthesis, still deserves further investigations. The one-
pot, two-step synthesis (pathway c), although useful exclusively for the synthesis of 8-
aryl/heteroaryl NAD
+
 derivatives, has successfully allowed the synthesis of several 
NAD
+
 derivatives in a very short time.  
Therefore, a small library of NAD
+
 derivatives substituted on C-2, C-6 or C-8 of the 
adenine ring with aryl/heteroaryl groups was generated, to be tested on different NAD
+
-
consuming enzymes as inhibitors for drug discovery or NNSs as biochemical tools. 
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3 CONFORMATIONAL AND SPECTROSCOPIC ANALYSIS OF 
ARYL/HETEROARYL ADENINE-MODIFIED AMP AND NAD+ 
DERIVATIVES 
The NAD
+
 derivatives synthesized in Chapter 2 were designed for their biological 
application as inhibitors and/or NNSs toward NAD
+
-consuming enzymes. To perform 
their functions, the compounds have to interact with the enzymes and their active sites, 
consequently requiring particular conformations that are adaptable to the enzyme 
recognition. A certain degree of flexibility in the molecule is required for enzyme 
recognition. In particular, in the case of nucleosides/nucleotides, a fundamental feature 
is the orientation of the nucleobase in relation to the ribose. Of course, the presence of 
additional groups on the adenine-modified NAD
+
 derivatives, able to change the natural 
nucleobase orientation and the normal H-bonding or hydrophobic interactions of the 
natural β-NAD+ within the enzyme active sites, influences the recognition and its 
strength, and it is responsible for the compounds activity as inhibitors and/or NNSs.  
In view of the potential activity of aryl/heteroaryl adenine-modified NAD
+
 derivatives 
as NNSs for NAD
+
-consuming enzymes, their spectroscopic features could lead to their 
application as biochemical probes for the development of sensitive assays based on 
spectroscopic techniques, such as UV/Vis absorption or fluorescence emission 
spectroscopies. For example, it is known, as will be discussed in 3.3.2, that adenine 
rings, substituted in position 8 with aryl/heteroaryl groups, belong to the class of 
emissive nucleobases.  
Therefore, this chapter will first describe the conformational properties of the natural 
AMP and β-NAD+, and their derivatives synthesized in Chapter 2, to help later correlate 
structures with the bio-activities observed. Then, their spectroscopic features will be 
described to explore the suitability of aryl/heteroaryl NAD
+
 derivatives as biochemical 
probes for NAD
+
-consuming enzymes. 
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3.1 Conformational analysis of nucleosides and nucleotides  
Nucleosides and nucleotides are characterized by free or restricted rotation around 
several bonds, which allows them to assume different conformations in solution. The 
topology of a nucleoside in solution is determined by interdependent conformational 
equilibria involving the most flexible bonds in the structure. The nucleobase is oriented 
perpendicularly to the plane of the ribose ring and can mainly assume two different 
conformations, syn and anti, by rotation around the N-glycosidic bond. The torsion 
angle around this bond, χ, determines which conformation is favoured (Figure 3.1).176  
 
 
Figure 3.1 Glycosidic conformational ranges of nucleosides and nucleotides. 
The rotation around the N-glycosidic bond is not free, due to the steric hindrance 
between the nucleobase and the ribose. For this reason, the anti conformation, in which 
the nucleobase is pointing away from the ribose, is generally favoured by 
nucleosides/nucleotides compared to the syn conformation, which has a higher energy 
(Figure 3.2).  
270°
180°
90°
0°
345°
165°
75°
255°
High syn syn
O1 
C2 
C3 
C4 
C1 
Plane
of base
High anti
anti
χ
Chapter 3 
 
85 
 
 
Figure 3.2 Adenine conformations in the natural adenosine/AMP and the aryl/heteroaryl adenine-
modified adenosine/AMP derivatives. 
The syn/anti equilibrium largely influences the ribose conformation: indeed, the ribose 
can pucker its structure, assuming the North (N, or C3′-endo) or South (S, or C2′-endo) 
conformation (Figure 3.3), in equilibrium to each other. The general ratio between N 
and S conformations for β-D-ribonucleosides is 1:1, but because the N-conformation is 
more hindered than the S-conformation, nucleosides/nucleotides with the nucleobase in 
the syn orientation will prefer the S to the N conformation.
167, 177
 
 
 
Figure 3.3 Ribose conformations of nucleosides (R = H) and nucleotides (R = Pi). 
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3.1.1 Conformation of aryl/heteroaryl adenine-modified AMP derivatives 
A conformational analysis was performed on the various substituted AMP derivatives 
synthesized in Chapter 2 (Table 3.1). The natural AMP exists predominantly with the 
adenine in anti conformation, while the less hindered S-conformation is slightly 
favoured by the ribose.
178
 To determine the preference of the adenine between syn and 
anti conformation in the AMP derivatives, it is possible to observe the difference in 
chemical shift of H-2′ between the natural AMP and the different derivatives (ΔH-2′). In 
particular, a downfield shift for H-2′ compared to its chemical shift in AMP indicates a 
deshielding due to the adenine assuming a syn conformation and, consequently, the 
ribose favouring an S-conformation. The coupling constant, J1ꞌ,2ꞌ, is related to the 
percentage of the ribose population in S conformation.
179, 180
 
 
cmpd 
Position of 
substitution 
R (substituent) 
S-type conformer 
(%) (10J1ꞌ,2ꞌ) 
H-2′ 
(ppm) 
ΔH-2′ 
(ppm)
a syn/anti 
AMP  H 52 4.75 – anti 
7a 2 Iodo 57 4.72 -0.03 anti 
7b 2 Phenyl 49 4.68 -0.07 anti 
8a 6 Phenyl 53 4.68 -0.07 anti 
8b 6 Pyrrol-2-yl 55 4.75 0 anti 
9a 8 Bromo 60 5.19 0.44 syn 
9b 8 Phenyl 62 5.21 0.46 syn 
9c 8 3-(N-Boc-
aminomethyl)phenyl
b 58 5.51 – syn 
9d 8 3-(Aminomethyl)phenyl 62 a); 64 b) 5.17 0.42 syn 
9e 8 Pyridin-3-y – 5.22 0.47 syn 
9f 8 Pyridin-4-yl 51 5.27 0.52 syn 
9g 8 2,4-DMT-pyrimidin-5-yl 62 5.19 0.44 syn 
9h 8 Pyrrol-2-yl 62 5.19 0.44 syn 
9i 8 Furan-2-yl 57 5.31 0.56 syn 
9j 8 1H-Pyrazol-4-yl 62 5.25 0.50 syn 
9k 8 5-Formyl-thien-2-yl – 5.30 0.55 syn 
9l 8 5-Bromo-thien-2-yl 61 5.42 0.67 syn 
9m 8 Indol-2-yl 57 5.42 0.67 syn 
9n 8 Benzofuran-2-yl 53 5.39 0.64 syn 
aΔH-2′ has been calculated as the difference between the chemical shift of H-2′ of the aryl/heteroaryl 
adenine-modified AMP derivatives and H-2′ of AMP (4.75 ppm) in D2O (referenced for D2O,  4.79 
ppm). 
b 1
H NMR spectrum for 9c recorded in CD3OD. 
Table 3.1 Conformational analysis of the various aryl/heteroaryl adenine-modified AMP derivatives 
synthesized in this study. 
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As shown in Table 3.1, a clear trend amongst the various substituted AMP derivatives 
could be observed. In particular, AMP derivatives substituted on C-2 and C-6 adopted a 
favoured anti conformation and an S-type conformer percentage ≥ 50. In contrast, AMP 
derivatives substituted on C-8 preferred a syn conformation with an S-type conformer 
percentage > 50. Looking at the molecular structures of the several AMP derivatives 
(Figure 3.2), these were the expected behaviours. Indeed, AMP derivatives substituted 
on C-2 were very hindered on the pyrimidine ring and, therefore, they could not afford a 
syn conformation which would bring a huge steric hindrance with the ribose. Regarding 
the AMP derivatives substituted on C-6, that have the substituent heading in the 
opposite direction compared to the ribose, they could assume the same anti 
conformation as the natural AMP. Finally, AMP derivatives substituted on C-8 
preferred to place the substituents far from the ribose, assuming therefore a syn 
conformation, in which the pyrimidine ring steric hindrance was less strong than that 
deriving from the substituents. 
3.1.2 Conformation of aryl/heteroaryl adenine-modified NAD+ derivatives 
The conformations of the NAD
+
 derivatives followed approximatively the same trend 
described for the corresponding AMP derivatives. Therefore, the NAD
+
 derivatives 
substituted on C-2 had the adenine in anti conformation, slightly turning into syn 
conformation compared to the favoured anti conformation in the AMP derivatives. The 
NAD
+
 derivatives substituted on C-8 generally preferred the adenine in syn 
conformation and the ribose in S (Table 3.2).
70
 Slight differences of S-type conformer 
percentage and ΔH-2′ in the NAD+ derivatives compared to the AMP derivatives, were 
due to a different arrangement of the riboses and the adenine ring within the β-NAD+ 
structure. Indeed, β-NAD+ is a very flexible molecule because of a variety of rotatable 
bonds and many different functional groups, which are able to interact in several ways 
with each other, with the solvent and/or with the amino acids of the enzymatic pockets 
where β-NAD+ is the substrate.  
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cmpd 
Position of 
substitution 
R (substituent) 
S-type conformer 
(%) (10J1ꞌ,2ꞌ) 
H-2′ 
(ppm) 
ΔH-2′ 
(ppm)
a syn/anti 
β-NAD+ - H 55 4.71 – anti 
13a 2 Iodo 53 4.74 0.03 anti 
13b 2 Phenyl – 4.84 0.13 anti 
15b 8 Phenyl 59 5.14 0.43 syn 
15c 8 3-(N-Boc-
aminomethyl)phenyl 
– 5.16 0.45 syn 
15e 8 Pyridin-3-yl 57 5.24 0.53 syn 
15g 8 2,4-DMT-pyrimidin-5-yl 55 5.08 0.37 syn 
15h 8 Pyrrol-2-yl 48 5.33 0.62 syn 
aΔH-2′ has been calculated as the difference between the chemical shift of H-2′ of the aryl/heteroaryl 
adenine-modified NAD
+
 derivatives and H-2′ of β-NAD+ (4.71 ppm) in D2O (referenced for D2O,  
4.79 ppm). 
Table 3.2 Conformational analysis of the various aryl/heteroaryl adenine-modified NAD
+
 derivatives 
synthesized in this study. 
3.2 Nucleobases and their photochemical properties 
Absorption and emission spectroscopies are based respectively on the measurement of 
light absorbed or emitted by molecules. Depending on the energy of the absorbed light, 
different phenomena can occur in the molecules and, consequently, different techniques 
have been developed to explore them.  
UV/Vis absorption spectroscopy looks at the absorption by the molecules of UV/Vis 
light, which promotes the electrons in the external shell from the ground state, S0, to an 
electronically excited state, S1. Then, the excited electrons decay back to the S0 
dissipating the energy by different processes, non radiative in the form of heat, or 
radiative by emission of photons. The last process is called photoluminescence. 
Photoluminescence processes can be divided into fluorescence (F) and phosphorescence 
(P) (Figure 3.4). The former occurs when excited and ground states have the same spin 
multiplicities (S1  S0); by contrast, the latter occurs when they have different spin 
multiplicities (T1  S0). The quantum yield (Φ) is a relative fluorescence measurement 
of the compounds, indicating the fraction of excited molecules that decay back by 
fluorescence emission.
181-183
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Figure 3.4 Physical processes occurring when a molecule absorbs UV/Vis light. S0 is the electronic 
ground state of the molecule; S1 and T1 are respectively the excited singlet and triplet states at lower 
energy. The straight arrows indicate radiative processes with emission of photons,while the curly ones the 
non radiative processes to dissipate energy. A (Absorption), F (Fluorescence), P (Phosphorescence), IC 
(Internal Conversion), ISC (Inter System Crossing). 
Fluorescence spectroscopy is a very sensitive technique, largely used in biochemistry to 
investigate and understand many major biochemical topics (e.g. structure, binding, 
recognition). Intrinsically fluorescent biological molecules are present in nature and act 
as natural biochemical probes (e.g. β-NADH, tryptophan, phenylalanine and tyrosine).85 
In the case of nucleic acids, the most common nucleobases, such as purines and 
pyrimidines, are generally not emissive in neutral aqueous conditions. However, rare 
exceptions of naturally occurring emissive nucleobases can be found in nature and used 
as “built-in” probes.47, 184, 185  
In particular, adenine and its corresponding nucleoside, adenosine, can be considered 
not emissive, since their quantum yields are very low (respectively 3 x 10
-4
 and 5 x 10
-5
) 
and the excited-state lifetimes of the order of picoseconds. In adenine, the decay to the 
ground state occurs by internal conversion, adopted by the nucleobases as a natural 
defence to protect the nucleic acids from the photodecomposition. Surprisingly, the 
adenine isomer, 2-amino purine (2-AP), where the NH2 is in position 2 instead of 6 on 
the purine ring, is strongly emissive (Φ = 0.66, and 0.68 for the ribonucleoside) with a 
long excited-state lifetime. In this case, the electronic stabilization of the C-2 
surrounded by three nitrogens would decrease the energy of the excited state, 
minimizing the internal conversion of the excited molecules to the ground state. This is 
just an example of how small changes in the nucleobase structure can modify 
completely its photochemical properties.
186-189
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Owing to the importance of the nucleic acids and their crucial role in life, a deep 
knowledge about their structure and the biological processes in which they are involved, 
such as DNA replication, repair, and recombination, transcription and translation, and 
many others, are some of the most attractive, challenging and always relevant source of 
scientific interest. In addition, nucleosides, nucleotides and their derivatives are 
involved as substrates or signalling molecules in many cellular processes. Therefore, the 
study of their activities and binding to the proteins is important to understand 
fundamental biological processes. For this reason, major efforts have been undertaken 
to synthesize emissive nucleobases that, introduced in nucleosides and their derivatives, 
allow their study by fluorescence spectroscopy. 
3.3 Design of emissive nucleosides 
3.3.1 Fluorophore features 
For the design of emissive nucleosides, many factors influencing the fluorescence 
properties have to be taken in consideration. The main features that characterize a good 
fluorophore are summarised below: 
 Extended electron delocalization; the more extended the delocalization, the more 
stable and at lower energy (red shift) is the excited state, minimising the 
photodecomposition of the molecule. 
 Rigidity of the fluorophore; too many rotational and vibrational levels in the excited 
state can cause the decay to the ground state via vibrational relaxation, decreasing 
the fluorescence emission. 
 Quantum yield of the fluorophore (Φf) is the ratio of photons absorbed to photons 
emitted by fluorescence; the maximum value for Φf is 1. The higher the quantum 
yield, the stronger is the fluorescence of the fluorophore and, consequently, the 
sensitivity of the fluorescence detection, even at low concentrations of the 
fluorophore. 
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 Solvatochromism, or fluorescence changes of the molecules depending on the 
surrounding environment, such as the polarity and the H-bonding ability of the 
solvent. The solvent molecules that solvate the fluorophore assist the stabilization of 
its excited state by solvent relaxation. The stronger the solvation, the higher is the 
solvent relaxation; hence, the more stable and at lower energy (red shift) is the 
excited state and the larger is the distance between λex and λem (Stokes shift). 
 Quenching, or any process which decreases the fluorescence of a molecule. It can be 
caused by quenchers present in the sample, such as O2, or by the same fluorophore, 
if present in too high concentrations (self-quenching). The quenching can be due to 
intra/intermolecular collisions (dynamic quenching); or to the formation of not 
emissive fluorophore-quencher complexes (static quenching).
181-183
 
Keeping in mind all these factors influencing the fluorescence, it is possible to design 
fluorophores with suitable features to their use. 
3.3.2 Families of existing nucleobase-modified emissive nucleosides 
Several approaches have been followed to obtain emissive nucleosides, such as the 
modification on the nucleobase or the ribose.
47, 185
 Herein, the attention has been 
focused on the main families of emissive nucleosides modified on the nucleobase.
184, 190
  
Figure 3.5 shows the emissive nucleosides obtained by the replacement of the 
nucleobases with well known fluorophores, as polycyclic aromatic hydrocarbons 
(PAH), or natural heterocycles, as pteridines; or by the introduction on the nucleobases 
of fluorophores not directly conjugated with them. This family of emissive nucleosides 
is characterized by the fluorescent properties of the attached fluorophores.
191
 
Since the fluorescence is due to an extended delocalization of π-electrons, it is possible 
to obtain emissive nucleosides extending the electronic delocalization of the natural 
nucleobases. From this approach, the so-called expanded and extended nucleobases 
have been generated (Figure 3.6).  
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Figure 3.5 Emissive nucleosides obtained by replacement of the nucleobases or introduction on their 
skeleton of known fluorophores. 
 
Figure 3.6 Expanded and extended nucleosides, obtained by extension of the π-electrons delocalization of 
the nucleobases. 
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The expanded nucleobases have additional aromatic rings fused to the natural 
nucleobases to extend their electronic conjugation (inspired by the rare natural wye 
nucleosides found in tRNA
192, 193
).
83, 194-196
 In contrast, the extended nucleobases have 
known fluorophores connected via electronically conjugated linkers.
130, 197-200
 The 
emissive nucleosides belonging to these families are characterized by peculiar 
fluorescent properties, since all the conjugated groups of the molecule are an integral 
part of fluorophore.  
Finally, the isomorphic nucleobases are heterocycles resembling the natural 
nucleobases in size and H-bonding patterns, but with characteristic fluorescent features 
(Figure 3.7).
151, 152, 172, 200-203
 
 
 
Figure 3.7 Emissive isomorphic nucleosides. 
Many of them contain aryl/heteroaryl groups as substituents on the purine and 
pyrimidine skeleton. It has already been reported that adenosines substituted on C-8 of 
the adenine ring with aryl/heteroaryl groups belong to the class of emissive isomorphic 
nucleosides,
130, 200, 202
 while those substituted on C-2 and C-6 are weakly emissive, as 
experimental evidence will suggest in this study.  
In this chapter, the spectroscopic analysis of aryl/heteroaryl adenine-modified AMP and 
corresponding NAD
+
 derivatives, synthesized in Chapter 2, will be performed in view 
of their possible biochemical applications. 
Chapter 3 
 
94 
 
3.4 Measurements of quantum yield for aryl/heteroaryl adenine-modified AMP and 
NAD+ derivatives 
The most common method to measure the unknown quantum yield of a fluorophore, Φx, 
is the comparative method,
204, 205
 which involves the use of standards with known Φst 
values. Indeed, assuming that solutions of standard and sample at the same λex absorb 
the same number of photons, the ratio between the integrated fluorescence intensities of 
the two solutions will be the ratio of their Φ values, from which Φx can be easily 
calculated. 
In practice, the quantum yield measurements can be affected by many factors that 
influence the experimental results. The choice of the standards, which must have similar 
λex and, possibly, also λem to the compound with unknown Φx, is critical. The cross-
calibration of two standards with each other is crucial for robust and reliable results, 
since the Φst is used to calculate Φx. Only when the cross-calibration gives Φst values in 
agreement with those in the literature, it is possible to proceed to the measurement of Φx 
with a certain level of confidence. In addition, the choice of a proper range of 
concentrations to guarantee a linear response in the absorbance and fluorescence 
measurements is fundamental to correctly measure Φx. Indeed, at high concentrations 
the self-quenching phenomena are quite common due to intermolecular collisional 
energy transfers. 
For the Φx measurement, absorbance and fluorescence spectra of sample and standard at 
different dilutions are recorded and their integrated area plotted, fluorescence versus 
absorbance. The gradient of the two extrapolated lines (Gradx and Gradst) can be 
substituted in the following equation [1] and corrected for the refractive indexes of 
sample and standard solutions (ηx and ηst), allowing the calculation of Φx: 
Φx = Φst (
     
      
) (
  
 
   
 )                           [1] 
 values were calculated for different AMP and NAD+ derivatives synthesized in 
Chapter 2, using 2-amino pyridine and tryptophan as standards, previously cross-
calibrated to each other. AMP and NAD
+
 derivatives substituted respectively in 2 and 6 
position on the adenine ring turned out to be poorly emissive. A simple evaluation of 
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their fluorescence was performed by visualization under UV light (254/365 nm) of their 
spots in TLC, showing no trace of fluorescence;  values were calculated only for the 
6-(pyrrol-2-yl) AMP (8b) and the corresponding NAD
+
 derivative (14b), which showed 
in these conditions to be slightly more fluorescent than the others. In contrast, 8-
substituted AMP and NAD
+
 derivatives were good fluorophores and, therefore,  
values were calculated for many of them.  
3.5 Spectroscopic analysis of aryl/heteroaryl adenine-modified AMP derivatives 
Table 3.3 summarises the spectroscopic analysis for aryl/heteroaryl adenine-modified 
AMP derivatives synthesized in Chapter 2. Different trends in λex, λem, Stokes shift and 
 values were observed in the series of fluorescent 8-aryl/heteroaryl AMP derivatives 
depending on the nature of the substituent; the values followed approximately the same 
trends in water and methanol. 
 
cmpd 
Position of 
substitution 
R (substituent) solvent λex/nm λem/nm 
Stokes 
shift
a
/cm
-1
 
AMP – H Water  260 380 12146 – 
7b 2 Phenyl Water  270 374 10299 – 
8a 6 Phenyl Water  288 387 8882 – 
8b 6 Pyrrol-2-yl Water  340 382 3234 0.0041 
9b 8 Phenyl 
Water  274 381 10250 0.669 
MeOH 281 376 8991 0.225 
9c 8 
3-(N-Boc-
aminomethyl)phenyl 
Water  274 383 10387 0.888 
MeOH 281 378 9132 0.639 
9e 8 Pyridin-3-yl 
Water  277 401 11163 0.0034 
MeOH 287 406 10213 0.021 
9f 8 Pyridin-4-yl 
Water  284 421 11458 0.032 
MeOH 293 422 10433 0.044 
9g 8 2,4-DMT-pyrimidin-5-yl 
Water  270 410 12647 0.021 
MeOH 272 404 12012 0.147 
9h 8 Pyrrol-2-yl 
Water  306 374 5942 0.231 
MeOH 306 376 6084 0.272 
9i 8 Furan-2-yl 
Water  302 378 6658 0.538 
MeOH 300 375 6667 0.638 
9k 8 5-Formyl-thien-2-yl Water  334 436 7004 0.084 
a 
Stokes shift = (1/ex - 1/em). 
Table 3.3 Spectroscopic analysis in water and methanol of natural AMP and aryl-heteroaryl adenine-
modified AMP derivatives synthesized in this study. 
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Firstly, the absorbance spectra of 8-aryl/heteroaryl AMP derivatives were studied. They 
presented two absorbance bands due to different electronic transitions, that at longer 
wavelengths (lowest energy) diagnostic for the substituents introduced on the adenine 
ring and, therefore, for larger π-electron delocalizations. In Figure 3.8, the absorbance 
spectra of phenyl (9b), pyridin-3-yl (9e) and pyrrol-2-yl (9h) AMP derivatives are 
shown to compare the effect of phenyl, electron-poor and electron-rich substituents on 
the λex maxima. Analysing the shift of λex with the substituents, a red shift 
(bathochromic effect) occurred moving from the phenyl, through the electron-poor, to 
the electron-rich substituted adenine rings (Figure 3.8, Figure 3.9). Indeed, 2,4-DMT-
pyrimidine has the excited state with the highest energy because of the partial aromatic 
delocalization due to its tautomeric form. To follow, the phenyl ring with an equal π-
electron delocalization. Then, the pyridine with the energetic difference between the 
ground (HOMO) and the excited state (LUMO) smaller than benzene, because of the 
non-bonding orbitals containing the nitrogen lone pair (HOMO) at higher energy. 
Finally, the electron-rich heterocycles, better π-donors than the six-membered rings, 
with the smaller difference between HOMO and LUMO due to the large π-electron 
delocalization.  
 
 
Figure 3.8 Absorbance spectra of AMP and 9b,e,h in water. 
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Figure 3.9 Variations of λex with the different substituents in water and methanol for the 8-aryl/heteroaryl 
adenine-modified AMP derivatives synthesized in this study. 
The fluorescence spectra of 8-aryl/heteroaryl AMP derivatives showed a main emission 
band between 370 and 440 nm, typical for the emission of the substituted adenine rings. 
A less intense band between 650 and 900 nm could be due to Pd(II) impurities, deriving 
from the Suzuki-Miyaura cross-coupling. Indeed, Pd(II) can form Pd(II)-adenine 
complexes with the exocyclic NH2 and N-7, or N-1 (Figure 3.10).
206, 207
  
 
 
Figure 3.10 Fluorescence emission spectra of 9b,e,h in water at λex maxima (see Table 3.3). 
The λem for the 8-aryl/heteroaryl AMP derivatives followed a less clear trend compared 
to λex along the different substituents. However, with few exceptions, the trend for λem 
was the same followed by the Stokes shift values, that clearly increased from the 
electron-rich, through the phenyl, to the electron-poor substituted adenine rings (Figure 
3.11). The λem and Stokes shift depend on vibrational and solvent relaxation; the 
stronger these two effects, the larger is the Stokes shift and the longer is the λem. 
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Electron-rich substituted adenine rings, having a large π-electron delocalization, are 
more rigid and planar than those phenyl and electron-poor substituted, having minor π-
electron distribution. Consequently, λem and Stokes shift, depending on vibrational 
relaxation, were larger for electron-poor and phenyl substituted adenine rings, having 
many vibrational energetic levels in the excited state, than those that were electron-rich 
substituted (Figure 3.11). In addition, electron-poor substituted adenine rings had longer 
λem and larger Stokes shift than those phenyl substituted because of a higher solvent 
relaxation, due to their H-bonding ability and large dipole moment in the excited state. 
The Stokes shift values were generally larger in water than in methanol because of more 
H-bonds, which caused a higher solvent relaxation. However, electron-rich substituted 
adenine rings appeared unaffected by the solvent change, with their Stokes shift values 
unchanged between water and methanol. Therefore, these substituents could be 
insensitive to the surrounding environment, as confirmed later from their unchanged  
values.  
 
 
 
 
Figure 3.11 Variations of λem, Stokes shift and quantum yield () values with the different substituents in 
water and methanol for the 8-aryl/heteroaryl adenine-modified AMP derivatives synthesized in this study. 
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The  values for the substituted adenine rings seemed to follow a precise trend along 
the introduced substituents, as well as λex, λem and Stokes shift. In particular, they 
increased moving from the electron-poor, through the electron-rich, to the phenyl 
substituted adenine rings (Figure 3.11). The trend was similar between water and 
methanol. From the previous considerations, electron-rich substituted adenine rings 
would be expected to be the most fluorescent in the series because of a larger π-electron 
delocalization, rigidity and planarity, and limited sensitivity to the solvent effect. 
However, a new factor, the dynamic/static quenching, could influence  values. Indeed, 
the strong planarity of electron-rich substituted adenine rings would favour the 
intermolecular base stacking interactions with consequent fluorescence decrease.  
The  values should increase in methanol compared to water because of a minor 
solvent relaxation. This effect was observed for electron-poor substituted adenine rings; 
in contrast,  values decreased for those phenyl substituted, and remained 
approximately the same for electron-rich substituted adenine rings. In the first case, the 
strongly emissive phenyl substituted adenine rings could undergo a dynamic/static 
fluorescence quenching, decreasing overall their  values. Regarding the electron-rich 
substituted adenine rings, the unchanged  values could be due to their insensitivity to 
the solvent, already observed in the Stokes shift values. 
The spectral properties of AMP derivatives with the same substituent but in different 
positions were analysed (Table 3.4, Figure 3.12). Moving from the AMP derivatives 
substituted on C-6 to those substituted on C-2 and C-8, λex, even more than λem, 
underwent a substantial blue shift (hypsochromic effect), responsible for an increase of 
Stokes shift. In addition, in the case of 8-substituted AMP derivatives, a significant 
increase in  was observed. Therefore, it was suggested that the substitution of the 
exocyclic amino group in position 6 on the adenine ring with aryl/heteroaryl groups 
helped stabilize the electronic configuration of the 6-substituted adenine rings, 
decreasing the gap between HOMO and LUMO, larger otherwise in 2 and 8-substituted 
adenine rings. In addition, the removal of the exocyclic amino group would decrease the 
H-bonding ability of 6-substituted AMP derivatives and, consequently, their Stokes 
shift values. 
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Phenyl substituent Pyrrol-2-yl substituent 
cmpd C λex/nm λem/nm 
Stokes 
shift
a
/cm
-1
 
 cmpd C λex/nm λem/nm 
Stokes 
shift
a
/cm
-1  
7b 2 270 374 10299 – – – – – – – 
8a 6 288 387 8882 – 8b 6 340 382 3234 0.0041 
9b 8 274 381 10250 0.669 9h 8 306 374 5942 0.231 
a 
Stokes shift = (1/ex - 1/em). 
Table 3.4 Comparative spectroscopic analysis of adenine-modified AMP derivatives with the same 
substituent (phenyl and pyrrol-2-yl) in different positions. 
 
 
Figure 3.12 Comparison of fluorescence of adenine-modified AMP derivatives with the same/similar 
aryl/heteroaryl substituent in different positions. To notice the influence of the position of the exocyclic 
amino group on the fluorescence. The direction of the arrow indicates an increase in fluorescence. 
It is important to notice the change in fluorescence related to the position of the 
substituent and the exocyclic amino group on the purine ring (Table 3.4, Figure 3.12). 
As discussed in 3.2, 2-AP is more fluorescent than adenine because of the presence of 
the exocyclic amino group on C-2 instead of C-6. This relatively simple change of 
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position of the substituent decreases the internal conversion of the excited molecules to 
the ground state and, consequently, increases their fluorescence. In the same way, 
looking in Figure 3.12 at the differently substituted adenine rings, it can be observed 
that, when the substituent is on the pyrimidine ring, as in 2-amino-6-(2-thienyl) 
purine,
203
 8a, 8b and 7b, the presence of the exocyclic amino group in the specific 
position 2 is fundamental to generate the fluorescence, more than its absence/presence 
in generic positions. In contrast, its presence in position 6 does generate fluorescence 
only if the substituent is on the imidazole ring. Therefore, energetic differences in 
excited states of adenine rings substituted in different positions are responsible for their 
quantum yield changes. 
3.6 Spectroscopic analysis of aryl/heteroaryl adenine-modified NAD+ derivatives 
Table 3.5 summarises the spectroscopic analysis for aryl/heteroaryl adenine-modified 
NAD
+
 derivatives synthesized in this study. As for the AMP derivatives, different trends 
in λex, λem, Stokes shift and  values were observed in the series of fluorescent 8-
aryl/heteroaryl NAD
+
 derivatives depending on the nature of the substituents. 
 
cmpd 
Position of 
substitution 
R (substituent) solvent λex/nm λem/nm 
Stokes 
shift
a
/cm
-1
 
β-NAD+ – H Water 259 380 12294 – 
13b 2 Phenyl Water 268 380 10998 – 
14a 6 Phenyl Water 289 400 9602 – 
14b 6 Pyrrol-2-yl Water 344 388 3297 0.0012 
15b 8 Phenyl 
Water 272 381 10518 0.2067 
MeOH 274 378 10041 0.080 
15c 8 
3-(N-Boc-
aminomethyl)phenyl 
Water 274 383 10387 0.150 
MeOH 273 379 10245 0.148 
15e 8 Pyridin-3-yl 
Water 273 401 11692 0.0035 
MeOH 276 399 11169 0.016 
15g 8 2,4-DMT-pyrimidin-5-yl 
Water 268 412 13042 0.0026 
MeOH 267 411 13122 0.0054 
15h 8 Pyrrol-2-yl 
Water 309 374 5624 0.0053 
MeOH 307 371 5619 0.055 
a 
Stokes shift = (1/ex - 1/em). 
Table 3.5 Spectroscopic analysis in water and methanol of natural β-NAD+ and aryl-heteroaryl adenine-
modified NAD
+
 derivatives synthesized in this study. 
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The trends along the series of the NAD
+
 derivatives were generally similar to those 
observed for the AMP derivatives. In contrast to the AMP derivatives, the Stokes shift 
values for the NAD
+
 derivatives were approximately the same in water and methanol 
(Table 3.5). This suggested that the NAD
+
 derivatives were generally less influenced by 
the solvatochromism effect than the corresponding AMP derivatives. In addition,  
values remained generally the same, or increased in methanol compared to water. This 
trend, not apparently due to the solvatochromism effect, was attributed to a new factor 
occurring in the NAD
+
 derivatives, such as a dynamic/static fluorescence quenching due 
to the intramolecular stacking interactions, or close proximity between the nicotinamide 
and the substituted adenine rings. These interactions could be disrupted by methanol or 
less polar solvents, which would help β-NAD+ passing from a folded to an extended 
conformation. This phenomenon and other evidence for its occurrence will be largely 
discussed in 3.7.  
Looking carefully at the absorbance spectra of the NAD
+
 derivatives, it was observed 
that the lowest energy band was the result of overlapping bands, due to the substituted 
adenine and the nicotinamide ring (Figure 3.13).  
 
 
Figure 3.13 Absorbance spectrum of 15e in water. The absorbance spectrum is the pink line; the broken 
lines (blue) indicate the overlap for the bands related to the substituted adenine and nicotinamide rings. 
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The fluorescence emission spectra of 8-aryl/heteroaryl NAD
+
 derivatives, shown in 
Figure 3.14, again presented the two typical bands observed for the AMP derivatives.  
 
 
Figure 3.14 Fluorescence emission spectra for 15b,c,e,g,h (0.8 μM in water) at λex maxima (see Table 
3.5). 
Further spectroscopic analyses were performed on 8-aryl/heteroaryl NAD
+
 derivatives. 
In particular, the fluorescence changes with the pH were investigated. Indeed, the 
fluorescence can be strongly influenced by the pH, since different protonation states can 
generate in the fluorophore different π-electron delocalization and distribution. In the 
case of the 8-aryl/heteroaryl NAD
+
 derivatives, the fluorophore examined was the 
substituted adenine ring, which could be protonated on the basic N-1 (Figure 3.15).  
 
 
Figure 3.15 Protonation of N-1 of 8-aryl/heteroaryl adenine-modified NAD
+
 derivatives. 
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At acidic pH, the positive charge on the protonated N-1 destabilized the π-electron 
delocalization on the adenine ring decreasing its fluorescence (hypochromic effect). By 
contrast, at basic pH, the aromaticity of the adenine ring was re-established and the 
fluorescence increased (hyperchromic effect).  
This behaviour was observed for all 8-aryl/heteroaryl NAD
+
 derivatives, with the 
exception of 15g, where fluorescence decreased as the pH increased (Figure 3.16). 
Indeed, at acidic pH, the nitrogens on the 2,4-DMT-pyrimidine would be protonated 
with two partial positive charges; therefore, they would be able to form an extended 
network of H-bonds, making the substituted adenine ring more rigid and, consequently, 
more fluorescent than at basic pH (Figure 3.17). Plotting the fluorescence versus the 
pH, it was possible to extrapolate the pKa values for N-1 of 8-aryl/heteroaryl NAD
+
 
derivatives (Figure 3.16).
172
  
 
 
Figure 3.16 Fluorescence emission at different pH for 15b,c,e,g,h. Conditions: NaOAc/AcOH buffer (50 
mM) was used for pH 3 and 4; KH2PO4/NaOH buffer (50 mM) was used for pH 6; Tris/HCl buffer (50 
mM) was used for pH 7, 8 and 9. The compound concentrations were respectively: 1.01 μM for 15b, 3.9 
μM for 15c, 3.6 μM for 15e, 3.5 μM for 15g, 0.81 μM for 15h. Fluorescence emission spectra were 
recorded at λex maxima (see Table 3.5), rt. Emission spectra areas were normalized to the highest value 
for each compound and the values were fitted to the pKa single equation using GraFit5 (except for 15g, 
fitted to a single exponential equation).  
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The pKa calculated by potentiometric titration for β-NAD
+
 is 3.88 ± 0.02.
186, 208
 As 
shown in Table 3.6, the pKa values obtained for 8-aryl/heteroaryl NAD
+
 derivatives 
were close to that of the natural β-NAD+, although following a certain trend depending 
on the nature of the substituent, which influenced the basicity of N-1.  
 
cmpd R (substituent on C-8) pKa 
β-NAD+  208 H 3.88 ± 0.02 
15b Phenyl 3.81 ± 0.04 
15c 3-(N-Boc-aminomethyl)phenyl 3.95 ± 0.14 
15e Pyridin-3-yl 2.69 ± 0.18 
15h Pyrrol-2-yl 4.07 ± 0.21 
Table 3.6 pKa values for the natural β-NAD
+
 and 15b,c,e,h.  
The phenyl substituents in 15b and 15c did not change substantially the π-electron 
delocalization of the adenine ring, which had very similar pKa values to β-NAD
+
. The 
electron-poor substituents, withdrawing electrons from the adenine ring, decreased the 
pKa of N-1; in particular, the pyridine ring in 15e at acidic pH would be present as the 
pyridinium ion, a very strong electron-withdrawing group. The electron-rich 
substituents, as the pyrrole in 15h, donated electrons to the adenine ring increasing the 
basicity of N-1 and, therefore, its pKa. A red shift (bathochromic effect) in λem was 
observed for 15e and 15g as the pH increased. This effect could be due to a stronger 
vibrational relaxation occurring at basic pH, because of the lack of H-bonds occurring at 
acidic pH (Table 3.7, Figure 3.17). In contrast, λem for the other substituted adenine 
rings did not undergo any substantial shift with the pH (Table 3.7). 
 
 λem/nm 
cmpd R (substituent on C-8) pH 3 pH 4 pH 6 pH 7 pH 8 pH 9 
15b Phenyl 385 382 383 383 383 383 
15c 3-(N-Boc-aminomethyl)phenyl 383 383 383 384 384 384 
15e Pyridin-3-yl 374 390 404 404 406 406 
15g 2,4-DMT-pyrimidin-5-yl 380 387 413 413 413 415 
15h Pyrrol-2-yl 375 375 375 375 375 375 
Table 3.7 λem maxima of 15b,c,e,g,h at different pH. Conditions: NaOAc/AcOH buffer (50 mM) was used 
for pH 3 and 4; KH2PO4/NaOH buffer (50 mM) was used for pH 6; Tris/HCl buffer (50 mM) was used 
for pH 7, 8 and 9. Fluorescence emission spectra at λex maxima (see Table 3.5), rt. 
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Figure 3.17 Network of H-bonds around 15e and 15g, responsible for the red shift of λem in 15e and 15g 
with the increase of the pH, and the hypochromic effect at basic pH in 15g. Conditions: NaOAc/AcOH 
buffer (50 mM) was used for pH 3 and 4; KH2PO4/NaOH buffer (50 mM) was used for pH 6; Tris/HCl 
buffer (50 mM) was used for pH 7, 8 and 9. The compound concentrations were respectively: 3.6 μM for 
15e and 3.5 μM for 15g. Fluorescence emission spectra were recorded at λex maxima (see Table 3.5), rt. 
Emission spectra areas were normalized to the highest value for each compound. 
3.7 Fluorescence quenching in 8-aryl/heteroaryl NAD+ derivatives 
3.7.1 Fluorescence basis for internal quenching in NAD+ derivatives 
As mentioned in 3.6, clues for a dynamic/static fluorescence quenching due to the 
intramolecular interactions between the nicotinamide and the 8-aryl/heteroaryl adenine 
rings of the corresponding NAD
+
 derivatives were found comparing  values in water 
and methanol. Indeed, the values suggested a fluorescence quenching occurring in 
water, where the β-NAD+ scaffold would assume a folded conformation with the 
hydrophobic aromatic rings in close proximity with each other. Methanol would disrupt 
these interactions solvating the aromatic rings and allowing the passage of β-NAD+ 
from a folded to an extended conformation with re-establishment of the fluorescence.
64, 
209
 
A thorough investigation was undertaken to explore this phenomenon in the series of 8-
aryl/heteroaryl NAD
+
 derivatives synthesized in this project. Similar studies have been 
previously undertaken with another important fluorescent NAD
+
 derivative, ε-NAD+,87 
already introduced in Chapter 1 (Figure 3.18). This compound and its derivatives (ε-
AMP, ε-ADP, ε-ATP, ε-ADPR, cεADPR) have been extensively studied since the early 
1970s, and have found wide applications as fluorescent probes for several enzymes, due 
to their characteristic fluorescent features.
83, 210
 Indeed, etheno-derivatives are 
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characterized by λex and λem not interfering with those of biological systems (Table 3.8). 
Moreover, their high  values make them very good fluorescent probes.  
 
cmpd λex/nm λem/nm Stokes shift
a
/cm
-1  
ε-NAD+  83 306 410 8289 0.028 
ε-AMP 306 400 7680 0.56 
Tryptophan
181
 295 353 5570 0.13 
Tyrosine
181
 275 304 3469 0.14 
Phenylalanine
181
 260 282 3000 0.02 
a 
Stokes shift = (1/ex - 1/em). 
Table 3.8 Spectroscopic properties of ε-NAD+ and fluorescent amino acids. 
In the case of ε-NAD+, a low quantum yield value is due to a strong internal 
fluorescence quenching occurring between the stacked ε-adenine and nicotinamide rings 
in the ε-NAD+ structure. These stacking interactions can be disrupted by chemical or 
enzymatic removal of the nicotinamide ring with consequent fluorescence increase. 
Indeed, the quantum yield value of ε-AMP is ~ 20 fold greater than the corresponding ε-
NAD
+
 (Table 3.8, Figure 3.18).
83, 87, 88
 The internal quenching occurring in the intact ε-
NAD
+
 compared to the ε-adenine moiety is the basis for the development of 
fluorescence-based assays for NAD
+
-consuming enzymes,
7
 that use β-NAD+ as a 
substrate, cleaving the high-energy bonds present in its structure (i.e. the pyrophosphate 
and N-glycosidic bond). A short review of the main assays for NAD
+
-consuming 
enzymes based on the fluorescence changes of ε-NAD+ has been presented in 1.4.2. 
The fluorescence quenching in ε-NAD+ is due to a mixed dynamic/static quenching. 
The dynamic quenching is mainly due to intramolecular collisional interactions of the 
excited molecule and, therefore, it affects the quantum yield and the fluorescence 
lifetime. In contrast, the static quenching is due to the formation of dark, not emissive 
complexes between the stacked bases in the ground state and, therefore, it affects the 
quantum yield but not the fluorescence lifetime. It is possible by measurement of 
fluorescence lifetimes to distinguish the two type of quenching and their contributions; 
it has been shown that ε-NAD+ is subjected to both, with prevalence of the static 
quenching. Moreover, it has been calculated that ε-NAD+ at 25 °C in water is present in 
a 45 ± 5% stacked conformation.
88
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Figure 3.18 ε-NAD+ and its fluorescence internal quenching. 
Different studies were undertaken to prove the existence of an intramolecular 
fluorescence quenching in the series of fluorescent 8-aryl/heteroaryl NAD
+
 derivatives. 
Interesting information could be deducted from the comparison of quantum yield values 
between AMP and NAD
+
 derivatives (Table 3.9). The quantum yield values of 8-
aryl/heteroaryl AMP derivatives were higher than the corresponding NAD
+
 derivatives, 
with the only exception of 8-(pyridin-3-yl) AMP (9e) and its corresponding NAD
+
 
derivative (15e).
172
 As for ε-NAD+, these differences in quantum yield could occur 
because of an intramolecular fluorescence quenching due to stacking and collisional 
interactions between the fluorophore and the nicotinamide ring. The larger the  
differences, the stronger would be the interactions between the two aromatic rings. 8-
(Pyrrol-2-yl) AMP (9h) and its corresponding NAD
+
 derivative (15h) showed the 
largest  difference in water amongst the NAD+ derivatives synthesized. This effect 
could be due to a stronger planarity of the 8-(pyrrol-2-yl) adenine ring, which facilitated 
the stacking interactions with the nicotinamide ring. When  values for this couple 
were measured in methanol,  difference decreased since the organic solvent helped the 
solvation and the separation of the hydrophobic aromatic rings in 15h with re-
establisment of the fluorescence. In contrast, 8-(pyridin-3-yl) AMP (9e) and its 
corresponding NAD
+
 derivative (15e) did not show any  difference either in water or 
methanol, indicating a possible lack of planarity in the 8-(pyridin-3-yl) adenine ring 
and, consequently, poor stacking interactions with the nicotinamide ring. 
  
Weak fluorescence Strong fluorescence!
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cmpd scaffold 
Position of 
substitution 
R (substituent) solvent AMP NAD AMP/NAD 
NAD+83 NAD 
n.a. n.a. Water 0.56 0.028 20 
AMP83 AMP 
14b 
8b 
NAD 
6 Pyrrol-2-yl Water 0.0041 0.0012 3.42 
AMP 
15b NAD 
8 Phenyl 
Water 0.669 0.2067 3.24 
9b AMP MeOH 0.225 0.080 2.81 
15c NAD 
8 
3-(N-Boc-
aminomethyl)phenyl 
Water 0.888 0.150 5.92 
9c AMP MeOH 0.639 0.148 4.32 
15e NAD 
8 Pyridin-3-yl 
Water 0.0034 0.0035 0.97 
9e AMP MeOH 0.021 0.016 1.31 
15g NAD 
8 
2,4-DMT-pyrimidin-5-
yl 
Water 0.021 0.0026 8.08 
9g AMP MeOH 0.147 0.0054 27.22 
15h NAD 
8 Pyrrol-2-yl 
Water 0.231 0.0053 43.58 
9h AMP MeOH 0.272 0.055 4.94 
n.a. not applicable. 
Table 3.9 Comparison of  values in water and methanol for ε-AMP/ε-NAD+, and aryl/heteroaryl 
adenine-modified AMP/NAD
+
 derivatives synthesized in this study. 
To further prove the existence of the internal quenching in 8-aryl/heteroaryl NAD
+
 
derivatives and its decrease passing from water to an organic solvent, a methanol 
titration of aqueous solutions of 8-aryl/heteroaryl NAD
+
 derivatives was performed 
(Figure 3.19). In fact, even if the trends did not completely agree with  values 
calculated in methanol for the different compounds, a general fluorescence increase was 
observed with the increase of methanol percentage, as expected from the disruption of 
the internal quenching in organic solvent.
211
 In addition, a blue shift in λem maxima for 
the different NAD
+
 derivatives was observed with the increase of the methanol 
percentage because of a lower solvent relaxation occurring in methanol compared to 
water (Table 3.10). However, the shift was so small that it did not substantially modify 
the Stokes shift values, as observed in 3.6, making the NAD
+
 derivatives quite 
insensitive to slight environmental changes.  
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Figure 3.19 MeOH titration of 15c,e,g,h. Conditions: aqueous solutions of the different NAD
+
 derivatives 
with several MeOH percentage (ranging from 10 to 90% MeOH with an interval of 20%) were prepared 
and their fluorescence emission spectra recorded at λex maxima (see Table 3.5), rt. The fluorescence 
emission values at λem maxima for the spectra at different MeOH percentage were normalized for those at 
λem maxima in H2O for each compound; then, the normalized values were plotted as function of the 
solvent composition. 
 
 λem/nm at different MeOH/H2O (%) 
cmpd R (substituent on C-8) 0 10 30 50 70 90 
15c 3-(N-Boc-aminomethyl)phenyl 384 382 382 382 379 380 
15e Pyridin-3-yl 406 415 405 401 399 407 
15g 2,4-DMT-pyrimidin-5-yl 411 414 410 410 409 409 
15h Pyrrol-2-yl 375 374 373 373 372 370 
Table 3.10 λem maxima of 15b,d,f,g at different MeOH percentage. Conditions: aqueous solutions of the 
different NAD
+
 derivatives with several MeOH percentage (ranging from 10 to 90% MeOH with an 
interval of 20%) were prepared and their fluorescence emission spectra recorded at λex maxima (see Table 
3.5), rt. 
Finally, a chemical hydrolysis of the fluorescent 8-aryl/heteroaryl NAD
+
 derivatives 
was performed to give conclusive evidence of the internal fluorescence quenching due 
to the intramolecular interactions between the fluorescent substituted adenine and 
nicotinamide rings. As discussed in 1.1, the nicotinamide N-glycosidic bond can be 
hydrolysed in 0.1 – 1 N NaOH with a first order reaction in hydroxide.8, 9, 11 The 
removal of NaM in 8-aryl/heteroaryl NAD
+
 derivatives would result in the formation of 
the corresponding 8-aryl/heteroaryl ADPR derivatives, with re-establishment of the 
fluorescence of the substituted adenine rings.  
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The chemical hydrolysis for all 8-aryl/heteroaryl NAD
+
 derivatives was followed by 
fluorescence (Figure 3.20) and, in the case of 8-(pyrrol-2-yl) NAD
+
 (15h), also by 
HPLC (Figure A1).
172
 As expected, a fluorescence increase was observed during the 
hydrolysis of all NAD
+
 derivatives examined. However, the fluorescence increase was 
higher for 15h, which showed the strongest fluorescence internal quenching amongst 
the NAD
+
 derivatives synthesized. The HPLC time-course for the basic hydrolysis of 
15h confirmed the formation of NaM and the corresponding ADPR derivative, 23. 
 
 
Figure 3.20 Fluorescence time-course for the basic hydrolysis of NAD
+
 derivatives 15b,c,e,g,h. 
Conditions: 0.8 μM in 0.1 N NaOH, rt; for λex and λem maxima, see Table 3.5. 
3.7.2 NMR basis for internal quenching in NAD+ derivatives 
To investigate if dynamic/static quenching was occurring in aryl/heteroaryl adenine-
modified NAD
+
 derivatives, NMR studies were undertaken. Indeed, the occurrence of 
π-stacking interactions between aromatic rings can influence the chemical shifts of their 
protons because of a “shielding-increasing” ring current. Therefore, an upfield shift 
should be observed with the increase of π-stacking interactions, which shield the 
aromatic protons; and viceversa, a downfield shift should occur when the π-stacking 
interactions decrease and the protons are deshielded.  
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This phenomenon has been largely studied on nucleosides and nucleotides which self-
associate by intermolecular π-stacking interactions depending on their concentration in 
aqueous solution.
212, 213
 The more diluted the solution, the less self-association is 
observed between the nucleobases. In the case of β-NAD+ and NAD+ derivatives, the 
prevalent intramolecular π-stacking interactions are concentration-independent; only at 
high concentrations, also intermolecular associations start to occur.
214-218
 Consequently, 
to show the occurrence of intramolecular π-stacking interactions in diluted aqueous 
solutions, a titration experiment monitored by 
1
H NMR was set up to observe the effect 
of increasing percentages of acetonitrile on the protons of the natural β-NAD+ and 8-
(pyrrol-2-yl) NAD
+
 (15h). Changes in the chemical shifts of the protons of the two 
molecules should show the passage of the β-NAD+ scaffold from a folded to an open 
conformation. This experiment was the analogue of the methanol titration performed on 
8-aryl/heteroaryl NAD
+
 derivatives and monitored by fluorescence in Figure 3.19. As 
expected, a downfield shift in the aromatic protons occurred with the increase of 
acetonitrile in both the natural β-NAD+ and 15h, with a stronger effect in the case of 
15h. Indeed, the 8-(pyrrol-2-yl) adenine ring could be able to establish stronger π-
stacking interactions than the adenine itself with the nicotinamide ring because of a 
more extended ring current and strong planarity.  
Following the titration of β-NAD+, 2N-H and 2-H showed a significant downfield shift 
with the increase of acetonitrile in solution, compared to a smaller shift for 4N-H and 
5N-H. In contrast, 6N-H and 8-H showed an upfield shift (Figure 3.21). Strong 
interactions between the pyrimidine part of the adenine ring and the nicotinamide would 
occur in water more than in acetonitrile, facilitated by the formation of H-bonds; the 
result would be the substantial shielding of 2N-H and 2-H. Conversely, 6N-H and 8-H, 
because of their positions on the aromatic rings, would be only partially involved in the 
shielding interactions occurring between the six-membered rings; this would result in a 
deshielding effect stronger in water than in acetonitrile. 
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Figure 3.21 
1
H NMR analysis of aromatic protons in β-NAD+ with increasing percentage of ACN.  
indicates the difference in chemical shift between the highest and the lowest ACN percentage: values are 
given in ppb (part per billion: 1000 ppb = 1 ppm). Conditions: solutions in D2O of β-NAD
+
 (0.0025 M) 
with several ACN percentage (ranging from 10 to 60% anhydrous ACN with an interval of 10%) were 
prepared and their 
1
H NMR spectra recorded at rt. The spectra were referenced to the protons of CH3 in 
ACN (H 2.06). 
Since the solvation of the aromatic rings in organic solvents promotes the passage of β-
NAD
+
 from a folded to an open conformation, a change in the conformation of the 
riboses and, consequently, in the chemical shifts and J coupling constants of their 
protons (Figure 3.22, Figure 3.23) should be observed.  
The chemical shifts and J coupling constants of 1′-H and 1′′-H were analysed. 1′-H and 
its J1ꞌ,2ꞌ did not undergo any substantial change with the solvent composition. On the 
other hand, 1′′-H did undergo an upfield shift, or a shielding effect, with increasing 
percentage of acetonitrile. This effect could be due to a change in the conformation of 
the nicotinamide ribose, which would bring 1′′-H far apart from the positively charged 
nicotinamide ring. In addition, J1ꞌꞌ,2ꞌꞌ decreased with increasing acetonitrile percentage, 
indicating the preference of the nicotinamide ribose toward a N-conformation in the β-
NAD
+
 extended conformation (see 3.1).  
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Figure 3.22 
1
H NMR analysis of 1′-H and 1′′-H in β-NAD+ with increasing percentage of ACN.  
indicates the difference in chemical shift between the highest and the lowest ACN percentage: values are 
given in ppb (part per billion: 1000 ppb = 1 ppm). Conditions: solutions in D2O of β-NAD
+
 (0.0025 M) 
with several ACN percentage (ranging from 10 to 60% anhydrous ACN with an interval of 10%) were 
prepared and their 
1
H NMR spectra recorded at rt. The spectra were referenced to the protons of CH3 in 
ACN (H 2.06). 
In Figure 3.23, the NMR peaks for 1′-H and 1′′-H are shown at different acetonitrile 
percentage. 1′′-H showed a substantial upfield shift compared to 1′-H with increasing 
acetonitrile percentage. The 1′′-H peak, during its upfield shift, overlapped the 1′-H 
peak at 20% of acetonitrile. 
 
 
Figure 3.23 
1
H NMR peaks of 1′-H and 1′′-H in β-NAD+ with increasing percentages of ACN. 
Conditions: solutions in D2O of β-NAD
+
 (0.0025 M) with several ACN percentage (ranging from 10 to 
60% anhydrous ACN with an interval of 10%) were prepared and their 
1
H NMR spectra recorded at rt. 
The spectra were referenced to the protons of CH3 in ACN (H 2.06). 
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In 15h, a downfield shift with increasing acetonitrile percentage occurred for all 
aromatic signals with stronger or weaker intensity, indicating an extended “shielding-
increasing” ring current involving all aromatic protons (Figure 3.24). However, 2-H, 
which in β-NAD+ was undergoing a strong downfield shift, in 15h showed only a very 
weak shift. This effect could be due to the deshielding effect played by the close 
phosphate group, since the adenine ring assumed in 15h a syn conformation (Figure 
3.25).  
 
 
Figure 3.24 
1
H NMR analysis of aromatic protons in 15h with increasing percentage of ACN.  
indicates the difference in chemical shift between the highest and the lowest ACN percentage: values are 
given in ppb (part per billion: 1000 ppb = 1 ppm). Conditions: solutions in D2O of 15h (0.0025 M) with 
several ACN percentage (ranging from 10 to 60% anhydrous ACN with an interval of 10%) were 
prepared and their 
1
H NMR spectra recorded at rt. The spectra were referenced to the protons of CH3 in 
ACN (H 2.06). 
In 15h, 1′-H and 1′′-H, conversely to their behaviour in β-NAD+, showed a downfield 
shift, or a deshielding effect, with increasing acetonitrile percentage (Figure 3.26). This 
effect could indicate the involvement of these protons in the “shielding-increasing” ring 
current, stronger in 15h than in β-NAD+. In addition, J1ꞌ,2ꞌ and J1ꞌꞌ,2ꞌꞌ decreased with 
increasing acetonitrile percentage. Therefore, during the passage of 15h from a folded to 
an open conformation, both riboses puckered toward a N-conformation (see 3.1), 
especially the nicotinamide ribose.  
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Figure 3.25 β-NAD+ and 15h folded conformations. 
 
 
Figure 3.26 
1
H NMR analysis of 1′-H and 1′′-H in 15h with increasing percentage of ACN.  indicates 
the difference in chemical shift between the highest and the lowest ACN percentage: values are given in 
ppb (part per billion: 1000 ppb = 1 ppm). Conditions: solutions in D2O of 15h (0.0025 M) with several 
ACN percentage (ranging from 10 to 60% anhydrous ACN with an interval of 10%) were prepared and 
their 
1
H NMR spectra recorded at rt. The spectra were referenced to the protons of CH3 in ACN (H 2.06). 
From the 2D NOESY experiment on 15h, no particular NOE signals were observed, 
with the exception of that correlating 1′-H and 3pyrrole -H, as expected because of the 
syn conformation of the adenine and the consequent proximity of the two protons 
(Figure 3.25). Unfortunately, the molecular weight of 15h is in the range where the 
NOE signal should be theoretically zero; consequently, the 2D NOESY experiment did 
not allow observation of any interaction between the aromatic bases. 
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Of course, it is difficult to predict only from the 
1
H NMR experiments the presence of 
β-NAD+ and its derivatives in solution in a folded or open conformation. Many studies 
have been undertaken to find a univocal solution using different techniques; however, 
contrasting opinions have been often reached.
64, 214-216
 Surely, intramolecular 
interactions between the aromatic bases are present in aqueous solutions of β-NAD+, 
due to stacking or just proximity effects. However, it is not possible to exclude the 
presence of intermolecular stacking interactions depending on the concentration. In 
addition, the interactions between the nucleobases could occur in many different ways, 
depending on the orientation of the aromatic faces.
214
 The results shown here seem at 
least to confirm the presence of interactions between the aromatic bases in aqueous 
solutions and, in particular, a stronger effect occurring in 15h compared to β-NAD+. 
This is in agreement with what we would expect from a more extended π-electron 
delocalization occurring in the 8-(pyrrol-2-yl) adenine, which increases the eventual π-
stacking interactions with the nicotinamide ring.  
3.8 Conclusions 
In contrast to the non-emissive adenine derivatives modified in position 2 or 6 with 
aryl/heteroaryl substituents, the fluorescence features of 8-aryl/heteroaryl adenine 
derivatives make them interesting compounds from the perspective of the applicability 
as biochemical tools to investigate enzymatic structures, bindings and activities. Indeed, 
since the development of the ε-adenine derivatives and their versatile biological 
applications, not many other isomorphic fluorescent adenine derivatives have been 
developed with the same purpose of fluorescent probes. However, in this series of 
isomorphic emissive 8-aryl/heteroaryl adenine derivatives a new fluorophore class can 
be identified with tunable fluorescent properties and, in some cases, as will be shown 
later, unique behaviours toward certain types of enzymes. A comparison between ε-
adenine and 8-aryl/heteroaryl adenine derivatives is shown in Table 3.11 and Figure 
3.27. 
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ε-adenine derivatives 8-aryl/heteroaryl adenine derivatives 
Fixed modification (etheno bridge) Variable modification (aryl/heteroaryl substituent) 
N-1 and NH2 blocked N-1 and NH2 free for H-bonds 
Adenine in anti conformation Adenine in syn conformation 
λex = 306 nm; λem = 410 nm (ε-NAD
+
) λex = 309 nm; λem = 374 nm (15h) 
AMP/NAD = 20 (ε-NAD
+
)  AMP/NAD = 44 (15h) 
Table 3.11 Comparison between ε-adenine and 8-aryl/heteroaryl adenine derivatives. 
A characteristic feature of 8-aryl/heteroaryl adenine derivatives is their highly variable 
structure, due to the large range of substituents that can be introduced on C-8 of the 
adenine ring by Suzuki-Miyaura cross-coupling. As shown later in the chapter, by 
changing the substituent, it is possible to modulate the fluorescent properties of the 
compounds. Therefore, it would be theoretically possible to predict the fluorescent 
properties depending on the nature of the introduced substituents. This structural 
variability is not applicable to the ε-adenine, where the etheno bridge, extending the 
aromaticity of the modified adenine ring, is responsible for the fluorescent properties of 
the compounds. No substantial modifications can be performed on its structure to 
change or tune the fluorescent features of this fluorophore class, resulting therefore in a 
big disadvantage compared to emissive 8-aryl/heteroaryl adenine derivatives.  
In addition to the fact that ε-adenine structure cannot be modified to increase 
fluorescence, the introduction of the etheno bridge between the exocyclic amino group 
and N-1 on the pyrimidine ring blocks two important moieties responsible for enzyme 
recognition and binding. Conversely, the new fluorophore class leaves the adenine 
structure unaltered making the compounds more similar to the natural substrate and, 
therefore, more likely to interact with the enzymes.  
The two fluorophore classes differ also in the orientation of the modified adenine rings 
related to their riboses; indeed, ε-adenine prefers an anti conformation, while 8-
aryl/heteroaryl adenine a syn conformation. This difference could have separate 
influences on their biological activities toward NAD
+
-consuming enzymes, as will be 
discussed in Chapter 4 and 5.  
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Figure 3.27 Structures for -adenine and 8-aryl/heteroaryl adenine derivatives. 
A common feature between the two fluorophore classes is represented by the internal 
fluorescence quenching occurring in the NAD
+
 derivatives. Based on the example of ε-
NAD
+
 and depending on its ability to act as a NNS for NAD
+
-consuming enzymes, 8-
(pyrrol-2-yl) NAD
+
 (15h), the most promising fluorescent 8-aryl/heteroaryl NAD
+
 
derivative synthesized in Chapter 2, will be used to set up fluorescence-based assays for 
NAD
+
-consuming enzymes. Indeed, this compound, as seen with ε-NAD+, is 
characterized by λex and λem not interfering with the protein fluorescence; in addition, its 
fluorescence quenching, ~ 2 fold stronger than ε-NAD+, could allow an increase in 
sensitivity of the fluorescence-based assays. 
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4 EVALUATION OF 8-ARYL/HETEROARYL NAD+ DERIVATIVES AS 
FLUORESCENT PROBES FOR NAD+-CONSUMING ENZYMES 
As mentioned in Chapter 1, NAD
+
-consuming enzymes are fundamental in all 
organisms as they are involved in many major biological processes. These enzymes use 
β-NAD+ as a substrate/co-substrate, cleaving the high energy bonds present in its 
structure; then, the energy released can be used for the synthesis of signalling molecules 
or transferred to other acceptors to catalyze further reactions. Several different types of 
NAD
+
-consuming enzymes are present in cells and have a variety of functions, often 
related to each other. The knowledge of their activities is therefore crucial to understand 
many biological processes and their pathological implications. 
This chapter will review activities and reaction mechanisms of some representatives of 
major classes of NAD
+
-consuming enzymes, in particular those belonging to the ecto-
enzymes class, such as NPPs, ADPRCs and NADases, responsible for the extracellular 
β-NAD+ homeostasis. Since β-NAD+ is the only substrate involved in their catalytic 
reactions, they will be used as a model for the proof of concept of the use of NAD
+
 
derivatives as biochemical tools.  
In particular, the biological evaluation of 15h as a fluorescent NNS for the selected 
NAD
+
-consuming enzymes will be provided, and its use for the development of 
fluorescence-based assays for their monitoring will be assessed. Indeed, this compound, 
amongst all NAD
+
 derivatives synthesized in Chapter 2, has shown the best fluorescent 
features to compete with ε-NAD+ as an alternative biochemical probe for the monitoring 
of the NAD
+
-consuming enzyme activities. Its fluorescence stability between pH 6 and 
9, the pH working range for several NAD
+
-consuming enzymes, and its λex and λem not 
overlapping with those of biological systems, make it a good fluorophore for biological 
applications. In addition, the internal fluorescence quenching occurring in 15h is ~ 2 
fold bigger than that occurring in ε-NAD+, possibly making it a more sensitive probe in 
fluorescence-based assays. Moreover, the intact adenine structure in 15h could be an 
advantage compared to ε-NAD+ in terms of interactions and recognition by NAD+-
consuming enzymes.  
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4.1 Nucleotide pyrophosphatases (NPPs) 
Nucleotide pyrophosphatases/phosphodiesterases (NPPs) belong to the same class of 
enzymes, able to catalyze the hydrolysis of pyrophosphate or phosphodiester bonds of a 
variety of nucleotides to give nucleoside 5′-monophosphates.16 A broad range of 
possible substrates are accepted by NPPs.  
Mammalian NPPs are also called ecto-NPPs (ENPPs) since most of them are ecto-
enzymes, or enzymes situated on the outer membrane of the cell and characterized by 
having their catalytic site in the extracellular space. The activity of these enzymes in the 
extracellular space seems to be fundamental to regulate the extracellular balance 
between nucleotides and nucleosides connected to a variety of events, such as 
nucleotide/nucleoside signalling (purinergic modulation signalling), the salvage 
pathway of many nucleotides, bone and cartilage mineralization, and insulin 
signalling.
16, 17, 219, 220
 Because of these activities, an increased interest toward 
mammalian ENPPs has developed to fully characterize and define their structure, active 
site and reaction mechanism.  
ENPPs share the same reaction mechanism already identified for snake venom 
phosphodiesterases:
48
 it is a two-step mechanism, involving a covalent enzyme-
nucleotidylate intermediate by a threonine catalytic residue (Scheme 4.1).
221
 The ENPPs 
catalytic site contains two divalent cations, coordinating the phosphate group of 
pyrophosphate or phosphodiester bonds of the incoming nucleotides, BppB′ and BpB′ 
respectively. A nucleophilic residue, such as threonine (T256) in human NPP1, attacks 
the phosphate with consequent release of a leaving group, such as a nucleotide B′p or a 
nucleoside B′, and formation of a covalent enzyme-nucleotidylate intermediate (I). 
Therefore, a molecule of water, activated by coordination to the cation, would attack the 
phosphate, regenerating the catalytic threonine and releasing the product, a nucleoside 
5′-monophosphate, Bp.16, 222  
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Scheme 4.1 Catalytic mechanism of ENPPs. 
The observed dependence of the efficiency of the pyrophosphatase reactions on divalent 
cations in the reaction buffer can be explained by the necessary presence in the active 
site of two cations to catalyze the reaction.
223, 224
 In addition, the optimum basic pH for 
the pyrophosphatase reaction helps to speed the second reaction step, where a more 
nucleophilic hydroxide, instead of a neutral molecule of water, would attack the 
phosphate group.  
In contrast to the several studies performed on snake venom phosphodiesterases and 
ENPPs, little information is known about the commercially available nucleotide 
pyrophosphatase from Crotalus adamanteus venom. This enzyme has wide application 
in the chemo-enzymatic synthesis of nucleotide derivatives with quite good yields
225
 but 
has not been fully characterized. Here, its activity as a nucleotide pyrophosphatase, its 
properties and reaction mechanism will be discussed in accordance with its assumed 
similarity to other well described nucleotide pyrophosphatases/phosphodiesterases.  
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4.1.1 Fluorescence-based assay for nucleotide pyrophosphatase 
Compound 15h was tested as a NNS of the commercially available nucleotide 
pyrophosphatase (NPP) from Crotalus adamanteus venom. This enzyme catalyzes the 
cleavage of β-NAD+ on the pyrophosphate bond to produce AMP and β-NMN. 
The enzymatic reaction was monitored by HPLC to check the suitability of 15h as a 
substrate for NPP; in fact, the enzyme recognised the NNS and catalyzed its hydrolysis 
on the pyrophosphate bond generating β-NMN and 9h,172 as confirmed by the use of 
standards for the two reaction products (Figure 4.1).   
 
 
Figure 4.1 HPLC time-course of the enzymatic reaction of NPP from Crotalus adamanteus venom and 
15h. Conditions: NPP (0.01 U/mL), 15h (24.74 μM), MgCl2 (10 mM), Tris/HCl buffer (50 mM, pH 8), 30 
ºC; all concentrations are final concentrations. Data from single experiment, peak area vs time [min], data 
plotting to a 1
st
 order rate equation with Grafit5. 
Since NPP was able to recognise and convert 15h into 9h, the opportunity for 
monitoring the enzymatic reaction by fluorescence was investigated. Owing to the 
fluorescence internal quenching occurring in 15h compared to 9h (Chapter 3, see 3.7.1), 
a fluorescence increase due to the production of 9h from the cleavage of 15h was 
observed with the progress of the enzymatic reaction (Figure 4.2), proving the 
possibility to prepare fluorescence-based assays to monitor NPP activity, similar to 
those developed with ε-NAD+.87, 89 
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Kinetic experiments for the estimation of kinetic parameters, as Km and Vmax, for NPP 
toward the new substrate 15h were set up. After confirming the linearity of the 
fluorescence response across a range of concentrations for both 15h and its enzymatic 
product 9h, initial reaction velocities were measured as a function of NPP concentration 
at a fixed 15h concentration to explore the rate changes with NPP concentration 
(Appendix 8, Figure A2). Initial velocities were found to be proportional at low NPP 
concentration, before the substrate 15h became the limiting factor. A suitable 
enzyme/substrate ratio was established to have smooth enzymatic reaction rates from 
which to calculate linear initial velocities. Afterwards, the substrate concentration was 
varied to generate a saturation curve for the determination of the value of Km. 
At this stage, the experiment set-up required a considerable optimization to establish the 
appropriate conditions to reduce and control the variability affecting the results and 
attributed to several factors influencing the fluorescence signal. Major issues identified 
were the temperature changes within the wells of the microplate, due to the addition of 
the cold enzyme solution at the beginning of the reaction, and the instability of the 
fluorescence signal. To address these problems, a few precautions were taken, such as 
the addition of all components of the reaction into the microplate at room temperature 
and always in the same order; a fluorescence stabilization period was allowed before 
starting the reaction; shaking of the microplate occurred before each cycle of 
measurement; use of 120 μL total volume in the wells (100 – 250 μL is the volume 
range suggested for the NUNC 96 plate). The introduction of positive and negative 
controls into the microplate was useful to check the variability sources in the 
experiments. The buffer alone was used as a negative control, while the reaction 
product, 9h, at a fixed concentration was used as a positive control. Their variability 
was checked across the plate after the fluorescence signal stabilization and during the 
reaction time to guarantee a uniform fluorescence signal. No particular fluorescence 
trends were noticed across the plate, indicating the suitability of NUNC 96 plate for 
these experiments.  
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All experiments were run at least in duplicate. The raw data showed time-courses of 
fluorescence intensity, expressed in RFU [relative fluorescence unit], versus time [sec]. 
The fluorescence difference between the positive control (9h at a fixed concentration) 
and the negative control (buffer) allowed conversion of the fluorescence intensity into 
9h concentration [μM], necessary to estimate Vmax (Figure 4.2). 
 
 
Figure 4.2 Fluorimetric assay of NPP from Crotalus adamanteus venom and 15h. a) fluorescence time-
course as fluorescence emission [RFU] vs time [sec]; b) fluorescence time-course as 9h concentration 
[μM] vs time [sec]. Conditions: NPP (0.007 U/mL), 15h (0.2 – 6 μM), MgCl2 (10 mM), Tris/HCl buffer 
(50 mM, pH 8), 30 ºC, λex = 300 nm, λem = 410 nm, gain 15%. Enzyme addition at 420 sec. Positive 
control: 9h (3 μM). Negative control: buffer; all the concentrations are final concentrations. Each data 
point is the mean of experiments run in duplicate, data plotting with Excel. 
Variation of initial velocity with 15h concentration was well described by the 
Michaelis-Menten equation (Figure 4.3), and Lineweaver-Burk and Hanes-Woolf plots 
(Appendix 8, Figure A3).
172
 Values for Km and Vmax of NPP related to 15h were 
determined by non-linear regression analysis of the Michaelis-Menten plot, resulting in 
an average Km value of 1.5 ± 0.4 μM and Vmax of 0.001 ± 0.0001 μmol·min
-1
·mg
-1
. 
  
0
0.5
1
1.5
2
2.5
3
0 1000 2000 3000 4000 5000
[9
h
] 
m
M
time [sec]
[15h] 0.2uM
[15h] 1uM
[15h] 2uM
[15h] 3uM
[15h] 4uM
[15h] 5uM
[15h] 6uM
-1000
1000
3000
5000
7000
9000
11000
0 1000 2000 3000 4000 5000
F
lu
o
re
s
c
e
n
c
e
 E
m
is
s
io
n
 [
R
F
U
]
time [sec]
[15h] 0.2uM
[15h] 1uM
[15h] 2uM
[15h] 3uM
[15h] 4uM
[15h] 5uM
[15h] 6uM
neg contr
pos contr
a b
NPP
Chapter 4 
 
126 
 
The presence of Mg
2+
 in the buffer was required to stimulate the enzymatic reaction;
223, 
224
 indeed, Vmax showed a drop of ~ 3.5 fold when the reaction was carried out in 
absence of MgCl2 (data not shown).  
 
 
Figure 4.3 Michaelis-Menten plot of NPP from Crotalus adamanteus venom with 15h. Conditions: NPP 
(0.007 U/mL), 15h (0.2 – 5.2 μM), MgCl2 (10 mM), Tris/HCl buffer (50 mM, pH 8), 30 ºC, λex = 300 nm, 
λem = 410 nm, gain 15%; all concentrations are final concentrations. Initial velocity values (V0) were 
calculated from the corresponding time-courses measuring the fluorescence signals generated when 10% 
product was formed. Each data point is the mean (± SD) of experiments run in duplicate, data plotting 
with Excel. 
To assess the NPP site of 15h binding and transformation, experiments were performed 
to evaluate the impact of β-NAD+, AMP and β-NMN on the rate of hydrolysis for 15h 
by NPP. Competition experiments with β-NAD+ showed a decrease of NPP activity 
related to 15h for increasing quantity of β-NAD+ in solution: at concentrations of β-
NAD
+
 above ca 250 μM, there was no significant indication of catalysis. An IC50 value 
of 12.8 ± 3.8 μM was estimated for β-NAD+ (Figure 4.4).  
For greater insight into the mode of inhibition exhibited by β-NAD+ toward the activity 
of NPP related to 15h, kinetic analysis was performed for a range of β-NAD+ 
concentrations (Figure 4.5, Appendix 8, Figure A4). From the data analysis, β-NAD+ 
turned to be a competitive inhibitor of 15h; indeed, Vmax did not change with increasing 
β-NAD+ concentrations, while the Km value of 15h related to NPP increased because of 
a lower affinity for the binding site.  
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This was in agreement with what observed in the IC50 experiment. In addition, a Ki 
value for β-NAD+ of 7.4 ± 1.7 μM was estimated from the Dixon plot (Figure 4.5). 
 
 
Figure 4.4 IC50 estimation for β-NAD
+
 toward the activity of NPP from Crotalus adamanteus venom and 
15h. Conditions: NPP (0.007 U/mL), 15h (4.4 μM), β-NAD+ (0 – 350 μM), MgCl2 (10 mM), Tris/HCl 
buffer (50 mM, pH 8), 30 ºC, λex = 300 nm, λem = 410 nm, gain 15%; all concentrations are final 
concentrations. Initial velocity values (V0) were calculated from the corresponding time-courses 
measuring the fluorescence signals generated when 10% product was formed. The insert shows the range 
of β-NAD+ (0 – 25 μM) where the NPP activity drastically decreases. Each data point is the mean (± SD) 
of experiments run in duplicate, data plotting with Excel. 
 
Figure 4.5 Dixon plot for β-NAD+ inhibition toward the activity of NPP from Crotalus adamanteus 
venom and 15h. Conditions: NPP (0.007 U/mL), 15h (0.2 – 5 μM), β-NAD+ (8 – 15 μM), MgCl2 (10 
mM), Tris/HCl buffer (50 mM, pH 8), 30 ºC, λex = 300 nm, λem = 410 nm, gain 15%; all concentrations 
are final concentrations. Initial velocity values (V0) were calculated from the corresponding time-courses 
measuring the fluorescence signals generated when 10% product was formed. Each data point is the mean 
(± SD) of experiments run in duplicate, data plotting with Grafit5. The x value for the lines intersection is 
equal to -Ki; the y value for the lines intersection is equal to 1/Vmax. 
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To understand the influence of AMP and β-NMN on the NPP activity and their possible 
mode of inhibition related to 15h, kinetic analyses were performed for a range of AMP 
(Figure 4.6) and β-NMN concentrations.  
 
 
Figure 4.6 Dixon plot for AMP inhibition toward the activity of NPP from Crotalus adamanteus venom 
and 15h. Conditions: NPP (0.007 U/mL), 15h (0.2 – 5 μM), AMP (8 – 40 μM), MgCl2 (10 mM), Tris/HCl 
buffer (50 mM, pH 8), 30 ºC, λex = 300 nm, λem = 410 nm, gain 15%; all concentrations are final 
concentrations. Initial velocity values (V0) were calculated from the corresponding time-courses 
measuring the fluorescence signals generated when 10% product was formed. Each data point is the mean 
(± SD) of experiments run in duplicate, data plotting with Grafit5. The x value for the lines intersection is 
equal to -Ki; the y value for the lines intersection is equal to 1/Vmax. 
From the data analysis, AMP turned to be a competitive inhibitor of 15h; indeed, Vmax 
did not change, while the Km value for 15h increased with increasing β-NAD
+
 
concentrations. The estimated Ki for AMP from the Dixon plot was 7.5 ± 1.6 μM. 
Oppositely to AMP, b-NMN turned to not compete with 15h for NPP binding site in 
our experimental conditions; indeed, both Km and Vmax for 15h toward the NPP activity 
remained approximately the same with increasing β-NAD+ concentrations (data not 
shown). 
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4.1.2 Kinetic analysis of NPP activity 
The Km and Vmax values obtained for 15h related to the activity of NPP from Crotalus 
adamanteus venom were compared to those found in the literature for β-NAD+ and 
other fluorescent derivatives (ε-NAD+, ε-PdAD+ and ε-hy4PdAD+) related to several 
pyrophosphatases (Table 4.1).
89, 223, 226-230
 NPPs are generally characterized by a wide 
substrate specificity, with the enzyme recognition requiring mainly the presence of a 
pyrophosphate bond. However, in detailed studies of some NPPs, particular trends in 
the substrate affinities were observed. In particular, a nucleotide pyrophosphatase 
isolated from Haemophilus influenzae showed different substrate affinities for the 
binding site depending on the aromatic rings of the analysed dinucleotides. It was found 
that the enzyme recognition was strongly influenced by the adenine ring and its 
modifications, more than by the presence of the nicotinamide ring and its derivatives. 
The poor substrate activity of ε-NAD+ appeared to be due more to the steric hindrance 
of the modified adenine ring in the active site than to the loss of the exocyclic amino 
group and, consequently, H-bonding ability.
226
  
 
Organism β-NAD+ ε-NAD+a or ε-PdAD+b 15h 
Km 
(mM) 
Vmax (μmol· 
min
-1
·mg
-1
) 
Km 
(mM) 
Vmax (μmol· 
min
-1
·mg
-1
) 
Km 
(mM) 
Vmax (μmol· 
min
-1
·mg
-1
) 
Haemophilus 
parasuis
227
 
0.0041 13.5 0.144
a 
2.5
a
 n.a. n.a. 
Haemophilus 
influenzae
226
 
0.0054 2.7 0.632
a
 3.6
a
 n.a. n.a. 
Yeast
228
 0.17 0.09 n.a.
c
 n.a. n.a. n.a. 
Potato
229, 230
 0.05 n.a. 0.013
a
 n.a. n.a. n.a. 
Rat liver
223
 0.028 n.a. n.a. n.a. n.a. n.a. 
Mouse 
splenocytes
89
 
n.a. n.a. 
0.29 – 
0.33
b
 
n.a. n.a. n.a. 
Crotalus 
adamanteus 
n.a. n.a. n.a. n.a. 0.0015 0.001 
aε-NAD+; bε-PdAD+; cnot available. 
Table 4.1 Enzymological properties for β-NAD+, ε-NAD+ and the related dinucleotide ε-PdAD+, and 15h 
with different nucleotide pyrophosphatases. 
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Compound 15h was found to have a very low Km value related to the NPP from 
Crotalus adamanteus venom, much closer to that of the natural β-NAD+ than those of 
etheno-derivatives for other NPPs. This result suggested a strong affinity of 15h for the 
enzyme active site, due to the similarity of 8-(pyrrol-2-yl) adenine to adenine of the 
natural β-NAD+. However, the low Vmax indicated that the substitution in position 8 on 
the adenine ring, although tolerated by NPP during the binding of 15h in the active site, 
was strongly influencing its catalytic mechanism. 
From the IC50 determination and the kinetic analyses performed to understand the β-
NAD
+
 mode of inhibition, β-NAD+ was confirmed to be a competitive inhibitor related 
to 15h, indicating their binding on the same ligand site.  
Regarding AMP and b-NMN, it would be expected that both, as reaction products, are 
competitive inhibitors related to β-NAD+ for the NPP activity. In fact, although AMP 
was found to be a strong competitive inhibitor for several NPPs (Table 4.2), β-NMN 
had no relevant activity, indicating again a stronger affinity of NPPs for the adenine 
moiety of the dinucleotides.
226, 227, 230
 In accordance with the literature, in this study 
AMP turned to be a competitive inhibitor related to 15h, with a Ki value similar to that 
of β-NAD+, indicating the strong affinity of NPPs for the adenine moiety of 
dinucleotides. In contrast, β-NMN did not exert any inhibition toward NPP from 
Crotalus adamanteus venom.  
 
Organism AMP β-NMN 
 Ki (mM) Ki (mM) 
Haemophilus parasuis
227 
0.0366 inactive 
Haemophilus influenzae
226
 0.0151 inactive 
Potato
230 
0.145 inactive 
Crotalus adamanteus 0.0075 inactive 
Table 4.2 Competitive inhibition of AMP and β-NMN toward different nucleotide pyrophosphatases. 
In addition, kinetic experiments were performed with the other 8-aryl/heteroaryl NAD
+
 
derivatives synthesized in Chapter 2, to confirm the reasonable choice of 15h as a 
fluorescent probe for the development of fluorescence-based assays. 15b and 15c acted 
both as NNSs toward NPP from Crotalus adamanteus venom, as confirmed by a 
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fluorescence increase occurring during the enzymatic reaction with NPP (Appendix 8, 
Figure A5, Figure A6). However, the fluorescence difference generated along the 
reaction course was smaller than that occurring with 15h, because of a smaller 
fluorescence internal quenching in 15b and 15c compared to 15h. By contrast, 15e and 
15g did not show any fluorescence increase during the progress of the enzymatic 
reaction. Assuming their activity as NNSs of NPP because of their belonging to the 
class of 8-substituted NAD
+
 derivatives, this result was predictable for 15e, since no 
fluorescence internal quenching was observed compared to its corresponding AMP 
derivative, 9e. However, this result was surprising for 15g, since it had shown a large 
fluorescence internal quenching compared to its corresponding AMP derivative, 9g. 
Probably, because of their extremely low  values, the fluorescence assay was not 
sensitive enough to detect the fluorescence changes.  
4.2 NAD+-glycohydrolases (NADases) and ADP-ribosyl cyclases (ADPRCs) 
Ca
2+
 is a secondary messenger involved in cellular signalling and several intracellular 
controlled events.
231
 The Ca
2+
 concentration inside the cells is ~ 10 – 100 nM and it is 
kept constant by the presence of Ca
2+
 channels, that actively pump Ca
2+
 from the 
cytosol to the extracellular space or into the endoplasmic reticulum in which it is stored. 
Sudden increases in the intracellular Ca
2+
 concentration, due to its release from the 
endoplasmic reticulum, are mediated by different Ca
2+
-release pathways. The best 
characterized is the IP3 (Inositol triphosphate)-mediated pathway, where IP3 binds and 
opens Ca
2+
 channels on the endoplasmic reticulum, allowing Ca
2+
 release in the cytosol. 
Another less understood pathway is that of Ca
2+
-induced Ca
2+
-release (CICR), where an 
intracellular Ca
2+
 increase, due to influx from the extracellular space or to the IP3-
pathway, generates a further Ca
2+
 release from the endoplasmic reticulum via ryanodine 
receptors, another type of internal Ca
2+
 channel, completely independent from the IP3 
channel.  
Cyclic ADPR, cADPR, has been found to be an endogenous regulator of the CICR 
pathway, effective as much as IP3 in the IP3-pathway.
232, 233
 cADPR is formed by the 
removal of NaM from β-NAD+, and cyclization of the remaining ADPR between N-1 of 
the adenine ring and C-1′′ of the “northern” ribose (the one linked to NaM in the whole 
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β-NAD+) in the β-configuration.234, 235 cADPR metabolism is controlled by different 
enzymes, its formation being catalyzed by ADP-ribosyl cyclases, while its degradation 
to ADPR catalyzed by cADPR-hydrolases.  
ADP-ribosyl cyclase (ADPRC) was first isolated from sea urchin eggs as a membrane-
bound protein, but was then found in higher quantity on the Aplysia invertebrates as a 
soluble protein.
236
 This enzyme initially showed only cyclase activity, catalyzing the 
consumption of β-NAD+ to cADPR. In contrast, cADPR-hydrolases were found 
prevalently in brain extracts as membrane-bound proteins.
237
 Homology studies 
underlined the similarity of the ADPRC sequence with that of the human antigen CD38, 
supporting the idea of them belonging to the same class of enzymes. Nevertheless, a 
differentiation in preferential activities has occurred during the evolution of these 
enzymes: ADPRC has preferentially developed the cyclase activity, while CD38 shows 
prevalently NAD
+
-glycohydrolase (NADase) activity.
56, 63
 Later, ADPRC was shown to 
have cADPR-hydrolase activity
238
 and NADase activity
71
 when stressed in particular 
conditions. Likewise, CD38 was shown to have cyclase activity in conditions that do 
not favour the hydrolysis of β-NAD+ to ADPR.232, 239 Moreover, cADPR-hydrolases 
found in brain extracts as membrane-bound proteins,
237
 showed in turn cyclase and 
NADase activity,
240
 as well as proclaimed NADases showed cyclase activity.
241
  
These enzymes are therefore multifunctional and, depending on the substrate or the 
reaction conditions, show preferential activities. A unifying mechanism for Aplysia 
ADPRC, CD38 and NADases has been proposed to explain the activity differentiation 
between these multifunctional enzymes belonging to the same class (Scheme 4.2). A 
partitioning mechanism would be involved, rather than a sequential one, in which a 
common oxocarbenium ion would be formed from β-NAD+ after the removal of NaM; 
the oxocarbenium ion would then evolve preferentially to cADPR or ADPR by 
competitive pathways.
238
 As will be discussed in 4.2.3, the cADPR-hydrolase activity of 
Aplysia ADPRC is an example of a limiting form of the partitioning mechanism, in 
which the enzyme sequentially forms cADPR, then hydrolysing it to ADPR in presence 
of high enzyme concentrations.  
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Scheme 4.2 Partitioning mechanism for Aplysia ADPRC, CD38 and NADases. 
4.2.1 Fluorescence-based assay for NAD+-glycohydrolase  
Compound 15h was tested as a NNS of the commercially available NAD
+
-
glycohydrolase (NADase) from porcine brain. This enzyme catalyzes the cleavage of 
the nicotinamide N-glycosidic bond of β-NAD+ to produce NaM and ADPR. 
The enzymatic reaction was monitored by HPLC to check the suitability of 15h as an 
NADase substrate. In fact, the enzyme recognised the NNS and consumed it catalyzing 
its hydrolysis at the nicotinamide N-glycosidic bond to generate the ADPR derivative, 
23, and NaM (Figure 4.7).
172
 The reaction product, 23, was identified by 
1
H NMR. 
Once it was established that 15h was used as a NNS by NADase, the monitoring of the 
NADase activity by fluorescence was attempted. However, NADase is a membrane-
bound enzyme and, consequently, completely insoluble in the reaction buffer. This 
problem made it difficult to carry out the enzymatic reaction on a microplate reader, 
unless a soluble form of the enzyme was used,
87, 91, 242, 243
 or samplings during the 
experiments were performed.
243, 244
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Figure 4.7 HPLC time-course of the enzymatic reaction of NADase from porcine brain and 15h. 
Conditions: NADase (0.009 U/mL), 15h (24.74 μM), Tris/HCl buffer (50 mM, pH 8), 37 ºC; all 
concentrations are final concentrations. Data from single experiment, peak area vs time [min], data 
plotting to a 1
st
 order rate equation with Grafit5. 
Since the purpose of the experiments was not to develop a fluorescence-based assay for 
NADase, but to show the applicability of 15h as a biochemical tool to monitor several 
enzymatic reactions, we did not attempt the solubilization of the NADase. Instead, the 
fluorescence monitoring of the enzymatic reaction was performed in a cuvette to find 
out the suitability of 15h for such applications. Unfortunately, no fluorescence increase 
was observed. This result was ascribed to the turbidity of the reaction mixture and the 
scattering due to the enzyme in suspension, which did not allow any measurement of 
fluorescence changes.  
The only alternative to prove a fluorescence change during the progress of the 
enzymatic reaction was to sample the reaction mixture and read its fluorescence using 
the microplate reader. After filtering, diluting and reading the fluorescence of the 
samples, a fluorescence increase was finally observed and a time-course obtained 
(Figure 4.8), supporting once again the idea of using 15h as a fluorescent probe for the 
monitoring of NAD
+
-consuming enzyme activities. These results suggested that it is 
likely that a continuous fluorimetric assay could be set up with 15h using a solubilized 
form of the NADase enzyme. 
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Figure 4.8 Fluorimetric assay of NADase from porcine brain and 15h. Fluorescence time-course as 
fluorescence emission [RFU] vs time [min]. Conditions: NADase (0.0075 U/mL), 15h (5.25 μM), 
Tris/HCl buffer (50 mM, pH 8), 37 ºC, λex = 300 nm, λem = 410 nm, gain 15%; all concentrations are final 
concentrations. Data from single experiment, data plotting to a 1
st
 order rate equation with Grafit5. 
4.2.2 Fluorescence-based assay for ADP-ribosyl cyclase  
Compound 15h was tested as a NNS of the commercially available ADP-ribosyl cyclase 
(ADPRC) from Aplysia californica. This enzyme catalyzes the cyclization of β-NAD+ 
to cADPR with removal of NaM. 
It is known from the literature that 8-substituted NAD
+
 derivatives are recognised by 
this enzyme and used as NNSs to give 8-substituted cADPR derivatives.
112
 The 
enzymatic reaction was monitored by HPLC to check the suitability of 15h as an 
ADPRC substrate. In fact, the enzyme recognised the NNS and consumed it, catalyzing 
the removal of NaM and cyclization of the remaining ADPR intermediate to the cADPR 
derivative, 24 (Figure 4.9).
172
 The reaction product, 24, was identified by 
1
H NMR.  
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Figure 4.9 HPLC time-course of the enzymatic reaction of ADPRC from Aplysia californica and 15h. 
Conditions: ADPRC (0.05 U/mL), 15h (12.37 μM), HEPES buffer (50 mM, pH 7.4), 25 °C; all 
concentrations are final concentrations. Data from single experiment, peak area vs time [min], data 
plotting to a 1
st
 order rate equation with Grafit5. 
The possibility to develop a fluorescence-based assay to monitor the ADPRC activity 
using 15h as a fluorescent probe was explored. A fluorescence increase during the 
enzymatic reaction due to the loss of NaM was expected, by analogy with the behavior 
shown with NPP and NADase. However, it was not clear whether a fluorescence 
increase or decrease would occur following the cyclization of the ADPR intermediate to 
the cADPR derivative, 24.  
Several attempts were made in a cuvette to find the right substrate/enzyme ratio which 
allowed a fluorescence change to be observed during the progress of the enzymatic 
reaction. The results allowed us to visualize the mechanism suggested in the literature 
for the enzymatic reaction.
26
 Indeed, as shown in Figure 4.10, moving to more diluted 
enzyme concentrations and increasing the substrate/enzyme ratio (as indicated in the 
brackets), the enzymatic reaction became increasingly slower highlighting the existence 
of two or more reaction steps.  
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Figure 4.10 Fluorescence changes observed during the enzymatic reaction between ADPRC from Aplysia 
californica and 15h. Conditions: ADPRC (0.000055 – 0.0055 U/mL), 15h (0.09 μM), HEPES buffer (50 
mM, pH 7.4), 25 °C, λex = 300 nm, λem = 410 nm; all concentrations are final concentrations. Data 
plotting with Excel. 
At the moment of enzyme addition to start the reaction, a sudden fluorescence increase 
was observed, probably due to the removal of NaM and, consequently, the disruption of 
the internal quenching in 15h, now transformed into the more fluorescent ADPR 
intermediate. Then, the latter, bound to the enzyme, would start folding to cyclize into 
24. This cyclization would cause a change in the electronic delocalization on the 
substituted adenine ring, resulting in a final drop of fluorescence with the release of the 
product by the enzyme.  
A further confirmation to this two-step reaction, consisting in the removal of NaM and 
following cyclization of the ADPR intermediate to cADPR, was given by the HPLC 
assay. First, it was observed that the rate constant for the formation of NaM, kNaM, was 
twice that for the formation of 24, k24 (kNaM 0.3525 min
-1
; k24 0.1700 min
-1
), indicating 
that the formation of the two products was not simultaneous. Moreover, no trace of the 
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ADPR intermediate appeared in the chromatogram, suggesting the binding of the 
intermediate to the enzyme with subsequent release of the cyclized product.   
To be able to kinetically characterize 15h related to ADPRC from Aplysia californica, 
we used high enzyme concentrations allowing us to monitor the decrease in 
fluorescence due to the release of 24. An enzyme concentration range between 0.025 
and 2.5 U/mL was investigated to find the appropriate enzyme/substrate ratio that 
allowed the calculation of linear initial velocities (Figure 4.11).  
Surprisingly, at the highest enzyme concentrations (1.25 – 2.5 U/mL), after the initial 
fluorescence drop due to the formation of 24, a fluorescence increase was observed.
172
 
In the literature it is known that ADPRC from Aplysia californica shows a cADPR-
hydrolase activity unmasked only at high enzyme concentration, revealing this enzyme 
to be multifunctional in respect of its apparent unique ADPRC activity.
238
 Using 15h 
and its exclusive fluorescent properties, we were able to monitor this secondary activity 
of the enzyme transforming the newly formed 24 into the ADPR derivative, 23.
172
 
 
 
Figure 4.11 Fluorimetric assay of ADPRC from Aplysia californica and 15h: initial velocity (V0) as 
function of ADPRC concentration. Fluorescence time-course as fluorescence emission [RFU] vs time 
[sec]. Conditions: ADPRC (0.025 – 2.5 U/mL), 15h (9.6 μM), HEPES buffer (50 mM, pH 7.4), 25 °C, λex 
= 300 nm, λem = 410 nm, gain 15%. Positive control: 15h (9.6 μM); negative control: buffer; all 
concentrations are final concentrations. Initial velocity values (V0) were calculated from the reaction time 
measuring the fluorescence signals generated when 10% product was formed. Initial velocity values were 
fitted to a linear equation (insert) with Excel: y = 7.0142x+1.0531, r² = 0.9348. Each data point is the 
mean (± SD) of experiments run in duplicate.  
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To estimate Km and Vmax of 15h related to the ADPR-cyclase activity of ADPRC from 
Aplysia californica, the substrate concentration was varied to generate a saturation curve 
(Appendix 8, Figure A7). Unfortunately, the small range of 15h concentration with a 
linear fluorescence response was not enough to generate a saturation curve that could be 
used by Michaelis-Menten equation to determine accurately the enzymatic parameters 
related to 15h. Therefore, a Km > 34 μM (concentration limit with a linear fluorescence 
response for 15h) and Km/Vmax of 3.7 min·mg·L
-1
, extrapolated by Hanes-Woolf plot, 
could be estimated for 15h (Appendix 8, Figure A8).
172
 
Then, the estimation of Km and Vmax of 15h related to the cADPR-hydrolase activity of 
ADPRC from Aplysia californica was attempted. However, also in this case, the small 
range of 15h concentration with a linear fluorescence response was not enough to 
generate a saturation curve that could be used by Michaelis-Menten equation (Appendix 
8, Figure A9). This indicated quite high Km for the cADPR-hydrolase activity of 
ADPRC from Aplysia californica when using 15h, as confirmed in the literature by 
HPLC studies revealing a Km for the natural cADPR of 1.04 ± 0.15 mM and a Vmax of 
3.34 ± 1.15 μmol·min-1·mg-1.238 
4.2.3 Mechanistic aspects of ADPRC activity 
In the literature the reaction mechanism of the ADPRC from Aplysia californica is well 
described and consistent with the results reported here, obtained by the fluorimetric and 
HPLC experiments, that suggest a two-step reaction (Figure 4.12).
26
 The enzymatic 
reaction proceeds via binding of β-NAD+ in the catalytic site; there, E179 interacts by 
H-bonding with 2′′, 3′′-OH of the nicotinamide ribose, destabilizing the nicotinamide N-
glycosidic bond and favouring the formation of the oxocarbenium intermediate 
following the release of NaM.
30
 In the catalytic site, the oxocarbenium intermediate is 
stabilized on the nicotinamide ribose and the diphosphate group by an extended network 
of H-bonds; slowly, the intermediate undergoes minor movements bringing the adenine 
ring, previously in anti conformation and stacked with Y81, into a syn conformation 
with the adenine ring stacked with W140. At this stage, N-1 of the adenine ring, more 
nucleophilic than N-7, points to the electrophilic C-1′′, where the cyclization takes 
place.  
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Figure 4.12 Reaction mechanism for N-1 cyclization of 15h with ADPRC from Aplysia californica. 
This mechanism is in agreement with that suggested by the HPLC assay, where the 
immediate release of NaM would be followed by a slower release of the product, since 
an intermediate is formed which rearranges to give the final cADPR.  
As shown in 3.1.2, 8-aryl/heteroaryl substituted NAD
+
 derivatives, in particular 15h, 
have the adenine ring in syn conformation because of the steric hindrance caused by the 
substituent in position 8.
70
 Consequently, if at the moment of binding, 15h has the 
adenine in a syn conformation in contrast to the anti in the natural β-NAD+, then, at the 
moment of cyclization, 15h already has the right syn conformation with N-1 pointing in 
the direction of C-1′′. Since the rate-limiting step in the reaction mechanism seems to be 
the cyclization, the comparable Km values for 15h and β-NAD
+
 related to ADPRC from 
Aplysia californica could be explained by their similarities in the cyclization position 
(Table 4.3).
172
 
Fluorescence-based assays to study the activity of ADPRC from Aplysia californica 
were already present in the literature and based on the fluorescence changes of the well 
known ε-NAD+, or other dinucleotides, such as NGD+, NHD+ and NXD+ (see 1.4.3).69, 
90, 232, 239, 245
 Conversely from 15h, all these compounds showed an increase of 
fluorescence with the progress of the enzymatic reaction. In particular, NGD
+
, NHD
+
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and NXD
+
 became fluorescent only after their cyclization to cGDPR, cIDPR and 
cXDPR. All these dinucleotides were characterized by the cyclization position on N-7, 
due to the lack of availability of N-1, as in the case of ε-NAD+, or to the weak 
nucleophilicity of the amidic/imidic N-1 compared to N-7 in the case of NGD
+
, NHD
+
 
and NXD
+
 (Figure 4.13). Studies on the fluorescent properties of adenine rings 
substituted on N-1 and N-7 suggested that, while the substitution on N-1 did not cause 
any fluorescence, substitution on N-7 generated fluorescence;
69
 this would explain the 
reduced fluorescence of 24 compared to 15h, and the strong fluorescence of cGDPR, 
cIDPR and cXDPR compared to NGD
+
, NHD
+
 and NXD
+
. 
 
 
Figure 4.13 Cyclic ADP-ribose derivatives obtained by cyclization on N-1 or N-7 with ADPRC from 
Aplysia californica. 
 
 β-NAD+ 15h ε-NAD+ NGD+ NHD+ NXD+ 
Km [μM] 39
69
, 135
58
 > 34 6.2
69
 1.7
69
, 15.5
58
 0.5
69
, 8.8
58
 6.2
69
 
Vmax [μmol·min
-1
·mg
-1
] 500
69
 ~ 20 94.4
69
 36.3
69
 4.6
69
 50
69
 
Table 4.3 Enzymological properties for β-NAD+, 15h, ε-NAD+ and other dinucleotide substrates of 
ADPRC from Aplysia californica. 
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All the dinucleotides cyclizing in N-7 of the adenine ring turned out to have extremely 
low Km values compared to those of β-NAD
+
 and 15h (Table 4.3), showing stronger 
affinities for ADPRC from Aplysia californica than the natural substrate itself. This 
behaviour could be explained with the favourable anti conformation of the purine rings 
having N-7 pointing in the direction of C-1′′, ready for the cyclization without the need 
to rotate as in the case of adenine in β-NAD+.69 
As already mentioned in 4.2, Aplysia ADPRC, characterized at a first investigation only 
by the cyclase activity,
236
 turned out to be a cADPR-hydrolase
238
 as well as a 
NADase.
63, 71
 These activities show up only in particular conditions in which the 
enzyme is forced to follow a different from the preferred mechanism. A partitioning 
mechanism, more than a sequential mechanism, is responsible for the choice of the 
reactions performed by CD38, NADases and ADPRC belonging to the same family (see 
4.2, Scheme 4.2). 
In the case of the NADase activity of ADPRC, unless the cyclization is completely 
blocked by the use of some NAD
+
 derivatives,
71
 the rate for the cyclization is so fast 
compared to the solvolysis that the enzyme would follow a macroscopic sequential 
mechanism, where β-NAD+ is first converted to cADPR (cyclase activity), which then 
undergoes hydrolysis to give ADPR (cADPR-hydrolase activity). This sequential 
reaction mechanism can be clearly visualized in the experiments performed using 15h 
as a fluorescent NNS for ADPRC,
172
 where an initial fluorescence drop, indicating the 
formation of 24, changes into a fluorescence increase due to the formation of 23 (Figure 
4.11).  
In other respects, with ε-NAD+ it would not be possible to distinguish between cyclase 
and cADPR-hydrolase activities of ADPRC from Aplysia californica, since its 
fluorescence would increase after the formation of both cεADPR and ε-ADPR. 
Moreover, cεADPR is quite resistant to the hydrolysis90 and, therefore, it would not 
probably be susceptible to the cADPR-hydrolase activity.  
In principle, the continuous monitoring of the sequential reaction mechanism for the 
formation of ADPR from β-NAD+ via cADPR would be possible using NGD+, NHD+ 
and NXD
+
. Indeed, these compounds should show a fluorescence increase with the 
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formation of the cyclic product (cyclase activity), followed by a fluorescence decrease 
with the formation of the corresponding nucleotide diphosphoribose derivatives 
(cADPR-hydrolase activity). Only NHD
+
 is actually used to fluorimetrically monitor the 
cADPR-hydrolase activity,
69, 245
 since its cyclic derivative, cIDPR, is less hydrolytically 
stable than cGDPR
69, 232, 239
 and cXDPR. Nevertheless, no application of cIDPR for the 
monitoring of the recently discovered cADPR-hydrolase activity of ADPRC from 
Aplysia californica has been found in the literature. 
The study and understanding of ADPRC from Aplysia californica is important from a 
biological perspective since this enzyme belongs to the same family of human CD38, 
that is involved in the β-NAD+ regulation and Ca2+ signalling. In addition, it is used for 
the chemo-enzymatic synthesis of well known or novel cADPR derivatives, useful as 
biochemical tools or potential inhibitors of the Ca
2+
-signalling pathway. Hence, it is 
essential to know more about this enzyme, its reaction mechanism and its specifity. 
The previous results, showing on analytical scale the occurrence of the cyclization by 
ADPRC of 15h into the less fluorescent product, 24, were subsequently confirmed by 
the preparation of 24 on a synthetic scale allowing its spectroscopic analysis.
246
 ADPRC 
from Aplysia californica was used to cyclize 15h into 24 on a synthetic scale; the 
reaction progress was monitored by HPLC and the reaction mixture purified by anion-
exchange chromatography to give the desired product with a 96% yield (Scheme 4.3).
246
  
 
 
Scheme 4.3 Synthetic pathway to 8-(pyrrol-2-yl) cADPR, 24. (i) Suzuki-Miyaura cross-coupling; (ii) 
morpholidate formation; (iii) coupling with β-NMN (R); (iv) cyclization with ADPRC from Aplysia 
californica. 
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In the literature it has been reported that cADPR is quite stable in basic conditions;
234
 
indeed, the N
1
-ribosyl bond does not undergo any hydrolysis or rearrangement at pH 10, 
and the pyrophosphate bond is hydrolysed only under strong basic condition. However, 
cADPR is slightly acid-labile, its half-life for spontaneous hydrolysis at 37 °C is 24 h, 
and it can be easily hydrolysed by NADases or ADPRC with cADPR-hydrolase 
activity, but not by NPPs.
234, 235
 Compounds 15h and 24 were subjected to similar 
hydrolytic conditions (0.1 N NaOH and HCl) to identify the chemical stability of 24 
compared to 15h (Appendix 8, Figure A10).  
Spectroscopic and 
1
H NMR analyses for 24 were performed and compared to 15h; the 
results are summarised in Table 4.4 and Table 4.5.
246
 Compound 24 showed a 
substantial red shift in λex compared to 15h, with consequent decrease in Stoke shift, 
which indicated a minor vibrational relaxation due to the constrained conformation of 
the adenine ring cyclized in N-1 position. The  value of 24, as expected from the 
fluorescence-based assay for ADPRC, was less than 15h, probably due to the change of 
the electron delocalization along the adenine ring, now positively charged. 
The 
1
H NMR spectrum clearly showed the cyclization product. Indeed, the nicotinamide 
signals disappeared, while a considerable downfield shift was noticed for 2-H on the 
adenine ring and, consequently, for 1′-H and 1′′-H, deshielded because of the newly 
formed N
1
-ribosyl bond and the positively charged adenine ring. 
 
cmpd λex/nm λem/nm Stoke shift
a
/cm
-1  
15h 309 374 5624 0.0053 
24 316 378 5190 0.004 
a 
Stokes shift = (1/ex - 1/em). 
Table 4.4 Spectroscopic analysis and  values of 15h and 24 in water. 
cmpd 2-H (ppm) 1′-H (ppm) 1′′-H (ppm) 
15h 8.09 5.73 5.91 
24 8.98 6.42 6.16 
All the spectra are referenced for D2O ( 4.79 ppm). 
Table 4.5 
1
H NMR analysis for 15h and 24. Comparison of chemical shift (ppm) for 2-H, 1′-H and 1′′-H. 
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5 EVALUATION OF ARYL/HETEROARYL ADENINE-MODIFIED 
NAD+ DERIVATIVES AS INHIBITORS AND NON-NATURAL 
SUBSTRATES FOR NAD+-CONSUMING ENZYMES 
In Chapter 4, 15h, the most promising fluorescent NAD
+
 derivative belonging to the 
class of those 8-aryl/heteroaryl substituted, was evaluated as a biochemical probe for 
NAD
+
-consuming enzymes; in particular, its role as a NNS was analysed. Of course, the 
activity of 15h as a NNS for NAD
+
-consuming enzymes implies a competitive 
inhibition with the natural substrate β-NAD+, which was only superficially explored in 
the previous enzymatic evaluation of 15h.  
Herein, greater attention will be given to the inhibitory effects of the aryl/heteroaryl 
adenine-modified NAD
+
 derivatives toward NAD
+
-consuming enzymes. It will be 
stressed how competitive inhibition does not necessarily correlate with substrate 
activity, as was the case with the enzymes analysed in Chapter 4. Instead, for complex 
enzymes that involve more than one substrate in their reactions, the situation can change 
due to the more complicated catalytic mechanisms and active sites, requiring elaborate 
and discriminating factors in the recognition and use of their substrates. NAD
+
-
dependent DNA ligases and sirtuins have been chosen in this project as complex NAD
+
-
consuming enzymes to evaluate the biological activities of the differently substituted 
NAD
+
 derivatives as inhibitors and/or NNSs. These enzymes require β-NAD+ as a co-
substrate in their reactions and have in their structures specific adenine binding 
domains, which reflect on the different activities exerted by the adenine-modified NAD
+
 
derivatives as inhibitors and/or NNSs. 
5.1 NAD+-dependent DNA ligases 
DNA is continuously exposed to damage and lesions deriving from the physiological 
processes in which it is involved, for instance, mismatches during DNA replication, or 
DNA strand breaks due to aborted topoisomerase activity. However, DNA damage is 
mostly due to processes unrelated to its biological roles, like the attack from ROS and 
environmental factors, such as ultraviolet light, radioactive exposure or tobacco 
products.  
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To defend themselves, living cells have developed complicated and efficient systems to 
detect DNA damage and repair it; the DNA-damage response (DDR) implies an 
intricate cascade of signalling processes and enzymatic activities that are not yet fully 
understood, but are continuously under study.
247
 DNA polymerases, ligases, 
methyltransferases, helicases, endonucleases, PARPs and many other enzymes are 
fundamental components of the DDR. Defects in DDR are associated with the 
development of many diseases, such as heritable neurodegenerative diseases and cancer. 
In the latter case, there is a strong connection between cancer and DDR, since defects in 
DDR cause genome instability and, therefore, mutations and malignancies; however, 
DDR is also responsible for cancer-therapy resistance. Consequently, DDR inhibitors 
can in some cases be used for anticancer therapy. 
DNA ligases are essential enzymes found in all living cells, involved in DNA 
replication, repair and recombination;
15, 248, 249
 their activity consists of sealing DNA 
single-strand breaks between 5′-phosphate and 3′-hydroxyl termini. DNA ligases have 
been differentiated into two classes depending on their co-substrate specificity; 
eukaryotic DNA ligases are ATP-dependent, while bacterial and some viral DNA 
ligases are NAD
+
-dependent. In fact, ATP-dependent DNA ligase sequences have been 
found in bacteria in addition to the NAD
+
-dependent ones, even though they are 
expressed only in particular conditions;
250
 in contrast, NAD
+
-dependent DNA ligases 
have never been found in eukaryotic organisms.  
The restricted distribution in bacteria, the necessary requirement for bacteria viability 
and the absolute co-substrate uniqueness make NAD
+
-dependent DNA ligases a 
possible target for the development of antibacterial drugs. NAD
+
-dependent DNA 
ligases from different bacteria have been structurally characterized to better understand 
their activities and reaction mechanism, and to develop possible inhibitors. High 
homologies have been found between sequences of several bacterial DNA ligases, 
showing highly conserved motifs and the same modular architecture. The sequence 
similarity with ATP-dependent DNA ligases is quite poor, as expected because of the 
different co-substrate; however, NAD
+
-dependent and ATP-dependent DNA ligases 
share exactly the same reaction mechanism (Scheme 5.1).
249
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Scheme 5.1 Reaction mechanism for DNA ligation by ATP and NAD
+
-dependent DNA ligases. 
The ligation of DNA occurs in three steps. In the first step, ATP or β-NAD+ binds to the 
active site of the enzyme; there, a nucleophilic lysine residue attacks the phosphate of 
the adenosine in the co-substrate with subsequent release of the leaving group, 
respectively pyrophosphate (PPi) and β-NMN, and formation of adenylated-ligase 
intermediate (1). In the second step, after the positioning of the DNA nick in the 
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proximity of the adenylated-ligase intermediate (1), the nucleophilic phosphate in the 5′ 
position attacks the phosphoramidate bond in 1 to form an adenylated-DNA 
intermediate (2). In the third and final step, the nucleophilic hydroxyl group in the 3′ 
position attacks the new pyrophosphate bond with formation of a phosphodiester bond 
between the 5′ and 3′ positions of the DNA (3), and release of AMP.     
The NAD
+
-dependent DNA ligases have a modular architecture consisting of four main 
domains linked by single chains (Figure 5.1). Domain 1 is formed by two subdomains; 
subdomain 1a, at the N-terminus, binds the β-NMN moiety of β-NAD+, while 
subdomain 1b is the adenylation domain, or the nucleotidyltransferase domain (NTase), 
since it binds the AMP moiety of β-NAD+. Domain 2 is the oligonucleotide binding site 
(OB). Domain 3 consists of subdomain 3a, a Cys4-type zinc finger, and subdomain 3b, 
containing a helix-hairpin-helix motif (HhH). Domain 4, at the C-terminus, is a BRCT 
domain (Breast cancer Carboxy-Terminal). The catalytic core of DNA ligase consists of 
subdomain 1b and OB, flanked by N and C-terminal domains arranged in a C-shape 
that clamps the double-stranded DNA.
251
  
Subdomain 1a has been shown to interact with the β-NMN moiety of β-NAD+, indeed it 
is not present in ATP-dependent DNA ligases.
252
 Its presence is fundamental to initiate 
the ligation reaction, but not essential in the case of preadenylated-enzyme and its 
interaction with DNA; this means that subdomain 1a is required for the β-NAD+ binding 
and the adenylation step. From crystallographic studies, it was possible to identify an 
“open” enzyme conformation, in which β-NAD+ was bound to the solvent exposed 
NTase domain. Therefore, the closure of subdomain 1a to bury β-NAD+ and interact 
closely with β-NMN puts the latter in an apical position as a leaving group during the 
nucleophilic attack of the lysine residue on the adenosine phosphate; the subdomain 1a 
has to swivel by almost 180° to switch from the “open” to the “closed” conformation.253 
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Figure 5.1 Structure of DNA ligase from E. coli (EcLigA) (PDB 2OWO) in complex with nicked DNA. 
Visualization by PyMol software. Subdomain 1a (light blue), subdomain 1b (green), OB domain 
(yellow), subdomain 3a (orange), subdomain 3b (red). 
Subdomain 1b is the adenylation domain, or the core of the DNA ligase. Several 
residues have been found to be fundamental in the NTase for the enzyme activity, their 
modifications bringing a considerable rate decrease or inactivation of the enzyme. The 
main residues in NTase, their interactions and their roles are summarised in Table 
5.1.
252, 254
 
The OB domain is involved in the oligonucleotide binding, as it contacts the double-
strand DNA covering the nick and help in positioning it into the NTase domain. Its 
action is supported by subdomain 3b, HhH, which binds both DNA strands in a non-
specific sequence manner across the minor groove. OB, NTase and HhH clamp the 
double-strand DNA along 19 bp.
255
 
1b1a
3b (HhH)
3b (Zn)
2 (OB)
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Residue Pos. Interaction Role 
Lysine 115 Part of KXDG conserved motif; nucleophilic 
attack to adenosine phosphate of β-NAD+ 
Formation of adenylated-
ligase intermediate (1) 
Aspartate 117 Part of KXDG conserved motif Stabilization active site 
Glycine  118 Part of KXDG conserved motif Stabilization active site 
Glutamate 173 Coordination of O-2′ of the adenosine ribose in β-
NAD
+
 and AMP 
Involvement in step 1 and 3 
Lysine  290 H-bonding with N-1 on adenine ring Stabilization of adenine 
conformation 
Lysine  314 H-bonding with the adenosine phosphate and O-2′ 
of the nicotinamide ribose in β-NAD+ 
Involvement in step 1 and 3 
Arginine 136 H-bonding with β-NAD+ pyrophosphate and 5′-
phosphate side of the nick  
Involvement in step 1 and 2 
Arginine 200 Interaction with subdomain 1a in closed 
conformation of adenylation domain; interactions 
with 3′-OH side of nick and DNA minor groove 
Involvement in step 1 and 3 
Arginine 208 
Arginine 218 Interaction with 3′-OH side of the nick Involvement in step 2 and 3 
Arginine  277 H-bonding with Ile284 Stabilization active site 
Aspartate 285 Interaction with Mg
2+ 
Metal binding 
Arginine 308 Interaction with 5′-phosphate side of the nick Involvement in step 2 and 3 
Table 5.1 Essential residues in the NTase domain of EcLigA and their roles. 
Subdomain 3a, the Cys4-type zinc finger, seems to hold OB and HhH during DNA 
binding, showing therefore a structural role.
251, 255, 256
 Finally, the C-terminal domain 4, 
BRCT, has a controversial role in DNA ligases; indeed, from the crystal structures of 
different enzymes, BRCT appears as a very flexible unit, with a structure that cannot to 
be properly resolved, and it is apparently not involved in the adenylation step. Indeed, 
DNA ligase proteins not including BRCT in their modular structures are still able to 
perform their ligation reaction, despite a lower rate. Moreover, DNA binding was 
shown to be tighter for a DNA ligase with BRCT domain compared to DNA ligase not 
containing it. Therefore, the BRCT domain could stabilize the DNA binding on DNA 
ligases, even though it does not interact directly with DNA.
251, 255-257
 Another possible 
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function as a signal transducer of the DNA-damage response could be assigned to 
BRCT; indeed, other well known proteins use this domain for protein-protein 
interactions to transmit signalling responses.
251
 Overall, the modular structure of NAD
+
-
dependent DNA ligase allows it to catalyze the ligation reaction involving considerable 
movements of the different domains.  
The first DNA ligase inhibitors were found by screening libraries of classes of 
compounds, including alkaloids, flavonoids, pyridochromanones, quinoline and 
quinacrine derivatives, and many others.
248, 258-260
 The scaffolds of the compounds 
showing inhibitory activity were subsequently optimized on the basis of computational 
studies to improve activity, selectivity, specificity, solubility, and many other factors.
73, 
74, 261, 262
 However, a deeper knowledge of the structure of NAD
+
-dependent DNA 
ligases allowed the design of more specific inhibitors. At the outset of this project, the 
crystal structures of several NAD
+
-dependent DNA ligases were resolved and 
published, showing the existence of a hydrophobic tunnel between the outside and the 
adenylation domain next to N-1, C-2 and N-3 of the adenine ring of β-NAD+; in 
particular, C-2 pointed exactly in the direction of the tunnel (Figure 5.2).
15, 255
  
 
 
Figure 5.2 Hydrophobic tunnel on NTase domain of DNA ligase from Enterococcus faecalis (PDB 
1TAE). C-2 of the adenine ring points in the direction of the tunnel. Visualization by PyMol software. 
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Many known inhibitors were docked into the active site and shown to fit into this 
tunnel.
15
 This observation initiated the discovery of NAD
+
-dependent DNA ligase 
inhibitors based on mimics of the adenine/adenosine structure substituted in position 
2,
261, 262
 which can compete for β-NAD+ binding. Indeed, ATP-dependent DNA ligases 
do not have this tunnel in their structure, providing the possibility that such inhibitors 
may act specifically against NAD
+
-dependent DNA ligases. 
Until now, different adenosine/ADP/ATP derivatives substituted in position 2 with alkyl 
or cycloalkyl substituents have been tested in vitro/in vivo as antibacterial agents with 
promising results (Figure 5.3).
73, 74, 263
 However, to the best of our knowledge no AMP 
or NAD
+
 derivatives have been reported as inhibitors of NAD
+
-dependent DNA ligases. 
It is likely that the difficult synthesis of NAD
+
 derivatives, their hydrophilicity, their 
flexible/multifunctional structure making β-NAD+ binding quite unspecific, together 
with their potential NNS activity interfering with that as inhibitors, have been the 
reasons why such compounds have not been described yet. 
 
 
Figure 5.3 C-2 adenine-modified adenosine derivatives and their efficacies as NAD
+
-dependent DNA 
ligases inhibitors.
73, 74, 263
 
In this project, the biological activity of the NAD
+
 derivatives and some of their 
corresponding AMP and AMP-morpholidate derivatives, modified in position 2, 6 or 8 
of the adenine ring, as inhibitors and/or NNSs was assessed toward EcLigA, one of the 
best characterized NAD
+
-dependent DNA ligases. In particular, the whole β-NAD+ 
scaffold, differently from adenosine or AMP scaffolds that could bind also to ATP-
dependent DNA ligases, should provide selectivity toward NAD
+
-dependent DNA 
ligases, as well as the introduction of substituents in position 2 on the adenine ring. In 
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addition, the introduction of aryl/heteroaryl substituents in position 2, 6 or 8 of the 
adenine ring and the biological activities of the corresponding derivatives would 
improve understanding of the enzyme active site and the essential interactions for the β-
NAD
+
 binding. 
5.1.1 Expression, purification and activity of Escherichia coli DNA ligase 
Escherichia coli DNA ligase (EcLigA) is a protein consisting of 671 amino acids, with 
a molecular weight of 74 kDa. The protocol for the overexpression and purification of a 
recombinant form of EcLigA, containing a 10-His-tag at the N-terminus of the protein 
that allows its straightforward purification, is well established in the literature
257
 and it 
was followed with minor changes to obtain highly pure EcLigA with 24 μM 
concentration (Figure 5.4). 
 
Figure 5.4 Purification of EcLigA. Lane M: marker of protein molecular weights; lane 1: crude extract of 
overexpressed proteins in the soluble fraction; lane 2: 10 x dilution of purified protein; lane 3: purified 
protein. Visualization of SDS-PAGE gel by Coomassie blue staining. 
The activity of EcLigA was tested by a gel electrophoresis assay of the ligation of 
nicked DNA (Figure 5.5 a). The DNA substrate was prepared by annealing of a 40-mer 
strand (LigSub1+2) with two complementary 18-mer (LigSub1) and 22-mer (LigSub2) 
strands forming a nick between the 18
th
 and 19
th
 bases of one strand; LigSub1 and 
LigSub2 were characterized by the addition of fluorescein (F) and a phosphate group 
(P) in their 5′ positions respectively. For the preparation of this substrate, the 
74 kDa83 kDa
62 kDa
47.5 kDa
1 2 3M
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appropriate ratio between the different strands and salt concentration were established to 
obtain complete annealing (Appendix 8, Figure A11). The ligation reaction was 
monitored by formation of a fluorescent 40-mer strand, migrating less than the 
fluorescent 18-mer strand on a denaturing gel, which separates DNA strands based on 
their molecular size (Figure 5.5 b).  
 
 
Figure 5.5 Ligation assay with fluorescent annealed nicked substrate. a) Scheme of ligation assay with 
fluorescent annealed nicked substrate; b) denaturing PAGE for time-course of ligation reaction with 
fluorescent annealed nicked substrate. Conditions: DNA substrate (0.125 μM), EcLigA (0.1 μM), β-
NAD
+
 (26 μM) in 1 x buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL BSA); all 
concentrations are final concentrations. Reactions incubated at 30 °C under shaking; samplings at 0, 1, 2, 
3, 5, 10, 15 and 30 min. Gel visualization by fluorescence imaging. 
Preliminary experiments were carried out to establish the conditions for the ligation 
reaction during the inhibition and NNS activity studies. Indeed, it is important to choose 
the right enzyme concentration and, consequently, the time sampling, to have 40 – 50% 
ligation in the control reaction without inhibitor. These conditions, varying from batch 
to batch of enzyme, allow clear detection of inhibition and activation of the enzyme 
activity in the same set of experiments, since the ligation is still not complete and not 
influenced by displacement of the inhibitors by the natural β-NAD+. Therefore, the 
following studies investigated the reaction in an initial state, not influenced by 
reversible reactions, inhibition by products or enzyme deactivation.  
For the NNS activity test, the reactions in some cases were maintained for longer to 
allow the NNS to be recognised and metabolized by the enzyme. Therefore, the enzyme 
activity and the substrate stability were checked over time to be sure they would not 
negatively influence the ligation reactions. EcLigA retained full activity after 90 min at 
fluor
5′
OH P
3′
3′ 5′
ligation
fluor
LigSub1 LigSub2
LigSub1+2
a b
0’ 1’ 2’ 3’ 5’ 10’ 15’ 30’
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30 °C; however, the activity dropped dramatically after 3.5 h at 30 °C. The annealed 
substrate was shown to be stable over 1 h (data not shown).  
To validate the gel electrophoresis assay and its application in the inhibition studies, 
quinacrine, a well characterized inhibitor of EcLigA, was tested at different 
concentrations and its IC50 estimated and compared with the value in the literature 
(Appendix 8, Figure A12). The obtained value, 3.9 ± 1.5 μM, was close to that in the 
literature, 1.5 ± 0.2 μM,260 indicating the suitability of the method in studying inhibitors. 
At this stage, it was possible to proceed with the biological testing of the synthesized 
compounds. The series of NAD
+
 derivatives substituted on either C-2, C-6 or C-8 and 
some of their corresponding AMP and AMP-morpholidate derivatives were 
successively tested as NNSs and inhibitors of EcLigA.  
5.1.2 Biological testing of 2-substituted AMP and NAD+ derivatives 
Firstly, 2-substituted AMP and NAD
+
 derivatives, respectively 7a-b and 13a-b, were 
tested as NNSs of EcLigA at 250 μM in the absence of β-NAD+ (Figure 5.6); this 
concentration, 10 fold larger than that used for the assay with the natural β-NAD+, was 
chosen to ensure detection of any substrate activity. From these experiments, a NNS 
activity was observed for both the NAD
+
 derivatives, 13a and 13b, but not for the AMP 
derivatives, 7a and 7b. This was expected because the AMP derivatives have a 
phosphate that is not reactive enough to be attacked by the nucleophilic lysine residue in 
the active site (see 5.1, Scheme 5.1).  
When the NNS activity for 13a and 13b was tested at different substrate concentrations 
between 50 and 250 μM, 13a showed the same or a lower activity than the natural β-
NAD
+
 at 26 μM (Figure 5.7 a), while 13b showed the same or slightly higher activity 
than the natural β-NAD+ at 26 μM (Figure 5.7 b). 
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Figure 5.6 Denaturing PAGE for the NNS activity of 2-substituted AMP and NAD
+
 derivatives at 250 
μM. Conditions: DNA substrate (0.5 μM), EcLigA (0.05 μM), 2-substituted derivative (250 μM) in 1 x 
buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL BSA); all concentrations are final 
concentrations. Reactions incubated at 30 °C under shaking and sampled at 15 min. Control reaction at 
the same conditions with β-NAD+ (26 μM) without any 2-substituted derivative. Gel visualization by 
fluorescence imaging. 
 
Figure 5.7 NNS activity of 2-substituted NAD
+
 derivatives at concentrations between 50 and 250 μM. 
Conditions: DNA substrate (0.5 μM), EcLigA (0.05 μM), 13a (a) (50 – 250 μM), 13b (b) (50 – 250 μM) 
in 1 x buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL BSA); all concentrations are 
final concentrations. Reactions incubated at 30 °C under shaking and sampled at 5 min. Control reaction 
at the same conditions with β-NAD+ (26 μM) without any 2-substituted derivative. Analysis of assay run 
on denaturing PAGE and gel visualized by fluorescence imaging. Data analysed using ImageJ. Each data 
point is the mean (± SD) of a set of experiments run in triplicate; data plotting with Excel. 
Next, inhibition studies were undertaken testing 2-substituted AMP/AMP-
morpholidate/NAD
+
 derivatives, respectively 7a-b, 10b, and 13a-b, at 200 μM with β-
NAD
+
 at 26 μM; the samplings were performed at 5 and 15 min (Figure 5.8 and 
Appendix 8, Figure A13). A clear inhibition was observed for the 2-iodo AMP and 
NAD
+
 derivatives, respectively 7a and 13a, which showed around 80% inhibition at 200 
μM at 5 min. Regarding the 2-phenyl derivatives, a clear inhibition under the 
experimental conditions was observed only for the AMP-morpholidate derivative, 10b, 
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showing around 70% inhibition, while AMP and NAD
+
 derivatives, respectively 7b and 
13b, showed no inhibition. At 15 min, the ligation for all reactions reached the level of 
the control reaction. IC50 values were measured for 7a and 13a (Appendix 8, Figure 
A14), and are summarised in Table 5.2. 
 
 
Figure 5.8 Inhibition of 2-substituted AMP/AMP-morpholidate/NAD
+
 derivatives at 200 μM. Conditions: 
DNA substrate (0.5 μM), EcLigA (0.05 μM), β-NAD+ (26 μM), 2-substituted derivative (200 μM) in 1 x 
buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL BSA); all concentrations are final 
concentrations. Reactions incubated at 30 °C under shaking and sampled at 5 and 15 min. Control 
reaction at the same conditions without any 2-substituted derivative. Analysis of assay run on denaturing 
PAGE and gel visualized by fluorescence imaging. Data analysed using ImageJ. Each data point is the 
mean (± SD) of a set of experiments run in triplicate; data plotting with Excel. 
 
cmpd scaffold Position of substitution R (substituent) IC50 (μM) 
7a AMP 2 Iodo 119.9 ± 23.4 
13a NAD 2 Iodo 137.6 ± 17.8 
2-MeSADP
263
 ADP 2 Methyl 4.1 ± 0.5 
2-MeSATP
263
 ATP 2 Methyl 1.1 ± 0.4 
Table 5.2 IC50 values ± SD for 7a and 13a toward EcLigA. 
An activity comparison between 2-iodo and 2-phenyl substituted derivatives was 
undertaken to investigate the influence of the substituents on the different biological 
activities observed for the compounds. EcLigA was inhibited by 2-iodo NAD
+
, 13a 
(Figure 5.8); however, due to its NNS activity (Figure 5.7 a), it actively competed with 
β-NAD+ for the same active site and catalytic reaction. Since in the inhibition study 13a 
was used in a large excess (200 μM) compared to β-NAD+ (26 μM), EcLigA (0.05 μM) 
would have bound in its active site more 13a than β-NAD+, independently from the 
different affinities (Km) of the compounds (Figure 5.9). The fact that the resulting 
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ligation was much slower than the control reaction with only β-NAD+ and gave at 5 min 
an inhibition overall, indicated that 13a was used preferentially as substrate because of 
its excess in the reaction media, but it had a very slow turnover (low kcat) along the 
different reaction steps compared to β-NAD+. Indeed, at 15 min the ligation reached the 
same level of the control reaction, strongly suggesting a kinetic difference between the 
reaction steps involving 13a and β-NAD+. 
In contrast to 13a, 2-phenyl NAD
+
, 13b, seemed to have no inhibitory activity toward 
EcLigA (Figure 5.8); however, its NNS activity (Figure 5.7 b) implied a competition of 
13b with β-NAD+ for the same active site. Also in this case, 13b was used in a large 
excess (200 μM) compared to β-NAD+ (26 μM); therefore, EcLigA (0.05 μM) would 
have bound in its active site more 13b than β-NAD+, independently from the different 
affinities (Km) of the compounds (Figure 5.9). The fact that the resulting ligation at 5 
min was the same as that for the control reaction, suggested that 13b had a very similar 
turnover compared to β-NAD+, hence EcLigA could perform its ligation at a similar rate 
than with β-NAD+.  
The 2-substituted AMP derivatives, 7a and 7b, as well as the corresponding NAD
+
 
derivatives, 13a and 13b, showed a distinct activity depending on the substituent 
introduced in position 2 on the adenine ring. Owing to the lack of the NNS activity due 
to the AMP scaffold, 7a and 7b provided some clues about the different affinities of the 
compounds, generated by the different substituents, toward the active site of EcLigA. 
The 2-iodo AMP, 7a, acted as an inhibitor of EcLigA in the presence of β-NAD+ at 5 
min (Figure 5.8); because of its analogy with 13a, 7a would presumably bind in the 
same β-NAD+ binding site, and the inhibitor activity would indicate its good affinity for 
EcLigA. The increased ligation at 15 min would be due to the displacement of 7a by β-
NAD
+ 
with the re-establishment of the normal enzyme activity. In contrast to 7a, the 2-
phenyl AMP, 7b, showed no inhibition (Figure 5.8). This effect could be due to a low 
affinity of 7b toward EcLigA; hence, 7b would not bind, or just weakly, to EcLigA and 
could be easily displaced by β-NAD+, giving no substantial inhibition overall. 
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Finally, the inhibitor activity of the 2-phenyl AMP-morpholidate, 10b, (Figure 5.8) 
would be due to its modification on the phosphate, since its corresponding AMP 
derivative, 7b, showed no inhibitor activity at all. 
 
Figure 5.9 Competition of 2-substituted NAD
+
 derivatives, 13a-b (light blue), with β-NAD+ (green) for 
EcLigA (E, brown). k1 is the binding constant of β-NAD
+
 to EcLigA; k2a and k2b are the binding constants 
respectively of 13a and 13b to EcLigA; k3 is the rate constant for the displacement reaction; k4 and k4a/b 
are the rate constants for the enzyme adenylation (E·AMP
*
) respectively with β-NAD+, 13a and 13b; k5 
and k5a/b are the rate constants for the nicked DNA adenylation (E + AMP
*
·nDNA) respectively with β-
NAD
+
, 13a and 13b; k6 and k6a/b are the rate constants for the ligation (E + AMP + DNA) respectively 
with β-NAD+, 13a and 13b. In the inhibition experiments, where the excess of 13a-b shifts the equilibria 
toward the binding of 13a-b compared to β-NAD+, the resulting ligation is due to differences in the rate 
of any of the steps involved in the metabolism of β-NAD+ and 13a-b.  
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5.1.2.1 Biological activities of 2-substituted AMP and NAD+ derivatives 
In agreement with the already developed inhibitors based on modifications of C-2 on 
the adenine ring of adenosine, ADP or ATP structures (see 5.1, Figure 5.3),
73, 74, 263
 2-
substituted AMP/AMP-morpholidate/NAD
+
 derivatives were found to be biologically 
active as inhibitors and/or NNSs of EcLigA, suggesting the validity of the introduction 
of substituents in position 2 on the adenine ring. 
Interesting observations came out of the screening of the activities of the different 
compounds. As suggested by the combined observations of NNS and inhibitor 
activities, 2-iodo NAD
+
, 13a, was a NNS for EcLigA with a slow turnover compared to 
β-NAD+, causing an inhibitory effect overall. In addition, 2-iodo AMP, 7a, not a NNS 
because of its AMP scaffold, showed inhibitor activity and, therefore, a certain affinity 
for EcLigA. The activities for 2-phenyl NAD
+
, 13b, and 2-phenyl AMP, 7b, were less 
clear. At first glance, the results showing no inhibition could be easily interpreted as no 
or weak binding to EcLigA; however, the NNS activity of 13b suggested a similar 
binding and turnover compared to β-NAD+, hence justifying the same extent of ligation 
as the control reaction. In contrast, 7b, due to the AMP scaffold, could not be a NNS for 
EcLigA, but neither did it not show any inhibitory activity, therefore suggesting that 7b 
could indeed have no activity.  
The reasons for the different activities could be clearly ascribed to the different nature 
of the substituents. Size, conformational and electronic differences explained the 
different behaviors. Looking at the AMP derivatives activities, not complicated by the 
presence of NNS activity, it was evident that iodine imparted to 7a a certain affinity for 
the enzyme active site, hence its ability to act as an inhibitor; in contrast, the phenyl 
group in 7b did not generate any inhibition, indicating a low affinity/binding to the 
enzyme. These effects are likely to be due to the different size of the substituents and, 
therefore, to their ability to fit into the hydrophobic tunnel of the enzyme in 
correspondence to the C-2 of the adenine ring. Indeed, iodine and phenyl groups have a 
substantially different van der Waals volume (Vw), respectively 19.64 and 45.84 
cm
3
·mol
-1
;
264
 therefore, they would have a different occupancy in the hydrophobic 
tunnel of NAD
+
-dependent DNA ligases. The phenyl substituent, larger than iodine, 
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could not fit properly into the tunnel, disfavouring the stabilization of 7b in the active 
site; this would justify its low binding to EcLigA and, therefore, its absent inhibitor 
activity. Instead, iodine could fit more easily into the tunnel, causing the higher affinity 
of 7a for EcLigA and, therefore, its activity as inhibitor.  
The conformation of iodine and phenyl substituted adenine related to the ribose has to 
be considered when comparing the different activities. In 3.1.1, an adopted anti 
conformation in solution for the 2-substituted AMP derivatives was confirmed by 
1
H 
NMR analysis, which tended toward a syn conformation for the 2-substituted NAD
+
 
derivatives (see 3.1.2), in particular for the 2-phenyl NAD
+
, 13b. In the active site of 
NAD
+
-dependent DNA ligases, the adenine of the natural β-NAD+ assumes a high syn 
conformation (Figure 5.10 a); in fact, in the literature it is known that often 
nucleosides/nucleotides with high syn or high anti conformations have high biological 
activities.
176, 265
 Therefore, 2-substituted NAD
+
 derivatives should be able to assume a 
high syn conformation in the active site, where the substituents point far from the ribose 
avoiding any steric hindrance (Figure 5.10 b). A more pronounced high syn 
conformation for 2-phenyl NAD
+
, 13b, due to the larger volume occupied by the phenyl 
substituent, could be responsible for its higher similarity to the natural β-NAD+, leading 
to its high substrate activity. 
 
 
Figure 5.10 β-NAD+ (a) and 13b (b) in the active site of DNA ligase from E. faecalis (PDB 1TAE). 13b 
is built on the β-NAD+ structure. The high syn conformation of the adenine ring related to the ribose 
tolerates the introduction of substituents in position 2 without interfering with the binding in the active 
site. Visualization by PyMol software. 
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Examining the activities of 13a and 13b, both iodine and phenyl substituted NAD
+
 
derivatives had NNS activities; this indicated the essential nature of the β-NAD+ 
scaffold in stabilizing in the active site the 2-phenyl AMP moiety, which alone did not 
bind properly to the enzyme. The different turnover of the two NAD
+
 derivatives used 
as NNSs by EcLigA could be explained as due to electronic differences between the 
iodine and phenyl substituted adenine rings. Indeed, iodine is more electron-
withdrawing than the phenyl group and, consequently, it can influence the electronic 
properties of the closest atoms in the aromatic ring.
176, 265
 Then, N-1 and N-3 on the 2-
iodo adenine could undergo a reduction of electron density reflecting on their H-
bonding ability and, therefore, on the conformation assumed by the adenine ring related 
to the ribose. As mentioned in 5.1, an essential residue in the active site of EcLigA is 
Lys 290,
254
 which is involved in H-bonding with N-1 on the adenine ring during all the 
three catalytic steps. Its presence is fundamental for making contacts with the adenine 
ring to keep it in the right position in the active site; its modification in mutants makes 
the enzyme almost inactive, suggesting its essential nature. In the case of 2-iodo NAD
+
, 
13a, the reduced electron density on N-1 would negatively influence its ability to form 
H-bonds with Lys 290, explaining the hypothesized slow turnover of 13a compared to 
β-NAD+ and, therefore, its resulting inhibitory activity. Conversely, 2-phenyl NAD+, 
13b, would keep intact the ability of N-1 to interact with Lys 290; indeed, the phenyl 
group would increase the electronic density on N-1, making the H-bonding even 
stronger than in the natural β-NAD+. This effect would explain the similarity and 
competition of 13b with β-NAD+, and the resulting lack of ligation inhibition overall.  
5.1.3 Biological testing of 6-substituted AMP and NAD+ derivatives 
The activity of 6-substituted AMP, AMP-morpholidate and NAD
+
 derivatives was 
tested toward EcLigA. Firstly, 6-substituted NAD
+
 derivatives, 14a and 14b, were 
tested as NNSs of EcLigA in the absence of natural β-NAD+ at 250 μM, choosing this 
high concentration to ensure detection of any eventual NNS activity. Both compounds 
showed no activity as NNSs of EcLigA (data not shown). 
Next, 6-substituted AMP/AMP-morpholidate/NAD
+
 derivatives, respectively 8a-b, 11a, 
and 14a-b, were tested as inhibitors of EcLigA. Inhibition studies were performed 
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testing the compounds at 250 μM, 10 fold higher than the natural β-NAD+, with 
sampling at 7 and 15 min (Figure 5.11). From inhibition experiments, the compounds 
showed no activity as inhibitors of EcLigA, with the exception of the 6-phenyl AMP-
morpholidate, 11a, which showed 60% inhibition at 250 μM at 7 min. At 15 min, the 
ligation for the reaction containing 11a increased to the level of the control reaction. 
The estimated IC50 value for 11a was 172.7 ± 4.1 μM (Appendix 8, Figure A15).  
 
 
Figure 5.11 Inhibition of 6-substituted AMP/AMP-morpholidate/NAD
+
 derivatives at 250 μM. 
Conditions: DNA substrate (0.5 μM), EcLigA (0.05 μM), β-NAD+ (26 μM), 6-substituted derivative (250 
μM) in 1 x buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL BSA); all concentrations 
are final concentrations. Reactions incubated at 30 °C under shaking and sampled at 7 and 15 min. 
Control reaction at the same conditions without any 6-substituted derivative. Analysis of assay run on 
denaturing PAGE and gel visualized by fluorescence imaging. Data analysed using ImageJ. Each data 
point is the mean (± SD) of a set of experiments run in triplicate; data plotting with Excel. 
5.1.3.1 Biological activities of 6-substituted AMP and NAD+ derivatives 
From activity tests of 6-substituted AMP/AMP-morpholidate/NAD
+
 derivatives, it was 
clear that the series of 6-substituted adenine derivatives was inactive toward EcLigA as 
inhibitors and NNSs, independent of the nature of the introduced substituent. Indeed, 
both phenyl and pyrrolyl substituents failed to show any kind of activity.  
Looking at the crystal structure of β-NAD+-bound DNA ligase from E. faecalis (PDB 
1TAE), there exists a small polar cavity that would be able to accommodate the 
exocyclic amino group in position 6 on the adenine ring, but which would probably be 
too narrow to accommodate a phenyl or a pyrrolyl substituent. In addition, since there 
are no essential residues in the active site that interact with the amino group in position 
6, its modification should not cause any effect on the activity of the enzyme. Therefore, 
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the lack of inhibitory activity of 6-substituted adenine derivatives could be due to their 
inability to strongly interact with the enzyme active site, consequently allowing an 
easier displacement by the natural β-NAD+. In addition, the lack of NNS activity could 
be due to some distortion of the adenine ring in the active site to accommodate the 
introduced substituent, which would not fit into the cavity for the exocyclic amino 
group. 
5.1.4 Biological testing of 8-substituted NAD+ derivatives 
NAD
+
 derivatives substituted in position 8, 15b,c,e,g,h, were tested as NNSs and 
inhibitors of EcLigA. For the NNS activity, the compounds were tested at 250 μM in 
the absence of β-NAD+; this concentration, 10 fold larger than that used for the assay 
with the natural β-NAD+, was chosen to ensure detection of any substrate activity. All 
compounds belonging to this series appeared inactive as NNSs, even after long reaction 
times. Indeed, in the attempt to assess their substrate activity, pre-incubation studies of 
8-substituted NAD
+
 derivatives with EcLigA were performed at different temperatures 
and reaction times starting the reaction with addition of DNA; nevertheless, none of 
these experiments showed any ligation activity (data not shown). In addition, when 
natural β-NAD+ was added to the unsuccessful reactions, the ligation immediately went 
to completion (Figure 5.12), indicating the enzyme retained full activity and, therefore, 
confirming its inability to use 8-substituted NAD
+
 derivatives as NNSs. 
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Figure 5.12 NNS activity test of 15h. Conditions: DNA substrate (0.125 μM), EcLigA (0.1 μM), 15h (250 
μM) in 1 x buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL BSA); all concentrations 
are final concentrations. Negative control at the same conditions without 15h. Reaction incubated at 30 
°C under shaking for 1 h; then, addition of β-NAD+ (26 μM), and reaction stopped and analysed by 
denaturing PAGE after 2.5 h. Gel visualization by fluorescence imaging, data analysis by ImageJ, and 
data plotting with Excel. 
Inhibition studies were performed by testing the compounds at 250 μM in the presence 
of β-NAD+ at 26 μM. From these experiments, 8-substituted NAD+ derivatives showed 
weak or no activity at all as inhibitors of EcLigA at 250 μM (Figure 5.13); only 15e and 
15h inhibited EcLigA around 40% at 250 μM.  
 
Figure 5.13 Inhibition of 8-substituted NAD
+
 derivatives at 250 μM. Conditions: DNA substrate (0.125 
μM), EcLigA (0.1 μM), β-NAD+ (26 μM), 8-substituted NAD+ derivative (250 μM) in 1 x buffer (30 mM 
Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL BSA); all concentrations are final concentrations. 
Reactions incubated for 10 min at 30 °C under shaking. Control reaction at the same conditions without 
any 8-substituted NAD
+
 derivative. Analysis of assay run on denaturing PAGE and gel visualized by 
fluorescence imaging. Data analysed using ImageJ. Each data point is the mean (± SD) of a set of 
experiments run in triplicate; data plotting with Excel. 
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5.1.4.1 Biological activities of 8-substituted NAD+ derivatives 
From activity tests of 8-substituted NAD
+
 derivatives, it was clear that this series was 
practically inactive toward EcLigA as inhibitors and NNSs, independent of the nature of 
the introduced substituent. To explain the inactivity of 8-substituted NAD
+
 derivatives, 
a deeper investigation of the enzyme active site was performed.  
Looking at the β-NAD+-bound DNA ligase from E. faecalis (PDB 1TAE), a clear steric 
hindrance between the position 8 on the adenine of β-NAD+ and a close loop delimiting 
the active site can be seen (Figure 5.14 a); consequently, the introduction of a 
substituent in position 8 on the adenine ring would cause an unavoidable clash with the 
loop (Figure 5.14 b).    
 
 
Figure 5.14 β-NAD+ (a) and 15h (b) in the active site of DNA ligase from E. faecalis (PDB 1TAE). 15h 
is built on the β-NAD+ structure. The introduction of substituents in position 8 on the adenine ring would 
interfere with the binding in the active site. Visualization by PyMol software. 
As discussed in 3.1.2, 8-substituted NAD
+
 derivatives are characterized by a 
pronounced syn conformation of the adenine ring, where the substituent in position 8 
points far from the ribose. Therefore, 8-substituted NAD
+
 derivatives would already 
have the appropriate syn conformation to fit in the active site of DNA ligase with the 
same binding mode of β-NAD+; however, the steric clash with the loop would prevent 
their initial accommodation into the active site. 
This observation raises the question as to whether 8-substituted NAD
+
 derivatives 
would be able to bind in the enzyme active site at all. In an attempt to answer this 
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question, the docking of a representative compound from the series of 8-substituted 
NAD
+
 derivatives, 15h, into the crystal structure of DNA ligase from E.faecalis (PDB 
1TAE) was performed and the resulting structures with the best scores were compared 
with the structure of the natural β-NAD+. The best docked structures showed 15h 
respectively in anti (a), syn (b) and high syn (c) conformation (Figure 5.15).  
 
 
Figure 5.15 Docking of 15h (pink) and superimposition with β-NAD+ (green) in the active site of DNA 
ligase from E. faecalis (PDB 1TAE). a) Docked 15h in anti conformation; b) docked 15h in syn 
conformation; c) docked 15h in high syn conformation. Visualization by PyMol software. 
In an attempt to avoid the steric clash between the substituent in position 8 and the loop, 
the docking software flipped the adenine of 180° around the N-glycosidic bond, keeping 
the ribose fixed in case a) to obtain an anti conformation; or flipped the adenine of 180° 
around the N-glycosidic bond and also rotated the ribose in case b) to allow the adenine 
to remain in the favoured syn conformation; or in case c), the adenine kept the high syn 
conformation without any torsion around the N-glycosidic bond moving back compared 
to its position in β-NAD+ to avoid the steric clash of the substituent with the loop.  
The assumption of an anti conformation by 15h in case a) would require a large 
conformational change and distortion of the nucleobase related to the ribose, 
representing an unrealistic situation. Instead, the maintenance of a syn conformation in 
case b) owing to the ribose rotation around the N-glycosidic bond is more likely to 
occur because of the ribose flexibility, as well as the maintenance of high syn 
conformation in case c), due to the backwards movement of the adenosine moiety to 
avoid the steric clash with the loop.  
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Another interesting observation among the different docked structures was that, by 
flipping the adenine of 180° around the N-glycosidic bond, C-8 and its substituent 
pointed into the hydrophobic tunnel, instead of C-2, as is the case of the natural β-
NAD
+
. Therefore, both the potential anti and syn (Figure 5.15 a and b respectively) 
conformations of the docked 15h would accommodate the pyrrolyl substituent inside 
the hydrophobic tunnel, stabilizing their position in the active site.   
These reasonable structures assumed by 15h in the active site of DNA ligase from E. 
faecalis show the possibility of the compound fitting in the active site. However, in all 
these potential structures the contacts with the essential catalytic residues in the binding 
site (Table 5.1) are destroyed. This effect could be fatal in terms of any possible binding 
and consequent activity as inhibitors and/or NNSs of 8-substituted NAD
+
 derivatives on 
the DNA ligases.       
5.1.5 Summary 
Summarising all the results obtained by the screening of AMP/AMP-
morpholidate/NAD
+
 derivatives substituted on C-2, C-6 or C-8 of the adenine ring, it 
was possible to conclude that only the series of the 2-substituted adenine derivatives 
showed biological activity toward EcLigA as inhibitors and/or NNSs, depending on the 
introduced substituent and its interactions within the active site. Indeed, both the 
presence of the hydrophobic tunnel in the enzyme structure in which the substituent in 
position 2 can be accommodated, and the high syn conformation of the adenine base 
related to the ribose, resembling the natural β-NAD+, allowed the stabilization of the 2-
substituted adenine derivatives in the active site and, therefore, their ability to interfere 
with the enzyme activity. In contrast, compounds belonging to the series of adenine 
derivatives substituted on C-6 and C-8 could not actively interact within the active site, 
consequently showing no activity.  
To create new antibacterial drugs acting on the activity of NAD
+
-dependent DNA 
ligases, the appropriate choice of substituents introduced in position 2 of the adenine 
ring has to be considered. As shown previously in the literature, the introduction of long 
alkyl chains that fit into the hydrophobic tunnel blocking the compounds in the active 
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site allows the development of efficient inhibitors of NAD
+
-dependent DNA ligases.
73, 
74
 From our studies, it emerged that the insertion of small electron-withdrawing groups 
in position 2 of the adenine ring, that are able to substantially change the H-bonding 
ability of the adenine ring could be important for developing good inhibitors. Moreover, 
the size of the substituents would be crucial in generating inhibitory activity; indeed, 
from our analysis it was suggested that a phenyl group was already too large to properly 
fit into the hydrophobic tunnel. This could be a limit to the application of the Suzuki-
Miyaura cross-coupling in modifying the C-2 position on the adenine ring, since only 
aryl groups smaller than the phenyl could be possibly inserted in the adenine ring to 
generate inhibitors. In addition, as expected because of their inactivity as NNSs, AMP 
derivatives would be more suitable backbones than NAD
+
 derivatives as inhibitors, 
since no side substrate activity could interfere in their influence on the enzyme activity. 
AMP-morpholidates, 10b and 11a, showed inhibitor activities toward EcLigA 
regardless of the introduced substitution and its position on the adenine ring. At the 
outset of this project, it was expected that AMP-morpholidates would either act as 
NNSs or inhibit the enzyme by covalent modification. Indeed, their phosphate, activated 
compared to that in the AMP derivatives, could undergo the nucleophilic attack by the 
lysine residue into the active site to form the adenylated-enzyme; then, the latter could 
be active and evolve in the next ligation steps, or be inactive and block the ligation. 
However, AMP-morpholidates did not show any NNS activity. Moreover, in the 
inhibition experiments the ligation increased at later times in the reaction with both 10b 
and 11a (Figure 5.8, Figure 5.11); therefore, the inhibition could not be due to covalent 
modification of the enzyme, but it is more likely to be due to reversible binding of the 
derivatives in the active site. The fact that 2-phenyl AMP-morpholidate, 10b, was active 
as an inhibitor in contrast to 2-phenyl AMP, 7b, and that 6-phenyl AMP-morpholidate, 
11a, was active as an inhibitor in contrast to all other derivatives belonging to its series, 
showed that the modification on the phosphate, and not those on the adenine ring, was 
responsible for the inhibition by AMP-morpholidates.  
Looking at the perspective for generating biochemical tools for biochemical 
investigations, the development of 2-substituted NAD
+
 derivatives as NNSs for NAD
+
-
dependent DNA ligases has been a useful achievement in this project. Indeed, the 
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different activities of the differently substituted NAD
+
 derivatives can be related to 
structural and mechanistic details of the enzyme, providing a deeper understanding and, 
therefore, a more strategic development of inhibitors.  
5.2 Sirtuins 
Protein acetylation/deacetylation is a fundamental process to regulate protein activity, 
localization, interaction, stability and degradation. Consequently, it contributes to 
cellular regulation of processes such as transcription, proliferation, apoptosis and 
differentiation, occurring in response to signalling pathways. As is the case for the 
phosphorylation performed by kinases with a broad substrate specificity, 
acetylation/deacetylation seems to involve many biological targets in answer to 
particular intracellular and extracellular signals.
266
  
The main and best known targets for acetylation modification are the histones, proteins 
found in all eukaryotic cells, involved in the packaging of DNA into chromatin and, 
therefore, responsible for gene regulation. Histones contain many basic lysine residues 
that can undergo acetylation/deacetylation modification by acetylases/deacetylases. 
When histones are acetylated on relevant lysine residues, the resulting charge on these 
amino acids becomes neutral overall and, therefore, histones do not interact so well with 
the negatively charged DNA; the latter can then be more easily unwound and 
transcribed or replicated by RNA or DNA polymerases. In contrast, when histones are 
deacetylated on relevant lysine residues, the resulting positive charge on these amino 
acids allows them to interact with the negatively charged DNA, winding it more tightly 
and avoiding its transcription or replication. The acetylation/deacetylation process is 
therefore part of the epigenetic changes in gene expression that occur without modifying 
the DNA sequence; thus, acetylases/deacetylases can regulate gene transcription and 
modulate gene silencing and transcriptional repression.  
Acetylases/deacetylases are better known as histone acetyltransferases (HATs) and 
histone deacetylases (HDACs), despite acting on a variety of substrates. HDACs, first 
isolated in yeast from Saccharomyces cerevisiae, are divided into four classes: I, II and 
IV classes formed by zinc-dependent deacetylases, while III class by NAD
+
-dependent 
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deacetylases. The latter class is responsible for gene silencing, from which its name, Sir, 
stands for “silent information regulator”.267  
In humans, seven NAD
+
-dependent HDACs have been isolated and, because of their 
homology with the yeast Sir family, these are called sirtuins. An increased interest in 
sirtuins has developed in the past years because of their involvement in a variety of 
biological processes. The transcriptional gene regulation and the implication of sirtuins 
in DNA repair are the main processes in which they are involved, together with cellular 
stress resistance, therefore ageing control and life span increase; metabolic regulation, 
as they influence glucose, fat and insulin metabolism; and apoptosis regulation, thus 
their possible implication as anticancer targets. All these processes have been connected 
since the discovery that enzymes, such as sirtuins, appear to be involved in the 
regulation of them all.
268-270
  
Sir2 from Saccharomyces cerevisiae, belonging to class III of NAD
+
-dependent 
HDACs, has been structurally characterized. The protein consists of a large domain 
containing a Rossmann-fold structure, with two small domains inserted; one of them is 
a zinc-binding module, not involved in the catalytic cycle (Figure 5.16 a). The β-NAD+-
binding pocket is characterized by three regions, A for the adenosine binding, B for the 
nicotinamide ribonucleoside binding and C, a deep region in the catalytic pocket 
involved in the nicotinamide cleavage (Figure 5.16 b). When β-NAD+ binds to the 
enzyme, NaM would fit in the B region but, in the presence of acetyl lysine, the enzyme 
would undergo a conformational change bringing NaM into the C region, where the N-
glycosidic bond is cleaved. 
As mentioned in 1.2.1, it is not certain if sirtuins cleave the nicotinamide N-glycosidic 
bond by an SN1 mechanism, via formation of the oxocarbenium ion intermediate, or by 
an SN2 mechanism, with nucleophilic attack by the oxygen of the acetyl lysine on C-1′′ 
and simultaneous release of NaM. However, the reaction products are the deacetylated 
lysine and the 2′-OAc-ADPR, in equilibrium with the 3′-OAc-ADPR.31, 267, 269 
As described in Chapter 1, inhibition or activation of sirtuins activity can regulate 
different biological processes and provide understanding of their mode of action. NaM, 
one of the sirtuins reaction products, is a non-competitive inhibitor for sirtuins. It seems 
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to bind in the C region of the catalytic pocket, more than in the B one, causing the 
regeneration of β-NAD+ by transglycosidation.31 Consequently, many sirtuins inhibitors 
based on mimicking NaM have been developed, together with others mimicking the 
adenosine
72
 and NAD
+
 structure (see 1.3.1).
31, 70, 267
  
 
 
Figure 5.16 a) Structure of archaeal Sir2-Af2 with β-NAD+ bound; b) β-NAD+-binding pocket (PDB 
1YC2). Visualization by PyMol software. 
Since several biological processes, such as life span increase, seem to be linked to an 
activation of the sirtuins activity, the discovery of sirtuins activators has become more 
important. A class of polyphenols, resveratrol being the most known and representative, 
has shown activator activity toward sirtuins; this effect seems to be connected with the 
binding of activators in the C region, where otherwise free NaM released from the 
reaction would bind and inhibit the sirtuins activity.
271
  
5.2.1 Biological testing of 8-substituted NAD+ derivatives 
As mentioned in Chapter 1, NAD
+
 derivatives can be effective inhibitors or NNSs of 
sirtuins depending on the substitutions performed to modify the structure of the natural 
substrate.
31
 It has been shown that carba-NAD
+
 (Figure 1.15), where the β-D-ribose of 
the nicotinamide ribonucleoside has been replaced with a 2,3-dihydroxycyclopentane 
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ring, is not a hydrolysable NAD
+
 derivative and, therefore, acts as an inhibitor of 
sirtuins. This compound has been a useful biochemical tool to investigate and 
understand the structure of the active site and the sirtuins reaction mechanism.
31
  
8-aryl/heteroaryl NAD
+
 derivatives, 15b, 15h
246
, 16-22, synthesized in Chapter 2 (see 
2.7.2, Scheme 2.20 and Figure 5.17), were tested as inhibitors and/or NNSs of human 
SIRT1-2
70
 in collaboration with Prof. M. Jung and co-workers. The assay described in 
Chapter 1 (see 1.4.7), using Z-MAL as a non-natural peptide substrate for sirtuins, was 
used to evaluate the activities of the tested compounds. 
 
 
Figure 5.17 8-aryl/heteroaryl NAD
+
 derivatives, 15b, 15h, 16-22, tested as inhibitors and/or NNSs of 
human SIRT1-2.
70
  
From the inhibition experiments with 8-aryl/heteroaryl NAD
+
 derivatives and a few of 
the corresponding adenosine and AMP derivatives at 50 μM, it emerged that, with the 
exception of 15h
246
 and 20, all 8-aryl/heteroaryl NAD
+
 derivatives exerted 
preferentially an inhibitory activity toward SIRT2 compared to SIRT1. For those 
compounds showing an inhibitory activity ≥ 50% at 50 μM on either sirtuins isoforms, 
IC50 values were estimated and found to be in the order of low micromolar 
concentration.
70
 In addition to the 8-aryl/heteroaryl NAD
+
 derivatives, the inhibitory 
activity was tested for the corresponding adenosine and AMP derivatives with bromo 
and phenyl substituents. With the exception of 8-phenyl AMP, all other derivatives 
showed no activity toward either SIRT1 nor SIRT2, indicating the necessity to have the 
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whole β-NAD+ scaffold to be effective inhibitors.70 With the hypothesis that 8-
aryl/heteroaryl NAD
+
 derivatives could act as NNSs for sirtuins and, consequently, 
influence the inhibition results, their substrate activity was also tested. With the 
exception of 15b, which showed a minor substrate activity, all other derivatives did not 
have any.
70
 
5.2.2 Biological activities of 8-substituted NAD+ derivatives 
Investigations using computational studies were undertaken to provide a better 
understanding of the mode of inhibition of 8-aryl/heteroaryl NAD
+
 derivatives and their 
apparent selectivity toward the different isoforms of human sirtuins. The alignment of 
sequences for SIRT1 and SIRT2 was used to analyse the similarities between the 
different isoforms; effectively, only a 44% identity was observed between the two 
enzymes.
70
  
Examining the crystal structures available for human SIRT2 (PDB 1J8F) and SIRT3 
(PDB 3GLT), a flexible loop with a high level of sequence conservation has been 
reported to be involved in the β-NAD+ binding and NaM release.31 However, in the 
different isoforms the loop seems to assume completely different conformations. 
Therefore, interferences between the substituents in position 8 and the flexible loop 
could be responsible for the selectivity of 8-aryl/heteroaryl NAD
+
 derivatives toward 
the different isoforms of human sirtuins and for their lack of substrate activity.
70
  
The few available crystal structures for different sirtuins isoforms containing β-NAD+ 
or ADPR show an adenine in anti conformation compared to the ribose. However, as 
discussed in 3.1.2, all 8-aryl/heteroaryl NAD
+
 derivatives have the adenine ring in a 
more or less definite syn conformation because of the steric hindrance between the 
substituent in position 8 and the ribose.
70
 From the docking of a representative 8-
substituted NAD
+
 derivative (17 in Figure 5.17) within SIRT2 (PDB 1J8F) and 
superimposition with β-NAD+ in the archaeal enzyme Sir2-Af2 (PDB 1YC2), the same 
anti conformation was observed for adenine in 17 and β-NAD+, suggesting that 8-
aryl/heteroaryl NAD
+
 derivatives could undergo conformational changes during their 
binding to the enzyme. Sirtuins themselves could be able to induce these conformational 
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changes with a different ability depending on the isoform involved, consequently 
influencing the inhibition selectivity of 8-aryl/heteroaryl NAD
+
 derivatives toward the 
different sirtuins isoforms. In support of this hypothesis, it was observed that 15h
246
 and 
20, characterized by a strong syn conformation (Table 3.2), had no inhibitor and 
substrate activities,
70
 presumably because sirtuins would not be able to overcome such 
definite conformations of the molecule.     
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6 CONCLUSIONS AND FUTURE WORK 
NAD
+
-consuming enzymes play a crucial role in important biological processes; hence, 
it is fundamental to require a better understanding of their biological activities, how 
they are modulated and how they influence each other and the activities of other 
important enzymes in cells. The development of NAD
+
 derivatives as biochemical tools 
for the study of this class of enzymes has been, and is still, one of the most challenging 
biochemical topics. 
Reviewing the substitutions performed on the existing NAD
+
 derivatives and their 
influences on the enzyme activities, the modification of the adenine ring appeared as the 
most suitable to confer selective biological activities as inhibitors and/or NNSs to the 
novel NAD
+
 derivatives toward a selected range of enzymes. Due to the recent and 
impressive advances in the application of palladium-mediated cross-couplings to the 
nucleosides/nucleotides modifications, the choice of using the Suzuki-Miyaura cross-
coupling to substitute the adenine ring made possible the development of aryl/heteroaryl 
adenine-modified NAD
+
 derivatives. In particular, positions 2, 6 and 8 were modified 
with phenyl, and, where possible, pyrrolyl groups to explore the different properties of 
the compounds and their activities generated by the introduction of hydrophobic and H-
bond making groups.  
The successful synthesis of aryl/heteroaryl NAD
+
 derivatives substituted on C-2, C-6 or 
C-8 of the adenine ring was accomplished following the optimization of the known 
multistep synthesis to generate the new classes of compounds. However, two additional 
strategies, requiring further studies, were investigated to accelerate the synthesis of the 
NAD
+
 derivatives. The pathway via phosphoramidite nucleoside intermediate was 
unsuccessful presumably because of the low nucleophilicity and insolubility of β-NMN 
in acetonitrile. Therefore, beyond a screening of polar aprotic solvents (e.g. DMSO, 
DMF, acetone) to improve the solubility of β-NMN, the replacement of DCI with other 
phosphoramidite activators (e.g. tetrazole, HOBt) during the coupling with β-NMN 
could bring the reaction to success. On the other hand, the pathway via β-NAD+ 
bromination/Suzuki-Miyaura cross-coupling in a one-pot, two-step procedure allowed 
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the successfull synthesis of different 8-aryl/heteroaryl NAD
+
 derivatives, although it did 
fail in the coupling with very electron poor boronic acids. 
The synthesized compounds were analysed from the spectroscopic and conformational 
perspective, showing interesting properties. In particular, 8-aryl/heteroaryl adenine 
derivatives showed fluorescent properties that could be modulated depending on the 
nature of the substituent introduced. In addition, as shown from our studies and previous 
data about the conformational properties of β-NAD+ and its well known derivative, ε-
NAD
+
, all of the synthesized NAD
+
 derivatives were characterized by a folded 
conformation in aqueous solution, due to the interactions between the hydrophobic 
aromatic rings in the molecule. This folded conformation could be released by solvation 
in organic solvents, bringing the opening of the β-NAD+ scaffold to an extended 
conformation. These conformational properties, combined with the fluorescence of 8-
aryl/heteroaryl NAD
+
 derivatives, were the basis of their use as fluorescent probes to 
monitor the activities of NAD
+
-consuming enzymes. Indeed, the folded conformation of 
the compounds caused a fluorescence quenching that could be disrupted by the 
separation of the modified adenine ring, the fluorophore under discussion, and the 
nicotinamide moiety with consequent fluorescence re-establishment. The enzymatic 
cleavage of the β-NAD+ scaffold on the pyrophosphate or the nicotinamide N-glycosidic 
bonds, catalyzed by NAD
+
-consuming enzymes, was therefore responsible for a 
fluorescence increase allowing monitoring of the enzymatic reactions.  
The use of fluorescent 8-substituted NAD
+
 derivatives as NNSs by NAD
+
-consuming 
enzymes made them useful biochemical probes to investigate enzymatic structures, 
activities and kinetics in more detail by monitoring their fluorescence changes. 
Therefore, fluorescence-based assays were successfully developed for selected NAD
+
-
consuming enzymes, giving interesting mechanistic information.  
The fluorescence principle of the assays using 8-aryl/heteroaryl NAD
+
 derivatives is 
essentially the same as those developed with the well known ε-NAD+. However, the use 
of our best fluorophore, 15h, containing a pyrrolyl group in position 8 on the adenine 
ring, increased the sensitivity of the assays compared to those using ε-NAD+ because of 
a stronger fluorescence increase during the enzymatic reaction. Moreover, the 
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application of 15h for the monitoring of enzymes for which ε-NAD+ failed in the 
development of continuous fluorescence-based assays could be investigated. For 
instance, as discussed in Chapter 1, ε-NAD+ was not a good substrate for PARPs and a 
continuous fluorescence-based assay could not be developed. Therefore, it would be 
worth testing 15h on PARPs activity to assess whether there were positive differences 
compared to ε-NAD+. 
In contrast to the 8-aryl/heteroaryl NAD
+
 derivatives, those substituted in position 2 and 
6 showed weak, or no fluorescence at all; therefore, they could not be used as 
fluorescent biochemical probes. Nevertheless, they were still useful tools to investigate 
enzymatic structures and mechanisms. In particular, the biological activities of 2-
substituted NAD
+
 derivatives toward DNA ligases gave clues to fundamental 
interactions between the β-NAD+ scaffold and its binding site.  
It was shown that 2-iodo and 2-phenyl NAD
+
 derivatives, both non-fluorescent, were 
NNSs of EcLigA. Therefore, an idea for developing fluorescent NNSs came from the 
considerations of their activities. Since a substituent in position 2 on the adenine ring is 
crucial to confer to the NAD
+
 derivatives the ability to bind in the active site by 
positioning the substituent into the hydrophobic tunnel, as well as to assume a high syn 
conformation resembling that of the natural b-NAD+, the substitution of the adenine 
ring with 2-amino purine (1) or 2,6-diamino purine (2)
190
 (Figure 6.1), both isomorphic 
fluorescent nucleobases (Chapter 3, see 3.3.2), may confer to the corresponding NAD
+
 
derivatives their fluorescence properties.  
 
 
Figure 6.1 Two possible fluorescent NNSs of NAD
+
-dependent DNA ligases: nicotinamide 2-amino 
purine dinucleotide (1) and nicotinamide 2,6-diamino purine dinucleotide (2). 
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These compounds could potentially be exploited for binding and kinetic/mechanistic 
studies. The binding studies could rely on the fluorescence enhancement of the NNSs 
following their passage from a folded quenched conformation in solution to an extended 
conformation in the active site. On the other hand, the DNA ligase activity could be 
monitored by the fluorescence increase due to the formation of the AMP derivative 
from the cleavage of the quenched NAD
+
 derivative (the same principle on which the 
monitoring of NPPs is based). In addition, kinetic and mechanistic details could come 
from the fluorescence changes occurring in the fluorescent adenine derivatives 
following their interactions with Lys 290 in the active site along the three different 
reaction steps. Indeed, the formation of the H-bond between N-1 and Lys 290 would 
change the electronic delocalization along the adenine-modified rings; hence, the 
formation of a partial positive charge on N-1 could bring a fluorescence quenching 
similar to that occurring in the N
1
-cADPR derivatives analysed in Chapter 4.  
Of course, these modifications could have some limitations. Firstly, the introduced 
amino group in position 2 is polar, so it is unlikely to properly interact with the 
hydrophobic tunnel of the DNA ligase, and could be unable to stabilize the NAD
+
 
derivatives in the active site. Secondly, 2-AP would lack the exocyclic amino group of 
the adenine ring, which could cause a decreased binding in the active site for this 
compound. However, since no fluorescent NAD
+
 derivatives have been reported as 
NNSs for NAD
+
-dependent DNA ligases (ε-NAD+ and 8-aryl/heteroaryl NAD+ 
derivatives did not show any activity), it would be worth exploring the activity of these 
two compounds in order to create fluorescent probes for NAD
+
-dependent DNA ligases. 
A comparison of activities exerted by 8-aryl/heteroaryl NAD
+
 derivatives against all of 
the enzymes examined in this project was undertaken to investigate their selectivity and, 
therefore, their potential application for in vitro/in vivo studies. A summary of the 
biological evaluation of the 8-substituted NAD
+
 derivatives against the different NAD
+
-
consuming enzymes is shown in Table 6.1. 
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 Activity 
Enzyme Inhibitor Substrate 
NPP (Crotalus adamanteus venom)   
NADase (porcine brain)   
ADPRC (Aplysia californica)   
Human SIRT1-2  – 
DNA ligase (EcLigA) – – 
Table 6.1 Activities of 8-aryl/heteroaryl NAD
+
 derivatives toward different NAD
+
-consuming enzymes. 
The tick  indicates that the compounds showed the specified activity toward the selected enzyme; the 
line – indicates that the compounds did not show the specified activity toward the selected enzyme. 
A certain selectivity exerted by 8-aryl/heteroaryl NAD
+
 derivatives against the different 
enzymes was observed. Indeed, with the exception of NADase and ADPRC sharing the 
same unifying catalytic mechanism (Chapter 4, see 4.2), the enzymes examined, though 
sharing the same substrate/co-substrate, have different active sites and modes of β-
NAD
+
 binding, which are responsible for their different catalytic reactions and, 
therefore, for the different activities shown by 8-substituted NAD
+
 derivatives. To 
underline the intrinsic structural differences that distinguish these enzymes and their 
activities, the available crystal structures for β-NAD+-bound ADPRC from Aplysia 
californica (a), archaeal Sir2-Af2 (b) and DNA ligase from E. faecalis (c) were 
examined and their active sites were compared (Figure 6.2).  
 
 
Figure 6.2 β-NAD+ in the active site of ADPRC from Aplysia californica (PDB 3ZWM) (a), archaeal 
Sir2-Af2 (PDB 1YC2) (b), DNA ligase from E. faecalis (PDB 1TAE) (c). Visualization by PyMol 
software. 
In ADPRC (Figure 6.2 a), the β-NAD+ binding site is completely exposed to the solvent 
and β-NAD+ is bound in a folded conformation, since the enzyme catalyzes its 
cyclization to cADPR. The adenine ring, free from any interaction with the enzyme and 
originally in an anti conformation related to the ribose, during the catalytic cycle will 
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orient in a syn conformation to facilitate the cyclization on N-1 (Table 6.2). Due to the 
lack of interactions of the adenine ring with the enzyme, the substitution in position 8 in 
the synthesized NAD
+
 derivatives could be tolerated by the enzyme and the compounds 
could fit in the active site already in a syn conformation, which facilitates the 
cyclization. 
In the archaeal Sir2-Af2 (Figure 6.2 b), the β-NAD+ binding site is quite exposed to the 
solvent and β-NAD+ is bound in an extended conformation. The adenine ring, in anti 
conformation related to the ribose (Table 6.2), interacts strongly with the active site 
residues though not directly involved in the catalytic reaction. Therefore, its 
modification interferes with the enzyme activity, making 8-substituted NAD
+
 
derivatives inhibitors of sirtuins.  
Finally, in DNA ligase (Figure 6.2 c), the β-NAD+ binding site is exposed to the solvent 
at the moment of the binding and β-NAD+ is bound in an extended conformation. The 
adenine ring, directly involved in the catalytic reaction (see 5.1), interacts with the 
active site residues. Its initial high syn conformation in β-NAD+ will turn into anti in the 
adenylated-enzyme intermediate (1) (Scheme 5.1), to finally return to high syn in the 
adenylated-DNA intermediate (2) (Scheme 5.1, Table 6.2). Hence, in the DNA ligase 
catalytic mechanism the adenine moiety is key for the enzymatic reaction and the β-
NAD
+
 binding is so specific that substitutions on the adenine ring, unless the adenine 
orientation in β-NAD+ is left unchanged, do not allow any enzymatic activity. Indeed, 
NAD
+
 derivatives substituted on C-6 and C-8 of the adenine ring, in which the 
substituents change the position/orientation of the adenine in the active site, did not 
exert any effect on the activity of EcLigA because they could not bind in any active way 
to the enzyme. 
Just from this simple visual analysis of the active site and β-NAD+ binding mode, it is 
possible to suggest a structural and, therefore, biological diversity between the three 
examined enzymes, justifying the different biological activity exerted by 8-substituted 
NAD
+
 derivatives.  
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Enzyme 
Adenine conformation changes during the catalytic cycle 
ADPRC 
(Aplysia 
californica) 
 
Human 
SIRT1-2 
 
DNA ligase 
(EcLigA) 
 
Table 6.2 Changes in the adenine conformation during the catalytic cycle in ADPRC, SIRT1-2 and DNA 
ligase. 
For the examined structures of ADPRC from Aplysia californica, archaeal Sir2-Af2 and 
DNA ligase from E. faecalis, a sequence alignment was performed, showing only 0.9% 
of identity. Therefore, structure similarities were estimated pairwise by comparing the 
results obtained with rigid and flexible structure alignments (Appendix 8, Table A1).
272, 
273
 The latter method allows consideration of proteins as flexible bodies, as they are in 
reality; hence, the program, instead of just answering how large is the similar part that 
two proteins share, as happens in the rigid structure alignment, it also estimates how 
much a protein can rearrange itself to be more similar to another one. All these analyses 
were in agreement with a deep structural diversity of the enzymes examined, confirming 
once again their different biological roles, though sharing the same substrate/co-
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substrate, β-NAD+. This structural diversity definitively reflected on the various 
activities exerted by 8-substituted NAD
+
 derivatives toward these enzymes. 
Summarising the results obtained in this project, it is possible to conclude that 
aryl/heteroaryl substitutions on different positions on the adenine ring can generate 
novel NAD
+
 derivatives with biological activities toward NAD
+
-consuming enzymes. 
The preferential action of aryl/heteroaryl adenine-modified NAD
+
 derivatives as 
inhibitors and/or NNSs toward specific NAD
+
-consuming enzymes offers the 
prospective of their use for in vitro/in vivo studies. Of course, such a step forward in 
their biological evaluation means considering many factors that until now have not been 
an issue. For instance, in the case of their activity on intracellular enzymes, such as 
sirtuins or DNA ligases, their resistance to the degradation exerted by ecto NAD
+
-
consuming enzymes or intracellular nucleases should be considered. Therefore, 
chemical modifications on the β-NAD+ scaffold or alternative delivering methods 
should be developed related to the use for which they are designed. However, the 
validity of their use as biochemical probes is already a great pace to widen the 
knowledge of fundamental biological processes involving NAD
+
-consuming enzymes. 
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7 EXPERIMENTAL 
7.1 General 
7.1.1 Synthesis and characterization 
All synthetic reagents were obtained commercially and used as received, including 
anhydrous solvents over molecular sieves, unless otherwise stated. Milli-Q water was 
used for the preparation of aqueous solutions and as solvent in the reactions. For the 
synthesis of phosphoramidites, CH2Cl2 was distilled over calcium hydride, and DIPEA 
was dried over molecular sieves (4 Å) for four days before the use. For the preparation 
of dinucleotides, MnCl2 solution in formamide was dried over molecular sieves (4 Å) 
and stored under nitrogen atmosphere. All reagents and solvents used for analytical 
applications were of analytical quality. TLC was performed on precoated slides of Silica 
Gel 60 F254 (Merck). Spots were visualized under UV light (254/365 nm). Reaction 
products were characterized by high-resolution mass spectrometry (HR-MS), 
1
H, 
13
C 
and 
31
P NMR spectroscopy, and HPLC. 
1
H NMR spectra were recorded at 298 K on a 
Varian VXR 400 S spectrometer at 400 MHz, or on a Bruker Avance DPX-300 
spectrometer at 300 MHz, or on a Bruker BioSpin GmbH at 400 MHz. 
13
C NMR 
spectra were recorded at 300 K on a Bruker BioSpin GmbH at 150.90 MHz and at 101 
MHz. 
31
P NMR spectra were recorded at 298 K on a Varian VXR 400 S spectrometer at 
161.98 MHz, or on a Bruker BioSpin GmbH at 161.98 MHz. Chemical shifts (δ) are 
reported in ppm (parts per million) and referenced to D2O, CD3OD or CDCl3 
(respectively, δH 4.79, 3.31, 7.26) for 
1
H NMR, and to CH3 of TEA, CD3OD or 
CDCl3 (respectively, δC 9.07, 49.00, 77.16) for 
13
C NMR. Coupling constants (J) are 
reported in Hz. Accurate electrospray ionization mass spectra were obtained on a 
Finnigan MAT 900 XLT mass spectrometer at the EPSRC National Mass Spectrometry 
Service Centre, Swansea. Ion-pair and ion-exchange chromatography was performed on 
a Biologic LP chromatography system equipped with a peristaltic pump and a 254 nm 
UV Optics Module. For detailed conditions, see 7.1.2. High performance liquid 
chromatography (HPLC) was performed on a Perkin Elmer series 200 equipped with a 
Supelcosil LC-18T column (25 cm x 4.6 mm, particle size 5 μm), a diode array detector 
(detection wavelengths: 254/280 nm) and a column oven (temperature: 30 ºC). For 
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detailed conditions, see 7.1.2. Absorbance spectra were recorded on a PerkinElmer 
Lambda 25 UV/Vis spectrometer at room temperature in FarUV quartz cells (path 
length 1.0 cm). Fluorescence spectra were recorded on a PerkinElmer LS-45 
spectrometer at room temperature in a quartz fluorescence cell (path length 1.0 cm). 
7.1.2 Chromatography conditions 
Preparative chromatography – purification method 1: Ion-pair chromatography was 
performed using Lichroprep RP-18 resin and a variable gradient of methanol against 
0.05 M TEAB (triethylammonium bicarbonate buffer). Product containing fractions 
were combined and reduced to dryness. The residue was co-evaporated repeatedly with 
methanol to remove residual TEAB. 
Preparative chromatography – purification method 2: Anion-exchange chromatography 
was performed using Bioscale
TM
 Mini Macro-Prep High Q cartridges and a gradient of 
0-100% 1 M TEAB (pH 7.3) against Milli-Q H2O. Product containing fractions were 
combined and reduced to dryness. The residue was co-evaporated repeatedly with 
methanol to remove residual TEAB. 
High performance liquid chromatography (HPLC): samples (injection volume: 20 μL) 
were analysed using a mobile phase composed of 0.05 M triethylammonium phosphate 
buffer at pH 8 (solvent A) and methanol (solvent B), according to the gradient steps in 
Table 7.1 (flow rate: 1.5 mL/min). 
 
Step Minutes (min) Gradient 
1 0 – 2 90% A – 10% B 
2 2 – 17 10 – 50% B 
3 17 – 19 50% B 
4 19 – 21 50 – 10% B 
5 21 – 25 90% A – 10% B 
Table 7.1 Gradient steps for HPLC analysis of the NAD
+
 derivatives. 
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7.1.3 Enzymology 
All reagents used for biological application were of analytical quality and solutions 
prepared with Milli-Q water. NPP from Crotalus adamanteus venom, NADase from 
porcine brain and ADPRC from Aplysia californica were purchased from Sigma. 
Human SIRT1-2 were expressed and purified as described
70, 274
 with minor 
modifications. EcLigA from E. coli was expressed and purified as described
250
 with 
minor modifications (see 7.7.1). pET-16b vector, His-tag binding column (IDA-based 
His-Bind Resin Ni
2+
 precharged) and its buffer kit were purchased from Novagen. 
Protein desalting was performed using a PD-10 Column (Sephadex G-25 Medium) and 
its buffer (20 mM Tris, 200 mM NaCl, pH 7.5). To quantify the protein concentration 
according to the Bradford method, the Bio-Rad Protein Assay, consisting of a protein 
dye reagent (Coomassie Brilliant Blue G-250 in acidic solution), was purchased from 
Bio-Rad (absorbance reading at 595 nm). The oligonucleotides for the ligation assay 
were supplied by Eurogentec. For fluorescence imaging, Molecular Dynamics Storm 
Phosphorimager was used. Fluorescence assays were performed in NUNC 96 plates on 
a BMG labtech PolarStar microplate reader equipped with suitable absorbance and 
emission filters.  
7.2 Synthesis 
7.2.1 General synthetic procedures 
A Iodination of C-2 by diazotization-iodine substitution134 
Isoamyl nitrite (3.1 equiv.) was added to a mixture of respectively 1a and 1c (1 equiv.) 
with I2 (1 equiv.), CH2I2 (10.4 equiv.) and CuI (1 equiv.) in the given volume of THF. 
The mixture was refluxed for the given time and then, cooled down at room 
temperature. Inorganic salts were removed by filtration, and the filtrate was evaporated 
to dryness in vacuo. The crude product was purified by silica gel chromatography, as 
indicated for each compound. 
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B1 Suzuki-Miyaura cross-coupling on C-6158 
6-chloro purine nucleoside (5) (1 equiv.), Na2PdCl4 (0.03 equiv.), TPPTS (2.5 equiv. to 
Pd), K2CO3 (2 equiv.) and aryl/heteroaryl boronic acid (1.2 equiv.) were placed in a 
flask and purged with nitrogen for 15 min. Degassed water was added by syringe to the 
reaction vessel and the mixture was stirred at 100 °C under nitrogen for the given time. 
When the reaction was complete, the mixture was evaporated in vacuo, and the crude 
product purified as indicated for each compound. 
B2 Suzuki-Miyaura cross-coupling on C-8172 
8-Br-AMP (9a) (1 equiv.) and the appropriate amounts of Na2PdCl4, TPPTS, K2CO3 or 
K3PO4, and aryl/heteroaryl boronic acid were placed in a flask and purged with nitrogen 
for 15 min. Degassed water was added by syringe to the reaction vessel and the mixture 
was stirred at the appropriate temperature under nitrogen for the given time. When the 
reaction was complete, the mixture was evaporated in vacuo, and the crude product 
purified by chromatography, as indicated for each compound. 
C 2′,3′-O-isopropylidene protection141 
The respective nucleoside (1 equiv.) was suspended in acetone and 70% HClO4 (2.5 
equiv.) was added to the mixture. The reaction was stirred at room temperature for 1.5 
h. Then, NH4OH 25% (5.6 equiv.) was added to the reaction, and the solution stirred for 
3 h. The mixture was diluted with EtOAc and extracted with brine (3x). Then, the 
organic phase was dried over anhydrous MgSO4 and evaporated to dryness in vacuo. 
The crude product was purified as indicated for each compound. 
D1 Phosphorylation of 5′-OH by POCl3 (method 1)
136, 144 
The respective 2′,3′-O-isopropylidene protected nucleoside (1 equiv.) was dissolved in 
the given solvent with optional proton sponge, and the solution cooled down to 2 °C in 
ice-bath. Then, the appropriate amount of POCl3 was added drop-wise to the reaction 
mixture, that was kept at 4 °C for 12 h. The reaction was quenched adding drop-wise 1 
M TEAB buffer. If proton sponge was present, the mixture was diluted with EtOAc and 
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extracted (3x). Then, the aqueous solution was evaporated to dryness in vacuo and the 
crude product purified by purification method 2, as indicated for each compound. 
D2 Phosphorylation of 5′-OH via phosphoramidite (method 2)113 
The respective 2′,3′-O-isopropylidene protected nucleoside (1 equiv.) was dissolved in 
anhydrous CH2Cl2 and co-evaporated twice to dryness. Then, it was dissolved again in 
anhydrous CH2Cl2, and DIPEA (2.5 equiv.) and the given quantity of 2-cyanoethyl N,N-
diisopropyl chlorophosphoramidite were added via syringe. The reaction was stirred 
under nitrogen at room temperature for the given time. Then, 5.0 – 6.0 M tBuOOH in 
nonane solution (4 equiv.) was added to the reaction and stirred for the given time. The 
mixture was diluted with EtOAc and extracted with a saturated sodium bicarbonate 
solution (2x) and brine (1x). The organic phase was dried over anhydrous MgSO4 and 
evaporated to dryness in vacuo; then, the residue was suspended in NH4OH 25% (30 
equiv.) under stirring at room temperature overnight. The solution was evaporated to 
dryness in vacuo, and the crude product used for the next step (see procedure E). 
E 2′,3′-O-isopropylidene deprotection136 
The respective 2′,3′-O-isopropylidene protected nucleotide was dissolved in water and 
stirred with Dowex 88 (H
+
) (ca 0.1 g) overnight. After filtration, the solution was 
evaporated to dryness in vacuo and the crude product purified by purification method 1, 
as indicated for each compound. 
F Synthesis of AMP-morpholidate derivatives112, 172 
The respective nucleotide (1 equiv.) was dissolved in DMSO, and then co-evaporated 
with DMF (3x). The residue was dissolved in anhydrous DMSO and morpholine (6 
equiv.) was added. After 5 min, 2,2′-dithiopyridine (3 equiv.) was added and, 
subsequently, triphenylphosphine (3 equiv.). The yellow solution was stirred at room 
temperature under nitrogen until TLC showed complete conversion. The product was 
isolated by purification method 1, or by precipitation as sodium salt with NaI in acetone 
(0.1 M), as indicated for each compound. The NaI solution was added drop-wise to the 
reaction mixture until a solid precipitate formed; then, the precipitate was washed 
Chapter 7 
 
189 
 
repeatedly with acetone until the solution was colourless. The crude product was dried 
and used in the next reaction step without further purification. 
G Synthesis of NAD+ derivatives112, 172 
The appropriate amounts of AMP-morpholidate and β-NMN were co-evaporated with 
pyridine (3x). The flask with the residual solid was purged with nitrogen for 15 min. 
Anhydrous MgSO4 (2 equiv.) and MnCl2 (0.2M in formamide, 1.5 equiv.) were added 
and the reaction was stirred at room temperature under nitrogen until TLC showed 
complete conversion. The reaction was stopped by drop-wise addition of acetonitrile 
until a white precipitate formed. The supernatant was removed and the solid dissolved 
in water and evaporated to dryness in vacuo. The crude product was purified by 
chromatography, as indicated for each compound. 
7.2.2 Preparation of 2-substituted AMP derivatives (7a-c) 
2-Amino-6-chloro-9β-(2′,3′,5′-tri-O-acetyl-D-ribofuranosyl)-purine (1a)134 
 
Triethylamine (8.7 equiv.), DMAP (12 equiv.) and acetic anhydride (10.7 equiv.) were 
added to a suspension of the commercially available 1c (0.4465 g, 1 equiv.) in 
acetonitrile (30 mL). The clear mixture was stirred at room temperature for 1 h, then 
quenched with MeOH and evaporated to dryness in vacuo. The crude product was 
extracted with EtOAc/water (2x) and the organic phase was dried over anhydrous 
MgSO4. After concentration to dryness in vacuo, the residue was crystallized from 
MeOH to give 1a as white crystals (0.5635 g, 89% yield). 
1
H NMR (400 MHz; CDCl3) 
δ: 7.87 (1H, s, 8-H), 6.00 (1H, d, J1′,2′ = 4.9 Hz, 1′-H), 5.95 (1H, apparent t, 2′-H), 5.74 
(1H, apparent t, 3′-H), 4.51 – 4.31 (3H, m, 4′-H, 5′-H2), 2.14 (3H, s, Ac), 2.10 (3H, s, 
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Ac), 2.09 (3H, s, Ac); 
13
C NMR (101 MHz; CDCl3) δ: 170.66, 169.73, 169.50, 164.16, 
159.20, 152.09, 140.82, 86.75, 80.14, 72.86, 70.61, 63.06, 51.05, 20.87, 20.70, 20.58.  
2-Iodo-6-chloro-9β-(2′,3′,5′-tri-O-acetyl-D-ribofuranosyl)-purine (1b)134 
 
The title compound was prepared according to the general synthetic procedure A, from 
1a (0.1257 g, 1 equiv.), isoamyl nitrite, I2, CH2I2 and CuI in THF (1.5 mL). The mixture 
was refluxed for 12 h and then, cooled down at room temperature. The crude product 
was purified by silica gel chromatography, washing the column with CH2Cl2 to remove 
the iodine, then with an eluent 98:2 CH2Cl2/MeOH. 1b was obtained as white crystals 
(0.1349 g, 85% yield). 
1
H NMR (400 MHz; CDCl3) δ: 8.20 (1H, s, 8-H), 6.18 (1H, d, 
J1′,2′ = 5.4 Hz, 1′-H), 5.76 (1H, apparent t, 2′-H), 5.57 (1H, m, 3′-H), 4.59 – 4.22 (3H, m, 
4′-H, 5′-H2), 2.15 (3H, s, Ac), 2.11 (3H, s, Ac), 2.08 (3H, s, Ac); 
13
C NMR (101 MHz; 
CDCl3) δ: 170.29, 169.64, 169.48, 152.02, 151.02, 143.28, 132.29, 117.06, 86.72, 
80.88, 73.41, 70.61, 62.99, 20.94, 20.64, 20.50.  
2-Iodo-6-chloro-9β-D-ribofuranosyl-purine (1d) 
 
The title compound was prepared according to the general synthetic procedure A, from 
the commercially available 1c (0.5544 g, 1 equiv.), isoamyl nitrite, I2, CH2I2 and CuI in 
THF (40 mL). The mixture was refluxed for 4 h and then, cooled down at room 
temperature. The crude product was purified by silica gel chromatography, washing the 
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column with CH2Cl2 to remove the iodine, then with an eluent 90:10 CH2Cl2/MeOH. 1d 
was obtained as a colourless oil (0.382 g, 51% yield). 
1
H NMR (400 MHz; CD3OD) δ: 
8.77 (1H, s, 8-H), 6.09 (1H, d, J = 5.0 Hz, 1′-H), 4.65 (1H, apparent t, 2′-H), 4.36 (1H, 
apparent t, 3′-H), 4.15 (1H, m, 4′-H), 3.90 (1H, dd, J5′a,4′ = 3.1 Hz, J5′a,b = 12.3 Hz, 5′a-
H), 3.79 (1H, dd, J5′b,4′ = 3.5 Hz, J5′b,a = 12.3 Hz, 5′b-H). 6-Chloro-9β-D-ribofuranosyl-
purine was eluted later as a side-product of the reaction. 
1
H NMR (400 MHz; CD3OD) 
δ: 8.86 (1H, s, 2-H), 8.75 (1H, s, 8-H), 6.16 (1H, d, J = 5.2 Hz, 1′-H), 4.71 (1H, 
apparent t, 2′-H), 4.38 (1H, apparent t, 3′-H), 4.16 (1H, m, 4′-H), 3.90 (1H, dd, J5′a,4′ = 
3.0 Hz, J5′a,b = 12.3 Hz, 5′a-H), 3.79 (1H, dd, J5′b,4′ = 3.3 Hz, J5′a,b = 12.3 Hz, 5′b-H). 
2-Iodo-9β-D-ribofuranosyl-adenine (4)134 
 
1b (0.1304 g, 1 equiv.) and 1d (0.382 g, 1 equiv.) were respectively dissolved in 7 N 
methanolic ammonia and heated at 60 °C for 12 h in a sealed tube. After degassing the 
solution, the latter was evaporated to dryness in vacuo; then, the residue was 
crystallized from water to give 4 as white crystals (0.0381 g, 40% yield from 1b, 0.1111 
g, 30% yield from 1d).
 1
H NMR (400 MHz; CD3OD) δ: 8.21 (1H, s, 8-H), 5.91 (1H, d, 
J1′,2′ = 6.1 Hz, 1′-H), 4.67 (1H, apparent t, 2′-H), 4.32 (1H, m, 3′-H), 4.15 (1H, m, 4′-H), 
3.89 (1H, dd, J5′a,4′ = 2.7 Hz, J5′a,b = 12.5 Hz, 5′a-H), 3.75 (1H, dd, J5′b,4′ = 3.0 Hz, J5′b,a 
= 12.5 Hz, 5′b-H); 13C NMR (101 MHz; CD3OD) δ: 157.17, 150.57, 141.59, 120.74, 
120.45, 90.96, 87.84, 75.42, 72.40, 63.26.  
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2-Iodo-9β-(2′,3′-O-isopropylidene-D-ribofuranosyl)-adenine (4a)135 
 
The title compound was prepared according to the general synthetic procedure C, from a 
suspension of 4 (0.148 g, 1 equiv.) in acetone (10 mL), adding 70% HClO4 (82 µL) and 
NH4OH (82 µL). The crude product was purified by silica gel chromatography with an 
eluent 98:2 CH2Cl2/MeOH. 4a was obtained as a colourless oil (0.160 g, 98% yield). 
1
H 
NMR (400 MHz; CD3OD) δ: 8.20 (1H, s, 8-H), 6.10 (1H, d, J1′,2′ = 3.2 Hz, 1′-H), 5.24 
(1H, m, 2′-H), 5.01 (1H, m, 3′-H), 4.34 (1H, m, 4′-H), 3.79 (1H, dd, J5′a,4′ = 3.7 Hz, J5′a,b 
= 12.0 Hz, 5′a-H), 3.72 (1H, dd, J5′b,4′ = 4.5 Hz, J5′b,a = 12.0 Hz, 5′b-H), 1.61 (3H, s, 
isoprop.), 1.38 (3H, s, isoprop.); m/z (ESI) 432.0167 [M-H]
-
, C13H15IN5O4
-
 requires 
432.0174. 
2-Phenyl-9β-(2′,3′-O-isopropylidene-D-ribofuranosyl)-adenine (4b)136 
 
4a (0.083 g, 1 equiv.), phenyl boronic acid (1.7 equiv.), Pd(OAc)2 (0.12 equiv.), (2-
biphenyl)dicyclohexylphosphine (0.16 equiv.) and K3PO4 (2.2 equiv.) were added in a 
sealed tube and purged with nitrogen for 10 min; after addition of anhydrous 1,4-
dioxane (3 mL), the tube was sealed and heated at 100 °C for 24 h. The reaction mixture 
was evaporated to dryness in vacuo and the crude product was purified by silica gel 
chromatography with a gradient 0-6% MeOH/CH2Cl2. 4b was obtained as white 
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crystals (0.0318 g, 43% yield). 
1
H NMR (400 MHz; CDCl3) δ: 8.33 – 8.08 (2H, m, Ph), 
7.83 (1H, s, 8-H), 7.46 (3H, m, Ph), 5.90 (1H, d, J1′,2′ = 4.6 Hz, 1′-H), 5.64 – 5.41 (1H, 
m, 2′-H), 5.19 (1H, m, 3′-H), 4.48 (1H, m, 4′-H), 3.81 (2H, m, 5′-H2), 1.66 (3H, s, 
isoprop.), 1.41 (3H, s, isoprop.); 
13
C NMR (101 MHz; CDCl3) δ: 160.95, 155.71, 
150.15, 140.86, 138.12, 130.27, 128.64, 128.47, 119.71, 114.30, 93.45, 85.92, 82.60, 
81.71, 63.34, 27.76, 25.48; m/z (ESI) 384.1670 [M+H]
+
, C19H22N5O4
+
 requires 
384.1666. 
2-(N-Me-Pyrrol-2-yl)-9β-(2′,3′-O-isopropylidene-D-ribofuranosyl)-adenine (4c)  
 
4a (0.083 g, 1 equiv.), tributyl-(N-Me-pyrrol-2-yl) stannane (5 equiv.), optional 
anhydrous LiCl (1.2 equiv.), PdCl2(PPh3)2 (0.06 equiv.) were added in a sealed tube and 
purged with nitrogen for 10 min; after addition of anhydrous 1,4-dioxane (2.5 mL), the 
tube was sealed and heated at 90 °C for 48 h. The reaction mixture was evaporated to 
dryness in vacuo and the crude product was purified by silica gel chromatography with 
an eluent 98:2 CH2Cl2/MeOH. 4c was never isolated pure, but in a mixture with the 
starting material 4a and stannane contamination; the 
1
H NMR showed 43-50% 
conversion. 
1
H NMR (400 MHz; CD3OD) δ: 8.30 (1H, s, 8-H), 6.97 (1H, br s, 5-H 
pyrrole), 6.86 (1H, br s, 3-H pyrrole), 6.20 (1H, d, J1′,2′ = 2.9 Hz, 1′-H), 6.16 – 6.11 (1H, 
m, 4-H pyrrole), 5.39 (1H, m, 2′-H), 5.02 – 5.00 (1H, m, 3′-H), 4.09 (3H, s, N-CH3), 
4.38 (1H, m, 4′-H), 3.87 – 3.67 (2H, m, 5′-H2), 1.7 – 1.3 (6H, 2s, 2 isoprop.). 
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Phosphoric acid mono-5′-[2-iodo-9β-(2′,3′-O-isopropylidene-D-ribofuranosyl)-
adenine] (4g)
136
 
 
The title compound was prepared according to the general synthetic procedure D1, from 
4a (0.0753 g, 1 equiv.) and POCl3 (0.1 mL, 6.2 equiv.) in anhydrous acetonitrile (2.5 
mL). The crude product was purified by purification method 1 (0-60% MeOH against 
0.05 M TEAB buffer over 350 mL, then isocratic 60% over 50 mL, flow: 3 mL/min, 
fraction size: 5 mL), to give 4g as a colourless oil (0.0102 g, 1.45 equiv. TEA, 9% 
yield).
 1
H NMR (400 MHz; D2O) δ: 8.35 (1H, s, 8-H), 6.19 (1H, d, J1′,2′ = 3.2 Hz, 1′-H), 
5.36 (1H, m, 2′-H), 5.17 (1H, m, 3′-H), 4.62 (1H, br s, 4′-H), 3.99 (3H, m, 5′-H2), 3.18 
(8.7H, q, J = 7.3 Hz, CH2 TEA), 1.66 (3H, s, isoprop.), 1.43 (3H, s, isoprop.), 1.25 
(13.2H, t, J = 7.3 Hz, CH3 TEA);
 31
P NMR (162 MHz; D2O) δ: 1.54.  
Phosphoric acid mono-5′-[2-phenyl-9β-(2′,3′-O-isopropylidene-D-ribofuranosyl)-
adenine] (4h)
136
 
 
The title compound was prepared according to the general synthetic procedure D1, from 
4b (0.0155 g, 1 equiv.), proton sponge (6 equiv.) and POCl3 (25 μL, 6 equiv.) in 
triethylphosphate (4 mL). The crude product was purified by purification method 2 (0-
100% 1 M TEAB buffer against H2O over 300 mL, flow: 2 mL/min, fraction size: 5 
mL), to give 4h as a colourless oil (yield not calculated because the product was full of 
TEA salts).
 1
H NMR (400 MHz; D2O) δ: 8.33 (1H, s, 8-H), 8.06 (2H, m, Ph), 7.49 (3H, 
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m, Ph), 6.32 (1H, br s, 1′-H), 5.44 (1H, s, 2′-H), 5.21 (1H, s, 3′-H), 4.61 (1H, s, 4′-H), 
4.01 (2H, m, 5′-H2), 3.35 (85.7H, q, J = 7.3 Hz, CH2 TEA), 1.68 (3H, s, isoprop.), 1.45 
(3H, s, isoprop.), 1.25 (88.7H, t, J = 7.2 Hz, CH3 TEA);
 31
P NMR (162 MHz; D2O) δ: 
0.23. 
Phosphoric acid mono-5′-[2-iodo-9β-D-ribofuranosyl-adenine] (7a) 
 
The title compound was prepared according to the general synthetic procedure E, from 
4g (0.0102 g, 1 equiv.). The crude product was purified by purification method 1 (0-
50% MeOH against 0.05 M TEAB buffer over 300 mL, then isocratic 50% over 50 mL, 
flow: 3 mL/min, fraction size: 5 mL), to obtain 7a as a colourless oil (0.0037 g, 1.86 
equiv. TEA, 36% yield). 
The title compound was prepared according to the general synthetic procedures D2 and 
E. A mixture of 4a and 4c (0.0308 g, 1 equiv., 43% of 4c by 
1
H NMR estimation) was 
dissolved in anhydrous CH2Cl2 (2 mL) and DIPEA (2.5 equiv.) and 2-cyanoethyl N,N-
diisopropyl chlorophosphoramidite (1 equiv.) were added via syringe. The reaction was 
stirred under nitrogen at room temperature for 2 h. Then, 5.0 – 6.0 M tBuOOH in 
nonane solution was added to the reaction and stirred for 1 h. After extractions, the 
organic phase was evaporated to dryness in vacuo and the residue was suspended in 
NH4OH under stirring at room temperature overnight. The solution was evaporated to 
dryness in vacuo, suspended in water and stirred with Dowex 88 (H
+
) overnight. The 
crude product was purified by purification method 1 (0-50% MeOH against 0.05 M 
TEAB buffer over 350 mL, then isocratic 50% over 50 mL, flow: 3 mL/min, fraction 
size: 5 mL), to obtain 7a as a colourless oil (0.005 g, 1.68 equiv. TEA, 19% yield).  
Chapter 7 
 
196 
 
1
H NMR (400 MHz; D2O) δ: 8.47 (1H, s, 8-H), 6.02 (1H, d, J1′,2′ = 5.7 Hz, 1′-H), 4.72 
(1H, apparent t, 2′-H), 4.50 – 4.44 (1H, m, 3′-H), 4.34 (1H, m, 4′-H), 4.07 – 3.89 (2H, 
m, 5′-H2), 3.17 (10.1H, q, J = 7.3 Hz, CH2 TEA), 1.25 (15.1H, t, J = 7.3 Hz, CH3 TEA);
 
13
C NMR (101 MHz; D2O) δ: 156.10, 150.29, 145.45, 140.40, 120.35, 87.93, 85.06, 
75.49, 71.26, 64.78, 47.49, 9.07; 
31
P NMR (162 MHz; D2O) δ: 1.65; m/z (ESI) 
473.9666 [M+H]
+
, C10H14IN5O7P
+
 requires 473.9670. 
Phosphoric acid mono-5′-[2-phenyl-9β-D-ribofuranosyl-adenine] (7b) 
 
The title compound was prepared according to the general synthetic procedures D2 and 
E. 4b (0.032 g, 1 equiv.) was dissolved in anhydrous CH2Cl2 (2.5 mL) and DIPEA (2.5 
equiv.) and 2-cyanoethyl N,N-diisopropyl chlorophosphoramidite (2 equiv.) were added 
via syringe. The reaction was stirred under nitrogen at room temperature for 2 h. The 
intermediate 4e was isolated as a mixture of diastereomers by silica gel 
chromatography, with an eluent 80:20 CH2Cl2/EtOAc with 3% TEA. 
1
H NMR (400 
MHz; CDCl3) δ: 8.42 – 8.34 (2H, m, Ph), 7.98 (1H, s, 8-H), 7.49 – 7.41 (3H, m, Ph), 
6.23 (0.5H, d, J1′,2′ = 2.1 Hz, 1′-H), 6.20 (0.5H, d, J1′,2′ = 2.1 Hz, 1′-H), 5.58 (0.5H, dd, J 
= 6.2, 2.1 Hz, 2′-H), 5.55 (0.5H, dd, J = 6.2, 2.1 Hz, 2′-H), 5.21 – 5.15 (1H, m, 3′-H), 
4.50 – 4.45 (1H, m, 4′-H), 3.96 – 3.66 (4H, m, 5′-H2, P-O-CH2), 3.51 (2H, m, N-CH), 
2.66 (2H, m, CH2-CN), 1.65 (3H, s, isoprop.), 1.42 (3H, s, isoprop.), 1.14 – 1.05 (6H, 
m, N-isoprop.);
 31
P NMR (162 MHz; CDCl3) δ: 148.98. Then, 5.0 – 6.0 M 
t
BuOOH in 
nonane solution was added to the reaction and stirred for 1 h. After extractions, the 
organic phase was evaporated to dryness in vacuo and the residue was suspended in 
NH4OH under stirring at room temperature overnight. The solution was evaporated to 
dryness in vacuo, suspended in water and stirred with Dowex 88 (H
+
) overnight. The 
crude product was purified by purification method 1 (0-50% MeOH against 0.05 M 
TEAB buffer over 350 mL, then isocratic 60% over 50 mL, flow: 3 mL/min, fraction 
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size: 5 mL), to obtain 7b as a colourless oil (0.0075 g, 0.92 equiv. TEA, 17% yield). 
1
H 
NMR (400 MHz; D2O) δ: 8.35 (1H, s, 8-H), 7.90 (2H, d, J = 7.0 Hz, Ph), 7.40 (3H, m, 
Ph), 6.11 (1H, d, J1′,2′ = 5.2 Hz, 1′-H), 4.68 (1H, apparent t, 2′-H), 4.48 (1H, m, 3′-H), 
4.32 (1H, br s, 4′-H), 4.17 – 3.98 (2H, m, 5′-H2), 3.13 (5.5H, q, J = 7.3 Hz, CH2 TEA), 
1.22 (9.6H, t, J = 7.3 Hz, CH3 TEA); 
13
C NMR (101 MHz; D2O) δ: 156.37, 152.78, 
152.38, 145.28, 134.60, 132.37, 131.31, 130.25, 129.66, 99.29, 88.30, 84.94, 75.33, 
71.21, 65.19, 59.67, 47.51, 9.07; 
31
P NMR (162 MHz; D2O) δ: 0.94; m/z (ESI) 
422.0870 [M-H]
-
, C16H17N5O7P
-
 requires 422.0871. 
Phosphoric acid mono-5′-[2-(N-Me-pyrrol-2-yl)-9β-D-ribofuranosyl-adenine] (7c) 
 
The title compound was prepared according to the general synthetic procedures D2 and 
E. A mixture of 4a and 4c (0.0308 g, 1 equiv., 43% of 4c by 
1
H NMR estimation) was 
dissolved in anhydrous CH2Cl2 (2 mL) and DIPEA (2.5 equiv.) and 2-cyanoethyl N,N-
diisopropyl chlorophosphoramidite (1 equiv.) were added via syringe. The reaction was 
stirred under nitrogen at room temperature for 2 h. Then, 5.0 – 6.0 M tBuOOH in 
nonane solution was added to the reaction and stirred for 1 h. After extractions, the 
organic phase was evaporated to dryness in vacuo and the residue was suspended in 
NH4OH under stirring at room temperature overnight. The solution was evaporated to 
dryness in vacuo, suspended in water and stirred with Dowex 88 (H
+
) overnight. The 
crude product was purified by purification method 1 (0-50% MeOH against 0.05 M 
TEAB buffer over 350 mL, then isocratic 50% over 50 mL, flow: 3 mL/min, fraction 
size: 5 mL), to obtain 7c as a yellow oil (0.0067 g, yield not calculated because of 
stannane impurities still present in the product). 
1
H NMR (400 MHz; D2O) δ: 8.91 (1H, 
s, 8-H), 8.21 (1H, d, J = 1.7 Hz, 5-H pyrrole), 7.62 (2H, d, 3-H pyrrole, 4-H pyrrole), 
6.28 (1H, d, J1′,2′ = 5.4 Hz, 1′-H), 4.81 (1H, m, 2′-H), 4.55 – 4.48 (1H, m, 3′-H), 4.40 
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(1H, br s, 4′-H), 4.14 (2H, m, 5′-H2), 3.98 – 3.86 (3H, m, N-CH3), 3.17 (5.2H, q, J = 7.3 
Hz, CH2 TEA); 
31
P NMR (162 MHz; D2O) δ: 0.54.  
7.2.3 Preparation of 6-substituted AMP derivatives (8a-b) 
6-Phenyl-9β-D-ribofuranosyl-purine (5a)147 
 
The title compound was prepared according to the general synthetic procedure B1, from 
5 (0.2 g, 1 equiv.), using Na2PdCl4, TPPTS, phenyl boronic acid and K2CO3 in water (6 
mL) at 100 ºC. After 1 h, the reaction was cooled down and extracted with EtOAc; the 
organic phase was dried over anhydrous MgSO4 and evaporated to dryness in vacuo to 
obtain 5a as a white powder (0.1136 g, 50% yield). 
1
H NMR (400 MHz; DMSO-d6) δ: 
9.02 (1H, s, 2-H), 8.93 (1H, s, 8-H), 8.84 (2H, d, J = 8.0 Hz, Ph), 7.55 – 7.65 (3H, m, 
Ph), 6.11 (1H, d, J1′,2′ = 5.5 Hz, 1′-H), 5.56 (1H, d, J = 5.7 Hz, 2′-OH), 5.25 (1H, d, J = 
5.0 Hz, 3′-OH), 5.13 (1H, t, J = 5.4 Hz, 5′-OH), 4.67 (1H, m, 2′-H), 4.23 (1H, m, 3′-H), 
4.02 (1H, m, 4′-H), 3.76 – 3.59 (2H, m, 5′-H2).  
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6-(Pyrrol-2-yl)-9β-D-ribofuranosyl-purine (5b) 
 
The title compound was prepared according to the general synthetic procedure B1, from 
5 (0.2 g, 1 equiv.), using Na2PdCl4, TPPTS, N-Boc-2-pyrrole boronic acid and K2CO3 in 
water (6 mL) at 100 ºC. After 24 h, the reaction was cooled down and evaporated to 
dryness in vacuo. The crude product was purified by purification method 1 (0-50% 
MeOH against 0.05 M TEAB buffer over 350 mL, then isocratic 60% over 50 mL, 
flow: 2 mL/min, fraction size: 5 mL) to obtain 5b as a yellow oil (0.0825 g, 37% yield). 
1
H NMR (400 MHz; CD3OD) δ: 8.69 (1H, s, 2-H), 8.59 (1H, s, 8-H), 7.51 (1H, dd, J5,4 
= 3.8 Hz, J5,3 = 1.4 Hz, 5-H pyrrole), 7.16 (1H, dd, J3,4 = 2.5 Hz, J3,5 = 1.4 Hz, 3-H 
pyrrole), 6.36 (1H, dd, J4,5 = 3.7 Hz, J4,3 = 2.6 Hz, 4-H pyrrole), 6.09 (1H, d, J1′,2′ = 6.0 
Hz, 1′-H), 4.79 (1H, apparent t, 2′-H), 4.37 (1H, m, 3′-H), 4.19 (1H, m, 4′-H), 3.91 (1H, 
dd, J5′a,b = 12.4 Hz, J5′a,4′ = 2.7 Hz, 5′a-H), 3.78 (1H, dd, J5′b,a = 12.4 Hz, J5′b,4′ = 2.9 Hz, 
5′b-H), 2.80 (4H, q, J = 7.2 Hz, CH2 TEA), 1.14 (5.9H, t, J = 7.3 Hz, CH3 TEA);
 13
C 
NMR (101 MHz; CD3OD) δ: 153.04, 151.97, 149.51, 145.16, 129.65, 128.79, 125.20, 
116.57, 111.86, 90.92, 87.88, 75.54, 72.46, 63.29, 47.30, 10.36; m/z (ESI) 316.1046 
[M-H]
-
, C14H14N5O4
-
 requires 316.1051. 
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6-Phenyl-9β-(2′,3′-O-isopropylidene-D-ribofuranosyl)-purine (5c) 
 
The title compound was prepared according to the general synthetic procedure C, from a 
suspension of 5a (0.1136 g, 1 equiv.) in acetone (8 mL), adding 70% HClO4 (70 µL) 
and NH4OH (70 µL). The mixture was extracted with EtOAc/brine (3x), and the organic 
phase dried over anhydrous MgSO4; then, the solution was evaporated to dryness in 
vacuo to give 5c as a colourless oil (0.109 g, 85% yield). 
1
H NMR (400 MHz; CD3OD) 
δ: 8.95 (1H, s, 2-H), 8.73 (1H, s, 8-H), 8.70 – 8.61 (2H, m, Ph), 7.62 – 7.50 (3H, m, 
Ph), 6.35 (1H, d, J1′,2′ = 3.0 Hz, 1′-H), 5.42 (1H, m, 2′-H), 5.09 (1H, m, 3′-H), 4.40 (1H, 
m, 4′-H), 3.80 (1H, dd, J5′a,b = 12.0 Hz, J5′a,4′ = 3.8 Hz, 5′a-H), 3.73 (1H, dd, J5′b,a = 12.0 
Hz, J5′b,4′ = 4.4 Hz, 5′b-H), 1.64 (3H, s, isoprop.), 1.40 (3H, s, isoprop.). 
6-(Pyrrol-2-yl)-9β-(2′,3′-O-isopropylidene-D-ribofuranosyl)-purine (5d) 
 
The title compound was prepared according to the general synthetic procedure C, from a 
suspension of 5b (0.0825 g, 1 equiv.) in acetone (8 mL), adding 70% HClO4 (56 µL) 
and NH4OH (56 µL). The mixture was extracted with EtOAc/brine (3x), and the organic 
phase dried over anhydrous MgSO4; then, the solution was evaporated to dryness in 
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vacuo to give 5d as a yellow oil (0.0367 g, 39% yield). 
1
H NMR (400 MHz; CD3OD) δ: 
8.71 (1H, s, 2-H), 8.59 (1H, s, 8-H), 7.51 (1H, dd, J5,4 = 3.8 Hz, J5,3 = 1.4 Hz, 5-H 
pyrrole), 7.15 (1H, dd, J3,4 = 2.5 Hz, J3,5 = 1.4 Hz, 3-H pyrrole), 6.36 (1H, dd, J4,5 = 3.8 
Hz, J4,3 = 2.6 Hz, 4-H pyrrole), 6.27 (1H, d, J1′,2′ = 3.2 Hz, 1′-H), 5.38 (1H, m, 2′-H), 
5.08 (1H, m, 3′-H), 4.39 (1H, m, 4′-H), 3.80 (1H, dd, J5′a,b = 12.0 Hz, J5′a,4′ = 3.7 Hz, 
5′a-H), 3.73 (1H, dd, J5′b,a = 12.0 Hz, J5′b,4′ = 4.3 Hz, 5′b-H), 1.63 (3H, s, isoprop.), 1.40 
(3H, s, isoprop.).  
Phosphoric acid mono-5′-[6-phenyl-9β-(2′,3′-O-isopropylidene-D-ribofuranosyl)-
purine] (5g) 
 
The title compound was prepared according to the general synthetic procedure D1, from 
5c (0.109 g, 1 equiv.) and POCl3 (0.1 mL, 3.6 equiv.) in anhydrous acetonitrile (3 mL). 
The crude product was purified by purification method 1 (0-50% MeOH against 0.05 M 
TEAB buffer over 300 mL, isocratic 50% over 50 mL, isocratic 60% over 50 mL, flow: 
3 mL/min, fraction size: 5 mL), to give 5g as a colourless oil (0.024 g, 2.4 equiv. TEA, 
12% yield). 5g was partially deprotected in the reaction conditions to give 8a as a 
colourless oil (0.0448 g, 2.18 equiv. TEA, 24% yield). 
1
H NMR (400 MHz; D2O) δ: 
8.80 (1H, s, 2-H), 8.75 (1H, s, 8-H), 8.07 (2H, m, Ph), 7.60 – 7.46 (3H, m, Ph), 6.27 
(1H, d, J1′,2′ = 3.2 Hz, 1′-H), 5.36 (1H, m, 2′-H), 5.20 (1H, m, 3′-H), 4.64 (1H, br s, 4′-
H), 3.91 (2H, m, 5′-H2), 3.14 (14.4H, q, J = 7.3 Hz, CH2 TEA), 1.69 (3H, s, isoprop.), 
1.45 (3H, s, isoprop.), 1.22 (21.8H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR (162 MHz; D2O) 
δ: 3.73.  
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Phosphoric acid mono-5′-[6-(pyrrol-2-yl)-9β-(2′,3′-O-isopropylidene-D-
ribofuranosyl)-purine] (5h) 
 
The title compound was prepared according to the general synthetic procedure D1, from 
5d (0.0179 g, 1 equiv.) and POCl3 (19 µL, 4 equiv.) in anhydrous acetonitrile (0.8 mL). 
The reaction mixture was kept at 4 °C for 48 h. The crude product was purified by 
purification method 1 (0-50% MeOH against 0.05 M TEAB buffer over 350 mL, then 
isocratic 60% over 50 mL, flow: 3 mL/min, fraction size: 5 mL) to give 5h as a yellow 
oil (0.0102 g, 1.8 equiv. TEA, 33% yield). 5h was partially deprotected in the reaction 
conditions to give 8b as a yellow oil (0.0017 g, 1.8 equiv. TEA, 6% yield).
1
H NMR 
(400 MHz; CD3OD) δ: 8.79 (1H, s, 2-H), 8.71 (1H, s, 8-H), 7.50 – 7.47 (1H, dd, J5,4 = 
2.2 Hz, J5,3 = 1.3 Hz, 5-H pyrrole), 7.15 (1H, dd, J3,4 = 2.2 Hz, J3,5 = 1.3 Hz, 3-H 
pyrrole), 6.35 (1H, m, 4-H pyrrole), 6.33 (1H, d, J1′,2′ = 3.2 Hz, 1′-H), 5.44 (1H, dd, J2′,3′ 
= 6.0 Hz, J1′,2′ = 3.2 Hz, 2′-H), 5.18 (1H, dd, J2′,3′ = 6.0 Hz, J3′,4′ = 1.8 Hz, 3′-H), 4.50 
(1H, m, 4′-H), 4.07 – 3.96 (2H, m, 5′-H2), 3.03 (10.8H, q, J = 7.3 Hz, CH2 TEA), 1.63 
(3H, s, isoprop.), 1.40 (3H, s, isoprop.), 1.22 (16.8H, t, J = 7.3 Hz, CH3 TEA); 
31
P 
NMR (162 MHz; CD3OD) δ: 1.65.  
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Phosphoric acid mono-5′-[6-phenyl-9β-D-ribofuranosyl-purine] (8a) 
 
The title compound was prepared according to the general synthetic procedure E, from 
5g (0.024 g, 1 equiv.). The crude product was purified by purification method 1 (0-50% 
MeOH against 0.05 M TEAB buffer over 300 mL, then isocratic 60% over 100 mL, 
flow: 3 mL/min, fraction size: 5 mL), to obtain 8a as a colourless oil (0.0064 g, 2.1 
equiv. TEA, 30% yield). 
The title compound was prepared according to the general synthetic procedures D2 and 
E. 5c (0.177 g, 1 equiv.) was dissolved in anhydrous CH2Cl2 (3 mL) and DIPEA (2.5 
equiv.) and 2-cyanoethyl N,N-diisopropyl chlorophosphoramidite (1 equiv.) were added 
via syringe. The reaction was stirred under nitrogen at room temperature for 1.5 h. 
Then, 5.0 – 6.0 M tBuOOH in nonane solution was added to the reaction and stirred for 
2 h. After extractions, the organic phase was evaporated to dryness in vacuo and the 
phosphate intermediate isolated and purified as a mixture of diastereomers by silica gel 
chromatography with an eluent 80:20 CH2Cl2/MeOH. 
1
H NMR (400 MHz; CDCl3) δ: 
8.96 (1H, d, J = 1.1 Hz, 2-H), 8.73 – 8.65 (2H, m, Ph), 8.28 (0.5H, s, 8-H), 8.23 (0.5H, 
s, 8-H), 7.54 – 7.43 (3H, m, Ph), 6.21 (0.5H, d, J1′,2′ = 2.3 Hz, 1′-H), 6.18 (0.5H, d, J1′,2′ 
= 2.3 Hz, 1′-H), 5.44 (0.5H, dd, J = 6.4, 2.3 Hz, 2′-H), 5.41 (0.5H, dd, J = 6.4, 2.0 Hz, 
2′-H), 5.12 (1H, dt, J = 6.5, 3.4 Hz, 3′-H), 4.50 – 4.41 (1H, m, 4′-H), 4.20 – 3.93 (4H, 
m, 5′-H2, P-O-CH2), 3.52 – 3.16 (4H, m, N-CH), 2.76 – 2.59 (2H, m, CH2-CN), 1.59 
(3H, s, isoprop.), 1.34 (3H, s, isoprop.), 1.15 (12H, d, J = 13.6 Hz, N-isoprop.); 
31
P 
NMR (162 MHz; CDCl3) δ: 14.17. The residue was suspended in NH4OH under stirring 
at room temperature overnight. The solution was evaporated to dryness in vacuo, 
suspended in water and stirred with Dowex 88 (H
+
) overnight. After filtration, the crude 
product was purified by purification method 1 (0-50% MeOH against 0.05 M TEAB 
Chapter 7 
 
204 
 
buffer over 300 mL, then isocratic 60% over 100 mL, flow: 3 mL/min, fraction size: 5 
mL), to give 8a as a colourless oil (0.0191 g, 1.37 equiv. TEA, 7% yield).
  
1
H NMR (400 MHz; D2O) δ: 8.86 (1H, s, 2-H), 8.78 (1H, s, 8-H), 8.23 – 8.08 (2H, m, 
Ph), 7.58 (3H, m, Ph), 6.25 (1H, d, J1′,2′ = 5.3 Hz, 1′-H), 4.68 (1H, m, 2′-H), 4.51 (1H, 
m, 3′-H), 4.40 (1H, m, 4′-H), 4.14 (2H, m, 5′-H2), 3.17 (8.2H, q, J = 7.3 Hz, CH2 TEA), 
1.25 (13.9H, t, J = 7.3 Hz, CH3 TEA);
 13
C NMR (101 MHz; D2O) δ: 156.04, 152.66, 
152.25, 145.22, 134.40, 132.36, 131.13, 130.14, 129.56, 88.31, 84.92, 75.37, 71.21, 
59.70, 47.50, 23.08, 9.07, 8.23;
 31
P NMR (162 MHz; D2O) δ: 2.98; m/z (ESI) 407.0754 
[M-H]
-
, C16H16N4O7P
-
 requires 407.0762. 
Phosphoric acid mono-5′-[6-(pyrrol-2-yl)-9β-D-ribofuranosyl-purine] (8b) 
 
The title compound was prepared from 5h (0.0102 g, 1 equiv. TEA), dissolving it in an 
acetic acid solution (AcOH/H2O, 1:9) at 90 °C for 3 h. After co-evaporation with EtOH 
(3x) to remove AcOH traces, the crude product gave 8b as a colourless oil (0.0082 g, 
complete conversion). 
1
H NMR (400 MHz; D2O) δ: 8.66 (1H, s, 2-H), 8.58 (1H, s, 8-H), 
7.26 (1H, dd, J5,4 = 3.8 Hz, J5,3 = 1.4 Hz, 5-H pyrrole), 7.21 (1H, dd, J3,4 = 2.5 Hz, J5,3 = 
1.4 Hz, 3-H pyrrole), 6.42 (1H, dd, J5,4 = 3.8 Hz, J3,4 = 2.6 Hz, 4-H pyrrole), 6.16 (1H, 
d, J1′,2′ = 5.5 Hz, 1′-H), 4.75 (1H, m, 2′-H), 4.52 – 4.47 (1H, m, 3′-H), 4.40 – 4.35 (1H, 
m, 4′-H), 4.18 – 4.06 (2H, m, 5′-H2); 
13
C NMR (101 MHz; D2O) δ: 152.94, 151.51, 
148.03, 144.01, 128.03, 127.34, 126.06, 115.89, 111.94, 88.04, 75.28, 71.24; 
31
P NMR 
(162 MHz; D2O) δ: 0.63; m/z (ESI) 396.0714 [M-H]
-
, C14H15N5O7P
-
 requires 396.0715. 
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7.2.4 Preparation of 8-substituted AMP derivatives (9b-n) 
Phosphoric acid mono-5′-[8-bromo-9β-D-ribofuranosyl-adenine] (9a)172 
 
To a solution of adenosine monophosphate 3a (0.5 g, 1 equiv.) in aqueous KH2PO4 (50 
mL, 0.25 M, pH 4), neat bromine (6.7 equiv.) was added drop-wise. The reaction was 
stirred at room temperature in the dark overnight. The aqueous solution was washed 
with CH2Cl2 until the colour remained pale yellow, and evaporated to dryness in vacuo. 
The crude product was purified by purification method 1 (0-10% MeOH against 0.05 M 
TEAB buffer over 400 mL, flow: 5 mL/min, fraction size: 5 mL) to give 9a as a 
colourless oil (0.56 g, 2.2 equiv. TEA, 60% yield). 
1
H NMR (400 MHz; D2O) δ: 8.03 
(1H, s, 2-H), 5.99 (1H, d, J1′,2′ = 6.0 Hz, 1′-H), 5.19 (1H, apparent t, 2′-H), 4.51 (1H, m, 
3′-H), 4.25 – 3.93 (3H, m, 4′-H, 5′-H2), 3.10 (13.8H, q, J = 7.3 Hz, CH2 TEA), 1.19 
(19.6H, t, J = 7.3 Hz, CH3 TEA); m/z (ESI) 423.9670 [M-H]
-
, C10H12BrN5O7P
-
 requires 
423.9663; TLC: Rf 0.27 (
t
BuOH/1M TEAB buffer 6:4). 
Phosphoric acid mono-5′-[8-phenyl-9β-D-ribofuranosyl-adenine] (9b)172 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.0833 g, 1 equiv.) using Na2PdCl4 (0.025 equiv.), TPPTS (2.5 equiv. to Pd), phenyl 
boronic acid (1.7 equiv.) and K2CO3 (1.5 equiv.) in water (2 mL) at 80 ºC. After 1 h, the 
reaction was complete. The crude product was purified by purification method 1 (0-60% 
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MeOH against 0.05 M TEAB buffer over 400 mL, flow: 3 mL/min, fraction size: 5 mL) 
and 2 (0-60% 1 M TEAB buffer against H2O over 800 mL, flow: 4 mL/min, fraction 
size: 5 mL) to give 9b as a colourless oil (0.0751 g, 1.6 equiv. TEA, 82% yield). 
1
H 
NMR (400 MHz; D2O) δ: 8.18 (1H, s, 2-H), 7.68 – 7.49 (5H, m, Ph), 5.81 (1H, d, J1′,2′ = 
6.2 Hz, 1′-H), 5.21 (1H, apparent t, 2′-H), 4.38 (1H, m, 3′-H), 4.01 (3H, m, 4′-H, 5′-H2), 
2.97 (7.8H, q, J = 7.3 Hz, CH2 TEA), 1.20 (16.4H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR 
(162 MHz; D2O) δ: 7.007; m/z (ESI) 422.0869 [M-H]
-
, C10H12BrN5O7P
-
 requires 
422.0871; TLC: Rf 0.6 (iPA/H2O/NH4OH 6:3:1). 
Phosphoric acid mono-5′-[8-(3-(N-Boc-aminomethyl)phenyl)-9β-D-ribofuranosyl-
adenine] (9c)
172
 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.074 g, 1 equiv.) using Na2PdCl4 (0.025 equiv.), TPPTS (2.5 equiv. to Pd), 3-(N-
Boc-aminomethyl)phenyl boronic acid (1.2 equiv.) and K2CO3 (3 equiv.) in water (2 
mL) at 80 ºC. After 1 h, the reaction was complete. The crude product was purified by 
purification method 1 (0-50% MeOH against 0.05 M TEAB buffer over 400 mL, flow: 
3 mL/min, fraction size: 5 mL) to give 9c as a colourless oil (0.0762 g, 1.3 equiv. TEA, 
78% yield). 
1
H NMR (400 MHz; CD3OD) δ: 8.18 (1H, s, 2-H), 7.68 – 7.63 (2H, m, Ph), 
7.55 – 7.46 (2H, m, Ph), 5.83 (1H, d, J1′,2′ = 5.8 Hz, 1′-H), 5.51 (1H, apparent t, 2′-H), 
4.49 (1H, m, 3′-H), 4.31 (2H, s, CH2NH2), 4.27 – 4.03 (3H, m, 4′-H, 5′-H2), 3.01 (8H, q, 
J = 7.3 Hz, CH2 TEA), 1.42 (9H, s, CH3 Boc), 1.19 (12.1H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR (162 MHz; D2O) δ: 7.013; TLC: Rf 0.64 (
t
BuOH/1M TEAB buffer 6:4). 
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Phosphoric acid mono-5′-[8-(3-(aminomethyl)phenyl)-9β-D-ribofuranosyl-adenine] 
(9d) 
 
The conformer 9d(a) was prepared according to the general synthetic procedure B2, 
from 9a (0.0712 g, 1 equiv.) using Na2PdCl4 (0.025 equiv.), TPPTS (2.5 equiv. to Pd), 
3-(N-Boc-aminomethyl)phenyl boronic acid (1.2 equiv.) and K2CO3 (3 equiv.) in water 
(6 mL) at 40 °C. After 2 days, the reaction seemed complete and the crude product was 
purified by purification method 1 (0-8% MeOH against 0.05 M TEAB buffer over 350 
mL, flow: 3 mL/min, fraction size: 5 mL) to give 9d(a) as a colourless oil (0.047 g, 0.5 
equiv. TEA, 85% yield). 
The two conformers, 9d(a) and 9d(b), of the title compound were prepared according to 
the general synthetic procedure B2, from 9a (0.042 g, 1 equiv.) using Na2PdCl4 (0.025 
equiv.), TPPTS (2.5 equiv. to Pd), 3-(aminomethyl)phenyl boronic acid (1.2 equiv.) and 
K2CO3 (3 equiv.) in water (3 mL) at 80 °C. After 2 h, the reaction seemed complete and 
the crude product was purified by purification method 1 (0-8% MeOH against 0.05 M 
TEAB buffer over 350 mL, flow: 3 mL/min, fraction size: 5 mL) and 2 (0-60% 1 M 
TEAB buffer against H2O over 700 mL, flow: 3 mL/min, fraction size: 5 mL). 
The conformer 9d(a) was prepared treating 9c with TFA in MeOH under reflux (pH 1) 
until to almost complete disappearance of the starting material. The mixture was 
evaporated to dryness and the crude product purified by purification method 1 (0-8% 
MeOH against 0.05 M TEAB buffer over 350 mL, flow: 3 mL/min, fraction size: 5 
mL). 
Conformer 9d(a): 
1
H NMR (400 MHz; D2O) δ: 8.24 (1H, s, 2-H), 7.75 – 7.58 (4H, m, 
Ph), 5.82 (1H, d, J1′,2′ = 6.2 Hz, 1′-H), 5.17 (1H, apparent t, 2′-H), 4.36 (1H, m, 3′-H), 
4.23 (2H, s, CH2NH2), 4.17 – 3.95 (3H, m, 4′-H, 5′-H2), 3.35 (8.1H, q, J = 7.3 Hz, CH2 
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TEA), 1.23 (12.2H, t, J = 7.3 Hz, CH3 TEA); m/z (ESI) 451.1150 [M-H]
-
, C17H20N6O7P
-
 
requires 451.1137; TLC: Rf 0.52 (iPA/H2O/NH4OH 6:3:1).  
Conformer 9d(b): 
1
H NMR (400 MHz; D2O) δ: 8.21 (1H, s, 2-H), 7.72 – 7.55 (4H, m, 
Ph), 5.80 (1H, d, J1′,2′ = 6.4 Hz, 1′-H), 5.17 (1H, apparent t, 2′-H), 4.37 (1H, m, 3′-H), 
4.21 (2H, d, CH2NH2), 4.19 – 3.98 (3H, m, 4′-H, 5′-H2), 1.22 (4.9H, t, J = 7.3 Hz CH3 
TEA); m/z (ESI) 451.1130 [M-H]
-
, C17H20N6O7P
-
 requires 451.1137; TLC: Rf 0.81 
(iPA/H2O/NH4OH 6:3:1).  
Phosphoric acid mono-5′-[8-(pyridin-3-yl)-9β-D-ribofuranosyl-adenine] (9e)172 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.0175 g, 1 equiv.) using Na2PdCl4 (0.02 equiv.), TPPTS (3 equiv. to Pd), 3-
pyridinyl boronic acid (1.2 equiv.) and K2CO3 (3 equiv.) in water (1 mL) at 100 ºC. 
After 24 h, the reaction was complete. The crude product was purified by purification 
method 1 (0-10% MeOH against 0.05 M TEAB buffer over 400 mL, flow: 3 mL/min, 
fraction size: 5 mL) and 2 (0-25% 1 M TEAB buffer against H2O over 350 mL, flow: 2 
mL/min, fraction size: 3 mL) to give 9e as a colourless oil (0.0123 g, 2 equiv. TEA, 
70% yield). 
1
H NMR (400 MHz; D2O) δ: 8.82 (1H, br s, 2-H pyridine), 8.70 (1H, br s, 
6-H pyridine), 8.22 (1H, s, 2-H), 8.18 (1H, m, 4-H pyridine), 7.64 (1H, br s, 5-H 
pyridine), 5.77 (1H, d, 1′-H), 5.22 (1H, apparent t, 2′-H), 4.38 (1H, m, 3′-H), 4.27 – 3.88 
(3H, m, 4′-H, 5′-H2), 3.14 (12.5H, q, J = 7.3 Hz, CH2 TEA), 1.21 (18.6H, t, J = 7.3 Hz, 
CH3 TEA); 
31
P NMR (162 MHz; D2O) δ: 7.013; TLC: Rf 0.34 (
t
BuOH/1M TEAB buffer 
6:4).  
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Phosphoric acid mono-5′-[8-(pyridin-4-yl)-9β-D-ribofuranosyl-adenine] (9f) 
 
The title compound was prepared according to general synthetic procedure B2, from 9a 
(0.045 g, 1 equiv.) using Na2PdCl4 (0.09 equiv.), TPPTS (3 equiv. to Pd), 4-pyridinyl 
boronic acid (1.5 equiv.) and K2CO3 (3.5 equiv.) in water (2 mL) at 100 °C. After 12 h, 
the reaction seemed complete. The crude product was purified by purification method 1 
(0-18% MeOH against 0.05 M TEAB buffer over 400 mL, flow: 3 mL/min, fraction 
size: 5 mL) and 2 (0-60% 1 M TEAB buffer against H2O over 400 mL, flow: 2 mL/min, 
fraction size: 5 mL) to give 9f as a colourless oil (0.0324 g, 1.58 equiv. TEA, 80% 
yield). 
1
H NMR (400 MHz; D2O) δ: 8.72 (2H, br s, 2-H pyridine, 6-H pyridine), 8.27 
(1H, s, 2-H), 7.78 (2H, br s, 3-H pyridine, 5-H pyridine), 5.86 (1H, d, J1′,2′ = 5.1 Hz, 1′-
H), 5.27 (1H, apparent t, 2′-H), 4.46 (1H, m, 3′-H), 4.14 (3H, m, 4′-H, 5′-H2), 3.17 
(8.7H, q, J = 7.3 Hz, CH2 TEA), 1.27 (13.1H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR (162 
MHz; D2O) δ: 7.019; m/z (ESI) 423.0821 [M-H]
-
, C15H16N6O7P
-
 requires 423.0824. 
Phosphoric acid mono-5′-[8-(2,4-DMT-pyrimidin-5-yl)-9β-D-ribofuranosyl-
adenine] (9g)
172
 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.0675 g, 1 equiv.) using Na2PdCl4 (0.025 equiv.), TPPTS (2.5 equiv. to Pd), 2,4-
DMT-5-pyrimidinyl boronic acid (1.2 equiv.) and K2CO3 (3 equiv.) in water (3 mL) at 
80 ºC. After 1 h, the reaction was complete. The crude product was purified by 
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purification method 1 (0-40% MeOH against 0.05 M TEAB buffer over 400 mL, flow: 
3 mL/min, fraction size: 5 mL) to give 9g as a colourless oil (0.074 g, 1.4 equiv. TEA, 
75% yield). 
1
H NMR (400 MHz; D2O) δ: 8.43 (1H, s, 6-H pyrimidine), 8.23 (1H, s, 2-
H), 5.56 (1H, d, J1′,2′ = 6.2 Hz, 1′-H), 5.19 (1H, apparent t, 2′-H), 4.44 (1H, m, 3′-H), 
4.14 – 3.82 (9H, m, 4′-H, 5′-H2, 2 OCH3), 2.83 (8.4H, q, J = 7.3 Hz, CH2 TEA), 1.09 
(12.3H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR (162 MHz; D2O) δ: 7.000; m/z (ESI) 
484.0976 [M-H]
-
, C16H19N7O9P
-
 requires 484.0987; TLC: Rf 0.35 (
t
BuOH/1M TEAB 
buffer 6:4). 
Phosphoric acid mono-5′-[8-(pyrrol-2-yl)-9β-D-ribofuranosyl-adenine] (9h)172 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.0175 g, 1 equiv.) using Na2PdCl4 (0.02 equiv.), TPPTS (3 equiv. to Pd), N-Boc-2-
pyrrole boronic acid (1.5 equiv.) and K2CO3 (3 equiv.) in water (1 mL) at 100 ºC. After 
24 h, the reaction was complete. The crude product was purified by purification method 
1 (0-12% MeOH against 0.05 M TEAB buffer over 150 mL, 12-40% over 200 mL, 
flow: 3 mL/min, fraction size: 5 mL) and 2 (0-5% 1 M TEAB buffer against H2O over 
50 mL, 5-28% over 75 mL, 28-40% over 20 mL, isocratic 40% over 20 mL, flow: 2 
mL/min, fraction size: 5 mL), to give 9h as a colourless oil (0.0098 g, 2.2 equiv. TEA, 
57% yield). 
1
H NMR (400 MHz; D2O) δ: 8.07 (1H, s, 2-H), 7.14 (1H, dd, J5,4 = 2.5 Hz, 
J5,3 = 1.4 Hz, 5-H pyrrole), 6.79 (1H, dd, J3,4 = 3.7 Hz, J3,5 = 1.3 Hz, 3-H pyrrole), 6.33 
(1H, dd, J4,3 = 3.5 Hz, J4,5 = 2.8 Hz, 4-H pyrrole), 6.05 (1H, d, J1′,2′ = 6.2 Hz, 1′-H), 5.19 
(1H, apparent t, 2′-H), 4.48 (1H, m, 3′-H), 4.22 (1H, m, 4′-H), 4.06 (2H, m, 5′-H2), 3.14 
(13.8H, q, J = 7.3 Hz, CH2 TEA), 1.20 (19.6H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR (162 
MHz; D2O) δ: 7.032; m/z (ESI) 411.0812 [M-H]
-
, C14H16N6O7P
-
 requires 411.2871; 
TLC: Rf 0.65 (
t
BuOH/1M TEAB buffer 6:4). 
Chapter 7 
 
211 
 
Phosphoric acid mono-5′-[8-(furan-2-yl)-9β-D-ribofuranosyl-adenine] (9i) 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.0554 g, 1 equiv.) using Na2PdCl4 (0.09 equiv.), TPPTS (2.3 equiv. to Pd), 2-
furanyl boronic acid (1.5 equiv.) and K2CO3 (3 equiv.) in water (6 mL) at 100 °C. After 
12 h, the reaction seemed complete. The crude product was purified by purification 
method 1 (0-30% MeOH against 0.05 M TEAB buffer over 400 mL, flow: 3 mL/min, 
fraction size: 5 mL) to give 9i as a colourless oil (0.031 g, 1.7 equiv. TEA, 67% yield). 
1
H NMR (400 MHz; D2O) δ: 8.10 (1H, s, 2-H), 7.69 (1H, br s, 5-H furan), 7.09 (1H, br 
s, 3-H furan), 6.60 (1H, br s, 4-H furan), 6.20 (1H, d, J1′,2′ = 5.7 Hz, 1′-H), 5.31 (1H, 
apparent t, 2′-H), 4.56 (1H, m, 3′-H), 4.13 (3H, m, 4′-H, 5′-H2), 3.12 (10.2H, q, J = 7.3 
Hz, CH2 TEA), 1.21 (15.2H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR (162 MHz; D2O) δ: 
6.975; m/z (ESI) 412.0652 [M-H]
-
, C14H15N5O8P
-
 requires 412.0664. 
Phosphoric acid mono-5′-[8-(1H-pyrazol-4-yl)-9β-D-ribofuranosyl-adenine] (9j) 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.1068 g, 1 equiv.) using Na2PdCl4 (0.1 equiv.), TPPTS (2.5 equiv. to Pd), 1H-
Pyrazole-4-boronic acid (2 equiv.) and K3PO4 (1.5 equiv.) in water (10 mL) at 100 °C. 
After 12 h, the reaction seemed complete. The crude product was purified by 
purification method 1 (0-40% MeOH against 0.05 M TEAB buffer over 300 mL, then 
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isocratic 45% over 100 mL, flow: 3 mL/min, fraction size: 5 mL) and 2 (0-100% 1 M 
TEAB buffer against H2O over 300 mL, flow: 2 mL/min, fraction size: 5 mL) to give 9j 
as a colourless oil (0.0569 g, 1.7 equiv. TEA, 57% yield).
 1
H NMR (400 MHz; D2O) δ: 
8.12 (1H, s, 2-H), 8.07 (2H, s, 3-H pyrazole, 5-H pyrazole), 5.90 (1H, d, J1′,2′ = 6.2 Hz, 
1′-H), 5.25 (1H, apparent t, 2′-H), 4.48 – 4.43 (1H, m, 3′-H), 4.23 (1H, m, 4′-H), 4.11 
(2H, m, 5′-H2), 3.15 (6.1H, q, J = 7.3 Hz, CH2 TEA), 1.23 (9.9H, t, CH3 TEA);
 31
P 
NMR (162 MHz; D2O) δ: 0.25; m/z (ESI) 412.0745 [M-H]
-
, C13H15N7O7P
-
 requires 
412.0776. 
Phosphoric acid mono-5′-[8-(5-formyl-thien-2-yl)-9β-D-ribofuranosyl-adenine] 
(9k) 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.0554 g, 1 equiv.) using Na2PdCl4 (0.09 equiv.), TPPTS (2.3 equiv. to Pd), 5-
formyl-2-thienyl boronic acid (1.5 equiv.) and K2CO3 (3 equiv.) in water (6 mL) at 100 
°C. After 12 h, the reaction was not finished, however the crude product was evaporated 
and purified by purification method 1 (0-30% MeOH against 0.05 M TEAB buffer over 
400 mL, flow: 3 mL/min, fraction size: 5 mL) and 2 (0-60% 1 M TEAB buffer against 
H2O over 400 mL, flow: 2 mL/min, fraction size: 5 mL) to give 9k as a colourless oil 
(0.0275 g, 1.6 equiv. TEA, 52% yield). 
1
H NMR (400 MHz; D2O) δ: 9.58 (1H, s, CHO), 
8.05 (1H, s, 2-H), 7.69 (1H, s, 4-H thienyl), 7.53 (1H, 1s, 3-H thienyl), 5.89 (1H, d, 1′-
H), 5.30 (1H, apparent t, 2′-H), 4.53 (1H, m, 3′-H), 4.16 (3H, m, 4′-H, 5′-H2), 3.10 
(9.6H, q, J = 7.3 Hz, CH2 TEA), 1.18 (14.6H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR (162 
MHz; D2O) δ: 7.019; m/z (ESI) 423.0376 [M-H]
-
, C15H15N5O8PS
-
 requires 456.0384. 
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Phosphoric acid mono-5′-[8-(5-bromo-thien-2-yl)-9β-D-ribofuranosyl-adenine] (9l) 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.0792 g, 1 equiv.) using Na2PdCl4 (0.1 equiv.), TPPTS (2.5 equiv. to Pd), 5-bromo-
2-thienyl boronic acid (0.5 equiv.) and K3PO4 (1.5 equiv.) in water (15 mL) at 100 °C. 
After 12 h, the reaction seemed complete. The crude product was purified by 
purification method 1 (0-40% MeOH against 0.05 M TEAB buffer over 250 mL, 40-
50% over 150 mL, flow: 3 mL/min, fraction size: 5 mL) to give 9l as a colourless oil 
(0.015 g, 1.9 equiv. TEA, 17% yield).
 1
H NMR (400 MHz; D2O) δ: 8.23 (1H, s, 2-H), 
7.43 (1H, d, J3,4 = 4.0 Hz, 4-H thienyl), 7.24 (1H, d, J3,4 = 4.0 Hz, 3-H thienyl), 6.02 
(1H, d, J1′,2′ = 6.1 Hz, 1′-H), 5.42 (1H, apparent t, 2′-H), 4.56 – 4.50 (1H, m, 3′-H), 4.28 
– 4.20 (1H, m, 4′-H), 4.07 (2H, m, 5′-H2), 3.17 (11.2H, q, CH2 TEA), 1.25 (17.9H, t, 
CH3 TEA); 
31
P NMR (162 MHz; D2O) δ: 2.73; m/z (ESI) 505.9554 [M-H]
-
, 
C14H14BrN5O7PS
-
 requires 505.9540. 
Phosphoric acid mono-5′-[8-(indol-2-yl)-9β-D-ribofuranosyl-adenine] (9m) 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.1068 g, 1 equiv.) using Na2PdCl4 (0.09 equiv.), TPPTS (3.5 equiv. to Pd), N-Boc-
indole-2-boronic acid (1.6 equiv.) and K2CO3 (3 equiv.) in water (6 mL) at 100 °C. 
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After 12 h, the reaction seemed complete. The crude product was purified by 
purification method 1 (0-45% MeOH against 0.05 M TEAB buffer over 500 mL, flow: 
3 mL/min, fraction size: 5 mL) to give 9m as a colourless oil (0.0966 g, 2.2 equiv. TEA, 
83% yield).
 1
H NMR (400 MHz; D2O) δ: 7.88 (1H, s, 2-H), 7.53 (1H, d, J = 8.0 Hz, 6-H 
indole), 7.33 (1H, d, J = 8.3 Hz, 9-H indole), 7.13 (1H, t, J = 7.5 Hz, 3-H indole), 7.02 – 
6.94 (2H, m, 7-H indole, 8-H indole), 6.17 (1H, d, J1′,2′ = 5.7 Hz, 1′-H), 5.42 (1H, 
apparent t, 2′-H), 4.55 (1H, m, 3′-H), 4.36 – 4.28 (1H, m, 4′-H), 4.09 (2H, m, 5′-H2), 
3.12 (13.2H, q, J = 7.3 Hz, CH2 TEA), 1.21 (20.4H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR 
(162 MHz; D2O) δ: 3.37; m/z (ESI) 461.0955 [M-H]
-
, C18H18N6O7P
-
 requires 461.0980. 
Phosphoric acid mono-5′-[8-(benzofuran-2-yl)-9β-D-ribofuranosyl-adenine] (9n) 
 
The title compound was prepared according to the general synthetic procedure B2, from 
9a (0.0396 g, 1 equiv.) using Na2PdCl4 (0.09 equiv.), TPPTS (3 equiv. to Pd), 2-
benzofuranyl boronic acid (2 equiv.) and K2CO3 (2 equiv.) in water (3 mL) at 100 °C. 
After 12 h, the conversion seemed at 50%. The crude product was purified by 
purification method 1 (0-40% MeOH against 0.05 M TEAB buffer over 400 mL, 
isocratic 50% over 50 mL, flow: 3 mL/min, fraction size: 5 mL) to give 9n as a 
colourless oil (0.0038 g, 1.4 equiv. TEA, 10% yield). 
1
H NMR (400 MHz; D2O) δ: 7.89 
(1H, s, 2-H), 7.40 (2H, m, 6-H benzofuran, 9-H benzofuran), 7.29 (1H, s, 3-H 
benzofuran), 7.20 (1H, m, 7-H benzofuran), 7.04 (1H, m, 8-H benzofuran), 6.28 (1H, d, 
J1′,2′ = 5.3 Hz, 1′-H), 5.39 (1H, apparent t, 2′-H), 4.63 (1H, m, 3′-H), 4.32 (1H, d, 4′-H), 
4.27 – 4.06 (2H, m, 5′-H2), 3.15 (8.5H, q, J = 7.3 Hz, CH2 TEA), 1.23 (16.6H, t, J = 7.3 
Hz, CH3 TEA); 
31
P NMR (162 MHz; D2O) δ: 0.82; m/z (ESI) 462.0848 [M-H]
-
, 
C18H17N5O8P
-
 requires 462.0820. 
  
Chapter 7 
 
215 
 
7.2.5 Preparation of aryl/heteroaryl adenine-modified NAD+ derivatives (13a-b, 
14a-b, 15b,c,e,g,h) 
Morpholin-4-yl-phosphonic acid mono-5′-[2-iodo-9β-D-ribofuranosyl-adenine] 
(10a) 
 
The title compound was prepared according to the general synthetic procedure F, from 
7a (0.009 g, 1 equiv.). The crude product was purified by purification method 1 (100% 
0.05 M TEAB over 60 mL, 0-60% MeOH against 0.05 M TEAB buffer over 300 mL, 
isocratic 60% over 100 mL, flow: 3 mL/min, fraction size: 5 mL) to give 10a as a 
colourless oil (0.0089 g, 1.1 equiv. TEA, 97% yield). 
1
H NMR (400 MHz; D2O) δ: 8.30 
(1H, s, 8-H), 6.01 (1H, d, J1′,2′ = 4.7 Hz, 1′-H), 4.76 (1H, m, 2′-H), 4.51 (1H, t, J = 4.9 
Hz, 3′-H), 4.31 (1H, m, 4′-H), 4.08 – 3.93 (2H, m, 5′-H2), 3.53 (4H, m, CH2 
morpholine), 3.17 (6.8H, q, J = 7.3 Hz, CH2 TEA), 2.88 (4H, m, CH2 morpholine), 1.24 
(9.8H, t, CH3 TEA); 
31
P NMR (162 MHz; D2O) δ: 7.37; m/z (ESI) 541.0105 [M-H]
-
, 
C14H19IN6O7P
-
 requires 541.0103. 
Morpholin-4-yl-phosphonic acid mono-5′-[2-phenyl-9β-D-ribofuranosyl-adenine] 
(10b) 
 
The title compound was prepared according to the general synthetic procedure F, from 
7b (0.0075 g, 1 equiv.). The crude product was purified by purification method 1 (100% 
0.05 M TEAB over 100 mL, 0-50% MeOH against 0.05 M TEAB buffer over 250 mL, 
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isocratic 60% over 50 mL, flow: 2.5 mL/min, fraction size: 5 mL) to give 10b as a 
colourless oil (0.0086 g, 1.1 equiv. TEA, 98% yield). 
1
H NMR (400 MHz; D2O) δ: 8.28 
(1H, s, 8-H), 8.01 (2H, m, Ph), 7.45 (3H, m, Ph), 6.10 (1H, d, J1′,2′ = 4.2 Hz, 1′-H), 4.87 
(1H, apparent t, 2′-H), 4.63 (1H, apparent t, 3′-H), 4.30 (1H, m, 4′-H), 4.00 (2H, m, 5′-
H2), 3.37 (4H, m, CH2 morpholine), 2.98 (6.6H, q, J = 7.3 Hz, CH2 TEA), 2.76 (4H, m, 
CH2 morpholine), 1.16 (10.1H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR (162 MHz; D2O) δ: 
7.42; m/z (ESI) 491.1452 [M-H]
-
, C20H24N6O7P
-
 requires 491.1450. 
Morpholin-4-yl-phosphonic acid mono-5′-[6-phenyl-9β-D-ribofuranosyl-purine] 
(11a) 
 
The title compound was prepared according to the general synthetic procedure F, from 
8a (0.0191 g, 1 equiv.). The crude product was purified by purification method 1 (100% 
0.05 M TEAB over 100 mL, 0-50% MeOH against 0.05 M TEAB buffer over 250 mL, 
isocratic 60% over 50 mL, flow: 3 mL/min, fraction size: 5 mL) to give 11a as a 
colourless oil (0.0172 g, 1.2 equiv. TEA, 82% yield). 
1
H NMR (400 MHz; D2O) δ: 8.78 
(1H, s, 2-H), 8.68 (1H, s, 8-H), 8.05 (2H, m, Ph), 7.58 – 7.45 (3H, m, Ph), 6.16 (1H, d, 
J1′,2′ = 4.6 Hz, 1′-H), 4.53 (1H, t, J = 4.9 Hz, 3′-H), 4.35 (1H, m, 4′-H), 4.12 – 3.96 (2H, 
m, 5′-H2), 3.48 (4H, m, CH2 morpholine), 3.16 (7.4H, q, J = 7.3 Hz, CH2 TEA), 2.87 
(4H, m, CH2 morpholine), 1.24 (11.6H, t, J = 7.2 Hz, CH3 TEA); 
31
P NMR (162 MHz; 
D2O) δ: 7.40; m/z (ESI) 476.1339 [M-H]
-
, C20H23N5O7P
-
 requires 476.1341. 
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Morpholin-4-yl-phosphonic acid mono-5′-[6-(pyrrol-2-yl)-9β-D-ribofuranosyl-
purine] (11b) 
 
The title compound was prepared according to the general synthetic procedure F, from 
8b (0.015 g, 1 equiv.). The crude product was purified by purification method 1 (100% 
0.05 M TEAB over 100 mL, 0-50% MeOH against 0.05 M TEAB buffer over 250 mL, 
isocratic 60% over 50 mL, flow: 3 mL/min, fraction size: 5 mL) to give 11b as a 
colourless oil (0.0132 g, 1.1 equiv. TEA, 88% yield). 
1
H NMR (400 MHz; D2O) δ: 8.54 
(1H, s, 2-H), 8.52 (1H, s, 8-H), 7.19 (2H, m, 5-H pyrrole, 3-H pyrrole), 6.39 (1H, s, 4-H 
pyrrole), 6.09 (1H, d, J1′,2′ = 4.6 Hz, 1′-H), 4.52 (1H, t, J = 4.9 Hz, 3′-H), 4.34 (1H, m, 
4′-H), 4.11 – 3.92 (2H, m, 5′-H2), 3.49 (4H, m, CH2 morpholine), 3.15 (6.3H, q, J = 7.3 
Hz, CH2 TEA), 2.85 (4H, m, CH2 morpholine), 1.23 (10.1H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR (162 MHz; D2O) δ: 7.41. 
Morpholin-4-yl-phosphonic acid mono-5′-[8-phenyl-9β-D-ribofuranosyl-adenine] 
(12b)
112
 
 
The title compound was prepared according to the general synthetic procedure F, from 
9b (0.0092 g, 1 equiv.) by NaI precipitation. 12b was obtained as sodium salt in 
quantitative yield. 
1
H NMR (400 MHz; D2O) δ: 8.23 (1H, s, 2-H), 7.74 – 7.46 (5H, m, 
Ph), 5.86 (1H, d, J1′,2′ = 5.3 Hz, 1′-H), 5.30 (1H, apparent t, 2′-H), 4.58 (1H, m, 3′-H), 
Chapter 7 
 
218 
 
4.17 – 3.95 (3H, m, 4′-H, 5′-H2), 3.46 (4H, m, CH2 morpholine), 2.82 (4H, m, CH2 
morpholine); m/z (ESI) 491.1452 [M-Na]
-
, C20H24N6O7P
-
 requires 491.1450. 
Morpholin-4-yl-phosphonic acid mono-5′-[8-(3-(N-Boc-aminomethyl)phenyl)-9β-
D-ribofuranosyl-adenine] (12c) 
 
The title compound was prepared according to the general synthetic procedure F, from 
9c (0.0425 g, 1 equiv.). The crude product was purified by purification method 1 (0-
50% MeOH against 0.05 M TEAB buffer over 300 mL, then 50-60% over 100 mL, 
flow: 3 mL/min, fraction size: 5 mL) to give 12c as a colourless oil (1.3 equiv. TEA, 
quantitative yield).
 1
H NMR (400 MHz; CD3OD) δ: 8.26 (1H, s, 2-H), 7.89 – 7.48 (4H, 
m, Ph), 5.86 (1H, d, 1′-H), 5.58 (1H, apparent t, 2′-H), 4.60 (1H, m, 3′-H), 4.51 – 3.85 
(5H, m, 4′-H, 5′-H2, CH2NHBoc), 3.55 (4H, m, CH2 morpholine), 2.91 (4H, m, CH2 
morpholine), 3.06 (8H, q, J = 7.3 Hz, CH2 TEA), 1.45 (9H, s, CH3 Boc), 1.24 (11.8H, t, 
J = 7.3 Hz, CH3 TEA). 
Morpholin-4-yl-phosphonic acid mono-5′-[8-(pyridin-3-yl)-9β-D-ribofuranosyl-
adenine] (12e) 
 
The title compound was prepared according to the general synthetic procedure F, from 
9e (0.0123 g, 1 equiv.) by NaI precipitation. 12e was obtained as sodium salt in 
quantitative yield. 
1
H NMR (400 MHz; D2O) δ: 8.84 (1H, m, 2-H pyridine), 8.71 (1H, 
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m, 6-H pyridine), 8.20 (1H, s, 2-H), 8.19 – 8.04 (1H, m, 5-H pyridine), 5.81 (1H, d, 1′-
H), 5.38 (1H, m, 2′-H), 4.62 (1H, m, 3′-H), 4.26 – 3.90 (3H, m, 4′-H, 5′-H2), 3.48 (4H, 
m, CH2 morpholine), 2.84 (4H, m, CH2 morpholine). 
Morpholin-4-yl-phosphonic acid mono-5′-[8-(pyrrol-2-yl)-9β-D-ribofuranosyl-
adenine] (12h) 
 
The title compound was prepared according to the general synthetic procedure F, from 
9h (0.0417 g, 1 equiv.) by purification method 1 (0-50% MeOH against 0.05 M TEAB 
buffer over 300 mL, then 50-60% over 100 mL, flow: 3 mL/min, fraction size: 5 mL) to 
give 12h as a colourless oil (1.3 equiv. TEA, quantitative yield). 
1
H NMR (400 MHz; 
D2O) δ: 8.16 (1H, s, 2-H), 7.13 (1H, s, 5-H pyrrole), 6.82 (1H, s, 3-H pyrrole), 6.35 
(1H, s, 4-H pyrrole), 6.08 (1H, br s, 1′-H), 5.44 (1H, br s, 2′-H), 4.42 – 3.89 (4H, m, 3′-
H, 4′-H, 5′-H2), 3.36 (4H, m, CH2 morpholine), 2.72 (4H, m, CH2 morpholine), 3.15 
(7.6H, q, J = 7.3 Hz, CH2 TEA), 1.21 (11.4H, t, J = 7.3 Hz, CH3 TEA). 
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P
1
-(2-Iodo-adenine-9β-D-ribofuranos-5′-yl)-P2-(nicotinamide-1β-D-ribofuranos-5′-
yl) pyrophosphate (13a)  
 
The title compound was prepared according to the general synthetic procedure G, from 
10a (0.0134 g, 1 equiv.) and β-NMN (2.4 equiv.). The reaction was stirred overnight. 
The crude product was purified by purification method 1 (0-50% MeOH against 0.05 M 
TEAB buffer over 360 mL, isocratic 50% over 40 mL, flow: 3 mL/min, fraction size: 5 
mL) and treated with Chelex to give 13a as a colourless oil (0.0093 g, 0.2 equiv. TEA, 
53% yield). 
1
H NMR (400 MHz; D2O) δ: 9.31 (1H, s, 2N-H), 9.06 (1H, s, 6N-H), 8.87 
(1H, m, 4N-H), 8.31 (1H, s, 8-H), 8.21 (1H, m, 5N-H), 6.02 (1H, d, J1′′,2′′ = 5.0 Hz, 1′′-
H), 5.91 (1H, d, J1′,2′ = 5.3 Hz, 1′-H), 4.74 (1H, br s, 2′-H), 4.54 – 3.98 (9H, m, 2′′-H, 3′-
H, 3′′-H, 4′-H, 4′′-H, 5′-H2, 5′′-H2), 1.24 (1.8H, t, J = 7.3 Hz, CH3 TEA); 
13
C NMR (126 
MHz; D2O) δ: 156.87, 147.44, 143.83, 141.65, 138.06, 130.41, 121.21, 101.62, 98.90, 
88.71, 88.27, 85.50, 79.19, 75.49, 72.29, 71.99, 67.03, 66.57, 60.58, 9.07; 
31
P NMR 
(162 MHz; D2O) δ: -11.4, -11.2; m/z (ESI) 787.9967 [M-2H]
-
, C21H25IN7O14P2
-
 requires 
787.9985. 
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P
1
-(2-Phenyl-adenine-9β-D-ribofuranos-5′-yl)-P2-(nicotinamide-1β-D-ribofuranos-
5′-yl) pyrophosphate (13b) 
 
The title compound was prepared according to the general synthetic procedure G, from 
10b (1.7 equiv.) and β-NMN (0.0234 g, 1 equiv.). The reaction was stirred overnight. 
The crude product was purified by purification method 1 (0-50% MeOH against 0.05 M 
TEAB buffer over 400 mL, flow: 3 mL/min, fraction size: 5 mL) to give 13b as a 
colourless oil (0.017 g, 1.18 equiv. TEA, 28% yield).
 1
H NMR (400 MHz; D2O) δ: 9.04 
(1H, br s, 2N-H), 8.83 (1H, br s, 6N-H), 8.61 (1H, m, 4N-H), 8.09 – 7.86 (3H, m, 5N-H, 
8-H, Ph), 7.45 (4H, m, Ph), 6.08 (1H, br s, 1′′-H), 5.76 (1H, br s, 1′-H), 4.84 (1H, br s, 
2′-H), 4.56 (1H, br s, 2′′-H), 4.43 – 4.01 (6H, m, 3′-H, 3′′-H, 4′-H, 4′′-H, 5′-H2, 5′′-H2), 
3.16 (7H, q, J = 7.2 Hz, CH2 TEA), 1.22 (10.6H, t, J = 7.2 Hz, CH3 TEA); 
13
C NMR 
(101 MHz; D2O) δ: 146.30, 142.68, 140.55, 138.29, 137.55, 137.23, 135.59, 131.55, 
131.52, 129.56, 129.49, 128.80, 100.61, 93.30, 87.75, 84.39, 78.37, 74.32, 71.26, 65.04, 
53.17, 52.17, 47.51, 9.07; 
31
P NMR (162 MHz; D2O) δ: -11.5, -11.7; m/z (ESI) 
738.1324 [M-H]
-
, C27H30N7O14P2
-
 requires 738.1331. 
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P
1
-(6-Phenyl-purine-9β-D-ribofuranos-5′-yl)-P2-(nicotinamide-1β-D-ribofuranos-
5′-yl) pyrophosphate (14a) 
 
The title compound was prepared according to the general synthetic procedure G, from 
11a (0.019 g, 1 equiv.) and β-NMN (1.8 equiv.). The reaction was stirred overnight. The 
crude product was purified twice by purification method 1 (0-50% MeOH against 0.05 
M TEAB buffer over 400 mL, flow: 3 mL/min, fraction size: 5 mL) and treated with 
Chelex to give 14a as a colourless oil (0.0171 g, 0.4 equiv. TEA, 56% yield). 
1
H NMR 
(400 MHz; D2O) δ: 9.18 (1H, s, 2N-H), 9.01 (1H, d, J6,5 = 5.8 Hz, 6N-H), 8.82 (1H, s, 2-
H), 8.78 (1H, s, 8-H), 8.66 (1H, d, J4,5 = 8.0 Hz, 4N-H), 8.11 (2H, d, J = 7.3 Hz, Ph), 
8.06 – 8.01 (1H, m, 5N-H), 7.57 (3H, m, Ph), 6.21 (1H, d, J1′′,2′′ = 5.4 Hz, 1′′-H), 5.88 
(1H, d, J = 4.2 Hz, 1′-H), 4.55 – 4.09 (10H, m, 2′-H, 2′′-H, 3′-H, 3′′-H, 4′-H, 4′′-H, 5′-
H2, 5′′-H2), 3.24 (2.4H, q, J = 7.3 Hz, CH2 TEA), 1.22 (4.1H, t, J = 7.2 Hz, CH3 TEA). 
13
C NMR (126 MHz; D2O) δ: 162.12, 156.90, 153.67, 153.43, 147.40, 146.20, 144.11, 
141.19, 138.05, 135.24, 133.34, 132.02, 131.14, 131.00, 130.54, 130.10, 101.56, 98.89, 
88.75, 85.62, 79.13, 75.74, 72.09, 67.00, 66.49, 60.58, 48.24, 9.07; 
31
P NMR (162 
MHz; D2O) δ: -11.3 (d, JP,P = 20.3 Hz), -11.7 (d, JP,P = 20.7 Hz); m/z (ESI) 723.1210 
[M-2H]
-
, C27H29N6O14P2
-
 requires 723.1222. 
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P
1
-[6-(Pyrrol-2-yl)-purine-9β-D-ribofuranos-5′-yl]-P2-[nicotinamide-1β-D-
ribofuranos-5′-yl] pyrophosphate (14b) 
 
The title compound was prepared according to the general synthetic procedure G, from 
11b (0.0084 g, 1 equiv.) and β-NMN (2.1 equiv.). The reaction was stirred overnight. 
The crude product was purified by purification method 1 (0-50% MeOH against 0.05 M 
TEAB buffer over 400 mL, flow: 3 mL/min, fraction size: 5 mL) to give 14b as a 
colourless oil (0.0132 g, 1.3 equiv. TEA, 87% yield). 
1
H NMR (400 MHz; D2O) δ: 9.11 
(1H, s, 2N-H), 8.94 (1H, d, J6,5 = 5.1 Hz, 6N-H), 8.69 (1H, s, 2-H), 8.61 (1H, s, 8-H), 
8.57 (1H, d, J = 7.7 Hz, 4N-H), 7.90 (1H, m, 5N-H), 7.23 (1H, s, 5-H pyrrole), 7.20 (1H, 
d, J3,4 = 3.1 Hz, 3-H pyrrole), 6.43 (1H, m, 4-H pyrrole), 6.17 (1H, d, J1′′,2′′ = 5.8 Hz, 1′′-
H), 5.91 (1H, d, J1′,2′ = 4.4 Hz, 1′-H), 4.60 – 4.12 (10H, m, 2′-H, 2′′-H, 3′-H, 3′′-H, 4′-H, 
4′′-H, 5′-H2, 5′′-H2), 3.18 (6.2H, q, J = 7.3 Hz, CH2 TEA), 1.25 (12H, t, J = 7.3 Hz, CH3 
TEA); 
13
C NMR (126 MHz; D2O) δ: 153.21, 151.85, 147.85, 146.39, 144.16, 143.33, 
143.31, 140.35, 129.02, 127.81, 127.11, 126.18, 116.04, 112.16, 101.03, 98.14, 87.89, 
87.59, 85.07, 78.47, 74.90, 71.57, 71.37, 59.83, 47.50, 9.07; 
31
P NMR (162 MHz; D2O) 
δ: -11.4, -11. 6; m/z (ESI) 714.1311 [M]+, C25H30N7O14P2
+
 requires 714.1320. 
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P
1
-(8-Phenyl-adenine-9β-D-ribofuranos-5′-yl)-P2-(nicotinamide-1β-D-ribofuranos-
5′-yl) pyrophosphate (15b)112, 172 
 
The title compound was prepared according to the general synthetic procedure G, from 
12b (1.2 equiv.) and β-NMN (0.0038 g, 1 equiv.). The reaction was stirred overnight. 
The crude product was purified by purification method 1 (0% MeOH over 50 mL, 0-
40% MeOH against 0.05 M TEAB buffer over 350 mL, flow: 3 mL/min, fraction size: 5 
mL) to give 15b as a colourless oil (0.004 g, 1.18 equiv. TEA, 41% yield). 
1
H NMR 
(400 MHz; D2O) δ: 9.21 (1H, s, 2N-H), 9.06 (1H, d, J6,5 = 6.4 Hz, 6N-H), 8.68 (1H, m, 
J4,5 = 8.1 Hz, J4.6 = 1.3 Hz, J4,2 = 1.5 Hz, 4N-H), 8.18 (1H, s, 2-H), 8.16 – 8.10 (1H, m, 
5N-H), 7.65 – 7.50 (5H, m, Ph), 5.90 (1H, d, J1′′,2′′ = 5.1 Hz, 1′′-H), 5.79 (1H, d, J1′,2′ = 
5.9 Hz, 1′-H), 5.14 (1H, apparent t, 2′-H), 4.43 – 4.06 (9H, m, 2′′-H, 3′-H, 3′′-H, 4′-H, 
4′′-H, 5′-H2, 5′′-H2), 3.14 (6.8H, q, J = 7.3 Hz, CH2 TEA), 1.22 (10.6H, t, J = 7.3 Hz, 
CH3 TEA); 
13
C NMR (150.90 MHz; D2O) δ: 154.05, 153.70, 153.30, 150.91, 146.55, 
143.18, 140.61, 132.04, 130.39, 130.25, 129.92, 129.63, 128.46, 119.14, 100.88, 89.82, 
89.61, 87.85, 83.78, 78.41, 71.32, 71.23, 71.14, 70.38, 70.23, 66.61, 65.69, 59.73, 
47.51, 9.07; 
31
P NMR (162 MHz; D2O) δ: -11.7 (d, JP,P = 20.6 Hz); -11.3 (d, JP,P = 20.6 
Hz); m/z (ESI) 738.1332 [M-2H]
-
, C27H30N7O14P2
-
 requires 738.1331; HPLC: retention 
time 10.34 min (79.4%); TLC: Rf 0.43 (iPA/H2O/NH4OH 6:3:1). 
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P
1
-{8-[3-(N-Boc-aminomethyl)phenyl]-adenine-9β-D-ribofuranos-5′-yl}-P2-
{nicotinamide-1β-D-ribofuranos-5′-yl} pyrophosphate (15c)172 
 
The title compound was prepared according to the general synthetic procedure G, from 
12c (1.2 equiv.) and β-NMN (0.0176 g, 1 equiv.). The reaction was stirred overnight. 
The crude product was purified by purification method 1 (0-10% MeOH against 0.05 M 
TEAB buffer over 190 mL, 10-30% over 50 mL, isocratic 30% over 50 mL, flow: 3 
mL/min, fraction size: 5 mL) to give 15c as a colourless oil (0.0331 g, 1.7 equiv. TEA, 
61% yield) and treated with Chelex to obtain the sodium salt. 
1
H NMR (400 MHz; D2O) 
δ: 9.16 (1H, s, 2N-H), 8.99 (1H, br s, 6N-H), 8.60 (1H, m, 4N-H), 8.07 (2H, m, 2-H, 5N-
H), 7.54 – 7.26 (4H, m, Ph), 5.85 (1H, br s, 1′′-H), 5.71 (1H, br s, 1′-H), 5.16 (1H, br s, 
2′-H), 4.49 – 3.77 (11H, m, 2′′-H, 3′-H, 3′′-H, 4′-H, 4′′-H, 5′-H2, 5′′-H2, CH2NH2), 1.33 
(9H, s, CH3 Boc); 
13
C NMR (150.90 MHz; D2O) δ: 158.95, 155.55, 153.21, 152.45, 
150.65, 148.28, 146.33, 142.95, 140.67, 140.41, 137.07, 134.10, 130.20 – 128.23, 
124.83, 118.92, 101.81, 100.66, 96.99, 89.71, 87.67, 83.67, 81.92, 78.22, 75.81, 71.34 – 
70.15, 66.34, 65.39, 44.10, 28.36; 
31
P NMR (162 MHz; D2O) δ: -11.3 (d, JP,P = 20.6 
Hz); -11.1 (d, JP,P = 20.6 Hz); m/z (ESI) 867.2120 [M-2H]
-
, C33H41N8O16P2
-
 requires 
867.2121; HPLC: retention time 17.96 min (99.5%); TLC: Rf 0.75 (iPA/H2O/ NH4OH 
6:3:1). 
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P
1
-[8-(Pyridin-3-yl)-adenine-9β-D-ribofuranos-5′-yl]-P2-[nicotinamide-1β-D-
ribofuranos-5′-yl] pyrophosphate (15e)172 
 
The title compound was prepared according to the general synthetic procedure G, from 
12e (0.0143 g, 1 equiv.) and β-NMN (1.1 equiv.). The reaction was stirred overnight. 
The crude product was purified by purification method 1 (0-10% MeOH against 0.05 M 
TEAB buffer over 300 mL, then 10-12% MeOH over 100 mL, flow: 3 mL/min, fraction 
size: 5 mL) to give 15e as a colourless oil (0.0068 g, 1.18 equiv. TEA, 24% yield). 
1
H 
NMR (400 MHz; D2O) δ: 9.29 (1H, s, 2N-H), 9.14 (1H, d, J6,5 = 6.0 Hz, 6N-H), 9.01 – 
8.65 (3H, m, 4N-H, 2-H pyridine, 6-H pyridine), 8.34 – 8.13 (3H, m, 2-H, 5N-H, 4-H 
pyridine), 7.70 (1H, br s, 5-H pyridine), 6.01 (1H, d, J1′′,2′′ = 5.1 Hz, 1′′-H), 5.80 (1H, d, 
J1′,2′ = 5.7 Hz, 1′-H), 5.24 (1H, apparent t, 2′-H), 4.51 – 4.11 (9H, m, 2′′-H, 3′-H, 3′′-H, 
4′-H, 4′′-H, 5′-H2, 5′′-H2), 3.19 (6.9H, q, J = 7.3 Hz, CH2 TEA), 1.27 (10.6H, t, J = 7.3 
Hz, CH3 TEA); 
13
C NMR (150.90 MHz; D2O) δ: 155.89, 153.53, 151.01, 150.53, 
149.62, 146.60, 143.28, 140.56, 139.32, 134.53, 129.60, 119.50, 100.89, 89.71, 87.92, 
84.08, 78.44, 71.38, 70.28, 66.41, 65.65, 47.52, 9.07; m/z (ESI) 739.1300 [M-2H]
-
, 
C26H29N8O14P2
-
 requires 739.1284; HPLC: retention time 7.07 min (95.8%); TLC: Rf 
0.62 (iPA/H2O/NH4OH 6:3:1). 
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P
1
-[8-(2,4-DMT-pyrimidin-5-yl)-adenine-9β-D-ribofuranos-5′-yl]-P2-[nicotinamide-
1β-D-ribofuranos-5′-yl] pyrophosphate (15g)172 
 
The title compound was prepared according to the general synthetic procedure G, from 
12g (1.5 equiv.) and β-NMN (0.0112 g, 1 equiv.). The reaction was stirred overnight. 
The crude product was purified by purification method 1 (0-22% MeOH against 0.05 M 
TEAB buffer over 300 mL, 22-40% over 50 mL, isocratic 40% over 50 mL, flow: 3 
mL/min, fraction size: 5 mL) to give 15g as a colourless oil (0.0139 g, 1.7eq TEA, 43% 
yield) and treated with Chelex to obtain the sodium salt. 
1
H NMR (400 MHz; D2O) δ: 
9.25 (1H, s, 2N-H), 9.08 (1H, m, 6N-H), 8.68 (1H, m, 4N-H), 8.33 (1H, m, 6-H 
pyrimidine), 8.10 (2H, br s, 2-H, 5N-H), 6.01 (1H, d, J1′′,2′′ = 5.4 Hz, 1′′-H), 5.49 (1H, d, 
J1′,2′ = 5.5 Hz, 1′-H), 5.08 (1H, apparent t, 2′-H), 4.53 – 3.85 (15H, m, 2′′-H, 3′-H, 3′′-H, 
4′-H, 4′′-H, 5′-H2, 5′′-H2, 2 OCH3); 
13
C NMR (150.90 MHz; D2O) δ: 169.85, 167.00, 
161.02, 155.64, 153.60, 152.48, 150.47, 148.31, 146.40, 143.03, 137.11, 134.25, 
129.37, 124.87, 119.49, 104.96, 101.81, 100.69, 97.02, 90.06, 87.71, 83.85, 81.78, 
78.28, 75.82, 71.78 – 70.43, 66.90 – 65.50, 59.66, 56.29, 55.60; 31P NMR (162 MHz; 
D2O) δ: -11.3 (d, JP,P = 20.6 Hz); -11.1 (d, JP,P = 20.6 Hz); m/z (ESI) 800.1447 [M-2H]
-
, C27H32N9O16P2
-
 requires 800.1448; HPLC: retention time 11.41 min (96.5%); TLC: Rf 
0.69 (iPA/H2O/ NH4OH 6:3:1). 
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P
1
-[8-(Pyrrol-2-yl)-adenine-9β-D-ribofuranos-5′-yl]-P2-[nicotinamide-1β-D-
ribofuranos-5′-yl] pyrophosphate (15h)172 
 
The title compound was prepared according to the general synthetic procedure G, from 
12h (1.5 equiv.) and β-NMN (0.0332 g, 1 equiv.). The reaction was stirred overnight. 
The crude product was purified by purification method 1 (0-10% MeOH against 0.05 M 
TEAB buffer over 400 mL, flow: 3 mL/min, fraction size: 5 mL) and 2 (0-80% 1 M 
TEAB buffer against H2O over 400 mL, flow: 3 mL/min, fraction size: 5 mL), to give 
15h as a colourless oil (0.0245 g, 1.01 equiv. TEA, 30% yield). 
1
H NMR (400 MHz; 
D2O) δ: 9.09 (1H, s, 2N-H), 8.92 (1H, d, J5,6 = 6.2 Hz, 6N-H), 8.60 (1H, d, J4,5 = 8.1 Hz, 
4N-H), 8.09 (1H, s, 2-H), 8.05 (1H, dd, J5,6 = 6.5 Hz, J5,4 = 7.8 Hz, 5N-H), 7.05 (1H, dd, 
J5,4 = 2.4 Hz, J5,3 = 1.2 Hz, 5-H pyrrole), 6.57 (1H, dd, J3,4 = 3.6 Hz, J3,5 = 1.1 Hz, 3-H 
pyrrole), 6.24 (1H, dd, J3,4 = 3.4 Hz, J5,4 = 2.9 Hz, 4-H pyrrole), 5.91 (1H, d, J1′′,2′′ = 6.1 
Hz, 1′′-H), 5.73 (1H, d, J1′,2′ = 4.8 Hz, 1′-H), 5.33 (1H, apparent t, 2′-H), 4.54 (1H, dd, J 
= 4.56 and 6.1 Hz, 3′-H), 4.41 – 3.98 (8H, m, 2′′-H, 3′′-H, 4′-H, 4′′-H, 5′-H2, 5′′-H2), 
3.15 (6.08H, q, J = 7.3 Hz, CH2 TEA), 1.24 (9.14H, t, J = 7.3 Hz, CH3 TEA); 
13
C NMR 
(150.90 MHz; D2O) δ: 154.89, 151.98, 150.90, 147.10, 146.40, 142.91, 140.48, 134.14, 
129.64, 124.27, 119.43, 113.82, 110.00, 100.81, 89.46, 87.79, 87.73, 83.81, 83.76, 
78.41, 71.24, 70.89, 70.02, 66.47, 65.61, 59.60, 47.52, 9.07; 
31
P NMR (162 MHz; D2O) 
δ: -11.9 (d, JP,P = 20.9 Hz); -11.4 (d, JP,P = 21.0 Hz); m/z (ESI) 727.1276 [M-2H]
-
, 
C25H29N8O14P2
-
 requires 727.1284; HPLC: retention time 7.68 min (99.8%). 
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7.2.6 Synthesis of 8-(pyrrol-2-yl) cADPR (24) 
8-(Pyrrol-2-yl)-adenine-[P
1
-(9β-D-ribofuranos-5′-yl)-P2-(1β-D-ribofuranos-5′-yl)] 
pyrophosphate (24)
246
 
 
A stock solution of ADPRC from Aplysia californica (50 U/mL) was prepared in 
HEPES buffer (50 mM, pH 7.4). To a solution of 15h (0.005 g) in HEPES buffer (13 
mL, 50 mM, pH 7.4) an appropriate volume of ADPRC stock was added to have a final 
enzyme concentration of 0.192 U/mL. The reaction was incubated for 1 h at room 
temperature until HPLC analysis indicated completion of the reaction. Afterwards, the 
solution was evaporated to dryness and the crude product purified by purification 
method 2 (0-80% 1 M TEAB buffer against H2O over 240 mL, flow rate: 2 mL/min, 
fraction size: 3 mL) to give 24 as a white residue (0.0051 g, 2.76 equiv. TEA, 96% 
yield). 
1
H NMR (400 MHz; D2O) δ: 8.98 (1H, s, 2-H), 7.23 (1H, dd, J5,3 = 1.4 Hz, 5-H 
pyrrole), 6.92 (1H, dd, J3,4 = 3.0 Hz, 3-H pyrrole), 6.45 (1H, dd, J4,3 = 3.1 Hz, J4,5 = 2.9 
Hz, 4-H pyrrole), 6.42 (1H, d, J = 5.3 Hz, 1′-H), 6.16 (1H, d, J = 3.3 Hz, 1′′-H), 5.53 
(1H, apparent t, 2′-H), 4.50 – 4.09 (9H, m, 2′′-H, 3′-H, 3′′-H, 4′-H, 4′′-H, 5′-H2, 5′′-H2), 
3.26 (16.6H, q, J = 7.3 Hz, CH2 TEA), 1.24 (24.8H, t, J = 7.3 Hz, CH3 TEA); 
31
P NMR 
(162 MHz; CD3OD) δ: -10.2 (d, JP,P = 11.7 Hz), -9.8 (d, JP,P = 11.3 Hz); m/z (ESI) 
607.0947 [M]
+
, C19H25N6O13P2
+
 requires 607.0949; HPLC: retention time 8.7 min. 
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7.3 Quantum yield measurements for AMP and NAD+ derivatives 
Fluorescence quantum yields (Фx) of AMP and NAD
+
 derivatives were determined by 
the comparative method,
204, 205
 using 2-amino pyridine in 0.1 M H2SO4 (Ф = 0.60) and 
tryptophan in water, pH 7.2 (Ф = 0.14), as reference standards. Absorbance spectra for 
all the compounds were recorded at room temperature from the most concentrated (Abs 
≤ 1) to the most diluted solution between 200 and 800 nm. Emission spectra of the same 
solutions were recorded at room temperature between 200 and 900 nm at λex maxima; 
the emission spectra for the same compound must be recorded with constant slit width 
to make valid the obtained quantum yield values. The integrated areas under the 
emission spectra were plotted as function of the integrated areas under the absorbance 
spectra at corresponding concentrations. The obtained gradient, Gradx, was then 
substituted in equation [1] (see page 94), where Gradst is known from the calibration of 
the two standards, performed with the same protocol, and st is known from the 
literature. After correction for the refractive index, η, of the solvents used in the 
measurements, it is possible to calculate x from equation [1]. 
7.4 Chemical hydrolysis of NAD+ derivatives172 
For the monitoring by fluorescence of the chemical hydrolysis of NAD
+
 derivatives, 0.1 
N NaOH solution was added to the cuvette and the reaction was started by the addition 
of a requisite volume of aqueous solution of the compounds to give a final 
concentration of 0.8 μM. The basic hydrolysis was monitored at λex and λem maxima for 
each compound at room temperature. In the case of 15h, the whole emission spectra at 
λex maxima was recorded over time (data not shown).  
The HPLC time-course for the basic hydrolysis of 15h was performed on a 49.5 μM 
solution in 0.1 N NaOH at room temperature. Each sample was quenched with an 
equivalent volume of 0.1 N HCl prior to injection into the HPLC. (for the HPLC 
method, see 7.1.2; retention times: NaM 3.8 min, 15h 7.3 min, 23 8.0 min). Peak areas 
were fitted to a 1
st
 order rate equation using GraFit5. The estimated rate constant for the 
formation of NaM, kNaM, from fitting the peak areas to a 1
st
 order rate equation is 0.0672 
min
-1
, and the t1/2 = 10.31 min, in agreement within error of each other with the 
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estimated rate constant for the formation of 23, k23, 0.0586 min
-1
, and the t1/2 = 11.83 
min. 
7.5 Protocols for HPLC assays of enzyme activities172 
7.5.1 Nucleotide pyrophosphatase (NPP) 
Separate stock solutions of 15h (82.48 μM) and NPP from Crotalus adamanteus venom 
(8.39 U/mL) were prepared in Tris/HCl buffer (50 mM, pH 8) containing MgCl2 (10 
mM). The reaction was started by addition of an appropriate volume of 15h stock (300 
μL, 24.74 μM) to the enzyme solution (1.2 μL, 0.01 U/mL) in the reaction buffer to give 
a final volume of 1 mL (all concentrations are final concentrations). The reaction was 
incubated at 30 ºC for 90 min. Samples were drawn at different time points and stored 
immediately on dry-ice for 20 min, to stop the enzymatic reaction. Samples were diluted 
as appropriate and analysed by HPLC (for the HPLC method, see 7.1.2; retention times: 
15h 6.5 min, β-NMN 1.8 min, 9h 7.7 min). The estimated rate constant k for the 
formation of 9h was obtained by fitting the peak areas to a 1
st
 order rate equation (k9h 
0.2457 min
-1
, t1/2 2.82 min) using Grafit5. 
7.5.2 NAD+-glycohydrolase (NADase) 
A stock solution of 15h (82.48 μM) was prepared in Tris/HCl buffer (50 mM, pH 8). 
NADase from porcine brain (0.01 U/mg) was accurately weighed and suspended in 
Tris/HCl buffer (50 mM, pH 8) and incubated for a few minutes at 37 ºC. The reaction 
was started by addition of an appropriate volume of 15h stock (300 μL, 24.74 μM) to 
the enzyme suspension (0.9 mg, 0.009 U/mL) in the reaction buffer to give a final 
volume of 1 mL (all concentrations are final concentrations). Samples were drawn at 
different time points and stored immediately on dry-ice for 20 min, to stop the 
enzymatic reaction. Samples were centrifuged, diluted as appropriate and analysed by 
HPLC (for the HPLC method, see 7.1.2; retention times: 15h 7.3 min, NaM 3.8 min, 23 
8.0 min). The estimated rate constants for the formation of NaM, kNaM, and the 
formation of 23, k23, were obtained by fitting the peak areas to a 1
st
 order rate equation 
(kNaM 0.1750 min
-1
, t1/2 3.96 min; k23 0.1696 min
-1
, t1/2 = 4.09 min) using Grafit5. In a 
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control experiment, 15h was incubated in Tris/HCl buffer (50 mM, pH 8) at 37 ºC over 
1 h without degradation. 
7.5.3 ADP-ribosyl cyclase (ADPRC) 
Separate stock solutions of 15h (82.48 μM) and ADPRC from Aplysia californica (50 
U/mL) were prepared in HEPES buffer (50 mM, pH 7.4). The reaction was started by 
addition of an appropriate volume of 15h stock (75 μL, 12.37 μM) to the enzyme 
solution (0.5 μL, 0.05 U/mL) in the reaction buffer to give a final volume of 500 μL (all 
concentrations are final concentrations). The reaction was incubated at 26 ºC for 1 h. 
Samples were drawn at different time points and stored immediately on dry-ice for 20 
min, to stop the enzymatic reaction. Samples were diluted as appropriate and analysed 
by HPLC (for the HPLC method, see 7.1.2; retention times: 15h 6.6 min, NaM 3.8 min, 
24 8.7 min). The estimated rate constants for the formation of NaM, kNaM, and the 
formation of 24, k24, were obtained by fitting the peak areas to a 1
st
 order rate equation 
(kNaM 0.3525 min
-1
, t1/2 1.97 min; k24 0.1700 min
-1
, t1/2 4.08 min) using Grafit5. 
7.6 Protocols for fluorescent assays of enzyme activities172 
7.6.1 Nucleotide pyrophosphatase (NPP) 
Separate stock solutions of 15h (17.6 μM), 9h (9.4 μM) and NPP from Crotalus 
adamanteus venom (8.39 U/mL) were prepared in Tris/HCl buffer (50 mM, pH 8) 
containing MgCl2 (10 mM), unless stated otherwise. β-NAD
+
 (964.7 μM), AMP (1730 
μM) and β-NMN (478.8 μM) stock solutions were prepared in Milli-Q water, unless 
stated otherwise. In the kinetic experiments, the requisite volume of substrate 15h or 
product 9h was added to individual wells of a 96-well plate, and Tris/HCl buffer (50 
mM, pH 8) containing MgCl2 (10 mM) was added as required to give a final volume of 
100 μL. In the inhibition experiments, the requisite volume of substrate 15h and β-
NAD
+
, or AMP, or β-NMN was added to individual wells of a 96-well plate, and 
Tris/HCl buffer (50 mM, pH 8) containing MgCl2 (10 mM) was added as required to 
give a final volume of 100 μL. In each experiment, two calibration wells were included 
for the determination of sample concentration from fluorescence intensity: one well 
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contained only Tris/HCl buffer (50 mM, pH 8) and MgCl2 (10 mM) and gave the „zero‟ 
readout (negative control), and the second contained 9h (3 μM) inTris/HCl buffer (50 
mM, pH 8) and MgCl2 (10 mM) (positive control). Samples and fluorimeter readings 
were allowed to stabilize by placing the plate in the microplate reader at 30 ºC and 
taking readings (excitation 300 ± 5 nm, emission 410 ± 5 nm, gain 15%) until a stable 
signal was obtained (typically ca 60 min). The data collection program was re-started 
and, after 7 min, the enzyme reaction was initiated by addition of enzyme stock solution 
(20 μL, 0.007 U/mL per well). Fluorescence emission was recorded for 60 min. All 
samples, including controls, were recorded in duplicate, and the mean of the two 
readings processed. To convert [RFU] to 9h concentration [μM], it was assumed that 
there is very little contribution to fluorescence from 15h related to 9h. For each assay 
point, the fluorescence emission [RFU], Ft, was converted to 9h concentration [μM], 
[9h]t, using the equation [2] and with reference to the fluorescence from 9h (3 μM), 
F3μM. From the resulting plot of [9h] vs time, initial velocity can be calculated from 
linear region at the beginning of each trace.  
      
               
                 
         [2] 
For the determination of kinetic parameters, Km and Vmax, enzyme (0.007 U/mL) and 
15h (0.2 μM – 6.5 μM) in Tris/HCl buffer (50 mM, pH 8) containing MgCl2 (10 mM) 
were used (total volume per well: 120 μL, all concentrations are final concentrations). 
Kinetic parameters were reported as the mean (± SD) of at least two data sets. For the 
IC50 determination of β-NAD
+
, increasing concentrations of β-NAD+ (0 – 350 μM) were 
introduced into assays of 15h (4.4 μM) and NPP (0.007 U/mL). For the kinetic analysis 
of β-NAD+ inhibition, enzyme (0.007 U/mL), 15h (0.2 μM – 5 μM) and β-NAD+ (8 μM 
– 15 μM) in Tris/HCl buffer (50 mM, pH 8) containing MgCl2 (10 mM) were used (total 
volume per well: 120 μL, all concentrations are final concentrations). For the kinetic 
analysis of AMP inhibition, enzyme (0.007 U/mL), 15h (0.2 μM – 5 μM) and AMP (8 
μM – 40 μM) in Tris/HCl buffer (50 mM, pH 8) containing MgCl2 (10 mM) were used 
(total volume per well: 120 μL, all concentrations are final concentrations). For the 
kinetic analysis of β-NMN inhibition, enzyme (0.007 U/mL), 15h (0.2 μM – 5 μM) and 
Chapter 7 
 
234 
 
β-NMN (7 μM – 17 μM) in Tris/HCl buffer (50 mM, pH 8) containing MgCl2 (10 mM) 
were used (total volume per well: 120 μL, all concentrations are final concentrations).  
7.6.2 NAD+-glycohydrolase (NADase) 
A stock solution of 15h (6.3 μM) was prepared in Tris/HCl buffer (50 mM, pH 8), 
unless stated otherwise. In the kinetic experiments, an appropriate volume of Tris/HCl 
buffer (150 μL, 50 mM, pH 8) was added to individual wells of a 96-well plate. 
NADase from porcine brain (0.01 U/mg) was accurately weighed and suspended in 
Tris/HCl buffer (50 mM, pH 8) and incubated for several minutes at 37 ºC. The reaction 
was started by addition of an appropriate volume of 15h stock (1 mL, 5.25 μM) to the 
enzyme suspension (0.9 mg, 0.0075 U/mL) in the reaction buffer to give a final volume 
of 1.2 mL (all concentrations are final concentrations). Samples (100 μL) were drawn at 
different time points and stored immediately on dry-ice for 20 min, to stop the 
enzymatic reaction. Then, from each one, 50 μL was drawn and added to the wells to 
give a final volume of 200 μL. Fluorescence emission was recorded at 37 ºC (excitation 
300 ± 5 nm, emission 410 ± 5 nm, gain 15%).  
7.6.3 ADP-ribosyl cyclase (ADPRC) 
Separate stock solutions of 15h (82.48 μM) and ADPRC (50 U/mL) from Aplysia 
californica were prepared in HEPES buffer (50 mM, pH 7.4), unless stated otherwise. 
In the kinetic experiments, the requisite volume of substrate 15h was added to 
individual wells of a 96-well plate, and HEPES buffer (50 mM, pH 7.4) was added as 
required to give a final volume of 198 μL. In each experiment, two calibration wells 
were included for the determination of sample concentration from fluorescence 
intensity: one well contained only HEPES buffer (50 mM, pH 7.4) and gave the „zero‟ 
readout (negative control), and the second contained 15h (34 μM) in HEPES buffer (50 
mM, pH 7.4) (positive control). Samples and fluorimeter readings were allowed to 
stabilize by placing the plate in the microplate reader at 25 ºC and taking readings 
(excitation 300 ± 5 nm, emission 410 ± 5 nm, gain 15%) until a stable signal was 
obtained (typically ca 40 min). The data collection program was re-started and, after 17 
min, the enzyme reaction was initiated by addition of enzyme stock solution (2 μL, 
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0.075 U/mL per well). Fluorescence emission was recorded for 80 min. All samples, 
including controls, were recorded in duplicate, and the mean of the two readings 
processed. To convert [RFU] to 15h concentration [μM], it was assumed that there is 
very little contribution to fluorescence from the reaction product, 24. For each assay 
point, the fluorescence emission [RFU], Ft, was converted to 15h concentration [μM], 
[15h]t, using the equation [3] and with reference to the fluorescence from 15h (34 μM), 
F34μM: From the resulting plot of [15h] vs time, initial velocity can be calculated from 
linear region at the beginning of each trace. 
       
               
                  
          [3] 
For the determination of kinetic parameters, Km and Vmax, enzyme (0.075 U/mL) and 
15h (2.1 μM – 33.9 μM) in HEPES buffer (50 mM, pH 7.4) were used (total volume per 
well: 200 μL, all concentrations are final concentrations). Kinetic parameters were 
reported as the mean (± SD) of at least two data sets. 
7.7 Escherichia coli DNA ligase (EcLigA)  
7.7.1 Expression and purification250 
The gene encoding DNA ligase from Escherichia coli (EcLigA) was previously cloned 
into pET-16b vector to introduce 10-His-tag at the N terminus of the protein and 
ampicillin resistance. The resulting plasmid, pRB20, was transformed in competent E. 
coli BL21 pLysS cells, plated on LB-agar containing chloramphenicol and ampicillin 
antibiotics. The plates were incubated at 37 °C overnight. Single colonies were 
inoculated into 5 mL LB media containing antibiotics, and incubated at 30 °C overnight. 
1 mL of overnight culture was inoculated into 100 mL LB media containing antibiotics, 
and incubated at 37 °C until growth had reached mid log phase (OD600 0.4 – 0.6). 
Therefore, IPTG was added to 400 μM final concentration to induce the protein over-
expression, and the culture incubated at 25 °C overnight. The culture was centrifuged 
and the pellets re-suspended in binding buffer (Table 7.2) and sonicated; the insoluble 
fraction was separated by centrifugation. The supernatant was filtered through a 0.45 
μm filter, then applied to a His-tag binding column, previously equilibrated with 
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binding buffer, to purify the over-expressed protein by affinity chromatography. 
Following sample loading, the column was rinsed with 10 mL binding buffer and 10 mL 
wash buffer to remove eventual proteins not-specifically interacting with the column 
resin; finally, the protein was eluted with 5 mL elution buffer (Table 7.2). The protein 
purity was confirmed by SDS-PAGE analysis. To desalt the protein from imidazole, 
size-exclusion chromatography was used. The protein concentration was determined 
using the Bradford method. Glycerol (30%) and DTT (1 mM) were added to the 
obtained protein, that was aliquoted and stored at -80 °C.  
 
Buffer Composition 
Binding buffer 5 mM imidazole, 0.5 M NaCl, 20 mM Tris/HCl pH 7.9 
Wash buffer 60 mM imidazole, 0.5 M NaCl, 20 mM Tris/HCl pH 7.9 
Elution buffer 1 M imidazole, 0.5 M NaCl, 20 mM Tris/HCl pH 7.9 
Table 7.2 Composition of buffers used for nickel-affinity chromatography. 
7.7.2 Preparation of DNA substrate 
A 40 bp double-stranded oligonucleotide containing a single-strand nick between bases 
18 and 19 was used as a substrate for the DNA ligation. It was obtained by annealing a 
18-mer (LigSub1) and a 22-mer (LigSub2) to a complementary 40-mer (LigSub1+2) in 
ratio 1:3:3 in 10 x TBE/KCl buffer (1.1 M Tris/borate pH 8.3, 25 mM EDTA, 1 M 
KCl): in particular, the 18-mer contained a fluorescein (F) molecule in 5′-position, and 
the 22-mer a phosphate group (Pi) in 5′-position (Table 7.3). The annealing was checked 
by native PAGE and the substrate stored at -20 °C. 
 
Oligonucleotide Sequence (5′ to 3′) 
LigSub1 F-GTA AAA CGA CGG CCA GTG 
LigSub2 Pi-AAT TCG AGC TCG GTA CCC GGG G 
LigSub1+2 CCC CGG GTA CCG AGC TCG AAT TCA CTG GCC GTC GTT TTA C 
Table 7.3 Oligonucleotides sequence used for the preparation of substrate for ligation assay. 
  
Chapter 7 
 
237 
 
7.7.3 Ligation assay 
Separate stock solutions of DNA substrate (5 μM), EcLigA (0.2 μM), β-NAD+ (181 
μM) and the different compounds (1 mM) were prepared in Milli-Q water. To test 
EcLigA activity, the requisite volumes of DNA substrate (0.75 μL, 0.125 μM) and β-
NAD
+
 (4.3 μL, 26 μM) were added to an appropriate volume of 1 x buffer (22 μL, 30 
mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL BSA) and incubated at 30 °C 
under shaking: the reaction was started with EcLigA addition (3 μL, 0.1 μM) to give a 
final volume of 30 μL (all concentrations are final concentrations). For the inhibition 
and the NNS activity experiments of C-2 and C-6 substituted derivatives, the requisite 
volumes of DNA substrate (1.5 μL, 0.5 μM), C-2 substituted derivatives (3 μL, 200 
μM), or C-6 substituted derivatives (3.75 μL, 250 μM), with/without β-NAD+ (2.15 μL, 
26 μM), were added to an appropriate volume of 1 x buffer (30 mM Tris/HCl pH 8, 4 
mM MgCl2, 1 mM DTT, 50 μg/mL BSA) to give a final volume of 11.25 μL; the 
reaction, incubated at 30 °C under shaking, was started with EcLigA addition (3.75 μL, 
0.05 μM) to give a final volume of 15 μL (all concentrations are final concentrations). 
For the inhibition and the NNS activity experiments of C-8 substituted derivatives, the 
requisite volumes of DNA substrate (0.75 μL, 0.125 μM), C-8 substituted derivatives 
(7.5 μL, 250 μM), with/without β-NAD+ (4.3 μL, 26 μM), were added to an appropriate 
volume of 1 x buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL 
BSA) to give a final volume of 27 μL; the reaction, incubated at 30 °C under shaking, 
was started with EcLigA addition (3 μL, 0.1 μM) to give a final volume of 30 μL (all 
concentrations are final concentrations). For the NNS activity experiments of 13a and 
13b, the requisite volumes of DNA substrate (1.5 μL, 0.5 μM), and 13a or 13b (0.75 – 
3.75 μL, 50 – 250 μM) were added to an appropriate volume of 1 x buffer (30 mM 
Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL BSA) to give a final volume of 
11.25 μL; the reaction, incubated at 30 °C under shaking, was started with EcLigA 
addition (3.75 μL, 0.05 μM) to give a final volume of 15 μL (all concentrations are final 
concentrations). In all the set of experiments, a control reaction was included to test 
EcLigA activity with only β-NAD+, not containing any tested compound. Samples were 
drawn at different time points and mixed with an equal volume of 1 x stop solution 
(deionized formamide, 0.5 M EDTA, 1 M NaOH, 20 mg bromophenol blue), then put in 
Chapter 7 
 
238 
 
ice. Afterwards, samples were run on a pre-warmed 15% polyacrylamide/urea 
denaturing gel.  
7.7.4 Gel electrophoresis 
For protein analysis, SDS-PAGE with 10% SDS-polyacrylamide resolving gel and 5% 
stacking gel was used. The protein samples were diluted with 4 x SDS-loading dye (200 
mM Tris, 8% SDS, 0.4% bromophenol blue, 40% glycerol, 20% DME) and loaded into 
the wells; a potential of 200 V was applied for 1 h in TGS buffer (25 mM Tris pH 8.3, 
192 mM glycine, 0.1% (w/v) SDS buffer). The gel was visualized by staining with 
Coomassie blue. 
For non-denaturing gel electrophoresis of DNA, or native PAGE, a 12% polyacrylamide 
gel was used. The DNA samples were diluted with 6 x loading dye (10 mM Tris/HCl 
pH 7.6, 0.03% bromophenol blue, 0.03% xylene, cyanol FF, 60% glycerol, 60 mM 
EDTA) and loaded into the wells; a potential of 50 V was applied for 3 h in TBE buffer 
(45 mM Tris/borate pH 8.3, 1.25 mM EDTA). The gel was visualized by fluorescence 
imaging using Molecular Dynamics Storm Phosphorimager. 
For denaturing gel electrophoresis of DNA, a 15% polyacrylamide/urea gel was used. 
The reaction samples were diluted with 1 x stop solution (20 mL deionized formamide, 
400 μL 0.5 M EDTA, 40 μL 1 M NaOH, 20 mg bromophenol blue), incubated at 95 °C 
for 5 min, and loaded into the wells of a pre-warmed denaturing gel; a potential of 400 
V was applied for 20 min in TBE buffer (45 mM Tris/borate pH 8.3, 1.25 mM EDTA). 
The gel was visualized by fluorescence imaging using Molecular Dynamics Storm 
Phosphorimager.  
7.7.5 Molecular modeling for DNA ligase 
All calculations were performed on an Intel Core Duo 2.8 Ghz MacBook Pro. The 
crystal structure of β-NAD+-bound DNA ligase from E.faecalis was obtained from the 
RCSB Protein Data Bank (PDB 1TAE). The protein was prepared for molecular 
modeling analysis using the MOE modeling package (CCG, Montreal, Canada). The 
ligand β-NAD+ and crystallographic water molecules were removed, leaving an empty 
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active center. Hydrogen atoms were added to the heavy atoms, and the residues were 
assigned with the appropriate protonation states at pH 7.4. The final protein was saved 
in TriposMol2 format and directly imported into the GOLD software package 
(CCDC,Cambridge, UK, Version 3.2) for subsequent docking calculations. 15h was 
built with the Builder module of MOE, and hydrogen atoms were assigned to all heavy 
atoms in the molecule: then, it was energy minimized using the MMFF94s force field 
and the conjugate gradient method, until the default derivative convergence criterion of 
0.01 kcal·mol
-1
·A was met. The phosphate groups were assigned a charge of −1, as 
appropriate at pH 7.4. The ligand file was exported into GOLD as Tripos Mol2 files. 
The ligand dockings into the catalytic site of 1TAE were performed using Gold Suite 
4.12 (CCDC, Cambridge, UK). The binding site was defined by the position of β-NAD+ 
in the original structure and the radius was set to 15 Å. All torsion angles in 15h were 
allowed to rotate freely. GoldScore was chosen as the scoring function, and the 
solutions were rescored using the ChemScore scoring function. 100 docking runs were 
performed for 15h. The resulting solutions were clustered on the basis of heavy atom 
rmsd values (1  ). The top-ranked solutions were visually analysed using PyMol 
(PyMOL Molecular Graphics System, Version 1.1, Schr dinger, LLC). To validate the 
docking protocol, β-NAD+ was redocked into the empty catalytic pocket of 1TAE using 
the above protocol, and the conformations of the top scored poses were compared to the 
crystal structure position of the ligand. All docking poses were exported as sdf files and 
imported into MOE as a database (mdb file). 
7.8 Sequence alignment and 3D alignment of protein structures 
A sequence alignment was undertaken for ADPRC from Aplysia californica (PDB 
3ZWM, Uniprot ID P29241), archeal Sir2-Af2 (PDB 1YC2, Uniprot ID O30124) and 
DNA ligase from E.faecalis (PDB 1TAE, Uniprot ID Q837V6) using the sequence 
alignment tool provided by Uniprot (Universal Protein Resource, 
http://www.uniprot.org).
275
 Pairwise 3D alignment for the chains A of the three proteins 
mentioned above was undertaken using the protein comparison tools, jFATCAT-rigid 
and jFATCAT-flexible, provided by RCSB Protein Data Bank (http://www.rcsb.org/). 
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8 APPENDIX 
 
Figure A1 HPLC time-course for the basic hydrolysis of 15h. Conditions: 15h (49.5 μM) in 0.1 N NaOH, 
rt. Data from single experiment, peak area vs time [min], data plotting to a 1
st
 order rate equation with 
Grafit5. 
 
 
Figure A2 a) Fluorescence calibration curves for 15h and 9h. Conditions: 15h or 9h (0.13 – 4.26 μM), 
MgCl2 (10 mM), Tris/HCl buffer (50 mM, pH 8), 30 ºC, λex = 300 nm, λem = 410 nm, gain 15%; all 
concentrations are final concentrations. Fluorescence intensity values were fitted to a linear equation with 
Excel. The estimated linear equations are, respectively: y = 2149.4x + 418.93 (r² = 0.994) for 9h, and y = 
2052.9x + 62.892 (r² = 0.991) for 15h. Each data point is the mean (± SD) of experiments run in 
duplicate. b) Fluorimetric assay of NPP from Crotalus adamanteus venom and 15h: initial velocity (V0) 
as function of NPP concentration. Conditions: NPP (0.0024 – 0.024 U/mL), 15h (0.09 μM), MgCl2 (10 
mM), Tris/HCl buffer (50 mM, pH 8), 30 ºC, λex = 300 nm, λem = 410 nm; all concentrations are final 
concentrations. Initial velocity values (V0) were calculated from the reaction time-courses (insert) 
measuring the fluorescence signals generated when 10% product was formed. Initial velocity values were 
fitted to a polynomial equation with GraFit5.  
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Figure A3 Fluorimetric assay of NPP from Crotalus adamanteus venom and 15h: a) Hanes-Woolf and b) 
Lineweaver-Burk plot. Conditions: NPP (0.007 U/mL), 15h (0.2 – 5.2 μM), MgCl2 (10 mM), Tris/HCl 
buffer (50 mM, pH 8), 30 ºC, λex = 300 nm, λem = 410 nm, gain 15%; all concentrations are final 
concentrations. Initial velocity values (V0) were calculated from the corresponding time-courses 
measuring the fluorescence signals generated when 10% product is formed. Initial velocity values were 
then fitted to linear equations with Excel. The estimated linear equation for Hanes-Woolf plot is y = 
651.08x + 2591.9 (r² = 0.9519); for Lineweaver-Burk plot, y = 2808.6x + 495.98 (r² = 0.9958). Each data 
point is the mean (± SD) of experiments run in duplicate.  
 
 
Figure A4 Fluorimetric assay of NPP from Crotalus adamanteus venom and 15h: Michaelis-Menten plot 
for β-NAD+ inhibition toward the activity of NPP from Crotalus adamanteus venom and 15h. Conditions: 
NPP (0.007 U/mL), 15h (0.2 – 5 μM), β-NAD+ (8 – 15 μM), MgCl2 (10 mM), Tris/HCl buffer (50 mM, 
pH 8), 30 ºC, λex = 300 nm, λem = 410 nm, gain 15%; all concentrations are final concentrations. Initial 
velocity values (V0) were calculated from the corresponding time-courses measuring the fluorescence 
signals generated when 10% product was formed. Each data point is the mean (± SD) of experiments run 
in duplicate, data plotting with Excel.  
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Figure A5 Fluorimetric assay of NPP from Crotalus adamanteus venom and 15b: a) fluorescence time-
course as fluorescence emission [RFU] vs time [sec]; b) Michaelis-Menten plot. Conditions: NPP (0.007 
U/mL), 15b (0.2 – 5 μM), MgCl2 (10 mM), Tris/HCl buffer (50 mM, pH 8), 30 ºC, λex = 300 nm, λem = 
410 nm, gain 15%; all concentrations are final concentrations. Initial velocity values (V0) were calculated 
from the time-courses measuring the fluorescence signals generated when 10% product is formed. Initial 
velocity values were fitted to the Michaelis-Menten equation with Grafit5. 
 
 
Figure A6 Fluorimetric assay of NPP from Crotalus adamanteus venom and 15c: fluorescence time-
course as fluorescence emission [RFU] vs time [sec]. Conditions: NPP (0.007 U/mL), 15c (0.2 – 5 μM), 
MgCl2 (10 mM), Tris/HCl buffer (50 mM, pH 8), 30 ºC, λex = 300 nm, λem = 410 nm, gain 15%; all 
concentrations are final concentrations. 
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Figure A7 Fluorimetric assay of ADPRC from Aplysia californica and 15h: ADPR-cyclase activity; 
fluorescence time-course as fluorescence emission [RFU] vs time [sec]. Conditions: ADPRC (0.075 
U/mL), 15h (2.12 – 33.9 μM), HEPES buffer (50 mM, pH 7.4), 26 ºC, λex = 300 nm, λem = 410 nm, gain 
15%. Enzyme addition at 1030 sec. Positive control: 15h (33.9 μM). Negative control: buffer. All 
concentrations are final concentrations. Each data point is the mean of experiments run in duplicate.  
 
 
Figure A8 Fluorimetric assay of ADPRC from Aplysia californica and 15h: Michaelis-Menten and 
Hanes-Woolf plot (insert). Conditions: ADPRC (0.075 U/mL), 15h (2.12 – 33.9 μM), HEPES buffer (50 
mM, pH 7.4), 26 ºC, λex = 300 nm, λem = 410 nm, gain 15%; all concentrations are final concentrations. 
Initial velocity values (V0) were calculated from the corresponding reaction time-courses measuring the 
fluorescence signals generated when 10% product is formed. Initial velocity values were fitted to the 
Michaelis-Menten plot with Grafit5, and to the Hanes-Woolf plot (insert) with Excel (estimated linear 
equation: y = 37.26x + 2947.7, r² = 0.8568). Each data point is the mean (± SD) of experiments run in 
duplicate.  
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Figure A9 Fluorimetric assay of ADPRC from Aplysia californica and 15h: cADPR-hydrolase activity; 
fluorescence time-course as fluorescence emission [RFU] vs time [sec]. Conditions: ADPRC (1.75 
U/mL), 15h (2.12 – 33.9 μM), HEPES buffer (50 mM, pH 7.4), 26 ºC, λex = 300 nm, λem = 410 nm, gain 
15%; all concentrations are final concentrations. Each data point is the mean of experiments run in 
duplicate.  
 
 
Figure A10 Comparison of hydrolytic stability for 15h and 24. Conditions: 15h and 24 respectively in 
NaOH (0.1 N) and HCl (0.1 N), 26 ºC, λex = 300 nm, λem = 410 nm, gain 15%. 
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Figure A11 Preparation of annealed substrate for ligation assay at different ratio 
LigSub1:LigSub2:LigSub1+2. Conditions: LigSub1 at 5 μM in 10 x TBE/KCl (50 mM) buffer; analysis 
by native PAGE and gel visualization by fluorescence imaging. 
 
 
Figure A12 IC50 estimation for quinacrine. Conditions: DNA substrate (0.5 μM), β-NAD
+
 (26 μM), 
EcLigA (0.05 μM), quinacrine·2HCl (0 – 5 μM) in 1 x buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 
mM DTT, 50 μg/mL BSA) incubated at 30 °C under shaking and sampled at 5 min; all concentrations are 
final concentrations. Analysis of assay run on denaturing PAGE and visualized by fluorescence imaging. 
Data analysed using ImageJ. Each data point is the mean (± SD) of a set of experiments run in triplicate; 
data plotting with Excel. 
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Figure A13 Denaturing PAGE for the inhibition of 2-substituted AMP/AMP-morpholidate/NAD
+
 
derivatives at 200 μM. Conditions: DNA substrate (0.5 μM), β-NAD+ (26 μM), EcLigA (0.05 μM), 2-
substituted derivative (200 μM) in 1 x buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 
μg/mL BSA) incubated at 30 °C under shaking and sampled at 5 (a) and 15 min (b); all concentrations are 
final concentrations. Control reaction at the same conditions without any 2-substituted derivative. Gel 
visualization by fluorescence imaging. 
 
 
Figure A14 IC50 estimation for 7a (a) and 13a (b). Conditions: DNA substrate (0.5 μM), β-NAD
+
 (26 
μM), EcLigA (0.05 μM), 7a or 13a (0 – 250 μM) in 1 x buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 
mM DTT, 50 μg/mL BSA) incubated at 30 °C under shaking and sampled at 5 min; all concentrations are 
final concentrations. Analysis of assays run by denaturing PAGE; visualization by fluorescence imaging 
and data analysis by ImageJ. Each data point is the mean (± SD) of a set of experiments run in triplicate; 
data plotting with Excel. 
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Figure A15 IC50 estimation for 11a. Conditions: DNA substrate (0.5 μM), β-NAD
+
 (26 μM), EcLigA 
(0.05 μM), 11a (0 – 250 μM) in 1 x buffer (30 mM Tris/HCl pH 8, 4 mM MgCl2, 1 mM DTT, 50 μg/mL 
BSA) incubated at 30 °C under shaking and sampled at 5 min. Analysis of assays run by denaturing 
PAGE; visualization by fluorescence imaging and data analysis by ImageJ. Each data point is the mean (± 
SD) of a set of experiments run in triplicate; data plotting with Excel. 
 
Enzyme (PBD) 
Twists P RMSD Score % Id % Similarity 
1TAE (chain A) 
0 0.454 8.96 108.39 2.5 13.57 
1YC2 (chain A) 
5 0.199 3.98 163.83 4.1 12.03 
1TAE (chain A) 
0 0.460 9.58 100.28 2.08 7.72 
3ZWM (chain A) 
5 0.525 4.98 131.42 4.59 10.09 
1YC2 (chain A) 
0 0.181 11.12 135.22 8.27 17.29 
3ZWM (chain A) 
4 0.0916 18.64 150.27 4.17 12.50 
Table A1 Structure pairwise alignment of ADPRC from Aplysia californica (PDB 3ZWM), archaeal Sir2-
Af2 (PDB 1YC2), and DNA ligase from E. faecalis (PDB 1TAE) by rigid FATCAT and flexible 
FATCAT. The flexible structure alignment works by identifying aligned fragment pairs and allowing 
flexibility in connecting them by twists in the structure. The more twists that are introduced in the 
structure, the less is the similarity between the two proteins. Twists = 0 in rigid FATCAT; twists ≥ 0 in 
flexible FATCAT. P is the probability value that two structures are similar (values < 0.05 indicates 
significant similarities); RMSD is the average distance between the Cα atoms of superimposed proteins; 
Score is the raw score of the alignment; % Id is the percent sequence identity in the alignment; % 
Similarity is the percent structure similarity in the alignment.  
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